SCAI-ACCi2 Interventional E-Abstracts  by unknown
   ABSTRACTS - SCAI-ACCi2 Interventional E-Abstracts B23 
S
C
A
I-A
C
C
i2
 Interventional E
-A
bstracts
IV.E-POSTER CONTRIBUTIONS
2900
SCAI-ACCi2 Interventional E-Abstracts
Saturday, March 29, 2008, 8:00 a.m. –  
Tuesday, April 1, 2008, 5:00 p.m.
2900-1 Plaque Prolapse With Cypher and TAXUS Stents 
Evaluated With Serial Intravascular Ultrasound Analysis
Seongjin Oh, Byoung-Keuk Kim, Dong Woon Jeon, Joo-Young Yang, Woong Chol Kang, 
Taehoon Ahn, Jung-sun Kim, Young-Guk Ko, Donghoon Choi, Yangsoo Jang, National 
Health Insurance Corporation Ilsan Hospital, Goyang, South Korea
Background: To evaluate the frequency, severity, and clinical implication of the plaque 
prolapse(PP) after sirolimus(SES) and paclitaxel(PES)-eluting stent implantation using 
volumetric intravascular ultrasound(IVUS) analysis.Methods:We used the POET 
trial data which is a prospective, multicenter, randomized trial aimed at demonstrating 
the efficacy of adjuvant balloons in PCI procedure using drug-eluting stents randomly 
allocated(SES vs. PES). Serial IVUS analysis was performed for both stent segment 
encompassing PP at post-procedure and matched location of the site of PP at 8month 
follow-up. The remaining stented segments without PP(non-PP) were also quantified as 
above. IVUS parameters at PP site were compared with non-PP site in each time course 
(post-procedure & follow-up) and also compared between SES and PES.
Results: PP were discovered at 18 sites (SES=5, PES=13, p=ns) in 17 stented 
segments of 216(8.3%)lesions. Post-procedure average PP area was 0.21mm2 in SES 
and 0.08mm2 in PES (p=ns). At follow-up, tissue volume increased at PP site was more 
prominent in PES compared with SES (1.25mm2 vs. 0.52mm2) although not statistically 
significant. Neointimal proliferation was similar between PP and non-PP site in both SES 
and PES (0.51mm2 vs. 0.52mm2 in SES/ 1.23mm2 vs. 1.25mm2 in PES). Restenosis 
rate and TLR were similar between PP and non-PP lesions.
Conclusions: The incidence of PP was similar in SES and PES. PP was not associated 
with exaggerated neointimal proliferation in either SES or PES. PP was not associated 
with restenosis or TLR.
2900-2 Primary Coronary Microcirculatory Dysfunction 
Predicts Procedure-related Cardiac Troponin-I Release 
in Humans, After Elective Percutaneous Coronary 
Intervention
Stephen Hoole, Paul White, Patrick Heck, Cameron Densem, Sarah Clarke, Leonard 
Shapiro, Peter Schofield, Michael O’Sullivan, David Dutka, Papworth Hospital, 
Cambridge, United Kingdom, Addenbrooke’s Hospital, Cambridge, United Kingdom
Background: Coronary microvascular endothelial dysfunction can impede myocardial 
perfusion after percutaneous coronary intervention (PCI) - a phenomenon known as 
“no-reflow”. Traditionally this is believed to be secondary to an endothelial ischemia-
reperfusion injury. However, primary microvascular dysfunction may account for an 
increased susceptibility to injury.
Method: Eighteen patients with single vessel coronary artery disease awaiting PCI were 
recruited. All were optimally medically treated and taking statins. Patients with diabetes 
were excluded. Simultaneous intracoronary distal pressure (Pd) and averaged peak 
velocity (APV), measured by Volcano® guide-wire, and central venous pressure (CVP) 
were recorded during successive low pressure balloon occlusions (BO1 and BO2), a high 
pressure balloon occlusion (POBA) and at stent implantation. Microvascular resistance 
(Rmicro) was calculated during coronary balloon occlusion: Rmicro = Pd (occl.) - CVP / APV 
(occl.). Serum cardiac troponin-I (cTnI) was measured at 24-hours. Mean microvascular 
resistance at each stage of PCI for cTnI tertiles were compared by one-way ANOVA.
Results: Procedure related cTnI release ranged from <0.02 to 7.06 ng/mL. The incidence 
of cTnI release after PCI was significantly associated with baseline microvascular 
resistance and this observation persisted on each successive balloon occlusion (Figure). 
Successive balloon inflations did not increase mean microvascular resistance significantly 
(p = 0.82).
Conclusion: Pre-existing coronary microvascular dysfunction predicts procedure - related 
cTnI release and microvascular endothelial dysfunction does not appear to increase with 
successive PCI stages. 
2900-3 Remote Ischemic Preconditioning in Humans Does 
Not Attenuate Ischemic Left Ventricular Dysfunction, 
Measured Invasively During Coronary Artery Balloon 
Occlusion
Stephen Hoole, Paul White, Patrick Heck, Sadia Khan, Cameron Densem, Sarah Clarke, 
Leonard Shapiro, Peter Schofield, Michael O’Sullivan, David Dutka, Papworth Hospital, 
Cambridge, United Kingdom, Addenbrooke’s Hospital, Cambridge, United Kingdom
Background: Remote ischemic preconditioning (remote IPC) is effective at attenuating 
myocardial ischemia-reperfusion injury and necrosis but evidence of protection from 
ischemic left ventricular (LV) dysfunction and myocardial stunning is less convincing. We 
investigated if remote IPC could reduce ischemic left ventricular dysfunction in humans 
during coronary balloon occlusion.
Methods: Twenty patients undergoing single vessel elective PCI had intraventricular 
contractility indices measured by LV conductance catheter: dP/dt max, dP/dt min and 
Tau. Measurements were recorded after one minute of low-pressure coronary balloon 
occlusion and during recovery after balloon deflation, and then repeated again 30 minutes 
later. In 10 randomly selected patients, remote IPC was performed: 3 x 5-minute blood 
pressure cuff inflations to 200mmHg around the upper arm interspersed with 5-minute 
intervals of cuff deflation, in the intervening 30-minute period.
Results: In the control group, the first coronary balloon occlusion did not significantly 
attenuate the contractility changes seen during the second balloon occlusion (Figure A: 
dP/dt min shown). Similarly, remote IPC administered after the first coronary occlusion did 
not reduce the ischemic LV dysfunction during subsequent coronary balloon occlusion for 
any of the three measured parameters of contractility (Figure B: dP/dt min shown).
Conclusion: Remote IPC does not attenuate ischemic left ventricular dysfunction in Man. 
2900-4 Correlation Between Morphological and Functional 
Characteristics of Culprit Lesions
Konstantinos Toutouzas, Virginia Markou, Sophia Vaina, Maria Drakopoulou, Manolis 
Vavouranakis, Elli Stefanadi, Christodoulos Stefanadis, 1st Department of Cardiology, 
University of Athens, Athens, Greece
Background: High risk plaques demonstrate certain morphological characteristics 
and increased local temperature. In this study we investigated the possible correlation 
between the IVUS morphological and the Thermography functional characteristics of 
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culprit lesions in patients (pts) with acute coronary syndromes (ACS) and chronic stable 
angina (CSA).
Methods: We enrolled 48 pts with ACS and 33 with CSA, undergoing percutaneous 
coronary intervention, matched for demographic and angiographic characteristics. We 
defined the ratio of lesion to reference external elastic membrane area as positive (pRi>1) 
or negative (nRi<1) remodelling index. Temperature difference (ΔT) between the culprit 
plaque and the proximal vessel wall was also measured.
Results: ΔΤ was greater in pts with ACS than CSA (0.08±0.03 vs 0.04±0.02oC, p<0.01) 
similar was pRi (1.15±0.18 vs 0.90±0.11, p<0.01). ΔΤ was greater in pts with pRi than 
nRi (0.07±0.03 vs 0.04±0.02oC, p<0.01). Among pts with pRi, those with ACS had 
increased ΔT than pts with CSA (0.08±0.03 vs 0.04±0.02oC, p<0.01, figure). Similar were 
the findings in pts with nRi (0.05±0.03 vs 0.04±0.02oC, p<0.05, figure). There was a 
correlation between ΔT and Ri (p<0.01, r=0.59).
Conclusion: This study demonstrated a correlation of IVUS morphological and 
Thermography functional characteristics in culprit lesions. More specifically these results 
provide new insights regarding the pathogenesis and risk stratification of pts with ACS. 
2900-5 The Relationship Between Multiple Biomarkers and 
Coronary Plaque Vulnerability by Use of Optical 
Coherence Tomography
Duk-Woo Park, Myeong-Ki Hong, Jong-Pil Park, Jae Hyoung Park, Jeong-Woo Lee, 
Won-Jang Kim, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Jae-Joong Kim, 
Seong-Wook Park, Seung-Jung Park, Asan Medical Center, Seoul, South Korea
Background: Many individual biomarkers have been related to high-risk coronary 
plaque and subsequent cardiovascular risk. Optical coherence tomography (OCT) is a 
high resolution imaging modality capable of identifying vulnerable plaque characteristics. 
We evaluated the relationships between multiple serum biomarkers and the morphologic 
features of coronary plaque characterized by OCT.
Methods: OCT was performed in the culprit lesions of patients undergoing cardiac 
catheterization. Lipid was semi-quantified as the number of quadrants on the cross-
sectional image. Fibrous cap thickness was measured at its thinnest part. Thin-cap 
fibroatheroma (TCFA) was defined as lipid rich plaque (≥ 2 quadrants) with a fibrous 
cap thickness < 65Μm. We measured 9 biomarkers at baseline: white blood cells (WBC) 
counts, C-reactive protein, erythrocyte sedimentation rate, fibrinogen, homocysteine, 
von Willebrand factor, lipoprotein (a), apolipoprotein A-1 and B-100. Logarithmic 
transformation was performed to normalize the distribution of the biomarkers.
Results: A total of 41 patients were enrolled in the study. Among the 9 multiple biomakers, 
a significant correlation was only found between WBC count and fibrous cap thickness (r 
= -0.47, p=0.002). Also, WBC count was the only biomarker showing significant difference 
between plaque with TCFA and without TCFA (6.5±2.3 vs. 5.2±1.7 x103/mm3, p=0.036). 
In multivariate regression models adjusting for conventional risk factors, WBC count was 
independently associated with fibrous cap thickness (adjusted estimated effect size per 
100 count/mm3, -0.8±0.3; p=0.007) and the probability of TCFA (adjusted relative risk per 
100 count/mm3, 1.05; 95% confidence interval, 1.02-1.11; p=0.036).
Conclusions: Among the multiple biomarkers for stratifying the cardiovascular risk, 
WBC count was the most informative biomarker for predicting the vulnerable plaque 
characteristics identified by use of OCT. Further studies may be needed to evaluate the 
value of inflammatory risk stratification and vulnerable plaque features with OCT on the 
clinical prognosis in these patients.
2900-6 Tissue Characterization of Coronary Plaque With Thin-
cap Fibroatheroma Identified by Optical Coherence 
Tomography
Duk-Woo Park, Myeong-Ki Hong, Jong-Pil Park, Jae Hyoung Park, Jeong-Woo Lee, 
Won-Jang Kim, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Jae-Joong Kim, 
Seong-Wook Park, Seung-Jung Park, Asan Medical Center, Seoul, South Korea
Background: Optical coherence tomography (OCT) is a reliable and reproducible 
imaging modality for detailed coronary plaque characterization. Despite the high resolution 
of OCT imaging, the accurate assessment of the coronary plaque composition is limited. 
Therefore, we performed the tissue characterization of vulnerable plaque assessed by 
OCT, using virtual Histology (VH)-intravascular ultrasound (IVUS).
Methods: Pre-intervention OCT and VH-IVUS was consecutively performed in the 
culprit lesions. Lipid was semi-quantified as the number of involved quadrants on the 
cross-sectional OCT image. The cross-sectional image with the highest number of lipid 
quadrants was used for analysis. Fibrous cap thickness was measured at its thinnest part. 
Thin-cap fibroatheroma (TCFA) was defined as lipid rich plaque (≥ 2 quadrants) with a 
fibrous cap thickness < 65Μm. VH-IVUS analysis was performed at the site of the largest 
necrotic core. Plaque composition was classified as fibrotic, fibrofatty, dense calcium, and 
necrotic core, in which absolute plaque area and relative percentages were reported.
Results: 41 coronary lesions were analyzed and OCT-derived TCFA was found in 23 
plaques (56%). Plaque classified as TCFA had a larger P&M area than non-TCFA plaques 
(p=0.024). In VH-analysis, TCFA showed significantly larger necrotic absolute area as 
compared to non-TCFA without the difference of fibrous, fibrofatty and dense calcium 
components (Table).
Conclusions: TCFA identified by OCT imaging showed more unstable tissue 
compositions with larger plaque and necrotic core area compared to non-TCFA.
Variables TCFA  (n=23) Non-TCFA (n=18) p Value
EEM area (mm2) 15.7±3.5 13.6±3.1 0.076
Lumen area (mm2) 5.4±2.2 5.3±1.7 0.8
P&M area (mm2) 10.3±2.6 8.4±2.3 0.024
Absolute areas (mm2)
Fibrotic 3.2±2.1 6.3±4.2 0.31
Fibrofatty 0.3±0.4 0.4±0.5 0.52
Dense calcium 1.0±0.6 0.8±0.6 0.33
Necrotic core 2.8±1.5 1.6±1.0 0.003
Percentages (%)
Fibrotic 42±20 44±26 0.81
Fibrofatty 4±5 7±11 0.20
Dense calcium 14±7 15±11 0.66
Necrotic core 41±20 32±21 0.19
2900-7 Vessel Shrinkage as a Mechanism of Atherosclerosis 
Progression in Diabetic Patients: A Serial Intravascular 
Ultrasound Study
Pilar Jiménez-Quevedo, Manel Sabate, Suzuki Nobuaki, Cecilia Corros, M. Cruz 
Ferrer, Marco Costa, Fernando Alfonso, Rosana Hernandez-Antolin, Esther Bernardo, 
Dominick Angiolillo, Camino Bañuelos, Javier Escaned, Carlos Macaya, Hospital Clínico 
San Carlos, Madrid, Spain, University of Florida, Jacksonville, FL
Background: Negative remodeling plays a major role in coronary narrowing in diabetic 
patients. The aim of this study was to identify predicting factors of vessel Shrinkage (VS) 
in diabetic patients, using serial IVUS analyses.
Methods: 235 coronary subsegments (45 patients) from the DIABETES I. II y III trial 
were included. Quantitative volumetric IVUS analyses from motorized pullbacks (0.5 
mm/sec) after the index procedure and at 9-month follow-up were performed in the 
same coronary segment. Non treated mild lesions (angiographic stenosis <25%) with 
>/=0.5mm plaque thickening and 5 >/=mm of length assessed by IVUS were included. 
Subsegmental analysis was performed dividing the lesions into three sections of equal 
length (subsegments). VS was defined as a ratio Δ vessel area/ Δ atheroma area<1. 
Statistical adjustment by multiple subsegments and multiple lesions per patient (GEE 
method) was performed.
Results: Mean lesion length was 10.3 mm. VS occurred in 36.7% and was associated 
with a significant decrease in lumen area at 9-month (VS:10.1±3.8mm2vs no-VS:11.1 
±3.8; p=0.04). Independent predictors of VS were: insulin-dependent diabetes (OR: 4.6; 
95% CI.1.4-15.1;p=0.01); glicated haemoglobin level (OR:1.5; 95% CI.1.05-2.1;p=0.02); 
apolipoprotein B level (OR:0.96; 95% CI.0.94-0.98;p<0.001); hypertension (OR:3.7; 95% 
CI.1.4-10.3;p=0.009); number of diseased vessels (OR:5.6; 95% CI.2.5-12.5;p<0.001) 
and prior revascularization (OR:17.5; 95% CI.6.5-46.9;p<0.001).
Conclusions: The present serial IVUS study demonstrates that VS contributes to 
coronary stenosis progression in diabetic patients. VS is influenced by insulin treatment 
and metabolic levels and is more frequent in patients with multivessel disease and prior 
revascularization.
2900-8 Assessment of Intra-coronary Inflammatory and 
Oxidative stress markers following percutaneous 
coronary interventions (PCI).
F. Khan Pohlel, Saurabh S. Dhawan, Abdul Sheikh, Arshed A. Quyyumi, Dean P. Jones, 
Syed T. Rab, Habib Samady, Ziyad B. Ghazzal, Emory University, Atlanta, GA
Background: A heightened inflammatory response to PCI is associated with a worse 
long term outcome. We investigated the mechanisms underlying the inflammatory 
response provoked by PCI with the hypothesis that it is triggered by an increase in 
oxidative stress.
Methods: In two separate studies we investigated changes in systemic markers of 
inflammation and oxidative stress. In study 1 of 220 patients with stable CAD, markers 
were measured before, 1 day, 1 week and 1 month after PCI and stenting. In study 2, 
these changes were measured in 13 patients with intracoronary sampling immediately 
before and after PCI. Arterial blood samples were obtained sequentially from the aorta, 
distal to target lesion pre-PCI, distal to target lesion post-PCI, and in a non-target vessel. 
Reduced (cysteine) and oxidized (cystine) levels reflected plasma oxidative stress, and 
inflammation was measured using CRP, IL-6 and MMP-9.
Results: In study 1, there was an increase in CRP (50%, p<0.001), IL-6 (100%, p<0.001), 
and MMP-9 (80%, p<0.001) 1 day after PCI. However, in study 2, there was no change 
in these markers of inflammation between pre-and post-PCI coronary arterial samples. 
Nevertheless, an increase in markers of oxidative stress was observed immediately post 
PCI; there was no difference between the aortic and post lesion cystine levels before PCI 
(58.2 and 55 ΜM, respectively, p=ns), however, after PCI, post lesion and non-target 
coronary arterial levels were significantly elevated (62.6ΜM and 67.3ΜM, respectively, 
p=0.02 compared to pre-PCI levels).
Conclusions: Oxidative stress increases immediately after PCI and subsequently 
(1 day) leads to an increase in systemic inflammatory response. Understanding the 
mechanisms underlying oxidation-mediated inflammatory activation by PCI will likely 
influence development of therapeutic strategies for improving outcomes after PCI.
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2900-9 Discrepancy of Calcium Detection Between Gray Scale 
Intravascular Ultrasound and Spectral Analysis of 
Radiofrequency Data
Taek-Geun Kwon, Dae-Woo Hyun, Ki-Young Kim, Jang-Ho Bae, Konyang University 
Hospital, Daejeon, South Korea
Background: We sought to evaluate 1) the discrepancy of calcium detection between 
gray scale intravascular ultrasound (IVUS) and VH-IVUS and 2) the association between 
coronay calcium and plaque composition.
Methods: Study subjects consisted of 162 consecutive patients (119 males, mean 
60yrs old). Subjects were divided to 3 groups based on gray scale IVUS findings; No 
calcification group (n=50), Spotty group (n=56) who had a lesion containing only small 
calcium deposits within an arc of less than 90° and diffuse group (n=56) who had a 
diffuse calcific lesion with an arc of more than 90° in more than 1 cross-sectional image 
of the lesion.
Results: With gray scale IVUS analysis, no calcification group was younger (54.4±13.0yrs 
vs. 61.1±10.7yrs and 64.2±9.9yrs, p=0.011 and p<0.001, respectively) than other groups, 
were likely to be male (84% vs. 62.5%, p=0.017), less smoker (50.0% vs. 23.2%, p=0.005) 
and less hypertension (48.0% vs. 71.4%, p=0.017) than diffuse group. With IVUS-VH 
analysis, no calcification group had some degree of dense calcified plaque, and had 
less plaque volume (162.1±121.7mm3 vs. 247.9±151.5mm3, p=0.003), fibro-lipid volume 
(11.2±12.3mm3 vs. 27.3±30.0mm3, p=0.001), and lipid core volume (17.7±22.7mm3 vs. 
30.3±22.3mm3, p=0.001) than diffuse group. However, there are no significant differences 
in other plaque composition between no calcification group and spotty group as well as 
dense calcified composition (5.7mm3 vs. 5.4mm3, p=NS). Calcium volume was correlated 
directly with plaque volume (r=0.80, p<0.001), fibrous volume (r=0.76, p<0.001) and 
lipid core volume (r=0.72, p<0.001) in no calcification group and correlated with plaque 
volume(r=0.43, P<.001), fibrous volume(r=0.34, P=.011) and lipid core volume(r=0.70, 
P<.001) in spotty group and correlated with plaque volume(r=0.60, P<.001), fibrous 
volume(r=0.48, P<.001) and lipid core volume(r=0.81, P<.001) in diffuse group.
Conclusions: This study showed that coronary calcium can be present even if invisible 
in gray scale IVUS and correlated with plaque volume and lipid core volume in patients 
with invisible calcium by gray scale IVUS.
2900-10 Relation of Plaque Size to Compositions as Determined 
by an in vivo Volumetric Intravascular Ultrasound 
Radiofrequency Analysis 
Myeong-Ki Hong, Chang-Bum Park, Cheol Whan Lee, Duk-Woo Park, Won-Jang Kim, 
Jong-Pil Park, Jeong-Woo Lee, Jae Hyoung Park, Gyung-Jung Kim, Seung-Whan Lee, 
Young-Hak Kim, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park, Asan Medical 
Center, Seoul, South Korea
Coronary plaque composition cannot be assessed accurately using grey-scale intravascular 
ultrasound (IVUS). Radiofrequency IVUS analysis characterizes atherosclerotic plaques 
into fibrotic, fibrofatty, dense calcium, and necrotic core. Using Virtual Histology (VH) 
IVUS, we evaluated the relation of plaque size to each plaque components in the de 
novo culprit/target lesions of 244 patients (78 with acute coronary syndrome and 166 
with stable angina). Volumetric VH-IVUS analysis was performed along a 10mm segment 
centered on the minimal lumen area and calculated using Simpson’s rule. Plaque volume 
(mm3) was significantly correlated with fibrotic volume (mm3) (r=0.886, p<0.001), necrotic 
core volume (r=0.716, p<0.001), fibrofatty volume (r=0.572, p<0.001) and dense calcium 
volume (r=0.382, p<0.001). There was a weak correlation between plaque volume, and 
percentage of fibrofatty plaque and dense calcium (r=0.140, p=0.030 and r=-0.146, 
p=0.023, respectively). Plaque volume was not significantly correlated with percentage 
of fibrotic plaque and necrotic core. Plaque burden (=plaque/vessel volume, %) was 
also significantly correlated with fibrotic volume (mm3) (r=0.714, p<0.001), necrotic core 
volume (r=0.573, p<0.001), fibrofatty volume (r=0.423, p<0.001) and dense calcium 
volume (r=0.411, p<0.001). However, there was no significant correlation between plaque 
burden and percentage of each plaque components (Table). In conclusion, as the plaque 
volume (mm3) or burden (%) increased, there was an increase of absolute amounts of 
each plaque components (fibrotic> necrotic core> fibrofatty> dense calcium). However, 
there were no significantly relevant correlations between plaque volume (or burden) and. 
percentage of each plaque components.
Table. Relation between plaque volume (mm3) and burden (%) vs. each plaque 
components in volumetric analysis 
Fibrotic Fibrofatty Calcific Necrotic
Plaque volume % mm3 % mm3 % mm3 % mm3
r=0.094 0.886 0.140 0.572 -0.146 0.382 -0.078 0.716
p=0.144 <0.001 0.030 <0.001 0.023 <0.001 0.224 <0.001
β=0.038 0.506 0.02z2 0.072 -0.036 0.055 -0.027 0.236
Plaque burden r=-0.004 0.714 0.040 0.423 0.012 0.411 -0.033 0.573
p=0.956 <0.001 0.539 <0.001 0.857 <0.001 0.612 <0.001
β=-0.006 1.571 0.024 0.205 0.011 0.229 -0.044 0.726
2900-11 Relationship Between Arterial Remodeling and 
Coronary Plaque Composition by an Intravascular 
Ultrasound Radiofrequency Analysis
Myeong-Ki Hong, Chang-Bum Park, Cheol Whan Lee, Duk-Woo Park, Won-Jang Kim, 
Jong-Pil Park, Jeong-Woo Lee, Jae Hyoung Park, Gyung-Jung Kim, Seung-Whan Lee, 
Young-Hak Kim, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park, Asan Medical 
Center, Seoul, South Korea
We evaluated the relation between coronary plaque composition by virtual histology (VH) 
intravascular ultrasound (IVUS) and arterial remodeling pattern. The study included 121 
patients (438 lesions) that underwent VH-IVUS study. There were 145 lesions with positive 
remodeling (remodeling index; RI ≥ 1.05) and 293 lesions with negative/intermediate 
remodeling (RI < 1.05). Compared with negative/intermediate remodeling, positive 
remodeling have a larger area of fibrotic plaque, fibrofatty plaque and necrotic core. 
However, there were no significant differences of percentage of each plaque components 
between the 2 groups except lesser percentage of dense calcium in positive remodeling 
(Table). RI was significantly correlated with an area of fibrotic plaque (r=0.262, p<0.001), 
fibrofatty plaque (r=0.149, p=0.002), dense calcium (r=0.112, p=0.019) and necrotic 
core (r=0.233, p<0.001). However, there were no significant correlation between RI and 
percentage of each plaque components. In conclusions, the percentage of each plaque 
components was similar between positive and nega tive/intermediate remodeling except 
lesser percentage of dense calcium in positive remodeling. Compared with negative/
intermediate remodeling, area of fibrotic plaque, fibrofatty plaque and necrotic core were 
significantly larger in positive remodeling due to a larger total plaque area.
Table. VH-IVUS findings 
Remodeling pattern Positive (n=145) Negative/intermediate (n=293) p
Absolute areas (mm2)
Fibrotic (Dark-green) 4.5 ± 2.2 3.5 ± 2.0 <0.001
Fibrofatty (Yellow-green) 0.5 ± 0.5 0.4 ± 0.5 0.024
Dense calcium (White) 0.7 ± 0.7 0.7 ± 0.6 0.7
Necrotic core (Red) 2.7 ± 1.3 2.2 ± 1.2 <0.001
Percentages (%)
Fibrotic 53 ± 13 51 ± 15 0.188
Fibrofatty 6 ± 5 5 ± 5 0.26
Dense calcium 8 ± 7 10 ± 8 0.046
Necrotic core 33 ± 12 34 ± 13 0.5
2900-12 Does Takotsubo Cardiomyopathy Result From Plaque 
Rupture? Insight From Intravascular Ultrasound 
Studies
Saquib Samee, Tania Chao, Teruo Okabe, Probal Roy, Tina L. Pinto Slottow, Daniel H. 
Steinberg, Rebecca Torguson, Subodh B. Joshi, Lowell F. Satler, Kenneth Kent, William 
O. Suddath, Joseph Lindsay, Ron Waksman, Augusto D. Pichard, Washington Hospital 
Center, Washington, DC
Background: Takotsubo cardiomyopathy (TC) is a disorder characterized by typical 
clinical and ECG manifestations of acute myocardial infarction, a characteristic contraction 
abnormality [“ballooning” of the left ventricle (LV) apex] with absence of obstructive 
coronary disease. Its pathogenesis is poorly understood. Some have postulated its cause 
to be associated with transient occlusion of the left anterior descending (LAD) coronary 
artery. This study utilized intravascular ultrasound (IVUS) in patients with typical TC to 
detect coronary atherothrombosis to test this hypothesis.
Methods: From a cohort of 52 patients who presented to the cardiac catheteriztion 
laboratory with typical chest pain, ECG changes, positive cardiac enzymes, typical LV 
apical ballooning and angiographically normal coronary arteries, 7 patients underwent 
IVUS at the time of initial angiography. IVUS imaging was interpreted by an independent 
reviewer.
Results: All 7 patients had atherothrombotic lesions in the proximal LAD by IVUS with 
a mean obstruction of 57% (48%-70%), 5 of the 7 (71%) patients had evidence of acute 
plaque rupture, and 1 had a tight calcific stenosis. In all 7 patients, the LAD wrapped 
around the LV apex.
Conclusions: These IVUS findings support the hypothesis that TC can result from 
plaque rupture with transient occlusion of wrap-around LAD causing LV stunning. 
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2900-13 Among Serum Lipid Profile Parameters High-Density 
Lipoprotein Cholesterol Is the Major Determinant of 
Coronary Plaque Burden: A Volumetric Intravascular 
Ultrasound Analysis
Eduardo Missel, Gary S. Mintz, Hector Garcia-Garcia, Ryan K. Kaple, Celia Castellanos, 
Sinan Biro, Jeffrey W. Moses, Gregg W. Stone, Martin B. Leon, Columbia University 
Medical Center, New York, NY, Cardiovascular Research Foundation, New York, NY
Background: Although statins are highly effective in reducing future adverse 
cardiovascular events, the effect on plaque burden (PB) measured by intravascular 
ultrasound (IVUS) is, at best, modest. We assessed the relationship of lipid profile to 
IVUS parameters in order to explain this paradox.
Methods: We performed volumetric IVUS analysis in a series of 625 patients and 
measured external elastic membrane (EEM), lumen, and plaque&media (P&M) areas 
and volumes and PB (EEM/P&M).
Results: Patient age was 62.3±11.1yrs with 75% males and 23% diabetics. There was 
a negative association between HDL-C levels and mean PB (r= -0.18, p<0.0001), mean 
P&M CSA (r= -0.16, p=0.0008), and P&M volume (r=-0.11, p=0.02). Total cholesterol 
LDL-C and triglycerides were not related to any of these IVUS parameters. Multiple 
regression analysis revealed that among lipid profile parameters, HDL-C was the only 
independent predictor of PB (p<0.0001). Patients with HDL-C<50mg/dl had higher mean 
P&M area (7.1±2.6 vs. 6.2±2.5mm2), P&M volume (349.7±203.7 vs. 293.8±173.5 mm2, 
p=0.004), and mean PB (45.0±8.7 vs. 40.9±9.7%, p<0.0001) than pts with normal HDL 
levels. Patients with HDL-C levels in the 3rd tertile (>58mg/dl) had significantly lower 
plaque burden (40.7%) when compared to the 1st (44.6%, p=0.002) or 2nd (44%, 
p=0.006) tertiles. Decreasing TC/HDL tertiles was associated with a progressively smaller 
plaque burden as well (p=0.008) (Figure). 
Conclusion: Among lipid parameters, HDL-C is the major determinant of coronary plaque 
burden. The modest benefits of statins in terms of plaque regression more likely result 
from the slight effect on increasing HDL-C levels than in reducing LDL-C levels.
2900-14 Clinical, Angiographic and Morphologic Features 
and Post-PCI Complications in Patients With Acute 
Coronary Syndromes and Attenuated Plaques Detected 
by IVUS
Sung Yun Lee, Gary S. Mintz, Seok-Yeon Kim, Teruo Okabe, Young Joon Hong, Augusto 
D. Pichard, Lowell F. Satler, Ron Waksman, Kenneth M. Kent, William O. Suddath, Neil J. 
Weissman, Cardiovascular Research Institute/Medstar Research Institute, Washington 
Hospital Center, Washington, DC, Cardiovascular Research Foundation, New York, NY
Background: Attenuated plaques are unusual intravascular ultrasound (IVUS) findings 
in patients with acute coronary syndrome; their significance is not fully understood.
Methods: We reviewed clinical presentation and angiographic and pre-intervention 
IVUS findings in 293 patients with acute coronary syndrome undergoing percutaneous 
coronary intervention (PCI) without a distal protection device: 184 with non-ST elevation 
myocardial infarction (STEMI) and 109 with STEMI.
Results: Attenuated plaque (defined as deep echo attenuation without calcification) 
was observed in 81 patients (27.6%): 43.1% of STEMI, 18.5% of non-STEMI (p<.001). 
Overall, the level of C-reactive protein (CRP), lesion site plaque burden, and remodeling 
index were significantly greater; lesion site luminal area was significantly smaller; and 
angiographic thrombus, initial coronary flow < TIMI 2, IVUS target lesion lobulated mass, 
positive remodeling, plaque rupture, and no reflow after PCI were more common in 
lesions with attenuated plaque (Table). There were no significant differences in cardiac 
risk factors; use of thrombolytics, angiomax, or GPIIbIIIa inhibitors; or peak levels of 
cardiac enzyme after PCI comparing the two groups.
Conclusion: Attenuated plaque was more common in patients with STEMI than non-
STEMI. Attenuated plaque was associated with a higher CRP level, more severe and 
complex lesion morphology, reduced coronary blood flow before PCI, and especially no-
reflow after PCI.
Attenuated 
plaque ( n=81 )
No attenuated 
plaque( n=212) p value
Laboratory 
data CRP (mg/dL) 28.5 ± 56.3 6.2 ± 7.2 0.002
Angiographic 
data
Initial coronary flow < TIMI 2 39 (48.1 %) 18 (8.5 %) 0.001
Angiographic evidence of 
thrombus 39 (48.1 %) 34 (16.0 %) 0.001
No reflow after PCI 38 (46.9 %) 20 (9.4 %) 0.001
IVUS lesion 
site
Vessel Area (mm2) 12.0 ± 3.9 11.6 ± 4.9 0.47
Lumen Area (mm2) 2.1 ± 0.9 2.6 ± 1.4 0.004
Plaque area (mm2) / 
Plaque burden (%)
9.9 ± 3.8 / 
81.6 ± 8.8
9.0 ± 4.5 / 
75.6 ± 11.2
0.09 / 
<0.001
Remodeling index (RI) / 
Positive remodeling (RI > 1.05)
0.99 ± 0.23 / 
30 (37.0 %)
0.91 ± 0.28 / 
51 (24.1 %)
0.013 / 
0.018
Lobulated mass / 
Plaque rupture
31 (38.3 %) / 
38 (46.9 %)
28 (13.2 %) / 
46 (21.7 %)
0.001 / 
0.001
2900-15 Virtual Histology Intravascular Ultrasound Analysis 
of Thin-Capped and Thick-Capped Fibroatheromas in 
Autopsied Coronary Arteries 
Sang-Wook Kim, Gary S. Mintz, Wang-Soo Lee, Hyoung-Joong Kim, Eon-Sub Park, 
Tae-Jin Lee, Bo-Mi Son, Sung-Yun Lee, Gi Hwan Kim, Soon-Auck Hong, Soo-Hee Choi, 
Kwang-Je Lee, Tae-Ho Kim, Chee-Jeong Kim, Wang-Seong Ryu, Neil J. Weissman, 
Chung-Ang University Hospital, Seoul, South Korea, Washington Hospital Center, 
Washington, DC
Thin fibrous cap can lead to plaque rupture. However, plaque characteristics and their 
mechanical properties also play an important role. Methods. We harvested 123 coronary 
arteries from 43 autopsied cases. Virtual histology intravascular ultrasound (VH-IVUS) 
imaging was performed beginning 30mm distal to the ostium of each coronary artery. 
Thin-capped fibroatheroma (TCFA) was defined as necrotic core >10% of plaque area 
associated with a plaque burden of >40% with the necrotic core in contact with the 
lumen for at least 3 image slices. VH-IVUS derived fibroatheromas (FA) were validated 
histopathologically. Positive remodeling was defined as a remodeling index (lesion/
reference EEM [external elastic membrane] area) >1.05. Results. Pt age was 49.2± 
9.12yrs and 82% were males. Four pts experienced sudden cardiac death and 39 non-
cardiac death. Overall, 8% (10/123) of coronary arteries showed a thick-capped FA and 
9% (12/123) showed a thin-capped FA. Greyscale IVUS showed no a trend toward a larger 
EEM area (12.70±1.61mm2 vs 10.88±2.48mm2, p=0.064) and lumen area (5.19±1.00mm2 
vs 4.36±1.16mm2, p=0.087) in TCFAs, but no difference in plaque burden (58.0±8.4% 
vs 59.8±5.8%, p=0.6), or remodeling index (1.15±0.24 vs 0.96±0.22, p=0.13). VH-IVUS 
showed relatively larger necrotic core and relatively more dense calcium in TCFAs, 
but relatively smaller necrotic cores and relatively more fibrous plaque in thick-caped 
FAs (Table). Conclusion. VH-IVUS findings of TCFAs and thick-capped FAs parallel 
histopathology. The role of calcium in the more-unstable TCFAs deserves further study. 
Thin-capped FA Thick-capped FA p-value
Fibrous, mm2 2.83±0.93 3.13±1.08 0.4969
Fibro-fatty, mm2 0.49±0.23 0.35±0.12 0.1084
Necrotic core, mm2 0.94±0.28 0.63±0.37 0.0356
Dense calcium, mm2 0.73±0.29 0.28±0.16 0.0003
Fibrous, % 55.43±7.37 71.77±5.59 <.0001
Fibro-fatty, % 9.53±3.13 8.16±2.41 0.2711
Necrotic core, % 19.85±5.19 13.86±2.74 0.0038
Dense calcium, % 15.15±4.12 6.21±3.08 <.0001
2900-16 Quantitative Colorimetry of Coronary Thin Cap 
Fibroatheroma in Human Autopsy Specimens
Fumiyuki Ishibashi, Jennifer Lisauskas, Thomas Meese, Sergio Waxman, Lahey Clinic, 
Burlington, MA
Background: We reported that high yellow color intensity (HYCI) of human carotid/
femoral atherosclerotic plaques, measured with quantitative colorimetry during 
angioscopy, is associated with lipid cores underneath thin fibrous caps (cap thickness 
<100 Μm, LCTCs). We hypothesized that certain color parameters would define coronary 
lesions with LCTCs, including thin-cap fibroatheroma (TCFA), and performed angioscopy 
with colorimetry in human coronary artery autopsy specimens.
Methods: Angioscopy was performed in 40 non-severely stenotic coronary segments 
from 17 autopsy hearts which were pressure perfused. Each arterial segment was cut, 
stained, and examined at 2 mm intervals for histopathologic analysis. Luminal coronary 
surface diagrams were constructed from histology to define the regions with LCTCs 
(consecutive surface regions of lipid cores underneath fibrous cap <100Μm) and to 
compare with angioscopic images. The surface color of LCTCs was measured from the 
angioscopy pullbacks using quantitative colorimetry with the L*a*b* color space (positive 
a*=red, positive b*=yellow).
Results: 81 angioscopic regions were determined (21 LCTCs and 60 non-LCTCs). The 
predominant histologic plaque types of 21 LCTCs were TCFA (n=14), fibroatheroma (n=2) 
and fibrocalcific plaque (n=5). A predefined HYCI (b*>23) was measured in 19 (90%) of 
21 LCTCs as compared with 14 (23%) of 60 non-LCTCs (p <0.0001). Among 33 HYCI 
regions, a* value was significantly higher in 19 LCTCs (6.53±1.51) as compared with 
14 non-LCTCs (-3.96±0.91, p <0.0001). The color (a*, b*) was (7.04±1.52, 29.48±1.52) 
in 21 LCTCs. The cut-off a* value for LCTCs was 0 derived from the receiver operating 
characteristics curve. In 81 angioscopic regions, the sensitivity and specificity of (a* >0, 
b* >23) or (a* >15, b* >0) for LCTCs were 95% and 97%, and for TCFAs were 93% and 
90%, respectively.
Conclusions: Coronary TCFAs can be reliably identified as high yellow/red color intensity 
regions by quantitative colorimetry during postmortem angioscopy. Further validation of 
these parameters in vivo is necessary. Prospective identification of TCFAs could lead to 
prevention of cardiovascular events.
2900-17 Incomplete stent apposition and Stent Fracture after 
Sirolimus-eluting stent implantation
Kyungheui Kim, Seongjin Oh, Byoung-Keuk Kim, Dong Woon Jeon, Joo-Young Yang, 
Deok-Kyu Cho, Lucy Youngmin Eun, National Health Insurance Corporation Ilsan Hospital, 
Goyang, South Korea, Myongji Hospital, Kwandong University, Goyang, South Korea
Background:Little is known about causes of stent fracture (SF) after sirolimus-eluting 
stent (SES) implantation. The present study investigated differences of the IVUS 
findings between segments with and without stent fracture in patients treated with SES.
Methods:Since January 2004, SF (25 fractures in 24 patients) after SES implantation 
were discovered and underwent intravascular ultrasound (IVUS) examination. 
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Measurements were performed at 7 cross sections in the same stent: center of SF site, 
proximal and distal edges of fractured stent and 4 remote sites 2.5 amd 5.0mm proximal 
and distal to SF site.
Results:IVUS parameters at the center of stent fracture were not different from the other 
sites (EEM area[mm2]; 16.44±3.50, 15.73±3.12, 15.97±3.64, 15.94±3.76, 15.72±3.64, 
15.64±3.95, 15.60±4.18, p=ns/ Stent area[mm2]; 8.46±2.28, 7.88±2.17, 7.79±2.26, 
7.75±2.08, 7.75±2.09, 7.82±1.87, p=ns) except Lumen area(mm2) (8.15±2.31[p<0.001], 
7.45±2.14[p=0.008], 8.14±8.90[p=ns], 6.48±2.26, 6.54±2.28[p=ns], 6.99±2.18[p=ns], 
7.50±2.00[p=0.007]). Stent under/over expansion, regional vessel remodeling, or 
excessive P&M (possible NIH) accumulation were not observed (P&M; 7.98±2.22 vs. 
7.85±2.15 vs. 8.18±2.75 vs. 7.83±8.74 vs. 7.98±2.33 vs. 7.89±2.60 vs. 7.78±2.77/ NIH; 
0.32±0.87 vs. 0.43±0.42 vs. -0.35±8.73 vs. 1.20±1.33 vs. 0.76±0.88 vs. 0.18±0.35). 
Incomplete stent appositions were more frequently found at the fractured stent edges 
compared with other sites (Table). Calcium profiles were not different between sites.
Conclusions:Incomplete stent apposition is more frequently found at the fractured 
stent edges after SES implantation, suggesting a role in the pathogenesis of this adverse 
event.
ISA and SF
5.0mm 
proximal 
to SF
2.5mm 
proximal 
to SF
Proximal 
edge of SF
Distal 
edge of 
SF
2.5mm 
distal to 
SF
5.0mm 
distal to 
SF
ISA 
frequency
1 
(4.2%)
1 
(4.2%) 3 (12.5%) 3 (12.5%)
0 
(0%)
1 
(4.2%)
ISA area 
(mm2) 1.0 0.9 0.6±0.4 0.9±0.4 1.0
ISA depth 
(mm) 0.75 0.62 0.8±0.5 1.8±2.5 0.42
ISA arc (° ) 103 72 145±52 102±19 84
2900-18 Coronary Microvascular Resistance Estimated by 
Intracoronary Hemodynamic Measurements Reflects 
Residual Myocardial Viability in Patients With Prior 
Myocardial Infarction
Koichi Tamita, Atsushi Yamamuro, Syuichiro Kaji, Minako Katayama, Takeshi Kitai, 
Takefumi Yamane, Yasuki Kihara, Takashi Akasaka, Kobe General Hospital, Kobe, 
Japan, Wakayama Medical University, Wakayama, Japan
Background: Fractional flow reserve (FFR) and coronary blood flow velocity reserve 
(CFR) represent physiological quantities and are useful to evaluate coronary lesion 
severity. However, resistive vessel dysfunction may blunt the maximal hyperemic response 
in patients with prior myocardial infarction (MI). The aim of this study was to examine the 
effect of residual viability on intracoronay physiological assessments in the infarct-related 
coronary arteries.
Methods: FFR and CFR were assessed in 61 consecutive patients with 61 intermediate 
coronary lesions (between 40% and 70% diameter stenosis by visual assessment) in 
the infarct-related coronary artery. Microvascular resistance (MVR) index was defined 
as the ratio of mean distal pressure to averaged peak blood flow velocity during maximal 
hyperemia. Patients were divided into two groups based on myocardial viability assessed 
by thallium-201 SPECT; 45 patients with viable myocardium and 16 patients with 
nonviable myocardium in the infracted area. Redistribution patterns or residual maximal 
myocardial activity >50% are indices of tissue viability.
Results: Intracoronay physiological assessments showed significantly lower hyperemic 
averaged peak blood flow velocity (28.8±9.9 vs 42.6±18.2 cm/s; p<0.01), higher FFR 
(0.88±0.07 vs 0.82±0.08; p<0.01), and higher HMR (2.80±0.98 vs 1.70±0.70 mmHg/
cm/s; p<0.0001) in nonviable myocardial group compared with viable group. The CFR did 
not differ between these two groups (2.37±1.07 vs 2.72±1.03; p=0.25). The optimal cutoff 
values to predict residual viable myocardium was 2.1 for MVR index (sensitivity=0.81 and 
specificity=0.78).
Conclusions: These data indicate that the hemodynamic impact of intermediate 
coronary lesions depends on the amount of residual myocardial viability in patients 
with prior MI. The evaluation of MVR index might be clinically useful to assess residual 
myocardial viability in those patients.
2900-19 TOPIMAGE Registry Results of Feasibility and Safety 
of IntraVascular MRI (IVMRI) for Measurement of Lipid 
Fraction Index of Coronary Plaque
Giora Weisz, Martin B. Leon, Horst Sievert, Jeffrey W. Moses, Stefan Verheye, Ruchira 
Glaser, Ran Kornowaski, Ron Waksman, Evelyn regar, Amir Lerman, David halon, 
William Wijns, Columbia University Medical Center, New York, NY, Cardiovascular 
Research Foundation, New york, NY
Background: The detection of vulnerable coronary lesions that may be responsible for 
major coronary events and sudden death has paramount preventive importance. Unstable 
non-calcified, lipid reach plaques are believed to play a major role of these events, and 
the ability to accurately quantify the amount of plaque lipid in coronary lesions may be a 
potential measure for further risk stratification. We evaluated the safety and feasibility of a 
novel Intra-Vascular Magnetic Resonance Imaging (IVMRI) catheter.
Methods: In the multi-center TOPIMAGE registry, an IVMRI catheter (TopSpin, Lod, 
Israel) was used for intra-coronary evaluation of intermediate lesions (<50% stenosis) 
for which revascularization is not indicated. The Lipid Fraction Index (LFI) of each lesion 
was measured at up to 6 regions within the plaque. The LFI is the normalized MR signal 
(range 0-100), and correlates with the lipid content in the atherosclerotic plaque. Based 
on ex-vivo prior studies, an LFI ≥ 35 signifies a lipid-rich plaque.
Results: Total of 104 patients (mean 65yrs, 26% diabetes, 60% hypertension, 75% 
hyperlipidemia) with stable (82%) and unstable angina (18%) were enrolled. In 99 patients 
at least one valid LFI was obtained, with total of 459 successful LFI measurements. 94% 
of the patients tolerated at least 3 measurements with the occlusive stabilization balloon. 
At least 3 valid LFI measurements or one high lipid measurement were obtained in 91 
patients (88%). In 66% of the patients there was at least 1 measurement with LFI ≥ 35, 
signifying lipid-rich lesions. LFI measurements were not significantly affected by patient, 
lesion, and other standard clinical factors. Only one device related complication occurred 
- coronary dissection treated with PCI.
Conclusions: The use of the IVMRI catheter is feasible and safe. In 88% of patients, 
IVMRI was able to obtain valuable data for lesion characterization. IVMRI may provide 
valuable information on plaque lipid characteristics for lesion assessment. Additional 
studies are warranted and are underway.
2900-20 Lipid-Rich Plaque Adjacent to Stenosis in Coronary 
Autopsy Specimens: Implications for Selection of Stent 
Length
Thomas M. Meese, Jennifer B. Lisauskas, Cory Doucet, Nisse Clark, Craig M. Gardner, 
Edward L. Hull, Stephen T. Sum, Sean P. Madden, Jay D. Caplan, James E. Muller, James 
A. Goldsteain, InfraReDx, Inc, Burlington, MA, William Beaumont Hospital, Royal Oak, MI
Background: Selection of stent length is generally based on length of stenosis as 
determined by angiography. However angiography cannot identify lipid-rich plaque (LRP) 
which has limited re-endothelialization capacity and may contribute to late thrombosis at 
the edge of a stent. We studied the relationship between stenosis and LRP in autopsy 
specimens to determine if assessment of LRP by near-infrared (NIR) spectroscopy would 
be useful for selection of stent length.
Methods: Stenosis (by IVUS) and LRP (by histology at 2mm intervals) were measured 
in 124 coronary autopsy specimens from 51 donor hearts. The hearts were also scanned 
with a NIR catheter to identify LRP with a method suitable for clinical use.
Results: LRPs were found adjacent to 30 of 70 stenoses. The adjacent LRPs extended 
an average of 5.3 mm from the maximum stenosis (std dev = 3.1 mm). Many of the LRPs 
located at the stenotic site, also extended further in the vessel (see below).
Conclusions: LRP, which provides a poor substrate for re-endothelialization of a 
coronary stent, is frequently encountered 10 or more mm from the center of a stenotic 
lesion. Identification of LRP in patients, which is possible with a novel NIR system could 
help identify the length of stent needed to span both stenotic and lipid-rich regions.
Coronary sections following NIR scan (red map). Lipid rich plaque (blue and yellow) 
extends 8 mm beyond stenosis (diameter in yellow bars). LRP appears yellow on NIR 
map.
2900-21 Transcatheter Restriction of Left Ventricular Cavity in 
Piglets
Eleftherios B. Sideris, Savvas Toumanides, Demetrios Bramos, Basilios E. Sideris, 
Spyridon D. Moulopoulos, Athenian Institute of Pediatric Cardiology, Athens, Greece
Background: To offer an alternative to surgery in eliminating post-infarction left 
ventricular (LV) aneurysms in high risk patients. Transcatheter restriction of LV aneurysms 
could improve morbidity and mortality associating with surgery, maintaining the benefits 
of improved ejection fraction and wall tension.
Methods: The procedure was performed in 15 piglets, 12-16 kg, after ketamine 
anesthesia. A transcatheter patch/balloon device was introduced in the left ventricle, 
through a 12F sheath after sub-xiphoid apical needle puncture. The device consists of 
a balloon catheter, with a sleeve type polyurethane patch mounted on the balloon and a 
floppy disk attached on the tail of the patch. The patch was inflated in diameters of 15-20 
mm using normal saline and contrast; it was pulled to the apex of the LV, with the tail of 
the patch occluding the residual myocardial hole and the floppy disk immobilizing the 
patch on the epicardium. Fluoroscopy and echocardiography were used for the device 
placement and the animals were followed for periods of 4 days to 3 months, when they 
were euthanized and had autopsies.
A Hybrid (surgical - interventional) approach was used in 3 acute experiments; LAD 
coronary artery ligation was performed with device placement after 90 minutes.
Results: All devices were successfully placed, restricting the left ventricular apical 
region. There was no significant change on the EKG or the blood pressure during the 
procedure. There was no case of tambonade. On follow-up all animals, except for two 
who develop severe infection did well. In autopsy the LV apical region was restricted 
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although most balloons lost part of their initial volume.The residual balloon size was larger 
if it was inflated with whole blood. The patches were fully endothelialized within 2 weeks. 
They were free of thrombus. Echo planimetry demonstrated restriction of 25-30% of left 
ventricular volume. The device could be also placed with the Hybrid method and was 
effective in experimental aneurysms.
Conclusion: Percutaneous restriction of the left ventricular apical region is feasible, 
simple and relatively safe in piglets. The method could be applicable in high risk patients. 
Feasibility clinical studies are justified.
2900-22 The Frequency of Coronary Artery Compression and 
Management Using a Removable Mitral Annuloplasty 
Device in the Coronary Sinus
Steven L. Goldberg, Richard Van Bibber, Joachim Schofer, Adrian Ebner, Tomasz 
Siminiak, Uta C. Hoppe, Michael Haude, Jean-Paul R. Herrman, Stephen J. Duffy, David 
Reuter, David M. Kaye, Cardiac Dimensions, Inc, Kirkland, WA
Background:The close relationship between the coronary sinus and the posterior mitral 
annulus has been used as a possible avenue for reducing mitral annular dimensions 
to treat functional mitral regurgitation (MR). One concern of this approach has been 
the potential for compromising the circumflex coronary artery which also runs in the 
atrioventricular groove.
Methods:Preliminary data from pts in the AMADEUS, PERSEUS and VERITAS safety 
and feasibility trials of the CarillonTM Mitral Contour SystemTM (CMCS) were evaluated 
for coronary artery compromise (CAComp), defined as impingement of a > 2mm diameter 
coronary artery to >50% narrowing, and/or a reduction in TIMI flow. The CMCS is placed in 
the coronary vein and tension applied to cinch the mitral annulus. Coronary arteriography 
is then performed to assess for CAComp while echo assessment for MR is being done. If 
improvement in MR is seen and there is no CAComp, the device is released. If CAComp is 
present the device can be recaptured. Coronary arteriograms were reviewed for evidence 
of coronary artery crossing and for CAComp. Post-procedure ECG’s were obtained, and 
in a subset of patients, cardiac enzymes (CK’s) were drawn. Patients were followed for 
subsequent myocardial infarctions.
Results: 63 pts underwent attempted implantation of the CMCS. Angiographic evidence 
for coronary artery crossing by the CMCS was seen in 52 (83%). However, CAComp was 
only seen 15 pts (24%), which successfully resolved with removal of the device. In 5 of 
these pts a second device was successfully placed more proximally without CAComp. In 
15% of pts CAComp limited utility of the CMCD. No pt developed Q-wave MI’s, either at 
time of implant or with follow-up. 45 pts had CK or CK MB drawn. Only 2 had CK >3 X 
ULN, both with occlusions of <1 mm branches - (one a distal branch of the right coronary 
artery, and one an AV groove branch of the circ), not considered to be important vessels 
by the operators at the time of implant.
Conclusions: Although a coronary sinus based annular remodeling device will 
frequently cross a coronary artery, coronary artery compromise is infrequent. Using a 
removable device allows for successful management of coronary artery compromises 
which may ensue.
2900-23 Intracoronary Red Light Irradiation for the Treatment of 
High-risk Non-culprit Atheromatic Plaques
Konstantinos Toutouzas, Nicholas Kipshidze, Maria Drakopoulou, Virginia Markou, 
John Karabelas, Christodoulos Stefanadis, 1st Department of Cardiology, University of 
Athens, Athens, Greece, Lenox Hill Hospital, New York, NY
Background: Intraluminal low-power red laser light (LPRLL) irradiation has been 
successfully applied to prevent restenosis after percutaneous coronary intervention. 
Recent studies have shown that LPRLL besides its antiproliferative effect induces 
reendothelialization by promoting nitric oxide production. Our study aimed to evaluate 
coronary thermography after LPRLL irradiation of high risk plaques.
Methods: Eleven patients with more than two angiographically significant lesions at 
different vessels were enrolled. Culprit lesions (CL) were identified by a combination 
of ECG, wall motion abnormalities, scintigraphic perfusion defects, and/or coronary 
angiogram. In non-CL (50-75% stenosis) coronary thermography was performed by a 
dedicated thermography catheter (Epiphany, Medispes S.W., ZUG, Switzerland) and 
temperature difference (ΔΤ) between the atherosclerotic plaque and the proximal vessel 
wall was assessed. If ΔΤ was >0.05OC irradiation with LPRLL was transmitted from a 
diode laser (650 nm) at an energy level of 10 mW. At the end of LPRLL irradiation repeat 
temperature measurement was performed.
Results: The average stenosis of the non-CL was 67±12%. Temperature measurement in 
the non-CL and application of LPRLL irradiation was performed without any complication. 
The mean ΔT at baseline was 0.09±0.08oC. Immediatelly after LPRLL irradiation ΔT was 
reduced to 0.05±0.04oC (p<0.02). No major adverse cardiac events at 30 days were 
reported. Further clinical, angiographic, IVUS and thermographic follow-up will soon be 
available.
Conclusions: A promising first application of LPRLL for the treatment of high risk 
plaques, as recognized by coronary thermography is demonstrated in this study. Further 
studies are required to evaluate this method for the treatment of high risk plaques.
2900-24 Ambulatory Radial Coronary Angioplasty: Is It a 
Feasible Approach?
Humberto Dighero, Angel Puentes, Flavio Zepeda, Hernan Donoso, Augusto Bellet, 
Pablo Sepulveda, Bruno Dighero, Carlos Wolff, Hospital San Juan De Dios, Santiago, 
Chile, Universidad de Chile, Santiago, Chile
Background: The transradial access in the procedures of percutaneous coronary 
revascularization has arisen like an alternative to the femoral route with low risk of local 
and general complications. The possibility of realizing this procedure in ambulatory form 
in stable patients and not having an acute infarct, could be an reasonable alternative in 
our patients population.
Method. From January 2005 to March 2006, 326 percutaneous coronary angioplasty 
were done, 241 by femoral route, 85 by radial route. There were 11 failures . Of the radial 
percutaneous coronary angioplasty, 77 were controlled, of which 38 were ambulatory with 
discharged after 2 hours of observation (G1) and 39 hospitalized (G2). By femoral route 
always hospitalized, 147 were controlled (G3) . Different variables for each group were 
analyzed. The statistic analysis was realized using nonparametric test, t student and tests 
Mann exact Whitney and of Fisher.
Results: Myocardial Infarct was the most frequent diagnosis (p < 0,05) in the G3 group 
and stable chronic angina in the group G1. Time of procedure (minutes): G3 = 78.6 versus 
G2 = 144.9 (p< 0,01), G3 = 78,6 versus G1 = 97.1 (p < 0,05) and G2 = 144.9 versus 
G1 = 97,1 (p< 0,01). The amount of contrast media was G3 < G1 (p < 0,01), G1 < G2 
(p< 0,01), G3 < G2 (p< 0,01). There were not significant differences in relation to the 
number of utilized catheters, angioplastied vessel and type of lesion. Neither differences 
were seen analyzing majors complications: Death, acute coronary Syndrome, Stroke and 
Transient Ischemic Attack. We did not find also differences in complications related to 
the punction site.
Conclusions. Ambulatory radial coronary angioplasty is a feasible procedure, with low rate 
of local complications and similar majors complications compared with the hospitalized 
radial coronary angioplasty and hospitalized femoral coronary angioplasty.
2900-25 Release of Bio-markers of Myocardial Damage After 
Direct Intramyocardial Injection of Gene and Stem Cells 
via the Percutaneous Transluminal Route
Federica Baldazzi, Erik Jorgensen, Jens Kastrup, Cardiac Catheterization Laboratory 
Department of Cardiology, University Hospital Rigshospitalet, Copenhagen, Denmark
Background: We aimed to quantify the release of cardiac markers of myocardial 
damage in relation to direct intramyocardial injections of genes and stem cells in patients 
with severe coronary artery disease.
Methods: We studied 71 patients with “no-option” coronary artery disease. Patients had, 
via the percutaneous transluminal route, a total of 11±1 (mean ± SD) intramyocardial 
injections of vascular endothelial growth factor genes (n=56) or mesenchymal stromal 
cells (n=15). Injections were guided to an ischemic area by electromechanical mapping, 
using the NOGA™/Myostar™ catheter system. ECG was monitored continuously until 
discharge.
Results: Plasma CKMB (upper normal laboratory limit=5 Μg/l) was 2.5Μg/l ±1.3 at 
baseline; increased to 9.2 ±8.9 after 8 hours (p < 0.0001) and then normalized to 4.8 ±3.5 
after 24 hours. TNT (upper normal limit=0.1 Μg/l) was 0.01 Μg/l ±0.004 at baseline; 0.13 
±0.09 after 8 hours (p< 0.0001); and 0.06 ±0.05 after 24 hours (p< 0.0001). A total of 8 
patients (17%), receiving a volume of 0.3 ml per injection, had CKMB rises exceeding 
3 times the upper limit, whereas no patient in the group receiving 0.2 ml had a more 
than two fold CKMB increase. No patient developed new ECG changes. There were no 
clinically important ventricular arrhythmias and no death. There was no relation between 
procedure time and enzyme release.
Conclusions: Direct Intramyocardial injections of stem cells or genes lead to 
measurable release of cardiac markers of myocardial damage, which is related to the 
injected volume.
2900-26 Percutaneous Coronary Intervention Utilizing a New 
Endothelial Progenitor Cells Antibody-coated Stent: 
a Prospective Single-center Registry in High Risk 
Patients. 
Giuseppe Patti, Marco Miglionico, Annunziata Nusca, Andrea D’Ambrosio, Germano 
Di Sciascio, Department of Cardiovascular Sciences, Campus Bio-Medico University, 
Rome, Italy
Background. Genous R-stentTM is a stainless steel coronary stent covered with 
antibodies specific to circulating endothelial progenitor cells (EPCs) surface antigens, 
designed to promote formation of a confluent functional endothelial layer over the device; 
conceivably this may prevent both stent thrombosis and restenosis. Aim of this study was 
to prospectively evaluate outcome with EPC capture stent implantation in a cohort of 
consecutive patients with high risk angiographic and/or clinical features.
Methods. From November 2005 to March 2007, 80 patients received 93 EPC capture 
stents at Campus Bio-Medico University of Rome. Patients had >2 of the following high 
risk features: diabetes mellitus (33%), unstable coronary syndromes (73%), left ventricular 
dysfunction (8%), multivessel intervention (9%), B2/C lesions (56%).
Results. Procedural success was achieved in 79/80 patients (98%); no post-procedural 
Q-wave myocardial infarction (MI), in-hospital death or emergency bypass surgery 
occurred; no patient had acute or subacute stent thrombosis. Follow-up was available in 
78 patients (mean 14±4 months): non cardiac death occurred in 1 patient, acute MI in 1 
patient; no patient required by-pass surgery; 10 patients (13%) underwent percutaneous 
target lesion revascularization (TLR); 3 patients (4%) had re-intervention on a non-target 
vessel. Kaplan-Meyer life-table analysis showed an event-free survival of 86% and a TLR-
free survival of 90%.
Conclusions. The cell capture stent is safe and effective, with satisfactory immediate 
results and mid-term outcome, without stent thrombosis. Whether those devices would 
represent a viable alternative to currently available drug-eluting or bare metal stents will 
need to be evaluated in larger randomized studies. 
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2900-27 Angiographic and Ultrasonographic Comparison 
of Sirolimus and Novolimus-Eluting Etents for the 
Treatment of Coronary Lesions: “Past and Future Head-
to-Head”
Julio Maia, Alexandre Abizaid, J Ribamar Costa, Jr., Daniel Chamié, Fausto Feres, Luiz 
Alberto P. Mattos, Rodolfo Staico, Ricardo Costa, Andrea Abizaid, Ana Cristina Seixas, 
Amanda G.M.R. Sousa, J Eduardo Sousa, Instituto Dante Pazzanese de Cardiologia, 
Sao Paulo, Brazil
Background: Despite the marked efficacy of 1st generation DES in reducing neointimal 
(NIH) formation, concerns regarding their long-term safety have been raised. Reduction 
in the dose of the anti-proliferative drug might represent an alternative to improve safety 
profile of DES. The Novolimus-eluting stent (NES) combines a stainless steel platform 
with a methacrylate polymer eluting a Sirolimus-analogue anti-proliferative drug, the 
Novolimus. As potential advantages, it carries less drug than the Cypher (84Μg of 
Novolimus vs. 140 Μg of Sirolimus) requiring less amount of polymer. We aimed to 
compare the midterm efficacy of this device to the Cypher (SES) stent.
Methods: A total of 15 pts were consecutively treated with NES and compared to our 15-
pts historical first-in-men cohort treated with SES. Only single, de novo, < 15mm lesions 
in native coronaries of 2.7 to 3.5 mm in diameter were included. The primary goal was 
the comparison of lumen loss by QCA and % of obstruction by IVUS at 4-month follow-
up (FU).
Results: Baseline clinical and angiographic characteristics were similar between the 
groups. Overall mean age was 60.8 years with 47% of diabetics. QCA and IVUS data 
are shown in the table
Conclusion: This preliminary analysis demonstrates the equivalence between the two 
DES systems in reducing NIH. The decrease in the dose of the anti-proliferative drug in 
the NES did not seem to impact the efficacy of this device. Long-term FU in larger and 
more complex cohorts of pts is necessary to confirm its safety profile. 
NES SES p
Reference Vessel Diameter, mm 3.01 ± 0.4 2.98 ± 0.4 0.85
Lesion length, mm 11.6 ± 2.5 12.9 ± 1.9 0.13
In-stent Late loss, mm 0.17 ± 0.12 0.09 ± 0.3 0.34
Binary restenosis, n (%) 0 (0%) 0 (0%) NA
IVUS NIH volume, mm3 5.0 ± 3.1 3.0 ± 4.8 0.18
IVUS % obstruction 3.9 ± 2.8 2.5 ± 3.6 0.26
2900-28 The efficacy of bilateral approach for the lesions with 
chronic total occlusion in acute results and follow up-
CARTTM Registry-
Masashi Kimura, Osamu Kato, Kenya Nasu, Yoshihisa Kinoshita, Mariko Ehara, 
Mitsuyasu Terashima, Etsuo Tsuchikane, Tetsuo Matsubara, Yasushi Asakura, Takahiko 
Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Background: A successful percutaneous recanalization of chronic coronary occlusions 
(CTO) results in improved survival, as well as enhanced left ventricular function, reduction 
in angina, and improved exercise tolerance. Successful recanalization of chronic total 
occlusions in native coronary arteries is no doubt one of the most technically challenging 
of lesion subsets. The aim of this study was to evaluate safety and feasibility of a new 
concept for CTO recanalization using bilateral approach including a Controlled Antegrade 
and Retrograde subintimal Tracking technique (CART technique).
Methods: A total of 170 consecutive patients (mean age 65 ± 13 years; 80.7 % males) 
who were enrolled in this prospective multicenter registry. This technique combines the 
simultaneous use of the antegrade and retrograde approaches. A subintimal dissection 
is created antegradely and retrogradely, which limit the extension of the subintimal 
dissection within the CTO portion.
Results: The CTO lesions (>1 month) were attempted for CTO recanalization using CART 
technique. Of 170 cases, 121 cases (71%) had previous attempts of CTO recanalization. 
History of prior myocardial infarction was present in 78 % of the patients. The CTO lesions 
were most frequently located in RCA (69.7 %) followed by LAD (25.5 %), LCX (3.4 %) 
and SVG (1.4 %). The success rate of retrograde wire cross and balloon cross were 89% 
(152/170) and 82% (140/170), respectively. Successful recanalization was achieved in 
93% (158/170) of the patients and procedure success rate was 91% (155/170).
Conclusion: Bilateral approach for CTO lesions using CART technique is feasible, safe, 
and has a higher success rate than previous approach. These results indicate that this 
technique can solve a major problem of CTO procedures.
2900-29 New Stress Echo Insight in Syndrome X: Left 
Ventricular Contractility and Coronary Flow Reserve 
Mismatch
Fausto Rigo, Giovanni Ossena, Valeria Cutaia, Margherita Richieri, Zanella Carlo, 
Enrico Favaretto, Antonio, Raviele, Italy
Background: Repolarization abnormalities in microvascular angina are not completely 
explained. Clinical findings demonstrate that these patients show conserved left 
ventricular contractility while coronary flow reserve and left ventricular contractility may 
be heterogeneous.
Methods: Since 2003 we have enrolled 187 pts, mean age 59±10y., with positive 
exercise test and normal coronary arteries at angiography, and matched them with 35 
homogeneous normal subjects with negative exercise test. Each of them underwent 
pharmacological stress-test with dipyridamole (0,84 mg/kg over 6 min), evaluating left 
ventricular contractility (systolic blood pressure / end systolic left ventricular normalized 
volume) and coronary flow reserve on left anterior descending coronary artery (CFR-
LAD) obtainable by transthoracic approach. In order to verify the relationship between the 
left ventricular contractility (LVC) and CFR we tested a new index derived from the ratio of 
both parameters and labelled it contractility-perfusion index (CPI).
Results: Syndrome X patients showed similar values in terms of resting LV contractility 
(Suga = 6,0 ± 1,6 vs 5,8 ± 1,3, p = ns) and lower values of CFR (2,5 ± 0,5 vs 3,2 ± 0,4, p 
< 0,001). Peak CPI had a lower mean value in the normal group (2,0 ± 0,5) vs Syndrome X 
patients (3,9 ± 1.4) (P<0,001). By matching CPI with ST displacement (mm) at ECG in all the 
study population a linear relationship was evidenced (r2=0.32); by applying a ROC analysys 
CPI resulted highly predictive in terms of ST segment displacement in these patients.
Conclusions: Patients with normal coronary arteries and positive exercise test showed 
normal resting LV contractility, quite similar to normal subjects, but lower values in terms 
of coronary flow reserve and higher CPI, therefore by matching these two parameters we 
can obtain a new index capable of predicting the presence repolarization abnormalities 
in these subjects.
2900-30 Differences in Intraventricular Pressure Can Account 
for the Variation in the Flow Velocity Profile Between 
the Left and Right Coronary Arteries
Nearchos Hadjiloizou, Justin E. Davies, Darrel P. Francis, Arun J. Baksi, Iqbal Malik, 
Rodney Foale, Kim Parker, Alun Hughes, Jamil Mayet, International Center for 
Circulatory Health, Imperial College and St Mary’s Hospital, London, United Kingdom
Background: Despite having similar origins and perfusion pressures, flow velocity 
waveforms in the left
main stem (LMS) and right coronary artery (RCA) are different. We speculate pressure 
differences originating from
the distal (intramyocardial) bed account for this. We apply Wave Intensity to identify 
proximal- and distaloriginating
pressures, to explore the differences in these velocity waveforms.
Methods: In 20 subjects with unobstructed coronary arteries, sensor-tipped intra-arterial 
wires were used to measure
simultaneous pressure and Doppler velocity in the LMS and proximal RCA. Wave Intensity 
was applied to derive
proximal- and distal-originating waves and were examined with respect to structural and 
anatomical properties.
Results: Diastolic-systolic ratio of peak velocity was less in the RCA than LMS (1.0±0.3 
versus 1.8±0.6, p<0.001).
The cause was lower diastolic velocity in RCA (36.4±17.0cm/s) than LMS (55.0±35.1cm/s), 
explicable by the lower
distal-originating suction wave (5.9±1.5 x103Wm-2s-1versus 13.2±5.9x103Wm-2s-1, 
p<0.02). Ventricular pressure
correlated with the suction wave in the LMS (r=0.6, p<0.01 for LV pressure) and RCA 
(r=0.7, p<0.05 for RV
pressure) but not with diameter, length or number of branches in these arteries.
Conclusion: Lower diastolic velocities account for the different velocity waveform in the 
proximal RCA and the
LMS. This is due to a smaller distal-originating suction wave which is explained by lower 
pressure in the right than
the left ventricle.
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2900-31 Optical Coherence Tomography (OCT) Guided Coronary 
Interventions
Francesco Prati, Maria Cera, Vito Ramazzotti, Fabrizio Imola, Rocco Giudice, 
Alessandro Manzoli, Mario Albertucci, San Giovanni Hospital, Rome, Italy
Background:Intravascular ultrasound (IVUS) proved to be able to guide coronary 
intervention. Optical coherence tomography (OCT) is a novel high resolution imaging 
technique that has the potential to improve the results of IVUS but requires a complicated 
images acquisition process.
Aim of the study was to evaluate a simplified non-occlusive technique of OCT acquisition 
(based on manual injection of Iodoxanolo 370) in guiding complex coronary intervention.
Methods: OCT with M2 Light Lab system was attempted in 70 patients (43 ACS and 
27 stable angina). A questionable quantitative coronary angiography (QCA) result was 
the reason for the study in 15 patients: (8 cases with intermediate stenosis and 7 with 
haziness) while in 5 patients had OCT to guide reintervention for DES restenosis. The 
remaining 50 patients had OCT guided interventions for significant >50% stenoses at 
QCA. In 15 cases OCT was repeated after stenting. Successful OCT images acquisition 
process was defined as images of sufficient quality as to measure vessel lumen and 
characterize the details of the plaque at target lesion and reference segment.
Results: OCT evaluation was successful in 65 (93%) of the patients. In 4/8 patients 
with intermediate lesions OCT avoided an interventional procedure by showing a non 
significant lesion (minimal lumen area >4 mm²). In 6/7 cases with haziness OCT revealed 
complicated plaques with thrombosis and were treated with PCI. In the remaining 
case a calcified non significant plaque was present. In all 5 cases with in-stent DES 
restenosis OCT quantified accurately the amount of neointimal tissue, detected stent 
underxpansion (in two cases) and, in presence of overlapping stent, measured the length 
of struts overlapping. After stenting implantation OCT revealed incomplete apposition 
and/or dissection in the adjacent segments in 26.6% (4/15) and in 20% (3/15) of the 
patients respectively. Overall OCT led to addional balloon dilatation and/or further stent 
implantation in 4 patients.
Conclusions: OCT proved to be capable of guiding complex interventional procedures, 
detailing vessel anatomy, and adequacy of stent implantation.
2900-32 Safety and Feasibility of a Nonocclusive Technique 
for Facilitated Intracoronary Optical Coherence 
Tomography (OCT) Images Acquisition
Francesco Prati, Maria Cera, Vito Ramazzotti, Fabrizio Imola, Rocco Giudice, 
Alessandro Manzoli, Mario Albertucci, Cath Lab San Giovanni Hospital, Rome, Italy
Background: To facilitate OCT images acquisition we have developed a novel simplified 
non occlusive technique based on hand-made infusion of a viscous iso-osmolar solution.
Aim of this study was to address the safety and efficacy of the non-occlusive OCT images 
acquisition modality in a patient population with complex coronary lesions, and in various 
clinical scenarios. 
Methods: OCT assessment was performed with the M2 Light Lab OCT image-wire in 64 
patients. The imaging acquisition technique was aimed at target lesion and proximal and 
distal reference segments. OCT images were deemed of good quality if they allowed both 
an accurate measurement of luminal area and a qualitative definition of the superficial 
plaque components.
Results: In 60 patients (93.75%) the procedure was successful. The mean images 
acquisition time was 5.3±1.4 min. No major complications and/or major arrhythmias were 
recorded. The average length of imaged segments was 28.62±6.08 mm. Of the13671 
OCT cross-section analyzed, 95.1% were deemed of sufficient quality to evaluate luminal 
area and plaque morphology (intra-observer variability 0.68, inter-observer variability 
0.71, p<0.01 for both).
Conclusions: The non-occlusive modality of OCT images acquisition is safe and 
effective, and allows expeditious measurement of the vessel lumen and characterization 
of the details of the atherosclerotic plaque at the target lesions and reference segments.
2900-33 Prearrhythmic Reduced Contractility in Patients With 
Ventricular Ectopy
Peter Soegaard, Thomas Fritz Hansen, Christian Jons, Arne Hagemann, Poul Erik 
Bloch Thomsen, Gentofte University Hospital, Copenhagen, Denmark
Background: We previously demonstrated local voltage potentials signifying conduction 
impairment in the sinus beats preceding ventricular premature beats (VPBs) and 
ventricular tachycardia (VT) in patients undergoing radiofrequency ablation. Using 
Tissue Doppler-Echocardiography (TDI) we investigated whether the impairment of the 
conductivity could lead to changes in the contractile performance of the sinus beats 
preceding ventricular arrhythmias.
Methods: Apical four chamber view with a frame rate above 160 Hz (GE VIVID VII). 
Patients. Twenty-two consecutive patients with VPBs/VT were examined. Half of the 
patients had no structural heart disease, 2 patients suffered from arrhythmogenic right 
ventricular dysplasia, 3 patients had ischemic heart disease, one patient aortic stenosis, 
and 5 patients had dilated cardiomyopathy. In 2 of those patients the cardiomyopathy was 
most likely caused by very frequent PVBs (30-50%/24h). 11 of the patients underwent 
radiofrequency ablation of the VPBs.
Results: By means of TDI, we demonstrated a highly statistically significant decrease in 
contractility, i.e. end-systolic displacement in the last sinus beat before the VPB compared 
to earlier sinus beats (8.54 mm versus 4.89 mm, p< 0.001). Furthermore, the time to peak 
end-systolic contraction of the last sinus beat was shortened significantly indicating pre-
activation of the interventricular septum resulting in pre-contraction compelling with the 
normal anterograde contraction of the sinus beat preceding the ventricular arrhythmias.
Conclusions: Ventricular ectopy is preceded by a significant decrease in contractility in 
the last sinus beat preceding VPBs. This new phenomonon was observed in consecutive 
patients with a broad variety of heart diseases and may contribute to the development of 
dilated cardiomyopathy in patients with frequent VPBs.
2900-34 Echocardiographic Analysis of Ventricular Torsion: A 
Novel Method for Detection of Developing Adhesions in 
Constrictive Pericarditis
Mohsen S. Alharthi, Panupong Jiamsripong, Anna Corazon Calleja, Partho P. Sengupta, 
Bijoy Khandheria, Aj Tajik, Marek Belohlavek, MAYO CLINIC, SCOTTSDALE, AZ
Background: Diagnosis of early stages of constrictive pericarditis (CP) is challenging. 
Torsion of the left ventricle (LV), ie, relative counterdirectional rotation angle between 
apical and basal LV segments, is essential for normal LV systolic and diastolic function. 
We hypothesized that torsion assessed by echocardiography is altered by developing 
pericardial-epicardial adhesions. The aim was to design an animal model of pericardial-
epicardial adhesions and study their impact on peak LV torsion and hemodynamics.
Methods: In 9 open-chest anesthetized adult pigs, the heart was exposed while 
preserving pericardium. We simulated adhesions by placing 8 to 12 Prolene stitches 
connecting pericardium with epicardium along the LV circumference at the apical-mid 
level, while sparing vascular areas. Then, an instantaneous tissue glue was instilled 
to the intrapericardial apical space. Using Velocity Vector Imaging, apical and basal 
LV rotation within subendocardium and subepicardium was recorded along with other 
echocardiographic and hemodynamic data at baseline and following the intervention. The 
data were expressed as mean ± SD and compared by a paired t-test at the P< 0.05 
significance level.
Results: See table. Systolic (SBP) and diastolic (DBP) blood pressures suggested 
only a trend toward SBP decrease but no significant changes in basal hemodynamics. 
However, stroke volume (SV), cardiac output (CO), ejection fraction (EF), and A-wave 
of LV filling flow (but not E-wave) as well as subendocardial (END) and subepicardial 
(EPI) LV torsion (Tor) decreased significantly suggesting the effect of “adhesions” on LV 
mechanical function.
Conclusion: Our experimental study suggests that the assessment of LV torsion velocities 
is a sensitive parameter specifically indicating alterations in LV apical-basal rotational 
mechanics in the presence of epicardial adhesions. Clinical tests of an early diagnostic 
utility of this approach are warranted. 
Variables Baseline Intervention P-value
SBP 112.7±10.4 mmHg 98.6±22.5 mmHg 0.06
DBP 79.1±7.8 mmHg 69±21.8 mmHg 0.14
SV 35.1±10 mL 17.3±4.6 mL <0.0001
CO 2.8±0.9 L/min 1.6±0.6 L/min 0.0002
EF 56.6±2.6% 40±6.1% <0.0001
E-wave 0.5±0.16 cm/s 0.4±0.04 cm/s 0.18
A-wave 0.52±0.1 cm/s 0.4±0.15 cm/s 0.04
Tor.END 8.6±2.2 degree 5.3±1.8 degree 0.0003
Tor.EPI 3.7±2.1 degree 2.4± 1.3 degree 0.0130
2900-35 A Model of Calcific Aortic Valve Stenosis: A Hybrid 
Model of Pig Aortic Root and Cadaver Heart Calcified 
Aortic Cusps
Francesco Maisano, Giuseppe Sangiorgi, Andrea Giacomini, Andrea Guidotti, Andrea 
Blasio, Ottavio Alfieri, Renu Virmani, San Raffaele Scientific Institute, MIlano, Italy, 
CVPath, International Registry of Pathology, Washington, DC
Background: New technologies are available to treat calcific aortic stenosis. We 
describe a model of a calcified and stenotic aortic valve to test novel devices to treat 
calcific aortic stenosis.
Methods: Ten aortic roots were harvested from slaughtered pig hearts, and dissected 
free from ventricular septum and mitral valve. The ascending aorta was transected 1 cm 
above the sino-tubular junction. 30 non damaged calcified cusps were obtained from 
10 human cadaver hearts of individuals with aortic stenosis. The calcified cusps were 
attached on the aortic surface of the pig leaflets using cyanoacrylate glue. The sino-
tubular junction was stabilized with a plastic O-ring. The roots were inserted in a bench 
model of left heart. Transvalvar pressure gradients (variable flows from 0 to 10 L/min) 
were obtained at baseline and following balloon dilatation.Results:
Mean annular diameter at baseline was was 23±2.9 mm. Following the application of 
calcified human leaflets, variable pressure gradients were obtained according to the 
degree of calcification of the cadaver heart cusps. Gradients were halved following 
balloon dilatation (fig 1).
Conclusions: The model reproduces the anatomy and function of the stenotic, calcified, 
aortic valve. The behaviour of the simulated valves was similar to what observed in 
naturally occurring aortic stenosis, both at baseline and following balloon dilatation. This 
model can be used to test new devices for the treatment of aortic stenosis both in bench 
and animal tests.
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2900-36 EXCELLA First-in-Man Study: Safety and Efficacy of 
Novolimus-Eluting Stent in De Novo Coronary Lesions
Alexandre Abizaid, Dimytri Siqueira, Jose de Ribamar Costa, Jr., Fausto Feres, Luis 
Fernando Tanajura, Peter Fitzgerald, Luiz Alberto Mattos, Rodolfo Staico, Andrea 
Abizaid, Amanda Sousa, J Eduardo Sousa, Instituto Dante Pazzanese de Cardiologia, 
São Paulo, Brazil
Background: First generation drug-eluting stents (DES) have markedly reduced 
restenosis. However, there is a major interest in developing new DES with greater flexibility, 
radiopacity and safety profile. The Elixir Medical Drug Eluting Stent is a novel DES that 
combines a chromium-cobalt platform with Novolimus (an antiproliferative Sirolimus-
analogue drug) and a polymer from methacrylate family. As potential advantages, it 
provides a lower drug dose as compared to Cypher® (85Μg of Novolimus vs. 140 Μg of 
Sirolimus) and has a lower polymer load. We sought to evaluate the safety and efficacy of 
this novel device in reducing neointimal hyperplasia as assessed by QCA and IVUS.
Methods: In April 2007 a consecutive cohort of patients with de novo lesions <14 mm 
in length, located in native coronaries of diameter from 3.0 to 3.5mm were consecutively 
enrolled in this First-In-Man study. By protocol, angiography and IVUS should be done 
at baseline and repeated at 4 and 9 months. Dual antiplatelet therapy was maintained 
for 6 months. Primary endpoint was QCA lumen loss at 4-month follow-up. Secondary 
endpoints included MACE, in-stent neointimal obstruction by IVUS and device success.
Results: A total of 15 patients were included with 67% female patients and diabetes 
was detected in 47% of the cohort. Angiographic and procedural success was achieved 
in all patients. At 4-month angiographic follow-up there was minimum in-stent late lumen 
loss (0.15±0.42 mm) by QCA and % volume obstruction (2.7 ± 2.7) by IVUS. Vascular 
positive remodeling and late ISA were not observed among these patients. No MACE 
was evidenced through six month follow-up. Nine month QCA and IVUS results will be 
presented at the meeting. 
Conclusions: In this first-in-man study, implantation of the Novolimus-eluting stent was 
proven to be feasible, safe and elicited minimum neointimal proliferation. Additional large 
clinical trials are required to confirm these promising results. 
2900-37 Six-Month Follow-up in the CARE Feasibility Study: 
Small Vessel Stenting in a High-Risk Population
Robert Whitbourn, Alexandre C. Abizaid, Jose R. Costa, Fausto Feres, Ricardo 
Costa, J Eduardo Sousa, Masao Yamasaki, Yasuhiro Honda, Peter J. Fitzgerald, The 
Cardiovascular Research Centre, St. Vincent’s Hospital, Melbourne, Australia, Instituto 
Dante Pazzanese de Cardiologia, São Paolo, Brazil
Background: Small target vessel size and diabetes are predictors for restenosis with 
current bare metal DES stents not designed for small vessel applications. The CARE I 
clinical study examined the feasibility and the use of nitinol stents with ultra-thin struts 
in the small coronary vasculature, using the Sparrow Coronary Stent Delivery System 
(CardioMind, Inc. Sunnyvale, CA), an 0.014” guidewire based delivery system.
Methods: CARE I was a prospective, feasibility clinical study designed to demonstrate 
the safety and performance of the CardioMind Coronary Stent in the treatment of single 
de novo native coronary artery lesions <= 14 mm long and 1.8 - 2.6 mm in reference 
diameter. The primary endpoint was 30 day MACE with angiographic and IVUS follow 
up at 6 and 12 months. The study enrolled 22 patients at 2 clinical sites in Australia and 
Brazil.
Results: 50% (11/22) of the patients were diabetic with the mean age at 61.9 ± 10.9 
yr . The mean RVD was 2.20 ± 0.20 mm with a mean lesion length of 10.86 ± 3.19 
mm, and 75% of the lesions were Type B2& C lesions. Procedural success was 100% 
with successful deployment of the CardioMind stent in 21/22 patients. Post-procedure % 
diameter stenosis was 15.78% ± 7.07% with an acute gain of 1.29± .27 mm. At 6 months, 
MACE was 0% (0/21) with in-stent % diameter stenosis of 38.12± 26.77%; in-stent LLL of 
0.73 ± 0.5 7 mm, and in-segment LLL of 0.61 ± 0.51 mm. Angiographic binary restenosis 
was 20% (4/20). Although a % NIV of 33.7± 8.9% was observed, this was offset by an 
increase in stent volume index of 13% and a corresponding decrease in the peri-stent 
plaque volume by 11%. The increased lumen area may be due in part to the outward 
self-expanding characteristics of the nitinol stent offsetting lumen loss due to neointima 
hyperplasia.
Conclusions: Treatment in small vessels with an ultra-thin strut, self expanding stent 
show promise in leading to an improved outcome due to an reduction in lumen loss 
when compared to current balloon expandable bare metal stents. Preliminary results 
demonstrate the feasibility and potential advantages of a self-expanding nitinol stent in 
a guidewire based delivery system specifically designed for navigation in this high risk 
patient population.
2900-38 Three-Dimensional Analysis of the Left Anterior 
Descending Coronary Artery: Comparison With 
Conventional Coronary Angiograms
Demosthenes G. Katritsis, Ioannis Pantos, Efthalia Tzanalaridou, Socrates Korovesis, 
George Paxinos, Efstathios P. Efstathopoulos, Athens Euroclinic, Athens, Greece
Background: Three-dimensional (3-D) reconstruction of conventional 2-D coronary 
angiograms is a novel and promising diagnostic modality. However, no study has 
compared three-dimensional (3-D) reconstruction with two-dimensional (2-D) coronary 
angiograms in respect to anatomic parameters that might affect plaque formation and 
rapture.
Methods: Sixty patients with stable left anterior descending (LAD) lesions and 60 
patients with an anteroseptal myocardial infarction and recanalized LAD were studied.
Results: Conventional angiography significantly underestimated the distance of the 
stenosis from the ostium of the LAD, 29.4 ± 14.5 vs 35.3 ± 18.5 mm, p<0.001, and the 
vessel curvature at the site of the lesion, compared to 3-D reconstruction, 147.6 ± 30.6 
vs 162.3 ± 11.2 degrees, p<0.001. Axial bending of the LAD due to ventricular contraction 
was underestimated by 2-D angiography (8.9 ± 8.9 vs 17.8 ± 7.78, p<0.001). There 
was no agreement between 2-D and 3-D analysis for either curvature on lesion or axial 
bending assessment, with intra-class correlation coefficient values 0.155 (-0.009, 0.315) 
and -0.022 (-0.183, 0.174), respectively. No significant agreement was found between the 
two methods in the detection of on-stenosis bifurcations (1.7%, κ = 0.086, p =0.349).
Conclusions: Conventional coronary angiography cannot provide accurate estimates 
of anatomic parameters such as distance of a coronary stenosis from the ostium of the 
vessel, coronary artery curvature at the site of stenosis, axial deformity and bending 
due to ventricular contraction, and classification of bifurcations. Reconstruction of the 
coronary tree in 3-D space is necessary for such estimations.
2900-39 Prospective Randomized Trial of Direct Endomyocardial 
Implantation of Bone Marrow Cells for Therapeutic 
Repair of Myocardial Damage After Acute Myocardial 
Infarction in a Canine Model
Sudip Datta, Peter Zeman, Katie Lekx, Rupinder Mann, Caroline N. Culshaw, Peter 
Merrifield, Yves Bureau, Glenn Wells, Jane Sykes, Frank Prato, Gerald Wisenberg, 
University of Western Ontario, London, ON, Canada
Background: The evaluation of stem cell therapy on infarct size reduction is difficult 
because of the natural history of scar shrinkage in the weeks after acute coronary 
occlusion. Monitoring of regional left ventricular function assesses only a surrogate 
endpoint of cell transplantation. Gadolinium-enhanced magnetic resonance imaging is a 
histologically-validated means of establishing the extent of permanent myocardial injury. 
Methods: This study was undertaken to track the rate and degree of infarct shrinkage 
following the transplantation of marrow-derived bone marrow monocytes (BMMC’s), 
and stromal cells into an acute canine myocardial infarction. Dogs underwent an LAD 
occlusion, followed by 3 hours of reperfusion. The five control animals received a sham 
injection of saline into the infarct region, whereas 4 dogs received Indium-111 tropolone 
labeled BMMC’s and 4 animals Indium labeled stromal cells, injected into the infarct 
region. Gd-enhanced infarct imaging with cine MRI to assess regional left ventricular 
function was performed on the day of surgery and weekly for 12 weeks. Indium imaging 
was performed for 3 weeks following surgery to confirm residence of the cells at the site 
of transplantation. 
Results: A decline in infarct size over the 12 weeks was observed in all groups reaching 
a plateau by 4 weeks. The stromal cell group had a significantly greater absolute decline 
in infarct size by 12 weeks than either the BMMC group or controls (40.6±7.8% of LV to 
15.3±3.4%-stromal, vs 16.8±12.2% to 5.2±2.7%-controls, and 12.0±7.4% to 2.8±2.9%-
BMMC’s, p<0.001). However, there was no difference in the relative decline in infarct 
size between any of the groups. Although a trend to a greater improvement in regional 
function for both the BMMC’s and stromal animals was found, this did not reach statistical 
significance. Indium imaging demonstrated persistence of the label at the site of injection 
into the infarction for at least 2 weeks following injection, with further imaging limited by 
radioactive decay. 
Conclusion: The benefit of cell transplantation was observed, but further study with a 
larger number of animals with equivalent baseline infarct size is necessary in the future.
2900-40 Renin-angiotensin system genes and Hypertension in 
Uzbek patients
Marietta Eliseyeva, Nigora Srojidinova, Nigora Tursunova, Bagrat Petrosov, Republic 
Specialized Centre of Cardiology, Tashkent, Uzbekistan
Background:The renin-angiotensin system (RAS) genes have been most extensively 
studied as hypertension candidate genes. However, the results are different in different 
population groups or studies.
Objectives: to study prevalence of I/D polymorphism of ACE gene, A1166C polymorphism 
of AT1R gene, M235T polymorphism of ANG gene and their association with cardiovascular 
remodeling in Uzbek patients with essential hypertension (EH).
Methods:We examined 174 ethnic Uzbek men with EH, mean age 49.3±7,9 yr and 60 
apparently healthy persons (mean age 45.1±7,0 yr). Left ventricular mass was measured 
by echocardiography.
Endothelial function was evaluated by measuring of the flow-mediated dilatation (FMD) of 
the brachial artery. Common carotid intima-media thickness (IMT) was measured by high 
resolution ultrasound. Examined polymorphisms were determined using PCR.
Results:The frequency distribution of examined gene genotypes and alleles in examined 
patients was as follows: ACE gene genotypes : II- 23.2%, ID-48.2%, DD-28.5% (p=0.000); 
I allele-47.4% and D allele- 52.6% (p=0.195). AT1R gene genotypes: AA-71.5%, AC-
27.3%, CC-1.2% (p=0.000); A allele-85,2% and C allele-14,8% (p=0.000). ANG gene 
genotypes: MM-16.3%, MT-68.6%, TT-15.1% (p=0.000); M allele-50.6% and T allele 
-49.4% (p=0.819). The distribution of all alleles was in Hardy-Weinberger equilibrium. 
D allele of ACE, T allele of ANG, C allele of AT1R are considered as damaging . Thus, 
combination of damaging alleles has been prevalent in 95.4% patients. Our results showed 
significant association of mixed carrying of D allele ACE gene + T allele ANG gene with 
high degree of LVH, endothelium dysfunction and greatest increase of thickness in intima-
media complex of common carotid. Our study has shown significant association: of ANG 
gene T allele with LVH, of ANG gene T allele and AT1R gene C allele with endothelial 
dysfunction, of ACE D allele with carotid atherosclerosis damage 
Conclusions:Results of research testify to association RAS genes polymorphism with 
cardiovascular remodeling in Uzbek patients with essential hypertension (EH).
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2900-41 Comparing the Outcomes Between Extracorporeal 
and Conventional Cardiopulmonary Resuscitation 
Among In-Hospital Adult Patients with Cardiac Arrest: 
Propensity-Matched Study
Jou-Wei Lin, Yih-Sharng Chen, Fang-Yue Lin, National Taiwan University Hospital, 
Taipei, Taiwan,ROC, National Taiwan University Hospital Yun-Lin Branch, Dou-Liou, Yun-
Lin, Taiwan,ROC
Background: The objective of this study was to determine the survival difference between 
extracorporeal membrane oxygenation (ECPR) and conventional cardiopulmonary 
resuscitation (CCPR) in patients experiencing in-hospital cardiac arrest (IHCA) due to 
cardiac origin by means of well balance on measurable selection criteria.
Methods: During the period between 2004 and 2006, 59 adult patients receiving ECPR 
and 113 receiving CCPR due to cardiac etiology were retrieved from a CPR registry 
in a tertiary medical center in Taiwan. A propensity-score based matching process was 
performed to equalize potential prognostic factors in both groups, and to formulate well-
balanced 1:1 matched cohort study.
Results: Unmatched patients who underwent ECPR experienced a better survival trend 
over those who received CCPR (p = 0.007). However, age, sex, underlying diseases, CPR 
duration, and initial cardiac rhythm could affect the predisposition for placing ECPR. The 
well-balanced CCPR (n = 46, age: 55+/-15) and ECPR groups (n = 46, age: 57+/-14) were 
composed of patients with equally distributed baseline characteristics. There was still a 
statistically significant difference in 30-day survival favoring ECPR over CCPR (log rank 
p = 0.042). Survival at 6 months and survival to discharge were probably higher in the 
ECPR group (p = 0.055 and p = 0.096, respectively).
Conclusions: A well-balanced design that equalized potential prognostic predictors has 
demonstrated a survival benefit with the supplement of ECPR over CCPR in the IHCA 
patients of cardiac origin. Further studies will be needed to identify potential subgroups 
that may benefit from ECPR.
2900-42 Regional Differences in Carotid Plaque Morphology and 
Shear Stress Using Combined 3T MRI, Ultrasound and 
Patient-Specific Computational Fluid Dynamics and the 
Effects of Short-Term Statin Treatment
John LaDisa, Jr., Robert Prost, Leanne Harmann, Tayyab Mohyuddin, Osama Zaidat, 
Jason Jurva, Mahazarin Kaikobad, Megan Bright, Raymond Q. Migrino, Medical College 
of Wisconsin, Milwaukee, WI
Background: Computational fluid dynamics (CFD) is a specialized tool to study 
hemodynamics that can augment plaque evaluation from MRI and ultrasound (US). We 
tested whether CFD could quantify hemodynamics in the common (C), bifurcation (B) 
and internal (I) carotid arteries of patients with moderate to severe plaque undergoing 
statin treatment.
Methods: 5 subjects (1F, 66±8 yrs) had 3T MRI and US at baseline and 6 months after 
statin treatment. Mean plaque volume (PV) was measured at C, B and I from T2W spin 
echo images (pixel size 0.5x0.5x2 mm). Subject-specific CFD models were created from 
MRI, US and blood pressure (BP) using CVsim software. Outlet boundary conditions that 
replicated flow and BP were applied. Simulations used a stabilized finite element solver. 
Time-averaged wall shear stress (SS) and PV were quantified and averaged over 2 mm 
increments.
Results: CFD modeling took 17±3 hrs/patient with excellent replication of clinical data. 
Mean PV and SS was higher in B compared to C and I (C, B, I: PV 117±25, 164±48, 
87±22 mm3, p=0.002; SS 16±8, 35±15, 24±13 dyn/cm2; p=0.02). 6-month statin 
treatment reduced mean PV (131±52 vs. 115±38 mm3, p=0.02) without significant SS 
reduction (25±14 vs. 25±14 dyn/cm2).
Conclusions: Carotid mean plaque volume and shear stress are highest in the 
bifurcation region. Six-month statin treatment reduced mean PV but not SS. CFD is a 
viable method to complement morphologic data obtained by MRI and US allowing 
physiologic description of regional hemodynamic perturbations. 
2900-43 Six Months Clinical Outcome of the AMC Single Center 
Real World Experience on Stent Thrombosis in Patients 
Treated With a GenousTM EPC Capturing Stent
Margo Klomp, Marcel A. Beijk, Miranda C. Kramer, Niels J. Verouden, Karel T. Koch, 
José P. Henriques, Jan Baan, René J. van der Schaaf, Marije M. Vis, Jan G. Tijssen, Jan 
J. Piek, Robbert J. de Winter, Academic Medical Center, Amsterdam, The Netherlands
Background: Clinical trials of drug-eluting stenting (DES) have demonstrated a marked 
reduction in the incidence of restenosis compared to bare metal stents. However, there 
are concerns about the safety of DES, in particular with respect to delayed healing, 
chronic inflammatory reaction, and the occurrence of stent thrombosis (ST).
The Endothelial Progenitor Cell (EPC)-capturing stent is coated with an antibody (CD34+) 
that binds circulating EPC’s which differentiate into a functional endothelial layer. This 
accelerated healing may reduce in-stent restenosis by reducing neointimal hyperplasia 
and smooth muscle cell proliferation and, in addition, may prevent ST. In this single center 
study, we report the 6 months clinical outcome and occurrence of ST in patients treated 
with an EPC-capturing stent.
Methods: Between September 2005 and March 2007, 248 patients were treated with an 
EPC-capturing stent for coronary artery stenosis. All patients were treated with statins for 
at least 1 week prior to PCI and dual anti-platelet therapy was prescribed for at least 1 
month. Clinical follow-up was obtained after 1 month and 6 months.
Results: Mean age of the population was 64 years and 73% were male. 16% of the 
patients were diabetic. A total of 299 lesions were treated of which 16% were CTO and 
23% were bifurcations. Mean stent length was 25 ± 12 mm and mean stent diameter was 
3.3 ± 0.37 mm.
At 6 months clinical follow-up, angiographically documented ST was 0.8% (2 patients had 
a ST after 6 hours and respectively 7 days). Furthermore, 1 patient suffered a non-ST 
elevated myocardial infarction after 2 months and 1 patient had a STEMI after 2 days in a 
small side branch of the treated bifurcated lesion. In total 3 patients died of which 1 patient 
from a cardiac cause after 104 days. Target lesion revascularization was 3.2%, and non-
target vessel revascularization was 2.4%. Total MACE at 6 month follow-up was 4.8%.
Conclusions: The percutaneous treatment of coronary artery stenosis with a Genous™ 
EPC-capturing stent in statin treated patients shows a good 6 month clinical outcome 
regarding stent thrombosis.
2900-44 Percutaneous Creation of an Arteriovenous Fistula: A 
Novel Approach at Treat Patients With Severe Chronic 
Obstructive Pulmonary Disease
Swetlana Kleschnew, Peter Kardos, Nina Wunderlich, Horst Sievert, CardioVascular 
Center, Frankfurt am Main, Germany
Background: COPD is one of the leading causes of disability and death. In the last 
stages of the disease long-term oxygen therapy is necessary.
To create an arteriovenous fistula is a new method which allows blood rich in oxygen to 
flow from an artery to a vein. This leads to an increase in oxygenated blood returning 
to the lung, so the oxygen content of the circulating blood also increases. This method 
utilizes the cardiovascular reserve to overcome a respiratory insufficiency.
The arteriovenous fistula is percutaneously created by the ROX AC1 system by delivering a 
self-expanding nitinol clip to the puncture site between the external iliac artery and vein.
Methods: Since July 2007 in three long-term oxygen therapy dependend patients (age 
49-58 years) with severe COPD (post-bronchodilator FEV1 <50%, post-bronchodilator 
FEV1/FVC < 70%) an arteriovenous fistula was created percutaneously under local 
anesthesia. Follow will be performed in regular intervals which include NYHA functional 
assessment, MMRC (Modified Medical Research Council Dyspnea Scale), SGRQ (St. 
George` s Respiratory Questionnaire) as well as ECG, echocardiography, Doppler 
ultrasound and righr heart catheterization and 6 minutes walk test.
Results: In all patients the AC1 system was successfully placed and the arteriovenous 
fistula was created without complications. Patients were discharged on the following day.
Up to now, one patient has completed the 12 week follow up. At this visit the fistula was 
open, PaO2 improved from 57.6 mmHg to 60.6 mmHg, PaCO2 from 52.0 mmHg to 49.8 
mmHg FEV1 from 32% to 34.6%, FEV1/FVC from 42% to 53.6%.
Hemodynamics: Cardiac output increased as intended from 4.98 l/min to 7.51 l/min. 6 min 
walking distance without oxygen increased from 420m to 540m, 6 min walking distance 
with supplemental oxygen increased from 510m to 540m. In the SGRQ an improvement 
by 4 points was observed. The patient reported a reduction of supplemental oxygen 
during exercise by 50 %. Since creation of the fistula he did not need oxygen at rest.
Conclusions: Arteriovenous fistulae can successfully be created percutaneously. 
Increased cardiac output and oxygen delivery may significantly help patients with 
advanced stage COPD.
2900-45 Real-Time Imaging of the Arterial Wall During Plaque 
Excision Using Optical Coherence Tomography (OCT): 
The NightHawk Device
Frank J. Zidar, Roger S. Gammon, Douglas A. Waldo, Paige Kobza, Austin Heart, Austin, TX
Background: Advancements in catheter-based interventions have improved clinical 
outcomes reducing the need for surgical revascularization and amputation in patients 
with peripheral arterial disease. The NightHawk is a unique device incorporating optical 
coherence tomography (OCT) technology onto the SilverHawk plaque excision platform 
which enables real-time arterial wall imaging during plaque excision.
Methods: Prospective, multi-center, non-randomized study of 100 patients - IDE trial. 
The purpose is to assess the proximity of the catheter to the arterial wall and correlate 
excised tissue with OCT images collected. Each target lesion is treated with two cutting 
passes using a NightHawk catheter imaging in the following manner: 1) Pre-cut imaging: 
pullback through the target lesion; 2) Cutting pass with imaging; 3) Post-cut imaging: 
pullback through the target lesion. Treatment is completed using the NightHawk or other 
modalities as indicated.
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Results: As of 10/31/2007, 10 subjects have been enrolled at 2 U.S sites and 18 lesions 
treated. The patients’ average age was 70 years and 50% were males. All patients had 
hypertension, 9/10 patients were diabetic, 6/10 were smokers, and 6/10 had coronary 
artery disease. The average lesion length was 23mm, the average reference vessel 
diameter was 2.9mm, and 16/18 lesions were below the knee. The average diameter 
stenosis improved from 13% to 86% and adjunctive angioplasty was used in one case. 
Operators predicted apposition based on OCT imaging prior to a cutting pass. Of 36 
cutting passes that were opposed based on OCT, plaque was excised in 33 (92%).
This study is ongoing and additional data (i.e., OCT imaging and histological analysis of 
excised tissue) will be available at the time of abstract presentation.
Conclusions: Plaque excision using the NightHawk can be safely performed with 
excellent device apposition. Plaque yield was associated with OCT-predicted apposition. 
As we develop a more thorough understanding of OCT’s many benefits in characterizing 
normal and diseased arterial walls, this may provide more effective and efficient plaque 
excision while potentially using less radiation and contrast.
2900-46 First In-Human Pediatric Experience With a 
Bioabsorbable Septal Implant for Fontan Fenestration 
Closure
Abhay Divekar, Reeni Soni, Health Science Center, Children’s Hospital, Winnipeg, 
Canada
Background: A number of permanent synthetic implants have been used for Fontan 
fenestration closure. This clinical series evaluates the feasibility and efficacy of a novel 
bio-absorbable septal implant for fenestration closure.
Methods: Three patients’, age 4-15 (mean 9.7) years, weight 15.8-45 (mean 34.6) kg 
underwent Fontan fenestration closure using a novel, self-centering, bio-absorbable 
septal implant (BioSTAR, NMT Medical, Boston). BioSTAR uses an heparin coated 
acellular porcine intestinal collagen layer matrix mounted on an MP35N STARFlex (NMT 
medical) “double umbrella” framework. The procedures were performed under general 
anaesthesia. Temporary balloon occlusion was performed after baseline diagnostic 
catheterization and angiography and if suitable a 23 mm BioSTAR implant was loaded 
and delivered using an 11 French proprietary delivery system (NMT Medical). Device 
positioning was confirmed by angiography through the delivery sheath. Heparin was 
used for procedural anticoagulation (ACT>200) and cephalexin for antibiotic prophylaxis. 
Coumadin (n=2) or aspirin and clopidogrel (n=1)
was used for post-procedure anticoagulation.
Results: Fenestration closure was successfully performed via the femoral (n=1) or 
internal jugular (n=2) vein under fluoroscopic control [fluoro time 11.3-19.1 (mean 15.3 
min)]. Fontan pressure increased by ≤ 3 mm Hg [from 10-14 (12.3) mm Hg to 10-16 (14) 
mm Hg]; and there was either an increase or no change in the mixed venous saturation 
[50-67 (58)% to 64-67 (65)%] during balloon occlusion. Systemic saturation increased 
from 80-93 (85.7)% to 95-97 (96.3)% immediately and at 6 weeks. There were no 
complications. There was no residual shunt by trans-thoracic echocardiogram at 24 hours 
and 6 weeks.
Conclusion: This first pediatric in-human experience demonstrates feasibility, safety 
and efficacy of a novel bioabsorable implant for Fontan fenestration closure. The short 
term results are encouraging. The low-profile and predicted absorption of the device and 
replacement with native tissue will hopefully minimize hemodynamic perturbations in the 
Fontan circuit. Larger series with longer follow-up and comparison with other devices is 
needed.
2900-47 Initial Results of PFO Closure With the Coherex Flat 
Stent
Isabel C. Reiffenstein, Cardio Vascular Center, Frankfurt, Germany, Washington Hospital 
Center, Washington DC, WA
Background: Percutaneous closure of patent foramen ovale (PFO) is frequently 
performed to prevent stroke and decompression sickness caused by recurrent paradoxical 
embolisms. The corpus of currently available closure devices extends into both atria. The 
Coherex FlatStent is a flat self-expanding stent which can be positioned in the tunnel 
of PFOs. With its micro-tined anchors it is placed selectively into the tunnel of the PFO. 
This is a report about the results in the first 6 patients in whom a PFO was closed with 
this novel device.<br Methods: The purpose of this multi-center study is to evaluate the 
safety and efficacy of the Coherex FlatStent PFO Closure System. The first use of the 
Coherex FlatStent in a human was performed on October 2, 2007. As of this writing, six 
patients with history of paradoxical embolism (age 18-65 years) have had their PFOs 
closed with this device. The Coherex FlatStent PFO Closure System comprises a self-
expanding FlatStent with integrated polyurethane foam in the intra-tunnel cells of the 
device. The foam is intended to stimulate tissue growth inside the tunnel. The FlatStent can 
be unsheathed in the PFO tunnel where it expands laterally. This process brings the walls 
of the septum primum and the septum secundum into apposition. Radiopaque markers 
allow for visualization of the arms during implant placement. All patients received 100 mg 
of aspirin for 6 months and 75mg clopidogrel for 3 months post-procedure. Results: In 
all six patients the Coherex FlatStent was successfully placed. Mean stretched balloon 
diameter was 7.1 mm (range 3.9 - 9.6 mm). The mean tunnel length measured by TEE 
was 10.8 mm (range 8.4 - 14 mm), the mean tunnel width measured by TEE was 3.1 mm 
(range 2 - 6 mm). No arrhythmias or other events were noted during follow-up.
Conclusions: This initial experience demonstrates that PFO Closure using the Coherex 
FlatStent PFO Closure System seems to be technically feasible and safe. To make a 
statement regarding the efficacy of the Coherex Flat Stent PFO-Closure System it will be 
necessary to perform more interventions and to consider the outcomes of the 1 month, 3 
month and 6 month Follow up.
2900-48 Is There a Correlation Between Aortic Valve 
Calcification and Paravalvular Leak After Transcatheter 
Aortic Valve Implantation?
Deepika Gopal, Paul Grayburn, David Brown, William Brinkman, Todd Dewey, Jill Fowler, 
Morley Herbert, Michael Mack, Medical City Dallas Hospital, Dallas, TX
Introduction: We compared the amount and pattern of aortic valve calcification pre-
procedure with observed paravalvular leak after transcatheter aortic valve implantation 
(TC-AVI) with balloon deployed stainless steel stent valve.
Methods: 64 multislice computerized tomography with 3-D reconstruction was performed 
on 12 patients undergoing TC-AVI. Using a plane orthogonal to the long axis of the 
ascending aorta with the annulus as reference line, serial cuts of 0.75mm were analyzed. 
Total area and the amount of calcification on each valve cusp, the annulus and anterior 
mitral valve leaflet was quantified and characterized. After implantation, a separate blinded 
reviewer assessed echocardiograms for amount and location of paravalvular leak.
Results: Paravalvular leaks occurred most commonly in the commissure between the 
right and left coronary cusps, and the left and noncoronary cusps but did not correlate 
with the total amount nor the pattern of distribution of calcium, which was heaviest on the 
noncoronary cusp. (Table 1) Quantification of the leak was moderate in 1 (8.3%), mild in 
3 (25%), trace in 1 (8.3%) and none in 7 (58.3%).
Conclusion: In this small series of patients with senile calcific aortic stenosis the pattern 
and amount of calcification was not predictive of the amount nor location of post procedure 
paravalvular leak. 
Paravalvular Leak
Area of Calcification (sq cm) None (7) Trace (1) Mild (3) Moderate (1)
R cusp 0.56 ± 0.20 0.30 0.84 ± 0.32 0.66
L Cusp 0.63 ± 0.42 0.45 0.55 ± 0.18 0.91
Non-Coronary Cusp 0.75 ± 0.36 0.48 0.89 ± 0.47 1.04
Total Area 1.94 ± 0.80 1.23 2.28 ± 0.51 2.61
2900-49 Clinical Experience in 0.010 Inch Guide Wire With Its 
Compatible Balloon Catheter System for Chronic Total 
Occlusion
Akihiko Takahashi, Masahiro Yano, Norimasa Taniguchi, Masao Sato, Shunsuke 
Nakajima, Yukari Takahashi, Sakurakai Takahashi Hospital, Kobe, Japan
Background:Chronic total occlusion (CTO) is a common and clinically relevant problem 
in coronary artery disease and percutaneous coronary intervention (PCI) success rates 
are not high. However, there were supposed to be micro channel in CTO lesion and in 
some case, guide wire with smaller caliber considered to be of advantage to penetrate 
the lesion. Recently, newly developed 0.010 guide wire (GW) and its compatible balloon 
catheter became available in Japan for downsizing whole PCI system. With using small 
caliber GW, we evaluated feasibility and efficacy of this system for CTO lesion.
Methods: From April to September 2007, we used Athlete eelTM guide wire and 
IKAZUCHI 10TM balloon catheter as prime choice for consecutive 23 CTO lesions with 
21 patients. Patients consist of 17 male and 6 female. Target CTO lesions located in 
RCA in 11 patients, LAD in 5 patients and LCX in 7 patients. Mean age was 69.5. For all 
lesions, we choose Athlete eel GW as a first GW with micro-catheter to penetrate CTO 
lesions and if failed, changed GW to stiffer 0.014 GW such as Conquest Pro TM GW with 
micro-catheter.
Results:Among these 23 CTO lesions, we succeeded in crossing the lesion with Athlete 
eel GW in 11 lesions (47.8%) and all the lesions were dilated with IKAZUCHI 10 balloon 
catheter. After balloon dilatation, drug-eluting stents or bare-metal stents were deployed. 
For another 12 lesion, after failing to penetrate the lesion with this 0.010 wire, we changed 
to Conquest Pro GW and succeeded in penetrating the lesion in 8 patients. Overall 
success rate was 82.6% and no major complication occurred.
Conclusions:These results suggest that Athlete eel GW presumably passes through 
micro channel in some CTO lesions due to small diameter and dimension by comparison 
to 0.014. GW. To use 0.010 GW and compatible balloon catheter is considered to be 
feasible and promising in treatment of CTO lesion.
2900-50 Assessment of the Lipid-Burden of Human Coronary 
Autopsy Specimens With a Catheter-Based Near-
Infrared Spectroscopy System: The NIR Lipid Burden 
Index
Edward L. Hull, Craig M. Gardner, Sean P. Madden, Jennifer B. Lisauskas, Stephen T. 
Sum, Thomas M. Meese, Tianchen Shi, Jay D. Caplan, James E. Muller, InfraReDx, Inc., 
Burlington, MA
Background: We tested the ability of a catheter-based near-infrared (NIR) spectroscopy 
system to identify the total lipid burden (LBI, an aggregate measure of the total lipid 
content of a scanned artery) in human coronary artery autopsy specimens.
Methods: Artery segments (n=126) from 51 donor hearts were perfused with whole 
human blood at physiologic temperature, pressure, and flow rate, and scanned with 
the InfraReDx system. Two-dimensional chemogram images of each artery segment, 
each pixel of which indicates the local probability for presence of LRP, were analyzed to 
determine the NIR-LBI.
Results: The NIR-LBI constructed from chemograms (see below) correlated with the average 
fibroatheroma cross-sectional area (AUC for LBI-based identification of fibroatheroma in an 
artery segment was 0.84 (97.5% CI = 0.78-0.91). LBI was greater in males (median male/
female LBI = 0.042/0.020, p=0.003, Rank-Sum test) and those with a cardiac cause of death 
(p=0.011, Kolmogorov-Smirnoff test, median LBI of 0.046 versus 0.038).
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Conclusions: In prospective, blinded validation, NIR-LBI accurately predicted the 
presence and average volume of fibroatheroma in human coronary artery segments 
and showed the expected trends with gender and cause of death. Because the catheter-
based system used in this study has been used in over 100 patients, a method is now 
available to determine the lipid burden of coronary arteries in living patients. This index 
may be helpful in identifying patients at greater risk of cardiac events. 
2900-51 Initial Assessment of a Novel Radioactive Tin-117m 
Stent in Porcine Coronary Arteries
Refat Jabara, Jimmy Li, Suresh Srivastava, Lakshmana Pendyala, Dongming Hou, 
Toshiro Shinke, Nicolas Chronos, Keith Robinson, Saint Joseph’s Hospital, Atlanta, GA
Background: Tin-117m (117mSn) is a novel conversion electron emitting radioisotope that 
deposits intense energy in a very short range. It can deliver high doses of radiotherapy to 
a target while minimizing collateral damage to adjacent normal tissue, and has been used 
clinically in the management of bone pain associated with osteosarcoma. There are several 
potential cardiovascular applications of 117mSn, one being an electroplating on stents; 
since the coronary media is 0.2-0.3mm thick, no adjacent tissue exposure would result.
Objective: To assess the feasibility and coronary artery effects of an117mSn-electroplated 
stent in a a clinically relevant animal model.
Methods: 72 stents of 3 types were implanted in pig coronaries Bare metal stents (BMS, 
n=14), Tin-only sham electroplated stents (Tin-only, n=15), and three incremental doses 
of radioactive 117mSn electroplated stents (Low 30ΜCi, n=14; Medium 60ΜCi, n=14; 
and High 150ΜCi, n=15). Pigs were terminated at one month for complete histological 
analysis.
Results: Intimal thickness varied according to stent type with highest level for the Low, 
Medium and High radioactive stents compared to BMS and Tin-only (0.43±0.06mm, 
0.41±0.06mm, and 0.47±0.07mm, vs. 0.17±0.02mm, and 0.26±0.03mm, respectively, 
P<0.001). % area stenosis was higher for radioactive stents compared to BMS and Tin-
only (51±6%, 51±4%, and 55±5%, vs. 27±2% and 35±3%, respectively, P<0.001).There 
was consistently a distinct, discrete, dense collagenous ring of tissue which included a 
densely cellular outer rim, in the perivascular space at the outer adventitial border ~0.2-
0.3mm radially outward from 117mSn stents. This appears to reflect a unique biological 
effect or ‘signature’ of this radioisotope in this application.
Conclusions: This study showed that novel radioactive 117mSn stents were compatible 
with porcine coronary artery implant. Although these devices exacerbated rather than 
inhibited in-stent neointima formation, unique histological effects were observed that 
support further investigation of 117mSn effects in the circulatory system to understand 
the interaction of this unique conversion electron energy with the vascular tissue.
2900-52 A Novel Anti-Inflammatory Salicylate-Based 
Bioabsorbable Polymer for Use in Fully Biodegradable 
Coronary Stents
Refat Jabara, Nicolas Chronos, Patrick Rivelli, Olex Hnojewyj, Keith Robinson, Saint 
Joseph’s Hospital, Atlanta, GA
Background: Permanent polymer platforms used in current DES have been shown to 
result in chronic inflammatory reactions which may contribute to increased risk of late 
thrombosis and rebound restenosis. Optimal polymer selection and the use of completely 
absorbable but biocompatible polymers are expected to minimize these risks.
Objective: To evaluate a novel potentially innately anti-inflammatory, salicylate-based 
bioabsorbable polymer eluting sirolimus in a clinically relevant animal model.
Methods: Four different types of stents (n=36) were implanted in pig coronary arteries 
using QCA to optimize stent apposition: bare metal stents (BMS); salicylic acid/adipic 
acid bioabsorbable polymer only coated stents (SA/AA); Cypher stents; and metal stents 
coated with salicylic acid/adipic acid bioabsorbable polymer containing sirolimus (SA/
AA + S). The dose density of sirolimus was 8.3 Μg/mm of stent length, with in vitro 
studies demonstrating elution over 30d and complete polymer degradation in 4-6 weeks. 
Animals were terminated at one month for angiographic restudy and histopathologic and 
histomorphometric analyses.
Results: Both SA/AA + S and Cypher stents had significantly lower angiographic % 
stenosis compared to BMS and SA/AA polymer only groups (6%±4 and 5%±4 vs. 15%±7 
and 16%±5, respectively, P<0.001). Intimal thickness was lower for SA/AA + S and Cypher, 
than for BMS (0.14mm±0.06 and 0.13mm±0.04 vs. 0.23mm±0.05, respectively, P<0.001). 
Histologic % area stenosis was also lower for SA/AA + S and Cypher, compared to BMS 
(22%±7 and 23%±6 vs. 33%±5, respectively, P<0.001). The inflammatory reaction to SA/
AA and to SA/AA + S was mild whereas inflammation in BMS and Cypher was more 
pronounced (P=0.072). 
Conclusions: This study showed favorable vascular compatibility and efficacy of a novel 
anti-inflammatory salicylate-based biodegradable polymer eluting sirolimus. Since there 
is a tendency for reduced vessel wall inflammatory response and this polymer is fully 
absorbable, there may be significant improvement over existing DES to reduce late stent 
thrombosis. Ongoing research with fully bioabsorbable stents from this unique class of 
anti-inflammatory polymer materials, is underway.
2900-53 Stent Fracture Occurs Earlier Than Expected: Serial 
Fluoroscopic Surveillance Study
Kyungheui Kim, Seongjin Oh, Byoung-Keuk Kim, Dong Woon Jeon, Joo-Young Yang, 
Deok-Kyu Cho, Lucy Youngmin Eun, National Health Insurance Corporation Ilsan 
Hospital, Goyang, South Korea
Background:Stent fracture(SF) after sirolimus-eluting stent(SES) is usually discovered 
with follow-up angiography.SF is not always associated with clinical recurrence so that we 
do not know the exact time when this adverse finding occurs.Methods:We demonstrated 
the usefullness of fluoroscopic surveillance for detecting SF in another study.We performed 
serial prospective fluoroscopic exam in high risk stent(33mm long stent) for SF at five 
follow-up sub-periods(at hospital discharge and 2weeks, 1month, 3months and 6months 
after intervention). All patients suspicious of SF were requested to undergo follow-up 
angiography and IVUS confirmation. Clinical, procedural and angiographic characteristics 
were analyzed at the time of 8month follow-up angiography.Results:From August 
2005 to January 2007, 131stents in 102patients(male 84%, age 62±29) were included 
in this analysis and 121patients(92.4%) completed 6months fluoroscopic surveillance. 
Total eight SF were discovered(6.6%) and their profiles were presented at the table. All 
stents were those implanted at right coronary artery and showed high prevalence of 
stent overlapping(50%). All SF were discovered before 1month follow-up period except 
one (after 2months) and three of them were found before hospital discharge(6,3 and 4 
days after intervention).Follow-up angiography was done in four patients and restenosis 
was not found in any of them.Conclusions:SF were discovered at earlier stage than 
expected.
profiles
Patient Age(yrs) Sex Target 
vessel
Reference 
Diameter 
(mm)
Minimal 
luminal 
diameter 
(mm)
Lesion 
length 
(mm)
Stent 
overlap Time to SF
1 40 M RCA 3.24 0.74 27.4 No At discharge
2 56 M RCA 3.43 0.93 27.0 No At 2 wks
3 71 M RCA 2.79 1.42 56.2 Yes At 1 month
4 56 M RCA 3.33 0.58 45.2 Yes At discharge
5 64 M RCA 2.87 0.84 30.2 No At discharge
6 52 M RCA 3.11 1.13 48.0 Yes At 1 month
7 62 F RCA 2.73 0.95 49.0 Yes At 1 month
8 70 M RCA 3.24 0.37 28.1 No At 2 
months
2900-54 Long-term Outcomes of Sirolimus- Versus Paclitaxel-
eluting Stent Recipients
Amanda M. Pfeiffer, Gregory J. Mishkel, Anna L. Moore, Stephen J. Markwell, Marc E. 
Shelton, Prairie Heart Institute @ St. John’s Hospital, Springfield, IL, Prairie Education & 
Research Cooperative, Springfield, IL
Background: It remains unclear whether sirolimus-eluting stents (SES) and paclitaxel-
eluting stents (PES) differ in long-term clinical outcomes. We sought to compare 3-year 
data in our large “real world” registry of drug-eluting stent (DES) recipients.
Methods: We included patients undergoing a 1st DES placement between 5/1/03 and 
12/31/06. Clinical follow-up was obtained at 6 months, 1-yr, and annually thereafter. 
Three year endpoints were all-cause mortality, non-fatal myocardial infarction (MI), stent 
thrombosis (ST), or clinically-driven target vessel revascularization (TVR).
Results:  Study cohort consisted of 5322 patients (7998 lesions). DES usage was 82.4% 
SES; 17.6% PES. Clinical follow-up was obtained on 97.2% of patients (average 682.6 
± 367.9 days). Groups were similar at baseline on gender, age, diabetic status, renal 
insufficiency, smoking history, and STEMI presentation. SES were placed more often in 
patients with unstable angina (33.6% vs 28.5%; p=0.003) and history of MI (24.1% vs 
21.0%; p=0.042). PES were utilized more frequently in lesions that were high risk (ACC 
defined) (45.2 % vs 37.4 %; p<0.001), involving a bifurcation (18.3% vs 10.1%; p<0.001), 
and longer length (21.3 ± 12.4 vs 19.5 ± 10.3; p<0.001). In-hospital outcomes were similar 
between groups. See table for Kaplan-Meier results.
Conclusions: PES were utilized in more complex lesions. This may account for the 
higher ST rate at 3 yrs. In our comparison of SES vs. PES, no difference is noted in TVR, 
MI, or mortality. 
PES 
(n=939)
SES 
(n=4383) p value
Three-year 
Kaplan-Meier 
event rates 
% (95% CI)
All-cause mortality 12.6 (9.3-16.9) 11.9 (10.6-13.2) NS
Non-fatal MI 4.3 (2.8-6.4) 5.0 (4.1-6.0) NS
TVR 8.8 (6.4-12.0) 10.4 (9.4-11.6) NS
Def/Prob ST 2.3 (1.4-3.9) 1.7 (1.2-2.3) 0.010
MACE 23.8 (19.4-29.0) 25.4 (23.7-27.2) NS
2900-55 Long-Term Outcomes of Sirolimus- Versus Paclitaxel-
Eluting Stents in Diabetic Patients
Amanda M. Pfeiffer, Gregory J. Mishkel, Anna L. Moore, Stephen J. Markwell, Marc E. 
Shelton, Prairie Heart Institute @ St. John’s Hospital, Springfield, IL, Prairie Education & 
Research Cooperative, Springfield, IL
Background: We sought to compare 3-year data on sirolimus-eluting stents (SES) 
versus paclitaxel-eluting stents (PES) in diabetics in our large “real world” registry of drug-
eluting stent (DES) patients.
Methods: All diabetic patients undergoing a 1st DES placement from 5/1/03 to 12/31/06 
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were included. Clinical follow-up was obtained at 6 months, 1-year, and annually thereafter. 
Three-year endpoints were all-cause mortality, non-fatal myocardial infarction (MI), stent 
thrombosis (ST), and clinically-driven target vessel revascularization (TVR).
Results:  The study cohort consisted of 1540 patients (2376 lesions). DES usage was 
82.1% SES; 17.9% PES. Clinical follow-up was obtained on 97.0% of patients (average 
681.7 ± 374.6 days). Groups were similar at baseline with regards to gender, age, renal 
insufficiency, smoking history, and STEMI presentation. SES were placed more often in 
patients that had a prior PCI (33.5% vs 25.7%; p=0.013) and with unstable angina at 
presentation (37.6% vs 26.8%; p=0.001). PES were utilized more in lesions that were 
high risk (ACC defined) (46.4 % vs 37.4 %; p=0.001), involving a bifurcation (20.5% vs 
10.0%; p<0.001), and longer length (21.1 ± 13.3 vs 19.2 ± 9.7; p<0.001). See table for 
Kaplan-Meier results.
Conclusions: All 3-year PES event rates were lower than SES, although not statistically 
significant. Despite PES use in more complex lesions, there was a trend toward decreased 
TVR. Choice of DES platform in diabetics warrants further study. 
PES 
(n=276)
SES 
(n=1264)
p 
value
Three-year Kaplan-
Meier event rates 
% (95% CI)
All-cause 
mortality 12.7 (7.8-20.3) 14.2 (11.9-17.0) 0.697
Non-fatal MI 4.9 (2.2-10.5) 6.8 (5.1-9.1) 0.643
TVR 8.8 (5.4-14.3) 16.0 (13.7-18.8) 0.054
Def/Prob ST 1.2 (0.4-3.8) 1.8 (1.0-3.3) 0.814
MACE 25.3 (18.1-34.7) 32.4 (29.1-35.9) 0.148
2900-56 An optimal bare-metal stents (BMS) expansion with 
intravascular ultrasound (IVUS) guidance may lead 
similar long-term outcomes as drug-eluting stents 
(DES) implantation in patients without diabetes 
mellitus.
Katsuo Noda, Shuichi Oshima, Seiji Hokimoto, Kumamoto chuo hospital, Kumamoto, 
Japan
Background and Methods: DES may be effective to reduce repeat percutaneous coronary 
intervention, but some important problems (prolonged anti-platelet drugs administration, 
increase in stent thrombosis every-year) have been concerned continuously. Thus, 
DES indication has been changing from most of all patients to some specific patients 
like diabetes, small vessels, or long lesions in the real world. Recently, some reports 
showed that BMS has became similar better long-term outcomes as DES in patients 
without diabetes. So we investigated the long-term outcomes of BMS implantation without 
diabetes in comparison with DES. Routinely, IVUS guidance and a high pressure post-
dilatation was performed due to achieve optimal BMS expansion. The optimal BMS 
expansion was defined as a minimum stent area of over 6.5 mm2 by IVUS.
Results: A consecutive series of 457 patients was divided into 2 groups (DES: 92, 
BMS: 365). There were no significant differences of clinical characteristics except for the 
condition of unstable angina (DES 13% vs. BMS 32%: p<0.01), LAD just-proximal lesion 
(DES 23% vs. BMS 9%: p<0.001), and severe calcified lesion (DES 1% vs. BMS 10%: 
p<0.05). The 30-day MACE was not different between 2 groups (DES 2.2% vs. BMS 0.6%: 
p=NS.). The minimum stent area was larger in BMS than in DES, significantly (6.6 mm2 
vs. 6.1mm2: p<0.01). After 1-year, TLR occurred in 3.3% in DES versus 5.8% in BMS 
(p=NS.), and the incidence of MACE was not different between DES and BMS (5.4% vs. 
7.0%: p=NS.). The stent thrombosis occurred 1.1% (n=1) in DES and 0.3% (n=1) in BMS. 
The optimal BMS expansion group was significantly lower incidence of 1-year MACE than 
the non-optimal BMS group (2.9% vs. 11.5%: p<0.05), and the incidence of MACE in 
optimal BMS expansion group was similar to that in DES group (2.9% vs. 5.4%).
Conclusions: Without diabetes, the early and long-term outcomes in BMS are 
acceptable in DES era. Particularly, if the optimal BMS expansion could be achieved, the 
long-term outcomes of BMS were equal to those of DES implantation. In view of the DES 
problems associated with thrombotic events or antiplatelet drugs administration, BMS 
implantation may be safe and effective in non-diabetic patients.
2900-57 Optimal Late Loss may be Desirable for Neointimal 
Healing Following Stenting: Angioscopic Comparison 
Between Sirolimus- and Zotarolimus-eluting Stents
Masaki Awata, Shinsuke Nanto, Masaaki Uematsu, Takakazu Morozumi, Tetsuya 
Watanabe, Toshinari Onishi, Osamu Iida, Fusako Sera, Hitoshi Minamiguchi, Hirokuni 
Akahori, Masamichi Yano, Shin Okamoto, Kuniyasu Ikeoka, Hironobu Tanaka, Haruyo 
Yasui, Jun-ichi Kotani, Seiki Nagata, Kansai Rosai Hospital, Amagasaki, Japan
Background: Delayed healing of the neointima following drug-eluting stent implantation 
may play a role in late stent thrombosis. Zotarolimus-eluting stent (ZES) appreciates 
extremely rare late stent thrombosis. We sought to compare the angioscopic findings of 
sirolimus-eluting stent (SES) and ZES to explore the neointimal healing following stenting. 
Methods: Follow-up angioscopy and angiography were performed 8±1 months after 16 
SES and 14 ZES implanted in de novo lesions. Neointimal coverage was graded as: 
grade 0 = struts were exposed; grade 1 = struts were covered, but not embedded by 
the neointima; grade 2 = struts were embedded, but were translucently seen; grade 3 = 
struts were embedded and invisible. Thrombi and yellow plaques underneath the stents 
were also explored. Results: Baseline patient and lesion characteristics were similar 
between the groups. Late loss was slightly, but significantly greater in ZES (0.51±0.17 
mm) than in SES (0.07±0.18 mm, P<0.0001). Neointimal coverage grade was greater in 
ZES (P=0.0004, Figure). Majority of ZES (71%) showed grade 3, whereas 63% of SES 
showed grade 1 coverage. Thrombi tended to be more frequent with SES (ZES: 7%; SES: 
31%, P=0.2), and yellow plaques were more frequent in SES (ZES: 14%; SES: 69%, 
P=0.004). ZES demonstrated good neoitimal healing. Conclusion: Although ZES showed 
slightly greater late loss than SES, neointimal healing appeared to be adequate in ZES. 
Optimal late loss may be desirable for adequate neointimal healing following stenting.
2900-58 Two-Year Safety and Revascularization Outcomes 
Following Coronary Artery Intervention Wth Bare-Metal 
Stents vs. Strategies of Selective or Predominant Drug-
Eluting Stents in a Community Setting
Michael E. Ring, Kenn B. Daratha, Robert A. Short, Denise A. Dominik, Lynn Shuler, 
Katherine R. Tuttle, Sacred Heart Medical Center, Spokane, WA, Washington State 
University, Spokane, WA
Background: Drug eluting stents (DES) have been shown to decrease target vessel 
revascularization rates compared to bare metal stents (BMS). However, recent reports 
suggest that DES may be associated with higher death and myocardial infarction (MI) 
rates. Further, the risk of serious bleeding associated with longer dual antiplatelet use 
required after DES in community practice is unclear.
Methods: We compared two-year outcomes of three groups of coronary stent patients 
at a single center (n=6,378). The first group predated market release of DES and only 
received BMS. The second group was characterized by selective, mostly on-label, use of 
DES (18% one or more sirolimus stents). The last group involved a strategy of predominant 
DES use (74% one or more paclitaxal stents). Safety (death, MI, hospitalization for 
bleeding) and total revascularization events, percutaneous coronary interventions (PCI) 
and coronary artery bypass grafting (CABG) were tracked using a comprehensive 28-
hospital regional database and the Social Security death index. Events were analyzed 
using Kaplan-Meier techniques; p-values are from log-rank tests.
Results:
Two-Year Safety and Revascularization Rates
Number 
Patients
Composite 
Safety 
Events
Death MI Bleeding Total Revasc. PCI CABG
BMS only 2,801 23.1% 10.1% 12.5% 4.4% 19.1% 15.5% 5.5%
Selective-DES 1,233 18.7% 7.4% 7.4% 3.6% 19.5% 17.3% 3.8%
Predominant-
DES 2,344 18.9% 7.6% 7.6% 4.3% 16.9% 15.5% 2.3%
Log-rank p 
S-DES vs 
BMS 
P-DES vs 
BMS 
S-DES vs 
P-DES
.002 
.002 
NS
.007 
.012 
NS
.015 
.001 
NS
NS 
NS 
NS
NS 
NS 
NS
NS 
NS 
NS
.022 
.001 
.012
Conclusions: Compared to a strategy of utilizing only BMS, strategies of selective or 
predominant DES use were associated with less frequent death and MI and no difference 
in rates of serious bleeding at two years. Total revascularization rates were not decreased 
with either DES strategy, although there was a decrease in CABG, especially with the 
predominant DES strategy.
2900-59 Complete Versus Incomplete Revascularization 
in Patients with Multivessel Disease Undergoing 
Percutaneous Coronary Intervention with Drug-Eluting 
Stents
Piera Capranzano, Dominick J. Angiolillo, Rossella Barbagallo, Alessio La Manna, 
Francesco Tagliareni, Konstantinos Dimopoulos, Rita Bucalo, Anna Caggegi, Alfredo 
R. Galassi, Theodore A. Bass, Corrado Tamburino, University of Catania, Catania, Italy, 
University of Florida, Jacksonville, FL
Background: Previous reports have shown that patients with multivessel disease 
(MVD) treated with coronary artery bypass grafting (CABG) have better outcomes 
when complete revascularization is achieved. There is limited data from the pre-drug-
eluting stent (DES) era on the prognostic implications of complete versus incomplete 
revascularization of MVD patients undergoing percutaneous coronary intervention (PCI) 
and there is no data currently available using DES. The aim of this study was to evaluate 
the long-term outcomes of complete versus incomplete revascularization in MVD patients 
undergoing PCI with DES. The primary endpoint measures were cardiac death and need 
for repeat revascularization.
Methods: Patients (n=508) with MVD undergoing PCI with DES (sirolimus- or paclitaxel-
eluting stent) were included. Revascularization was defined as complete when all 
segments with a stenosis ≥50% and diameter ≥2.25 mm were revascularized. Study 
confounders, including prior history of any type of revascularization or PCI with POBA or 
BMS, were excluded. Baseline characteristics of patients with compete and incomplete 
revascularization meeting study inclusion criteria were compared. After adjustment for 
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baseline characteristics, comparisons of outcomes between groups were made.
Results: Complete and incomplete revascularization was achieved in 42% and 58% 
of patients, respectively. There was higher prevalence of chronic renal failure (p<0.03), 
triple-vessel disease (p<0.0001) and presence of a total occlusion (p<0.0001) in patients 
with incomplete revascularization. All patients were followed for 26.5 (interquartile range: 
21.8-36.3) months. After adjustment for different baseline characteristics, the adjusted 
hazard ratio (HR) (95% CI) for the association between complete revascularization and 
outcomes were 0.37 (0.15-0.92, p=0.03) for cardiac death and 0.44 (0.28-0.68 p< 0.0001) 
for the need for subsequent revascularization.
Conclusions: Complete revascularization of patients with MVD treated with DES 
is associated with better long-term outcomes. Higher mortality rates and need for 
revascularization were observed in patients with incomplete revascularization.
2900-60 Intravascular Ultrasound Findings in Very Late Stent 
Thrombosis After Implantation of Sirolimus- or 
Paclitaxel-Eluting Stents
Stephane Cook, Parham Eshtehardi, Mario Togni, Rolf Vogel, Peter Wenaweser, Michael 
Billinger, Christian Seiler, Otto M. Hess, Bernhard Meier, Stephan Windecker, Swiss 
Cardiovascular Center, Bern, Bern, Switzerland
Background and Purpose. Very late stent thrombosis (ST) after drug eluting stent 
(DES) implantation has been associated with incomplete stent apposition and vessel 
remodelling. Necropsy studies suggest differences in the pattern of healing and chronic 
inflammation between sirolimus- (SES) and paclitaxel-eluting stents (PES). The purpose 
of the present study was to investigate differences of arterial structure between SES and 
PES in patients presenting with very late DES ST.
Methods. Intravascular ultrasound (IVUS) was systematically performed in 32 very late 
ST patients presenting 868±326 days after DES-implantation (18 SES, 14 PES). IVUS 
imaging was performed in the ST-segment (48% LAD, 12% RCX, 39% RCA) using 
motorized pullback (0.5 mm/s) prior to emergency percutaneous coronary intervention. 
Stent expansion was defined as minimum cross-sectional area (MSA) divided by 
reference lumen area. Stent malapposition was defined as lack of contact between any 
strut and the vessel wall.
Results. Stent length (SES: 29.6±21.6 mm; S: 28.2±14.0 mm, p=0.25) and number of 
stents per lesion (SES: 1.4±0.8; PES:1.6±0.6mm, p=0.41) were similar for SES and PES. 
IVUS findings are summarized in the table below. 
SES 
N=18
PES 
N=14 p-value
Reference Segment 
- EEM-CSA, mm2 
- Lumen-CSA, mm2
14.4 ± 5.6 
7.7 ± 2.3
15.8 ± 7.0 
9.1 ± 3.6
0.76 
0.19
Stent Segment 
- EEM-CSA, mm2 
- Lumen-CSA, mm2 
-
 Stent-CSA, mm2 
-Minimal Stent-CSA, mm2
23.7 ± 11.4 
6.1 ± 2.4 
6.5 ± 2.5 
5.8 ± 2.4
19.7 ± 9.2 
6.8 ± 2.1 
7.9 ± 2.5 
6.8 ± 2.2
0.52 
0.55 
0.95 
0.73
Stent Expansion 0.77 ± 0.25 0.80 ± 0.24 0.84
Maximal NIH-CSA, mm2 0.9± 1.2 0.7 ± 0.6 0.12
Incomplete stent apposition (ISA), % (n) 
-max CSA, mm2 
-length, mm
89% (16) 
7.8 ± 6.2 
9.6 ± 10.5
57% (6) 
4.8 ± 1.6 
4.4 ± 2.0
0.04 
0.06 
0.006
Conclusion. In patients with very late ST, SES shows a higher prevalence of ISA and 
larger ISA size than PES. The structural difference appears to be related to differential 
vessel remodelling in response to these devices, suggesting different inflammatory 
processes.
2900-61 Long-term Prognostic Implications of Treatment of 
Multivessel Coronary Artery Disease with Drug-eluting 
Stents Implantation
Piera Capranzano, Dominick J. Angiolillo, Rossella Barbagallo, Alessio La Manna, 
Francesco Tagliareni, Alessandra Sanfilippo, Cettina Ruperto, Gianpaolo Ussia, Alfredo 
R. Galassi, Theodore A. Bass, Corrado Tamburino, University of Catania, Catania, Italy, 
University of Florida, FL
Background: Drug eluting stents (DES) are associated with reduced need for repeat 
revascularization. This has led to hypothesize that percutaneous coronary interventions 
(PCI) with DES may be equivalent to surgical revascularization (CABG) in multivessel 
disease (MVD) patients. However, there are no definitive data to support this hypothesis, 
which has been recently shadowed by the raising concerns regarding the long-term safety 
of DES, particularly in complex patients. The aim of this study was to evaluate long-term 
clinical outcomes of patients undergoing multivessel PCI with DES.
Methods: Patients undergoing PCI with at least one DES (sirolimus- or paclitaxel-eluting 
stent) were collected in the Ferrarotto Hospital DES Registry (n= 1612). For the purpose of 
this analysis, patients undergoing multivessel PCI only with DES were included. Patients 
with any previous revascularization and with concomitant bare metal stent implantation 
were excluded. Major adverse cardiac events (MACE) including cardiac death, non-fatal 
myocardial infarction (MI), need for repeat target vessel revascularization (TVR) were 
recorded. Late (LST) and very late stent thombosis (VLST) were also recorded to define 
the safety of this approach. 
Results: A total of 338 (21%) patients met the study inclusion criteria. During a median 
follow-up of 31.6 months (interquartile range: 24.3-38.9), MACE occurred in 110 (32.5%) 
patients: cardiac death occurred in 18 patients (5.3%), non-fatal MI in 10 pts (2.9%), and 
TVR in 87 (25.7%) patients. The multivariate analysis showed that independent predictors 
of MACE were: triple-vessel disease (HR 2.02 CI 1.39-2.45, p<0.0001), diabetes (HR 
1.74, CI 1.19-2.52, p=0.004) and left ventricle ejection fraction ≤35% (HR 1.86 CI 1.06-
3.26, p= 0.03). LST occurred as follows: definite 0%, probable in 1 (0.3%) and possible 
in 3 (0.9%) patients. VLST occurred as follows: definite in 1 (0.3%), probable in 1 (0.3%) 
and possible in 6 (1.9%) patients.
Conclusions: Multivessel DES implantation can be safely performed on patients with 
complex coronary artery disease, among whom MACE more commonly occur in patients 
with diabetes, triple-vessel disease, and low left ventricle ejection fraction.
2900-62 Long-Term Outcomes of Sirolimus-Eluting Versus Bare-
Metal Stents in Patients Undergoing Percutaneous 
Coronary Intervention: A Single, Tertiary Care Hospital 
Experience
Anuj R. Shah, Jeffrey D. Mather, Jill Courtier, Deborah Murphy, Athanasios 
Kapetanopoulos, Bhupinder Singh, Rameez T. Sayed, Shafeeq Ahmed, Francis J. 
Kiernan, Raymond G. McKay, Hartford Hospital, Hartford, CT
Background: The long-term safety of drug-eluting stents remains controversial. We 
sought to determine long-term outcomes of sirolimus-eluting stents (SES) compared 
to bare-metal stents (BMS) in patients undergoing percutaneous coronary intervention 
(PCI).
Methods: A total of 4448 consecutive PCI patients treated with either SES (n=2976) 
or BMS (n=1472) between 12/ 2002 and 2/ 2007 were included in a propensity analysis 
to adjust for baseline clinical, demographic and angiographic differences between the 
cohorts. The matched-groups (SES, n = 991; BMS, n = 1027) were compared for long-
term outcomes (mean follow-up = 20.3 months; interquartile range 9.4 - 36.2), including 
mortality, myocardial infarction (MI) or repeat target lesion revascularization (TLR).
Results: In follow-up over 3 years in an unadjusted or adjusted Cox regression analysis, 
SES demonstrated a significant benefit over BMS for the composite end point of death, 
MI or repeat TLR (p<0.001: Hazard Ratio (HR)=1.6; 95% CI = 1.3 - 2.2), as well as for 
combined death or MI (p = 0.02: adjusted HR = 1.5; 95% CI = 1.1 - 2.1). The stent groups 
did not differ for mortality alone in the adjusted analysis (p = 0.08: adjusted HR = 1.4; 
95% CI = 0.9 - 1.9).
Conclusions: In this single-center registry, sirolimus-eluting stents demonstrated a 
significant protection over bare-metal stents for the composite outcome of death, MI and 
TLR and the combined endpoint of death or MI over a 3-year period. There were no long-
term mortality differences between the stent types.
2900-63 Polymer Integrity and Focal Platelets Deposition on 
Paclitaxel-Eluting Stent After Failure of Direct Stenting 
in Complex Coronary Lesions
Giulio Guagliumi, Giuseppe Musumeci, Roberta Rossini, Frank Kolodgie, Patricia 
Johnson, Vasile Sirbu, Robert Nolan, Laurian Mihalcsik, Ana Vojvodic, Orazio Valsecchi, 
Renu Virmani, Ospedali Riuniti di Bergamo, Bergamo, Italy, CVPath Institute Inc, 
Gaithersburg, MD
Aim: To evaluate the short term mechanical integrity of paclitaxel eluting stents (PES) and 
bare metal stents (BMS) following failure of direct stenting in complex coronary lesions.
Methods: We studied 26 patients (pts; 6 control and 20 test subjects) referred for 
coronary angioplasty. Test subjects, randomized 1:1:2 to BMS Libertè (BMS, n=5), Taxus 
Express2™ (TE2, n=5) and Taxus Libertè™ (TL, n=10), had direct stenting failures (DSF). 
Control stents (2 BMS, 2 TE2 and 2 TL) were inserted into the guide catheter of control 
pts for 2 minutes. All stents were analyzed by Scanning-Electron Microscopy (SEM) for 
a qualitative and semi-quantitative analysis in terms of coating displacement/scratching 
and platelet deposition.
Results: SEM analysis showed no loss of mechanical integrity on DSF. In BMS, a low 
amount of scratches were seen in both controls and DSF. In terms of coating displacement 
3 TE2 test subjects (60%) had coating displacement at strut surface. Both TL test and 
control subjects displayed bare spots on connecting struts. Four TL test group showed 
a tear-like coating displacement on the stent surface (40%; Fig. 1). There was a non 
significant trend of higher platelet density on TL stents compared to others.
Conclusions: DSF does not influence the mechanical integrity of BMS or PES units, but 
seems to be associated with a higher amount of scratches/coating displacement.
Fig. 1 Tear-like coating displacement, present on 4 of the TL test subjects
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2900-64 Do Cobalt Chrome Stent and Paclitaxel-Eluting Stent 
Have Equivalent Clinical Result in Noncomplex Lesion? 
Two-Year Follow-up
Hyeon-Cheol Gwon, on behalf of COPE study investigators, Samsung Medical Center, 
Sungkyunkwan University School of Medicine, Seoul, South Korea
Background: Recent study suggested excessive risk of late stent thrombosis after drug-
eluting stent (DES) implantation. This study was to compare the long-term safety of DES 
comparing bare metal stent (BMS).
Methods: This study was designed as a multicenter prospective randomized trial 
comparing VISION® stent (group V) and TAXUS® stent (group T) in a low risk group. 
Inclusion criteria were 1) stable or unstable angina or silent ischemia 2) treated lesion 
number ≤ 2 in separate vessels 3) target lesion stenosis is 50 - 95%, 3) native vessel 
stentable with at least 3.0-4.0 mm stent, and 4) lesions fully covered by one stent (length 
≤ 28 mm).
Results: Total 481 patients from 11 centers in Korea were included in this study. Two-year 
clinical follow-up was completed in 472 patients (98.1%). The baseline characteristics 
were similar between group V and T, except higher proportion of left anterior descending 
artery location in group T (V 34.6%, T 51.0%, p=0.001). Major adverse cardiac event 
and stent thrombosis rate (definite or probable stent thrombosis by ARC definition) was 
statistically not different between 2 groups for 2 years, and also between 1 and 2 years 
after the procedure. Target vessel revascularization rate was significantly lower in group T 
at 1 year (V 6.9%, T 1.3%, p=0.002), and also at 2 years (V 7.0%, T 2.6%, p=0.03).
Conclusions: Overall safety of DES seems to be similar to BMS for 2 years, without 
excessive risk of death or myocardial infarction as well as stent thrombosis, even in low 
risk patients.
MACE: major adverse cardiac event, TVR: target vessel revascularization, ST: stent 
thrombosis
Group V(N=235) Group T(N=237) p-value
MACE 27(11.4%) 20(8.4%) 0.26
Death 9(3.8%) 11(4.6%) 0.66
Death/MI 11(4.7%) 14(5.9%) 0.55
TVR 16(7.0%) 6(2.6%) 0.03
Subacute ST 1(0.4%) 0(0.0%) 0.31
Late ST 1(0.4%) 0(0.0%) 0.32
Very late ST 1(0.4%) 4(1.8%) 0.18
2900-65 Clinical and Angiographic Predictors of Restenosis and 
Target Lesion Revscularization After Implantation of 
Sirolimus-Eluting Stents in Bifurcation Lesions from 
the j-Cypher Registry.
Toshihiro Tamura, Kazuaki Mitsudo, Takeshi Kimura, Takeshi Morimoto, Kazushige 
Kadota, Hideki Abe, Osamu Doi, Seiichi Haruta, Yasuhiko Hayashi, Kazuo Hazi, 
Yoshikazu Hiasa, Takashi Honda, Naoto Inoue, Takaaki Isshiki, Kazuya Kawai, Atsushi 
Atsushi, Tomohiro Kawasaki, Yukio Kazatani, Masunori Matsuzaki, Taiichiroh Meguro, 
Akira Miura, Toshiya Muramatsu, On behalf of the j-CYPHER Registry investigators, 
Kyoto University Hospital, Kyoto, Japan
Background:The factors associated with the occurrence of restenosis after sirolimus-
eluting stent(SES) implantation in bifurcation lesions are currently unknown.
Methods:Design of the j-Cypher Registry was multi-center prospective enrollment of 
consecutive patients receiving SES from 41 centers in Japan. As of July 31, 2007, long-
term follow-up data were available in 10521 patients underwent successful implantation 
of SES. Target lesion revascularization(TLR) was defined as any revascularization 
procedure involving the target lesion.Among them, we identified 1736 patients(1854 
lesions) who were treated with SES in bifurcation lesions excluding left main coronary 
artery, left anterior discending artery ostium and circumflex coronary artery ostium. 1395 
patients(1500 lesions) were included in group S( finally stenting only main vessel) and 
341 patients(354 lesions) in group C(finally stenting main vessel and side branch). Two 
strategies were selected according to the operators’ discretion. We analyzed clinical 
and angiographic predictors of restenosis and TLR at long-term (follow-up period was 
462.6±222.7 days).
Results:783 lesions(43.4%) were true bifurcations.Follow-up angiography was 
performed on 59.4% lesions. Restenosis rate was 20.1%(main vessel:8.6% and side 
branch:14.1%) and TLR rate was 6.5%. There was no significant differences in restenosis 
rate between group C and S(18.0% and 20.6%, p=0.39). However the incidence of TLR 
was significantly higher in group C than group S(11.6% vs 5.3%, p<0.0001). With regard 
to angiographic restenosis, postprocedural side branch diameter stenosis was associated 
with a higher risk among baseline angiographic parameters. In the multivariable analysis 
of TLR, hemodialysis, total stent length, two stent approach and postprocedural main 
branch reference diameter were the strongest predictors.
Conclusions:For SES placement in bifurcation lesions, there was no significant 
differences in restenosis rate between group C and S. However hemodialysis, total stent 
length, two stent approach and postprocedural main vessel reference diameter were the 
most important predictors of TLR.
2900-66 Balancing the Risks of Restenosis and Stent 
Thrombosis in Bare-metal Versus Drug-eluting Stents: 
Results of a Decision Analytic Model
Pallav Garg, David Cohen, Thomas Gaziano, Laura Mauri, Brigham and Women’s 
Hospital, Harvard Medical School, Boston, MA, Saint Luke’s Mid-America Heart 
Institute, University of Missouri-Kansas City, Kansas City, MO
Background: While there are robust data on the restenosis benefit of drug-eluting (DES) 
vs. bare metal stents (BMS), the incremental risk of stent thrombosis, a rare but serious 
complication of percutaneous coronary intervention (PCI), is not known with certainty. We 
sought to define what incremental risk of very late stent thrombosis (VLST; >1 year) in 
DES would outweigh the restenosis benefit.
Methods: We developed a decision analytic Markov model comparing DES vs. BMS 
strategies for a contemporary PCI population. Procedure-related morbidity and mortality 
data from published literature were used to derive the model probabilities. Over a range of 
incremental risk and duration of risk of VLST, we identified the net benefit of DES vs. BMS 
in terms of quality-adjusted life expectancy (QALE).
Results: Beyond the first year of follow up, the threshold excess risk of very late DES 
thrombosis compared with BMS, above which BMS would be the preferred strategy, was 
0.14% per year (over 4 years of follow up). Under an assumption of equal stent thrombosis 
rates beyond year one, the DES strategy was superior to BMS in terms of quality-adjusted 
life expectancy (16.262 vs. 16.248 QALYs, difference = 0.014), but under the assumption 
of an incremental risk difference of 0.13% per year, the net benefit was substantially 
reduced (difference = 0.001 QALYs). This threshold increased as the population risk of 
restenosis increased and decreased as the vulnerable time window lengthened.
Conclusion: A small absolute increase in DES thrombosis compared with BMS after year 
1 (>0.14% per year) would result in BMS being the preferred strategy for the overall PCI 
population. Larger clinical trials with longer follow-up are needed to estimate the risk of 
very late stent thrombosis with greater certainty for existing and new drug-eluting stents.
2900-67 Clinical Correlates of Definite Drug-eluting Stent 
Thrombosis a Matching Case Control Analysis
Tina L. Pinto Slottow, Daniel H. Steinberg, Probal Roy, Teruo Okabe, Saquib Samee, 
Rebecca Torguson, Kimberly Smith, Zhenyi Xue, Joseph Lindsay, Augusto D. Pichard, 
Lowell Satler, William O. Suddath, Kenneth Kent, Ron Waksman, Washington Hospital 
Center, Washington, DC
Background: Stent thrombosis (ST) is a concerning but rare adverse outcome of drug-
eluting stent (DES) placement. Accurate determination of potential predisposing factors 
is challenging.
Methods: Each of the 80 patients with definite DES ST was matched to 5 patients 
without ST who underwent initial DES implant on the same day as the ST patient. Implant 
characteristics were compared and a conditional logistic regression model was created, 
controlling for age; sex; diabetes; hypertension; dyslipidemia; current smoking; history 
of renal impairment; myocardial infarction (MI) during admission; restenosis lesion; and 
stent number, diameter, and length.
Results: Baseline demographics were similar with a population that was 64% male and 
39.1% diabetic with a mean age of 63.6±13.1. The ST group had a higher incidence 
of current smokers, patients with MI during admission, and patients with restenotic 
lesions when compared to the no ST group. DES length and diameter were similar, but 
significantly more stents were implanted in the ST group. A multivariate model found ST 
to be independently associated with MI during admission, DES placement in a restenotic 
lesion, and number of stents deployed.
Conclusions: DES ST is an infrequent but highly morbid occurrence independently 
associated with MI during admission, DES placement in a restenotic lesion, and number of 
stents deployed. Careful consideration is warranted when using DES in these settings. 
Patient Characteristics (%) No ST 
n=400
ST 
n=80 p value
Age (years) 64.1±13.3 61.1±12.1 0.064
Male 65 58.8 0.288
Diabetes mellitus 37.3 48.1 0.072
Hypertension 82.6 77.5 0.284
Hypercholesterolemia 84.8 82.5 0.597
Current smoker 17.3 31.3 0.004
Chronic renal insufficiency 13.2 116.5 0.448
Myocardial infarction during admission 20.2 39.2 <0.001
Restenotic lesion (lesion-based) 4.1 10.8 <0.001
Number of stents (number) 1.7±0.9 2.0±1.1 0.015
Stent diameter (mm) 3.1±1.6 3.1±1.5 0.902
Stent length (mm) 20.4±6.2 20.8±6.9 0.608
Multivariate Analysis Odds Ratio 95% CI p value
MI during admission 2.5 1.4-4.4 0.002
Restenotic lesion 4.8 2.0-11.3 <0.001
Number of stents 1.6 1.2-2.2 0.003
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2900-68 Comparison of Incidence and Clinical Features of 
Coronary Stent Fracture after Sirolimus-Eluting Stent 
Implantation versus Bare Metal Stent Implantation
Yoshiharu Nishibori, Hiroshi Fujita, Akiko Matsuo, Kiyonari Matsuo, Yasutsugu Shiono, 
Naohiko Nakanishi, Shin-ichiro Yamaguchi, Keiji Inoue, Tetsuya Tanaka, Makoto 
Kitamura, Kyoto Second Red Cross Hospital, Kyoto, Japan
Background: In the bare metal stent (BMS) era, stent fracture was reported mostly in 
femoral stenting. However, since drug-eluting stent introduction, stent fracture started 
to be highlighted as a new potential mechanism of coronary restenosis after sirolimus-
eluting stent (SES) implantation. The aim of this study was to evaluate the incidence and 
clinical features of stent fracture after SES implantation versus BMS implantation.
Methods: We identified consecutive 462 patients who underwent revascularization with 
sirolimus-eluting Bx Velocity® stent from August 2004 to January 2007 (SES group). A 
control group was composed of 453 patients treated with standard Bx Velocity® stent 
preceding 30 months before the introduction of SES (BMS group). Stent fracture was 
identified by fluoroscopic evidence at follow-up angiogram.
Results: Angiographic follow-up rate was 92.0% (425/462) and 89.4% (405/453) in SES 
group and in BMS group, respectively. There were no significant differences in baseline 
patients’ characteristics between both two groups. The incidence of stent fracture in SES 
group was significantly higher (4.6% vs. 0.3%, p<0.001). The frequency of type B2/C 
lesion in SES group was significantly higher (76.1% vs. 67.8%, p=0.012). Especially, the 
frequency of total occlusion was 4.3% in SES group and 0.3% in BMS group (p<0.001). 
Maximum stent inflation pressure in SES group was significantly higher (19.6 +/- 2.36atm 
vs. 14.1 +/- 1.97atm, p<0.001). Implanted stent length per lesion in SES group was 
significantly longer (28.9 +/- 16.3mm vs. 15.9 +/- 4.56mm, p<0.001). And the frequency of 
patients with multiple overlapping stenting in SES group was significantly higher (30.2% 
vs. 3.0%, p<0.001).
Conclusions: Incidence of stent fracture of SES group was significantly higher than 
BMS group. However, rather than a specific problem with SES, stent fractures might be 
caused by complex lesion morphology and/or stenting techniques such as higher stent 
inflation pressure, long stenting, multiple overlapping stenting. Future studies should 
evaluate treatment strategy for SES restenosis with stent fracture.
2900-69 Clinical Outcomes Among 210 Patients With Definite/
Probable Stent Thrombosis
Tina L. Pinto Slottow, Daniel H. Steinberg, Probal Roy, Teruo Okabe, Saquib Samee, 
Zhenyi Xue, Kimberly Smith, Rebecca Torguson, Joseph Lindsay, Augusto D. Pichard, 
Lowell Satler, William O. Suddath, Kenneth Kent, Ron Waksman, Washington Hospital 
Center, Washington, DC
Background: Stent thrombosis (ST) is the most concerning adverse outcome of drug-
eluting stent (DES) placement.
Methods: Clinical outcomes of patients experiencing definite and definite/probable ST 
by the Academic Research Consortium definitions among the 8403 patients undergoing 
unrestricted percutaneous coronary intervention (PCI) with DES since April 2003 were 
examined. Clinical outcomes to 2 years of the patients with definite or probable ST were 
compared to those without ST.
Results: Baseline demographics were similar; the population was 65.4% male with a 
mean age of 64.5±12.2 years. 83 patients presented with 84 definite ST events. 210 
patients were adjudicated to have experienced definite or probable ST events. Outcomes 
in both groups were uniformly poorer with a much higher incidence of death, Q-wave 
myocardial infarction, and target vessel revascularization up to 2 years when compared 
to patients who did not experience definite or probable ST. (Table)
Conclusions: DES ST is an infrequent but highly morbid occurrence. 
Definite ST No ST ST p value
Outcomes - 1 year (%) n=4576 n=73
Death 6.1 25.4 <0.001
Myocardial infarction 1.6 48.5 <0.001
Target vessel revascularization 7.9 68.5 <0.001
Outcomes - 2 years (%) n=2994 n=66
Death 12.8 33.9 <0.001
Myocardial infarction 3.0 67.7 <0.001
Target vessel revascularization 15.1 83.3 <0.001
Definite/Probable ST No ST ST p value
Outcomes - 1 year (%) n=4459 n=184
Death 4.8 45.7 <0.001
Myocardial infarction 0.3 61.4 <0.001
Target vessel revascularization 7.6 47.9 <0.001
Outcomes - 2 years (%) n=2895 n=155
Death 10.8 58.1 <0.001
Myocardial infarction 0.4 83 <0.001
Target vessel revascularization 14.5 70.9 <0.001
2900-70 A Restricted Drug-eluting Stent Strategy in Patients 
Undergoing Non-urgent PCI Shows One-year Clinical 
Outcome Comparable to 100% DES Use
Marcel A. Beijk, Fazil M. Alidjan, Karel T. Koch, José P. Henriques, René J. van der 
Schaaf, Jan Baan, Jr., Marije M. Vis, Jan G. Tijssen, Jan J. Piek, Robbert J. de Winter, 
Academic Medical Center - University of Amsterdam, Amsterdam, The Netherlands
Background: Drug-eluting stents (DES) have shown a reduction in restenosis compared 
to bare metal stents (BMS). However, the benefit of DES may be limited in large vessels, 
short lesions and non-diabetic patients. Furthermore, concerns have risen about the long-
term safety of DES with respect to late stent thrombosis.
Our study reports the 1-year clinical outcome of a large cohort of patients undergoing 
non-urgent PCI applying a restricted DES strategy, i.e. using a DES in complex lesions 
with an increased risk of restenosis. Lesions with a low risk of restenosis were treated 
with BMS.
Methods: Between September 2002 and September 2005, a total of 3208 patients 
underwent a successful non-urgent PCI for a de novo coronary artery lesion. 2632 
patients were treated for non-complex lesions with solely BMS, 442 patients were treated 
with DES for at least one complex lesion, and 134 were treated with angioplasty. Lesions 
with an increased risk of restenosis were defined as a chronic total occlusion, lesions 
≥20mm in length, vessel diameter ≤2.8mm and all lesions in diabetic patients. Patients 
received dual anti-platelet therapy for 1 month after BMS and 6 months after DES. Clinical 
follow-up was obtained at one year.
Results: As per strategy, there were more diabetic patients in the DES-group (28% 
DES-group vs 18% BMS-group), lesions treated with DES were more often type C (44% 
vs 18%) and CTO (29% vs 12%), and were treated with longer stents (25±11mm vs 
17±6mm). At 1-year follow-up, the overall MACE rate was 11% which compares well to 
the results reported in the RESEARCH registry in which 100% DES was used. MACE 
in the BMS-group was 11% and in the DES-group 10%, percutaneous target vessel 
revascularization in the BMS-group was 7.5% compared to 4.7% in the DES-group. There 
was no difference in death or myocardial infarction. The total incidence of definite and 
probable stent thrombosis was 2.7% in the BMS-group and 3.6% in the DES-group.
Conclusions: This large study demonstrates that a restricted DES strategy in patients 
undergoing non-urgent PCI show 1-year clinical outcome and MACE rates comparable to 
100% use of DES. This strategy avoids the need for long-term dual anti-platelet therapy 
in the majority of stented patients.
2900-71 Long-term Struts Coverage of Paclitaxel Polymer-
eluting Stents Implanted During ST Elevation 
Myocardial Infarction
Giulio Guagliumi, Vasile Sirbu, Giuseppe Musumeci, Alexander Matiashvili, Roberta 
Rossini, Ana Vojvodic, Laurian Mihalcsik, Marco A. Costa, Orazio Valsecchi, Ospedali 
Riuniti di Bergamo, Bergamo, Italy, Case Western Reserve University, Cleveland, OH
Background: The use of drug eluting stents in ST elevation myocardial infarction 
(STEMI) remains controversial due to the risk of stent thrombosis. Uncovered stent struts 
were identified by pathology as the main predictor of late stent thrombosis. This study 
aimed to evaluate long-term stent strut coverage in patients (pts) treated with paclitaxel 
polymer eluting stents (Taxus Express2TM; PES) during STEMI using high resolution 
optical coherence tomography (OCT), which allows accurate assessment of in-vivo stent 
strut coverage at a micron-scale resolution (10 Μm).
Methods: We studied 30 consecutive STEMI pts with baseline TIMI 0-1 flow who 
underwent primary angioplasty using PES (n=51) and completed 12 month follow-up 
assessment with OCT imaging of the target vessel. OCT was performed with an automatic 
pullback at 15 frames/sec (1 mm per sec). Quantitative analysis of neointimal thickness, 
stent strut coverage and apposition was performed throughout the entire stent at every 
0.5 mm. Stent coverage was graded as: covered (>0.01 mm thickness) and uncovered 
struts (<0.01 mm). Clopidogrel and aspirin were mantained for one year in all pts.
Results: All 51 PES (mean length 21±6.9 mm) were evaluated by OCT. A total of 
15217 struts were analyzed. There were 92 (0.6%) malapposed struts and 247 (1.6%) 
uncovered. Mean neointimal thickness was 330±400 Μm. On average, 98.8% struts per 
stent were covered (range: 90.8-100). There were 28 PES (54.9%) which showed all 
struts to be completely covered. Two pts (6.6%) had at least one cross section image with 
> 30% of struts uncovered. There was no evidence of intraluminal thrombus. No stent 
thrombosis occurred during the study.
Conclusions: Strut coverage of PES implanted in the setting of primary PCI was 
almost complete at long-term follow-up as assessed by OCT and malapposition rate was 
relatively low. Whether the frequent finding of at least one uncovered stent strut has any 
clinical implication remains to be evaluated in large prospective clinical trials.
2900-72 The Incidence of Stent Thrombosis in Patients With 
Acute Coronary Syndrome and Stable Angina After 
Drug-eluting Stents Implantation
In Hyun Jung, Seong-Wook Park, Jong-Pil Park, Jae Hyoung Park, Jeong-Woo Lee, Won-
Jang Kim, Duk-Woo Park, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Myeong-
Ki Hong, Jae-Joong Kim, Seung-Jung Park, Asan Medical Center, Seoul, South Korea
Background: Despite the substantial benefit of drug-eluting stents (DES) on the 
suppression the neointimal growth, the long-term safety regarding stent thrombosis (ST) 
has been questioned recently. Data on the difference of the incidence of ST between 
acute coronary syndrome (ACS) and stable angina are limited in patients who underwent 
DES implantation.
Methods: We identified 3,153 patients who underwent DES implantation at our institution 
between Feb. 2003 and Mar. 2006, in whom 1,494 patients (47%) were presented with 
stable angina and 1,585 patients (53%) with ACS. Mean follow up duration was 29.6 ± 
10.0 months.
Results: Stent thrombosis occurred in 66 patients (the cumulative incidence of ST up 
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to 3 years was 2.1%). ST developed more frequently in patients with ACS, as compared 
with those with stable angina (44/1,585 pts (2.8%) vs. 22/1,494 pts (1.5%), p=0.013). 
Mean durations of development of ST in stable angina and ACS group were 30.1 ± 9.7 
and 28.9 ± 10.5 months, respectively. Cox-regression analysis showed that the incidence 
of ST was significantly higher in patients with ACS than that of patients with stable angina 
according to time duration (p=0.010, HR=0.51; 95%, CI 0.30-0.85) (Figure).
Conclusion: Threse results demonstrate that the long-term cumulative incidence of ST 
is significantly higher in ACS than in stable angina patients. Additional pharmacological 
efforts should be necessary to prevent ST in patients with ACS after DES implantation. 
2900-73 Rotational Atherectomy Followed by Drug-Eluting Stent 
Implantation in Calcified Coronary Lesions
Shinichi Furuichi, Giuseppe M. Sangiorgi, Cosmo Godino, Flavio Airoldi, Matteo 
Montorfano, Alaide Chieffo, Iassen Michev, Mauro Carlino, Antonio Colombo, San 
Raffaele Scientific Institute and EMO Centro Cuore Columbus, Milan, Italy
Background: Little is available on the outcome after rotational atherectomy (RA) followed 
by drug-eluting stents (DES) implantation in calcified coronary lesions. The aim of this 
study was to evaluate the outcome of patients with severe lesion calcification undergoing 
RA followed by DES implantation.
Methods: All complications and major adverse cardiac events (MACE), including cardiac 
death, myocardial infarction (MI) and target lesion revascularization (TLR) were recorded 
in-hospital and during follow-up.
Results: A total of 95 patients with 96 de novo severely calcified lesions were included. 
Twenty-nine patients (30.5%) had diabetes mellitus and 3 patient (3.2%) had chronic 
renal failure. There were 12 total occlusions (12.6%) and 23 lesions involving a major side 
branch (24.0%). Bailout RA was performed in 61 lesions (63.5%) because of impossibility 
to cross the lesion with a balloon or impossibility to expand a balloon after crossing. The 
reference vessel diameter was 2.68 ± 0.54 mm. Residual stenosis was 12.4 ± 6.8%. 
The total stent length per lesion was 48.4 ± 24.9 mm. Procedural success rate (< 30% 
residual stenosis with absence of in-hospital MACE) was 96.8%: 3 patients developed a 
non-Q-wave MI during hospitalisation. In addition, 1 minor coronary perforation (type II 
according to the Ellis classification) and 2 spiral coronary dissections (type D according 
to the NIHLBI classification) occurred during the procedure, however, without any 
MACE. The incidence of cumulative MACE was 13.7% at the mean follow-up period of 
14.7 months (range 6.0-57.7). Cardiac death occurred in 4 patients (4.2%). Q-wave MI 
occurred in 2 patients (2.1%). The rate of TLR was 9.5%. Two patients (2.1%) had definite 
stent thromboses within 1 week after stenting. The other 2 patients had sudden cardiac 
deaths at 198 days and 537 days after stenting, resulting in possible stent thromboses. 
Among patients with angiographic follow-up (47.4%), no coronary aneurysms were found 
in the stented segments.
Conclusion: RA followed by DES implantation in severely calcified coronary lesions 
appears to be feasible including high rate of procedural success and low-incidence of 
TLR considering this complex lesion subset.
2900-74 Paclitaxel-eluting Stents Blunt the Effect of Diabetes on 
Clinical Restenosis: A Pooled Analysis of the ARRIVE 
Program
D. Lynn Morris, John M. Lasala, David A. Cox, Lazar Mandinov, Donald S. Baim, Albert 
Einstein Medical Center, Philadelphia, PA
Background: Diabetes (DM) is associated with an increased risk of cardiovascular 
events and increased incidence (up to 60%) of restenosis following percutaneous 
coronary interventions compared to non-diabetic (non-DM) patients. In vitro, paclitaxel 
inhibits smooth muscle cell proliferation even in the presence of insulin resistance. We 
thus assessed whether the paclitaxel-eluting TAXUS Express (TE) stent reduces clinical 
restenosis as effectively in DM as in non-DM patients.
Methods: TE patients (1530 DM and 3242 non-DM) from the ARRIVE 1 and 2 registries 
were pooled, excluding patient characteristics globally contraindicated for TE*. Clinical 
events were evaluated at 1 year (95.5% follow-up) for DM and non-DM. Baseline 
differences were adjusted by propensity score.
Results: DM patients had more cardiac risk factors and comorbidities than non-DM, with 
an anticipated increase in 1-year mortality. However, TE-related cardiac death, MI, and ST 
were similar in DM and non-DM. TVR and TE-related TVR were nearly identical between 
groups. These findings were maintained following propensity score adjustment.
Conclusion: This study suggests that despite the known higher mortality rate for DM vs. 
non-DM, the TE stent has similarly low rates of stent-related death, MI, ST, and MCE in 
DM and non-DM. Moreover, the essentially equal rates of TVR and TAXUS-related TVR in 
indicated patients* with or without DM suggest that the TE stent can mitigate the adverse 
effect of diabetes as a risk factor for restenosis. 
Unadjusted Values, % (n) Adjusted for Propensity Score (%)
Non-
Diabetic 
N=3110
Diabetic 
N=1447 P-value
Non-
Diabetic Diabetic P-value
Major cardiac 
events† 7.5 (232) 9.1 (132) 0.053 7.6 8.9 0.16
--TAXUS-related 5.4 (169) 5.7 (82) 0.74 5.6 5.7 0.80
Cardiac death 1.3 (39) 2.5 (36) 0.0023 1.2 2.3 0.0142
--TAXUS-related 0.7 (23) 1.0 (15) 0.30 0.7 1.0 0.29
Myocardial 
infarction 1.6 (51) 1.8 (26) 0.70 1.6 1.8 0.67
--TAXUS-related 1.2 (38) 1.6 (23) 0.31 1.2 1.6 0.26
TVR 5.8 (179) 6.1 (88) 0.66 6.0 6.1 0.80
--TAXUS-related 4.4 (136) 4.1 (60) 0.73 4.5 4.3 0.70
All-cause Death 2.4 (75) 3.9 (56) 0.0060 2.3 3.7 0.0155
Stent thrombosis 
(per protocol)‡ 1.3 (40) 1.5 (21) 0.65 1.3 1.5 0.59
ARC ST (definite or 
probable) 1.3 (39) 1.6 (23) 0.36 1.2 1.7 0.29
*Patients with the following characteristics were excluded: vein graft stenting, 
bifurcation, left main stenting, cardiogenic shock, severe calcification, direct stenting of 
a total occlusion, thrombus present, severely tortuous vessels, or a total stent length 
>64 mm. 
†Major Cardiac Events (MCE) include target vessel revascularization (TVR), myocardial 
infarction (MI), and cardiac death. 
‡Includes angiographically confirmed and presumed stent thrombosis.
2900-75 Greater Healing Is Observed in Very Late Versus Late 
Drug-eluting Stent Lesions in Man
Gaku Nakazawa, Elena Ladich, Aloke V. Finn, Erik K. Mont, Robert Kutys, Allen P. 
Burke, Frank D. Kolodgie, Renu Virmani, CVPath Institute, Inc, Gaithersburg, MD
Background: Delayed arterial healing is the hallmark of drug eluting stents (DES) 
however, it remains unknown when healing is complete. We therefore examined our DES 
autopsy registry to investigate the differences in late and very late DES lesions.
Methods: From a total 181 DES lesions, 86 were late (30-360 days), and 47 were very 
late (>360 days). Analysis for fibrin deposition, strut coverage, inflammation score, and 
presence of giant cells was compared between late and very late lesions in those with and 
without acute stent thrombus (ST).
Results: The incidence of ST was equal in late and very late lesions (23% vs. 26%). 
Patent (non-ST) very late DES lesions showed better healing with significantly less 
uncovered struts and fibrin deposition compared to patent late DES lesions. Among ST 
lesions, delayed arterial healing was observed in both late and very late lesions with poor 
strut coverage and moderate fibrin depositio n (Table). The underlying pathologic risk 
factors specific for very late ST lesions were bifurcation, hypersensitivity reaction, and 
penetration of necrotic core in acute myocardial infarction patients.
Conclusions: DES healing was greater in very late versus late lesions in patent lesions. 
Stents with late and very late ST did not show significant differences in healing except for 
a decrease in fibrin score. The main underlying morphologic findings of very late ST are 
bifurcation, hypersensitivity reaction, and penetration of necrotic core in acute myocardial 
infarction patients.
Comparison between Late vs. Very Late DES Lesions in those with and without stent 
thrombosis
Non-ST 
Late 
(30-
360days)
Non-ST 
Very Late 
(360-
1800days)
p value 
for Non-
ST
ST 
Late 
(30-
360days)
ST 
Very Late 
(360-
1800days)
p 
value 
for ST
EEL, mm2 12.9±4.7 14.6±4.9 0.18 17.9±4.4 15.6±4.4 0.12
Stent Area, mm2 6.7±3.1 7.2±2.6 0.52 8.2±2.3 7.0±1.2 0.08
Stent length, mm 20.1±8.4 23.3±15.7 0.30 25.6±11.9 28.5±13.3 0.51
Neointimal 
thickness, mm 0.14±0.14 0.17±0.12 0.29 0.11±0.12 0.12±0.07 0.75
Inflammation score 1.1±1.1 1.2±0.8 0.50 1.2±1.3 2.6±2.1 0.09
Fibrin Score 1.7±1.3 0.9±1.0 0.04 2.8±1.0 1.6±1.2 0.005
Struts with fibrin, % 51±29 31±30 0.02 59±23 49±21 0.24
Struts with Giant 
cells, % 24±26 16±13  0.16 9±15 13±21 0.53
Uncovered / Total 
Struts 0.3±0.3 0.1±0.1 0.004 0.6±0.3 0.5±0.3 0.19
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2900-76 Surgical Treatment with Left Internal Mammary Artery 
Grafting versus Percutaneous Coronary Intervention 
with Drug Eluting Stent Implantation in Patients with 
Proximal Left Anterior Descending Artery Stenosis, 
Suffering from Chronic Stable Angina - Long-term 
Results
Konstantinos Toutouzas, Chrysoula Patsa, Sophia Vaina, Eleftherios Tsiamis, 
Anastasios Spanos, Elli Stefanadi, Manolis Vavouranakis, Eustratios Pattakos, Mathaios 
Panagiotou, Dimitrios Iliopoulos, Ioannis Chlorogiannis, Christodoulos Stefanadis, 
Hippocratio hospital, Athens, Greece
Background: Drug eluting stent (DES) implantation and left internal mammary artery 
grafting (LIMA) are two well-accepted treatment options for significant lesions of the 
proximal left anterior descending artery (pLAD). A limited number of small studies 
comparing the two procedures have shown conflicting results. In our study we performed 
a comparison between LIMA and DES for a single pLAD lesion, in patients (pts) suffering 
from chronic stable angina (CSA).
Methods: We enrolled 317pts with a lesion in the pLAD, who suffered from CSA: 207 
underwent DES implantation and 110pts LIMA grafting. Primary end points were the 
occurrence of major adverse cardiac events (MACE). MACE was defined as: Death, 
myocardial infarction and target lesion revascularization (TLR). The recurrence of angina 
was also evaluated. The pts were followed-up clinically
Results: The incidence of MACE was 5.31% in the DES and 2.72% in the LIMA group 
(p=0.39) during the 26.38±10.15 months follow-up period. TLR was 3.38% after DES and 
0% after LIMA (p=0.10). Recurrent angina occurred in 10pts (4.38%) in the DES group 
and in 7pts (6.36%) in the LIMA group (p=0.60), which were treated medically. The event-
free survival curve was similar in both groups: 94.68% for the DES group versus 97.27% 
for the LIMA (p = 0.14) (Figure).
Conclusion: We demonstrated that DES use in pLAD lesions has comparable long-term 
results with LIMA due to the decreased rate of TLR. Further, large scale, randomized trials 
will establish whether DES will be the treatment of choice.
2900-77 Safety of Protamine After Percutaneous Intervention 
With Drug-eluting Stent: A Retrospective Study
Dmitry Chuprun, Ephron Shohat, Scott Frankel, Mehandi Haran, Nancy Schulhoff, 
Robert Frankel, Maimonides Medical Center, Brooklyn, NY
Background: Reversal of anticoagulation with intravenous Protamine after percutaneous 
coronary intervention (PCI) is a simple and inexpensive method permitting early sheath 
removal. Despite several studies showing the safety of Protamine after percutaneous 
balloon angioplasty or bare metal stent , routine use of Protamine after drug-eluting stent 
(DES) placement has not been adequately evaluated.
Methods: Outcomes in 272 patients who underwent PCI during 2005 and received 
Protamine to normalize activated clotting time for manual sheath removal were reviewed. 
Those patients who underwent Angioseal placement without reversal of heparin during the 
same time period (n=353) served as controls. Postprocedural events in the subsequent 
30 days were analyzed.
Results: The two groups of patients were well matched according to demographic, 
clinical and procedural characteristics. A majority of the patients (92.5 %) had successful 
placement of DES and 2.6 % had balloon angioplasty alone. Fifty seven percent of 
the procedures were urgent or emergent. Two or more stents were placed in 40 % of 
the patients and PCI of more then one vessel was performed in 29%. The incidence 
of cardiovascular complications was not significantly different between the groups. No 
adverse reactions to Protamine were observed. 
Outcomes Protamine group n=272 Angioseal group n=353 P value
Periprocedural MI 10 (3.7 % ) 12 (3.4 % ) 0.852
Acute/subacute thrombosis 1 (0.4 % ) 4 (1.1%) 0.394
Death 1 (0.4%) 0 0.435
Stroke 24 hr after PCI 1 (0.4%) 0 0.435
Peripheral vascular injury 5 (1.8%) 1(0.3%) 0.091
Conclusion: Administration of Protamine after DES placement is not associated with an 
increased incidence of adverse cardiovascular events, even in the setting of high-risk 
procedures.
2900-78 Is Coronary Stent Fracture after Sirolimus-Eluting Stent 
Implantation An Adverse Event?
Yoshiharu Nishibori, Hiroshi Fujita, Akiko Matsuo, Yasutsugu Shiono, Kiyonari Matsuo, 
Naohiko Nakanishi, Shin-ichiro Yamaguchi, Keiji Inoue, Tetsuya Tanaka, Makoto 
Kitamura, Kyoto Second Red Cross Hospital, Kyoto, Japan
Background: Stent fracture is considered as a new potential mechanism of restenosis 
after sirolimus-eluting stents (SES) implantation. The aim of this study was to evaluate the 
prevalence and clinical impact of coronary stent fracture after SES implantation.
Methods: From our prospective institutional database, 336 patients were treated solely 
with SES from June 2004 to August 2006. Among 336 patients, 315 (93.8%) patients 
with a total of 377 lesions underwent follow-up angiography on an average of 240 days 
after the procedure.
Results: Stent fractures were observed in 17 lesions (4.5%). Of the 17 lesions with stent 
fracture, 7 were chronic total occlusion, 4 were diffuse long lesion, and 4 were in-stent 
restenosis lesion. In patients with stent fracture, the number of implanted SES per lesion 
was 2.18±1.29, the mean diameter and length of SES per lesion were 3.01±0.34mm and 
50.9±36.6mm, respectively. Fifteen of the 17 stent fractures were adjacent to the edge 
of previously implanted or overlapping stenting. One stent thrombosis case (1/17) and 
two coronary artery aneurysm cases associated with stent fracture (2/17) were seen in 
patients with stent fracture. Independent predictors of stent fracture were RCA location 
(OR 10.2, 95% CI 2.01-52.57, p=0.005), implanted SES length (>30mm) (OR 11.16, 
95% CI 3.40-36.70, p=0.001), and overlapping stenting (OR 10.15, 95% CI 1.53-79.54, 
p=0.004). In-stent binary restenosis rate was 47.1% (8/17) and 15.0% (54/360) in the 
lesions with stent fracture and without stent fracture, respectively (p<0.001). Whereas 
26 (7.2%) lesions without stent fracture underwent target lesion revascularization (TLR), 
5 (29.4%) lesions with stent fracture underwent TLR (p<0.001). In all lesions underwent 
TLR, only 16.1% (5/31) was with stent fracture.
Conclusions: Stent fracture was associated with complex coronary lesions, long 
stenting and/or multiple overlapping stenting. Stent fracture might be associated with the 
high incidence of TLR. However, lesions with stent fracture underwent TLR were small 
minority group in whole SES restenosis. Coronary stent fracture after SES implantation 
showed relatively favorable long-term prognosis.
2900-79 Left Main Bifurcation Percutaneous Treatment: Is 
Restenosis Influenced by the Type of Drug-eluting 
Stent?
Maria Elena Di Salvo, Gian Paolo Ussia, Piera Capranzano, Giambattista Barrano, 
Anna Caggegi, Alessio La Manna, Carmelo Sgroi, Alfio Monaco, Corrado Tamburino, 
Ferrarotto Hospital, Catania, Italy
Objective: Percutaneous transcatheter angioplasty (PCI) of unprotected left main coronary 
artery (ULMCA) bifurcation stenosis is a challenge for interventional cardiologists. Drug 
eluting stents (DES) showed a low rate of restenosis related to the different techniques. 
The objective of this analysis is to evaluate the mid-term results of bifurcation treatment 
by DES and to study whether restenosis is influenced by the type of implanted DES.
Method and Result: From June 2002 to August 2007 in our Institute PCI with DES of 
ULMCA was performed in 256 consecutive patients and 130 bifurcations were treated: 
106 (82% male, mean age 65.5 ± 9,2 years). Clinical presentation was acute myocardial 
infarction in 6%, unstable angina in 58%, diabetes mellitus was present in 34%, mean 
left ventricular ejection fraction was 49±10%. Techniques used were: culotte in 1 patient, 
V-stenting in 3, modified crush in 33, T-stenting in 27, provisional in 66 pts. In total 206 
DES were implanted: 70 (34%) Cypher, 123 (60%) Taxus and 13 (6%) Endeavor. In 64 
(49%) pts both branches were stented and in 80 (62%) pts kissing balloon was performed. 
Procedural success was 99%. In hospital adverse major cardiac events occurred in 4 
patients (3%) ). One pt died for in-stent subacute thrombosis, one pt had periprocedural 
acute thrombosis, two pts showed acute myocardial infarction. At discharge one patient 
died at three months for non cardiac death. At six months clinical follow up was obtained in 
113 patients, angiography was performed in 83 patients with 10.8% of in stent restenosis. 
In 7 patients in stent restenosis was focal and located at the ostium of circumflex artery, 
in 2 patients it was diffuse. Statistical analysis (we excluded of analysis ABT 578 eluting 
stent, regarding only small group of pts) showed no difference in restenosis incidence 
between Sirolimus and Paclitaxel (p=0.49). The type of technique used for PCI did not 
significantly correlate with the incidence of restenosis (p=0.72).
Conclusion: PCI of ULMC bifurcation with DES is a safe procedure, with good immediate 
and mid term results. The best bifurcation stenting technique has to be identified and 
follow up is not differently influenced by the use of Sirolimus or Paclitaxel stent.
2900-80 Large Registry Analysis of Patients Treated with Drug-
eluting Stents for Off-label Indications: A Comparison 
to Bare-metal Stents
John M. Galla, Sorin J. Brener, Stephen G. Ellis, Cleveland Clinic, Cleveland, OH
Background: The use of drug-eluting coronary stents (DES) for other than FDA approved 
indications has been associated with worse outcomes versus when they are applied for 
on-label indications. Comparisons of outcomes for off-label DES vs. bare-metal stents 
(BMS) use have not been reported. This analysis compared outcomes of DES to BMS in 
lesions categorized as off-label for DES.
Methods: Four thousand and two consecutive patients received coronary stents for an 
off-label DES indication at our institution since the commercial introduction of DES in April 
2003 through July 2007. Off-label indications included ST-segment elevation myocardial 
infarction (STEMI), chronic total occlusion (CTO), bypass graft, in-stent restenosis 
(ISR), long lesions (>30mm for paclitaxel-eluting (PES) or > 28mm for sirolimus-eluting 
stents (SES)) and vessel diameter (3.75mm for PES and 3.5mm for SES). Patients were 
prospectively followed for 3 years for death, myocardial infarction and hospitalization for 
revascularization. Cox proportional hazard analysis was performed including pertinent 
variables and a propensity score for receiving DES vs. BMS (c-statistic = 0.75).
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Results: 2959 (73.9%) patients with at least one off-label indication received at 
least one DES. Predictors of stent choice (odds ratio >1 favors DES) included STEMI 
(OR=0.66, 95%CI 0.52-0.85, p=0.001), ISR (7.13, 5.04-10.08, p<0.0001), lesion located 
within the proximal left anterior descending artery (1.49, 1.12-1.98, p=0.006) and larger 
vessel diameter (0.43, 0.38-0.49, p<0.0001). Compared to BMS, DES was associated 
with a significant reduction in mortality (HR=0.53, 0.42-0.67, p<0.0001). There was 
a trend toward fewer recurrent myocardial infarctions in the DES group (HR=0.66, 
0.38-1.13, p=0.13) with no observed difference in total (target and non-target) vessel 
revascularization rates.
Conclusions: When used in an off-label setting, DES appear to perform at least as well, 
and possibly better, than BMS in similar lesions. Further prospective studies are needed 
to verify these findings that, if confirmed, could alter the indications for DES use.
2900-81 Overlapping Drug-eluting Stents: Intravascular 
Ultrasound Insights From Cobalt Chromium Stent With 
Antiproliferative for Restenosis II (COSTAR II) Trial
Junya Ako, Ichizo Tsujino, Tomomi Koizumi, Katsuhisa Waseda, Yasuhiro Honda, Paul 
G. Yock, Dean J. Kereiakes, Mitchell W. Krucoff, Peter J. Fitzgerald, Stanford Unviersity, 
Stanford, CA, Duke University, Durham, NC
Background The safety and efficacy of overlapping drug-eluting stents (DESs) remain to 
be elucidated. In a subset of patients in COSTAR II trial (a randomized trial comparing 
CoStar cobalt chromium paclitaxel-eluting stent with TAXUS stent), the effects of 
overlapping DESs were examined. The aim of this intravascular ultrasound (IVUS) study 
was to compare the vascular responses of overlapping stenting.
Methods The degree of neointimal proliferation at 9 months follow-up was assessed by 
neointimal volume/stent volume x 100 (%NIV). Late incomplete stent apposition (LISA) 
was defined as separation of at least 1 stent strut from the vessel wall at follow-up, where 
post-procedure IVUS revealed complete apposition. Impaired strut continuity was defined 
as interrupted continuity of the stent struts.
Results Percent NIV of CoStar stents (19.7±13.4%, n=52) was significantly greater than 
TAXUS stents (10.7±9.9%, n=38). There was no significant difference between single and 
overlapping stenting in %NIV in either stent type (Figure). There were 2 cases of LISA 
in the single stent group (1 CoStar and 1 TAXUS), but none in the overlapping group. 
Impaired strut continuity was found in 13% of the overlapping group (7/53, 3 CoStar and 
4 TAXUS), and 0% (0/37) in the single stenting group.
Conclusions As compared with single stenting, overlapping stents equivalently reduced 
neointimal hyperplasia without excess LISA in both stents. Impaired strut continuity was 
more frequently observed in overlapping stents. 
2900-82 Clinical Implications of Drug-eluting Stent Fracture
Ung Kim, Jong-Seon Park, Won-Jae Lee, Sang-Hee Lee, Geu-Ru Hong, Dong-Gu Shin, 
Young-Jo Kim, Bong-Sup Shim, Yoon-Kyung Cho, Hyung-Seop Kim, Chang-Wook Nam, 
Sung-Wook Han, Seung-Ho Hur, Kwon-Bae Kim, Yoon-Nyun Kim, Sang-Boon Choi, 
Sang-Hoon Seol, Tae-Hyun Yang, Dae-Kyung Kim, Sung-Man Kim, Doo-Il Kim, Dong-
Soo Kim, Tae-Ik Kim, Yeungnam University Medical Center, Daegu, South Korea
Background: Stent fracture (SF) has been suggested as a cause of restenosis and 
cardiac events after sirolimus-eluting stent (SES) implantation. But, we don’t have any 
data about it’s prognosis and optimal therapeutic strategies. We have performed this 
study to evaluate the clinical outcomes of SES fracture. 
Methods: A total of 52 SFs from 42 consecutive patients who were implanted with SES 
in 4 centers were included in this registry. All therapeutic modalities (no treatment, balloon 
angioplasty, stent) were decided by the operator’s decision. Patients were followed up to 
evaluate major adverse cardiac events such as death, myocardial infarction and repeat 
revascularization. Follow up angiography was performed in selected patients.
Results: Average SF number was 1.2 per patients. Mean follow up duration from stent 
implantation to Fx detection was 277±153 days. SF was found with restenosis in 19 of 52 
SF lesions (37%). Ten patients (24%) presented with chest pain and 9 of them showed 
restenosis associated with SF. Twenty seven patients (62%) were treated by medically and 
15 patients (38%) were treated by intervention (stent 10, balloon 5). At long term follow 
up (469±291 days), total 5 MACE have occurred. Four patients (15%) had myocardial 
infarction, and 3 of these were related with very late stent thrombosis in medication arm. 
Otherwise, only 1 patient (7%) had TLR without myocardial infarction in PCI arm. No 
death was found. Conclusions: SF, even if it’s silent, is not safe and careful examination 
to find out the SF and closed attention for the cardiac events are needed.
2900-83 Proximal Calcification May Influence Performance 
of Polymer-based Drug-eluting Stents: A Detailed 
Intravascular Ultrasound Analysis
Ryota Sakurai, Masao Yamasaki, Junya Ako, Yoichiro Hongo, Akiyoshi Miyazawa, 
Seung-Ho Hur, Yasuhiro Honda, Paul G. Yock, Peter J. Fitzgerald, Stanford University, 
Stanford, CA
Background Polymers used in drug-eluting stents may be susceptible to mechanical damage 
during stent delivery. We sought to investigate the potential impact of proximal calcification on 
efficacy of the phosphorylcholine-coated zotarolimus-eluting Driver stent (ZES).
Methods This study enrolled 243 patients who underwent phosphorylcholine-coated ZES 
(n = 187) or uncoated Driver stent (BMS, n = 56) deployment with baseline and 8 months 
intravascular ultrasound (IVUS) examination. Proximal calcified plaque was defined as 
any plaque with superficial calcium arc >180° between the coronary ostium and the 
proximal stent edge detected by baseline IVUS.
Results The prevalence of proximal calcified plaque was similar between BMS and ZES 
(21.4% vs. 19.3%, p = 0.71). In each stent, baseline characteristics were comparable 
between patients with (px-Ca(+)) and without (px-Ca(-)) proximal calcified plaque. At 
8 months, IVUS measurements were similar between the 2 groups in BMS. In ZES, 
although maximum % neointimal area, defined as the maximum of (neointimal area / 
stent area x 100), was greater and minimum lumen area was smaller in the px-Ca(+) 
group than the px-Ca(-) group, volumetric IVUS measurements and angiographic in-stent 
restenosis rates were comparable between the 2 groups, as well as in BMS.
Conclusion Despite the slight increase in focal neointimal proliferation, moderate proximal 
calcification may not significantly attenuate the overall efficacy of phosphorylcholine-
coated ZES. 
Px-Ca(+) Px-Ca(-) p Value
BMS n=12 (21.4%) n=44 (78.6%)
Maximum % neointimal area, % 47.5 ± 19.9 47.1 ± 20.6 0.95
Minimum lumen area, mm2 3.6 ± 1.7 3.9 ± 1.8 0.58
Mean neointimal area, mm3/mm 2.2 ± 1.5 2.4 ± 1.9 0.71
% Neointimal volume, % 31.0 ± 20.0 29.4 ± 17.8 0.78
Mean lumen area, mm3/mm 5.0 ± 2.2 5.5 ± 2.1 0.45
In-stent restenosis rate, % 27.3 27.3 >0.99
ZES n=36 (19.3%) n=151 (80.7%)
Maximum % neointimal area, % 37.8 ± 15.4 32.2 ± 14.5 0.04
Minimum lumen area, mm2 4.2 ± 1.5 5.1 ± 1.8 0.01
Mean neointimal area, mm3/mm 1.3 ± 0.9 1.3 ± 0.9 0.77
% Neointimal volume, % 18.9 ± 11.2 16.8 ± 10.8 0.29
Mean lumen area, mm3/mm 5.8 ± 1.9 6.4 ± 1.9 0.07
In-stent restenosis rate, % 8.8 6.9 0.72
2900-84 Long-term Prognosis and Its Predictors in Non-left Main 
Coronary Bifurcation Lesion After Drug-eluting Stent 
Implantation
Myeong-Ki Hong, Chang-Bum Park, Cheol Whan Lee, Duk-Woo Park, Won-Jang Kim, 
Jong-Pil Park, Jeong-Woo Lee, Jae Hyoung Park, Gyung-Jung Kim, Seung-Whan Lee, 
Young-Hak Kim, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park, Asan Medical 
Center, Seoul, South Korea
We evaluated the long-term prognosis and its predictors in 430 patients (male: 75% and 
mean ages: 60.1 years) with non-left main coronary bifurcation lesions after drug-eluting 
stent implantation. Stenting technique consisted of simple cross-over technique in 337 
lesions (78%), crushing technique in 60 (14%), T-stenting in 12 (3%), kissing stenting 
in 10 (2%) and others in 11 (3%). Intravascular ultrasound (IVUS)-guided stenting was 
performed in 300 lesions (70%). Total stent length was 33.7±16.6mm. Major adverse 
cardiac events (MACE) were defined as cardiac death, acute myocardial infarction (AMI) 
or target lesion revascularization (TLR). Death, AMI, TLR and stent thrombosis was 
defined according to ARC criteria. Six-month angiographic follow-up was performed in 
311 patients (72% follow-up rate). Qualitative angiographic analysis data in both main 
vessel and side branch was shown in Table. Overall angiographic restenosis rate was 
15.4% (7.7% in main vessel and 9.6% in side branch). Incidence of stent thrombosis by 
ARC definition was 0.2% of late stent thrombosis and 0.9% of very late stent thrombosis. 
Three-year MACE free survival rate was 92.7%. By multiple logistic regression analysis, 
the independent predictors for MACE were left ventricular (LV) ejection fraction (EF) 
(p=0.048, OR=0.95, 95% CI:0.91-0.99), use of IVUS (p=0.017, OR=0.25, 95% CI:0.08-
0.78) and multi-vessel coronary intervention (p=0.006, OR=5.33, 95% CI:1.58-17.91). 
In conclusion, 1) simple cross-over stenting technique was performed in most of non-
coronary bifurcation lesions. 2) Long-term prognosis of non-left main coronary bifurcation 
lesions was quite favorable with overall angiographic restenosis of 15.4% and stent 
thrombosis of about 1%. 3) The independent predictors for MACE were LVEF, use of 
IVUS and multi-vessel coronary intervention.
Table. QCA analysis 
Main vessel Side branch
Reference vessel size, mm 2.9±0.4 2.3±0.4
MLD, pre-intervention, mm 0.9±0.5 1.2±0.7
MLD, post-intervention, mm 2.7±0.4 1.8±0.7
MLD, follow-up, mm 2.4±0.6 1.7±0.6
Acute gain, mm 1.8±0.6 0.7±0.8
Late loss, mm 0.3±0.6 0.2±0.6
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2900-85 Discrepancy Between Intravascular Ultrasound and 
Coronary Pressure Measurement Criteria to Assess 
Optimal Implantation of Sirolimus-eluting Stent
Hong-Seok Lim, Myeong-Ho Yoon, Hyoung-Mo Yang, Seong-Ill Woo, Un-Jung Choi, 
Jung-Won Hwang, Soo-Jin Kang, Byoung-Joo Choi, So-Yeon Choi, Gyo-Seung Hwang, 
Joon-Han Shin, Seung-Jea Tahk, Ajou University Medical Center, Suwon, South Korea
Background: Determination of pressure derived myocardial fractional flow reserve(FFR) 
has been proposed as a means to assess stent deployment. However, data comparing 
morphologic and functional criteria of optimal drug-eluting stent deployment are still 
limited. We investigated the relative value of FFR by comparing it with the intravascular 
ultrasound(IVUS) for evaluating optimal sirolimus-eluting stent(SES) implantation.
Methods: In 46 patients, a SES was implanted in 51 lesions located at proximal to 
mid coronary arteries followed by optional adjuvant dilatation with non-compliant high-
pressure balloon. IVUS assessment and FFR measurement were performed before and 
after the interventional procedure.
Results: Receiver operator characteristic analysis defined a optimal FFR cut point at > 
0.94 for the prediction of optimal stent deployment based on validated IVUS criteria(final 
minimal lumen area(MLA) ≥ 5mm2); at this threshold, the sensitivity, specificity, and 
predictive accuracy of FFR were 50%, 78%, and 62%, respectively. Both optimal IVUS 
and FFR results were achieved in 27 lesions(group A) but, 15 lesions had optimal IVUS 
and suboptimal FFR results(group B). Plaque burden, reference lumen area, final MLA 
and final minimal lumen diameter were not different between both groups. Length of 
stented segments was longer(56 vs. 43mm, p=0.023) in group B than group A.
Conclusions: An FFR > 0.94, measured after SES deployment, predicts an optimal 
result. however, an FFR ≤ 0.94 does not reliably predict an suboptimal stent result. In 
patients treated with multiple long SES implantation, an FFR might underestimate the 
stent result, compared it with IVUS.
2900-86 Prosepective Randomized Six-Month Comparison 
of Coronary Vasomotor Response Associated 
with Zotarolimus- Versus Sirolimus-Eluting Stent: 
Differential Recovery of Coronary Endothelial 
Dysfunction
Jin Won Kim, Byung Won Cheon, Jin Oh Na, Ji Hoon Kim, Cheol Ung Choi, Soon Yong 
Suh, Eung Ju Kim, Seung-Woon Rha, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh, 
Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea
Background: Zotarolimus-eluting stent(ZES: EndeavorTM) have been known to 
carry a lower risk of stent thrombosis due to rapid re-endothelialization. Objective: 
We prospectivley comapred the coronary endothelial dysfunction in patients with a 
Zotarolimus- versus Sirolimus-eluting stent (SES: CypherTM) implantation at 6 months 
follow-up. Methods: In 55 patients (male 21, 54.7±9.5 yrs) randomly treated with IVUS 
guided intervention using single stent to the mid segment of left anterior descending 
artery (20 ZES, 20 SES, 15 BMS: bare metal stent: DriverTM), endothelial function was 
estimated at pre-intervention and post-intervention 6 months follow-up, by incremental 
acetylcholine (Ach1 :10, Ach2: 20, Ach3: 50, Ach4: 100 Μg/min) and nitrate (200 Μg/
min) infusion into the left coronary ostium. The vascular response was quantitatively 
measured in the segment 5 mm proximal and distal to stent. All anti-anginal agents 
were withheld for at least 72 hours prior to coronary angiography. Results: At 6 months 
follow-up, significant vasoconstriction to Ach was observed in DES groups over the BMS 
group (Figure). There was a lesser vasoconstriction to Ach in the segments distal to ZESs 
than SESs (Figure). Conclusions: Vasoconstriction in response to Ach in the peristent 
region was less pronounced in ZES group than SES group at 6 months follow-up, which 
suggests that endothelial dysfunction associated with ZES can be restored more rapidly 
than those of SES. 
2900-87 Treatment of Drug-Eluting Stent Restenosis With the 
Same or Different Drug-Eluting Stent: To Switch or Not 
to Switch
Kimberly A. Smith, Rebecca Torguson, Zhenyi Xue, Daniel H. Steinberg, Tina L. Pinto 
Slottow, Probal K. Roy, Saquib Samee, Joseph Lindsay, Augusto D. Pichard, Lowell 
Satler, William O. Suddath, Kenneth Kent, Ron Waksman, Washington Hospital Center, 
Washignton, DC
Background: Drug-eluting stents (DES) have been proven as an effective treatment for 
bare metal in-stent restenosis (ISR). This study aimed to evaluate treatment of DES ISR 
with the same type versus an alternate DES type for the failed DES.
Methods: A cohort of 166 patients previously treated with a sirolimus-eluting stent (SES) 
or a paclitaxel-eluting stent (PES) who presented with restenosis and angina were treated 
with repeat DES implantation. Of these, 132 had a SES failure and 34 had a PES failure. 
At the time of restenosis, in the SES group 81 patients were treated with repeat SES while 
51 were treated with PES, and in the PES group, 9 patients were treated with repeat PES 
and 25 with SES. Overall, 90 patients were treated with the same DES and 76 received 
the other type of DES. Of these, 138 completed 12-month follow up.
Results: Baseline clinical and angiographic characteristics were similar among the 
groups. At 12 months the TVR-MACE rate for the SES patients treated with repeat SES 
was 25.4%. For SES patients treated with PES was it was 17.8%. For PES patients 
treated with repeat PES it was 28.6% and for PES patients treated with SES it was 26.1% 
with no difference between the groups (p=0.769).The 12-month clinical outcomes were 
similar among the groups (Table).
Conclusions: Switching the DES type for the treatment of DES restenosis does not yield 
better outcome when compared to the same DES, thus other modalities for treatment of 
DES restenosis should be considered.
Table: 12-Month Outcomes 
n (%) Same DES 
n=70
Other DES 
n=68 p value
TVR MACE 18 (25.7) 14 (20.6) 0.476
All Death 2 (2.9) 3 (4.4) 0.678
Q Wave Myocardial Infarction 3 (4.3) 1 (1.5) 0.620
TVR 16 (22.9) 11 (16.2) 0.323
Stent Thrombosis 1 (1.4) 0 (0) 1.000
2900-88 Multiple Versus Single Drug-Eluting Stenting in Patients 
With Small Coronary Lesion
Zhe Jin, Seung-Woon Rha, Kang-yin Chen, Yoshiyasu Minami, Jin Oh Na, Soon Yong 
Suh, Cheol Ung Choi, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, 
Dong Joo Oh, Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea
Background: Percutaneous coronary intervention (PCI) in patients (pts) with small vessel 
and diffuse disease is challenging because of the higher chance of recurrence even in the 
drug-eluting stent (DES) era. The efficacy and safety of multiple DES implantations in pts 
with diffuse long and small vessel is largely unknown.
Methods: From Sep, 2004 to Dec 2006, a total 104 pts with small vessel (diameter≤2.50 
mm), de novo coronary artery lesions were treated with DES. Two or more DESs were 
implanted in 24% of the enrolled pts. Mid-term angiographic outcomes, clinical outcomes, 
and the survival and freedom from MACEs of the Multi-stenting group (25 pts, 53 lesions) 
were compared with those of Single stent group (79 pts, 79 lesions).
Results: In this study, 25 pts received two or more DESs (DES/pt=2.12 ± 0.33). The 
baseline characteristics were matched between the two groups. The percentage of 
precedure success was high and there was no difference between the two groups (100% 
vs. 97.3%, P=0.517). At 6-month, the overall incidence of binary restenosis was in 23.1%. 
However, there was no significant difference between the two groups. Overall clinical 
outcomes were similar (Table) and during the 6-month follow up, the survival and freedom 
from MACEs was similar between DM and non DM group (96.0% vs. 96.2%, p=1.000).
Conclusion: Multiple DES implantations in pts with small vessels and diffuse long disease 
are safe and effective. Although the implanted stent number might not impact on the 
survival and freedom from MACEs after PCI at mid-term follow up, but the incidence 
of binary restenosis remained high, which need long-term follow up with larger study 
population.
Table. Clinical and angiographic outcomes at 6 Months 
Variables, n (%) Multi-stenting group (n=25 pts, 53 lesions)
Single stenting group 
(n=79 pts, 79 lesions) P value
Binary restenosis, % 26.7 20.8 0.552
Late lumen loss, mm 0.83 ± 0.70 0.74 ± 0.73 0.564
Total death 1 (4) 2 (2.5) 0.566
Q wave MI 0 (0) 0 (0) --
TLR 0 (0) 0 (0) --
TVR 0 (0) 1 (1.3) 1.000
Total MACE, n (%) 1 (4) 3 (3.8) 1.000
Stent thrombosis 1 (3.3) 0 (0) 0.240
2900-89 Midterm Outcomes of Drug-Eluting Stent Implatation in 
Patients With Small Vessel Disease
Zhe Jin, Seung-Woon Rha, Kang-yin Chen, Yoshiyasu Minami, Jin Oh Na, Soon Yong 
Suh, Cheol Ung Choi, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, 
Dong Joo Oh, Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea
Background Drug-eluting stents (DES) have provided a significant innovation for 
preventing in-stent restenosis. Small vessel diameter is a risk factor of in-stent restenosis 
following percutaneous coronary intervention (PCI). In this study, we evaluated the 
efficacy of PCI with DES in patients (pts) with small coronary lesions.
Methods From Sep 2004 to Dec 2006, a total of 735 pts (1064 lesions) with coronary 
artery lesions were treated with DES (Cypher or Taxus). The enrolled pts were divided 
into two groups according to the target vessel diameter: Small vessel group (≤2.5mm) and 
Non-small vessel group (>2.5mm). The procedural, angiographic and clinical outcomes 
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were compared up to 6 months.
Results In this study, 176 pts (200 lesions) were included in small vessel group and 
559 pts (864 lesions) in Non-small vessel group. The clinical and angiographic baseline 
characteristics were similar between the two groups. The percentage of procedure 
success was high and there was no difference between the two groups (97.9% vs. 97.6%, 
p=0.820). At 6 month, although the incidence of binary restenosis was higher in the small 
vessel group, but the clinical outcomes were not different between the two groups (Table). 
At 6-month follow up, the survival and freedom from MACEs was similar between the two 
groups (96.5% vs. 95.8%, p=0.549). Conclusion The procedural success, survival and 
freedom from MACEs were high in pts who had small coronary lesions undergoing PCI 
with DES up to mid-term follow up despite the incidence of binary restenosis was higher. 
The long-term clinical outcomes of this particular subset of patients should be evaluated 
with a larger study population.
Table. Clinical and angiographic outcomes at 6 Months 
Variables, n (%) Small vessel group (n=176 pts, 200 lesions)
Non-small vessel group 
(n=559 pts, 864 lesions) P value
Binary restenosis, % 21.3 9.3 <0.001
Late loss, mm 0.76 ± 0.68 0.69 ± 0.66 0.174
Total death 6 (3) 28 (3.3) 0.697
Cardiac death 4 (2) 17 (2) 0.976
Q wave MI 0 0 --
TLR 0 0 --
TVR 1 (0.5) 9 (1) 0.474
Total MACE 7 (3.5) 37 (4.3) 0.617
Stent thrombosis 1 (0.5) 0 () 1.000
2900-90 Eight-Month Volumetric IVUS Analysis in DM and Non-
DM Patients Treated With XIENCE V Everolimus-Eluting 
Coronary Stent
TAKAO SHIMOHAMA, Junya Ako, Masao Yamasaki, Ichizo Tsujino, Ali H.M. Hassan, 
Takao Hasegawa, Ryota Sakurai, Katsuhisa Waseda, Paul G. Yock, Yasuhiro Honda, 
Krishnankutty Sudhir, Gregg W. Stone, Peter J. Fitzgerald, Stanford University Medical 
Center, Stanford, CA
Background:Although drug-eluting stents markedly reduce neointimal hyperplasia in 
coronary lesions, diabetes remains a risk factor for restenosis after stenting. The aim 
of this study was to evaluate vessel response to the XIENCE V everolimus-eluting stent 
implantation in the treatment of diabetic patients.
Methods:Eight-month IVUS follow-up was performed in 115 lesions (36 DM: 79 non-
DM) treated with XIENCE V. Volume index (volume/length) was calculated for vessel 
(VVI), plaque (PVI), neointima (NIV), and lumen (LVI). Cross-sectional narrowing (CSN) 
was defined as neointimal area divided by stent area (%). To evaluate the length of 
severe narrowing, IH50 (% stent length with CSN >50% along the stented segment) 
was calculated. Neointima-free frame ratio was defined as the number of frames without 
IVUS-detectable neointima divided by the total number of frames.
Results:No difference was observed in %NIV (NIV/stent volume) or max %CSN between 
the DM and non-DM groups, resulting in equivalent LVI and minimum lumen area (MLA) 
at 8 months. IH50 and neointima-free frame ratio were also similar between the 2 groups. 
Both groups showed no significant peri-stent remodeling (VVI and PVI) during 8 months. 
One subject with late-acquired incomplete stent apposition was observed in the DM 
group.
Conclusions:The XIENCE V everolimus-eluting stent demonstrated significant 
suppression of neointimal hyperplasia with no increased adverse vessel response in 
diabetic patients up to 8 months.
DM Non-DM P Value
Baseline MLA, mm2 4.7±1.4 5.2±1.6 0.24
Follow up MLA, mm2 4.3±1.5 4.8±1.9 0.26
% NIV, % 8.3±7.9 6.5±6.0 0.17
Max CSN, % 24.0±17.3 21.0±14.6 0.33
IH50, % 0.82±2.88 0.28±2.41 0.31
Neointima-free frame ratio, % 33.3±28.9 35.8±29.1 0.67
2900-91 Late Restenosis After Sirolimus-Eluting Stent 
Implantation: The Impact of Lesion Complexity
Kazushige Kadota, Kazuaki Mitsudo, Katsumi Inoue, Tsuyoshi Goto, Satoki Fujii, 
Hiroyuki Yamamoto, Yasushi Fuku, Harumi Kato, Shingo Hosoki, Akitoshi HIrono, Seiji 
Habara, Kanjyo Yamamoto, Daiji Hasegawa, Masao Imai, Kurashiki Central Hospital, 
Kurashiki, Japan
Background:Despite reassuring long-term results from both FIM and RAVEL studies, 
the issue of concern is the possibility of late restenosis after sirolimus-eluting stent 
(SES) implantation, especially in complex lesions. We evaluated the prevalence of late 
restenosis after SES implantation and the effect of lesion complexity. Methods:From 
Nov. 2002 to Dec. 2005, 1333 consecutive patients (2186 lesions) were treated with 
SES and underwent the early follow-up (f/u) CAG after 6-8 months; the f/u rate 82.4% 
(1803 lesions). The late f/u CAG was conducted after 12 months for 1294 of the above 
1570 lesions without restenosis; the f/u rate 82.4%. Early restenosis is defined as one 
at the early f/u and late restenosis at the late f/u without early restenosis. The lesions 
were categorized as complex or non-complex according to the following definition based 
on SIRIUS trial; bifurcation, ostial, severely-angulated, proximal tortuous, LMT, graft, 
thrombus-containing, in-stent restenosis, total stent length >36mm, implanted stent 
number >2, 2.25mm stenting lesions and AMI and HD patients.
Results:Early/late restenosis and target lesion revascularization (TLR) rates were 
shown in table.
Conclusions:Both early/late restenosis rates after SES implantation were higher 
in complex lesions than in non-complex ones. Because late restenosis could occur 
occasionally after SES implantation in complex lesions, we have to follow up these lesions 
carefully after 8 months although early restenosis is not observed. 
2900-92 Incomplete Stent Apposition After Sirolimus- and 
Zotarolimus-Eluting Stents: IVUS Findings From a Non-
Selected Population
Dimytri A. Siqueira, Fausto Feres, Alexandre A.C. Abizaid, J. Ribamar Costa Jr., Ricardo 
A. Costa, Pedro B. Andrade, Leandro I. Lasave, Luiz A. Mattos, Rodolfo Staico, Galo 
A. Maldonado, Luiz F. Tanajura, Andrea S. Abizaid, Marinella P. Centemero, Aurea J. 
Chaves, Amanda G.M.R. Sousa, J.Eduardo M.R. Sousa, Instituto Dante Pazzanese de 
Cardiologia, São Paulo, Brazil
Background: Incomplete stent apposition (ISA) has been documented after DES and 
might be related to late stent thrombosis. Because DES differ in metal platform design, 
pharmacological agent and polymer compounds, ISA incidence among different DES 
and potencial adverse outcomes of patients (pts) who presented with ISA remains 
controversial. We sought to investigate the frequency and clinical outcomes of ISA after 
implantation of sirolimus- (SES) - with durable polymer - and zotarolimus- eluting stents 
(ZES) - with biocompatible polymer - in a non-selected population. Methods: From our 
clinical and core IVUS laboratory databases, 242 consecutive pts who underwent DES 
placement (175 pts with SES - Cypher® stent - and 67 pts with ZES - Endeavor™ stent 
) into native artery lesions and had serial IVUS performed (at index procedure and after 
6-months) were selected. Late ISA was defined as separation of at least 1 stent strut 
from the vessel wall in a segment without a side-branch and where the immediate post-
implantation IVUS revealed complete apposition of struts. Persistent ISA was defined as 
ISA observed at baseline and follow-up. Results: 7 pts (4 %) had late-acquired ISA after 
SES, localized almost exclusively at mid-portion of the stents (6/7). Another 12 (6,8% ) 
pts with SES had persistent ISA , all at the proximal edge of the stents. Among pts with 
ZES, none had late ISA and 4 had ISA observed after stent implantation that completely 
resolved at 6-months. Mean area and length of late ISA was 5,06 ± 0,81 mm2 and 3,59 
± 2,26 mm, respectively. There was a non-significant increase in vessel volume ( 377,2 
± 148,5 to 431,9 ± 155,1 mm3, p= 0,51 ) with no change in plaque volume ( 206,14 ± 
51,53 to 236,91 ± 68,40 mm3 , p=0,36 ) in pts who presented with late ISA. Amount 
of neointimal hyperplasia as measured as volume of neointimal tissue was significantly 
higher in ZES than SES ( 16,60 ± 5,84 mm3 vs 5.15±5.5 mm3 respectively , p<0.0001). 
After 18 months of follow-up, 1 patient treated with SES who developed late ISA had 
definitive stent thrombosis. Conclusions: In the current study, 7 pts (4%) treated with 
SES had IVUS-detected late ISA, one of them evolving with late stent thombosis. Late 
ISA was not observed after ZES.
2900-93 Meta-Analysis of Percutaneous Coronary Intervention 
Versus Coronary Artery Bypass Surgery: A New 
Analysis Incorporating Drug-Eluting Stent Data
Damian J. Kelly, Najam I. Siddiqi, Martin Holt, Kamal Chitkara, Anthony H. Gershlick, 
University of Leicester, Leicester, United Kingdom
Background: No meta-analysis has been published incorporating results of multi-
vessel Percutaneous Coronary Intervention (PCI) with Drug-Eluting Stents (DES) versus 
Coronary Artery Bypass Surgery (CABG).
Methods: We conducted a meta-analysis, using fixed and random-effects analyses, of 
6 trials on 4713 patients comparing PCI with CABG to determine whether DES reduced 
adverse outcomes. The Arterial Revascularization Therapies Study (ARTS); Stent or 
Surgery Trial; Argentine Randomized Trial 2 (ERACI 2); and Medicine, Angioplasty or 
Surgery Study involved PCI with Bare-Metal Stents (BMS); while ARTS 2 and ERACI 
3 used DES versus non-randomized historical CABG controls. The primary outcome 
measure was the combined incidence of death, myocardial infarction. The secondary 
end-point was the incidence of repeat revascularization.
Results: There was no difference in the primary clinical end-point between the BMS 
(n=1518) and CABG (n=1533) groups at one or five years: at one year this was reached 
by 9.4% of the PCI group and 10% of the CABG group, Relative Risk (RR) 0.94, p=0.60; 
and at 5 years by 19.7% of the BMS group and 20% of the CABG group, RR 0.99, 
p=0.89. Revascularization was required at one year in 16.1% of BMS and 3.3% of CABG 
patients, RR 4.83, p<0.001; and at five years in 30.3% of BMS and 7.5% of CABG 
patients, RR 4.06, p<0.001. Among the DES patients (n=832), the primary end-point was 
reached by 6.4% of patients at one year vs 9.8% of CABG controls (n=830), RR=0.61, 
p=0.003, although this follow-up period does not assess any potential risk of very late 
stent thrombosis. At one year 8% of DES patients required repeat revascularization vs 
4.0% of CABG controls, RR 1.94, p=0.002. Combining the BMS and DES trials, PCI 
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reduced the incidence of the primary endpoint at one year vs CABG (8.3% vs 10.3%, RR 
0.80, p=0.016), driven entirely by the DES trials. Repeat revascularization occurred more 
frequently following PCI than CABG (14% vs 3.8%, RR 3.66, p<0.0001).
Conclusions: Compared with multi-vessel PCI using BMS, there was no difference in 
the combined rate of death, myocardial infarction or stroke at one or five years following 
CABG. The need for repeat revascularization following PCI was attenuated by DES.
2900-94 Application of Newly Developed Virtual Discrete Model 
of Platelet Adhesion and Aggregation for Assseement 
of Stent Thrombosis
Shinya Goto, Hitoshi Kawahara, Mayumi Kajimura, Noriko Tamura, Yota Kawamura, 
Makoto Suematsu, Tokai University School of Medicine, Isehara, Japan, Keio University 
School of Medicine, Tokyo, Japan
Background. Late stent thrombosis raise caution with the use of drug eluting stents. 
Yet, the mechanism of platelet accumulation around stent is still to be elucidated. 
Methods. We have developed a new discrete model of platelet ahesion and aggregation 
at various blood flow condition. Virtual platelet we generated possess the function of three 
key adhesive platelet specific proteins of glycoprotein (GP) Ibα, GPIIb/IIIa and GPVI. 
Adhesive force of GPIbα with von Willebrand factor (VWF) changed with shear stress as 
previously demonstrated. Adhesive function of GPIIb/IIIa to both fibrinongen and VWF 
appeared only when platelets are activated after multiple GPIbα interaction with VWF or 
by GPVI stimulation by collagen. We have perfused this virtual platelet with various blood 
flow condition on a virtual arteries implanted with various shapes of stents modeled (A). 
Results. Upon perfusion of virtual blood containing our newly developed voigt model 
of platelet on virtual coronary arteries exposing virtual thrombogenic matrix of collagen 
and VWF, platelet started to adhere on them, get activated and form platelet thrombi. 
Platelet accumulation was augmented when stents were implanted on the injured 
arteries, especially downstream sites of stents (B). By comparison of the same stent in 
various opening opening width of stent strat (56 degree, 67 degree, 76 degree), number 
of platelets accumulated downstream of stent was the most with 67 degree at constant 
flow and 56 degree at pulsatile flow condition mimicking real coronary arterial blood flow 
(Figure). Conclusion. We have developed a virtual system to predict thrombogenicity of 
various shape of stents. 
2900-95 The Efficacy of Coronary Stenting at Lower Inflation 
Pressure Using the 2.5-mm Sirolimus-Eluting Stents in 
Very Small Vessels
Shinjiro Miyata, Hisashi Umeda, Tomoyuki Ota, Mitsunori Iwase, Ryoji Ishiki, Haruo 
Inagaki, Hideo Izawa, Toyoaki Murohara, Toyota Memorial Hospital, Toyota, Japan, 
Nagoya University Graduate School of Medicine, Nagoya, Japan
Background: Although coronary interventions for very small vessels are common in 
a clinical practice, the 2.25-mm sirolimus-eluting stents (SES) have not been available 
in Japan. The purpose of the present study was to assess the clinical and angiographic 
benefits of the 2.5-mm SES implantation at lower inflation pressure in very small coronary 
arteries.
Methods: A series of 110 consecutive patients with the reference diameters of <2.5 
mm undergoing the 2.5-mm SES implantation at lower initial inflation pressure (<10 atm) 
were compared with the historical group of 141 consecutive patients (<2.5 mm) treated 
by balloon angioplasty and/or bare-metal stenting (control group).
Results: The clinical and lesion characteristics were similar in the 2 groups. (See 
Tables).
Conclusions: With lower rates of restenosis and adverse cardiac events, SES 
implantation at lower inflation pressure might be a superior strategy in this particular 
population.
Angiographic and clinical outcomes in the 2 groups
SES (n=110) Controls (n=141) P Value
Reference diameter at baseline (mm) 2.22±0.21 2.26±0.20 0.089
Initial inflation pressure (atm) 7.7±1.0 7.8±2.6 0.666
Post dilatation (%) 84.5 85.0 >0.999
Late loss (mm) 0.18±0.50 0.53±0.52 <0.001
In-segment restenosis (%) 14.5 38.3 <0.001
Stent thrombosis / abrupt closure (%) 0.9 2.8 0.389
TLR at 360 days (%) 9.1 26.2 0.001
MACE at 360 days (%) 9.1 29.8 <0.001
Values are mean ± SD or percentages. SES = sirolimus-eluting stents; TLR = target 
lesion revascularization; MACE = major adverse cardiac events.
Multivariable predictors of restenosis
OR 95%CI P Value
2.5-mm SES use 0.22 0.10-0.49 <0.001
Lesion length 1.10 1.05-1.15 <0.001
Postprocedural MLD 0.25 0.10-0.64 0.004
Prior bypass surgery 3.67 1.23-10.95 0.020
Ostial location 3.08 1.18-8.03 0.021
SES = sirolimus-eluting stents; MLD = minimal lumen diameter.
2900-96 Paclitaxel-Eluting Stents Are Effective in Higher Risk 
Patients: Gender and Age Specific Sub-Group Analyses 
of the TAXUS OLYMPIA Registry
Oscar Mendiz, Martyn R. Thomas, Waqar H. Ahmed, Stephen Mascioli, Donald S. Baim, 
Fundacion Favaloro, Buenos Aires, Argentina
Background: Previous studies have shown that women and the elderly have a higher 
risk during and after coronary revascularization with bare metal stents. Data following the 
use of drug-eluting stents, however, is limited.
Methods: TAXUS OLYMPIA is a global, post-approval registry capturing baseline and 
outcomes data in patients (pts) receiving the TAXUS Liberté paclitaxel-eluting stent in 
routine clinical practice.
Results: Of the first 7124 pts enrolled in OLYMPIA 23% were women and 12% 
were >75 yrs. Compared to men, women were older and more likely to be diabetic or 
hypertensive, while fewer smoked, had prior intervention or MI. Pts >75 tended to be 
female, hypertensive and have complex lesions, but less likely to smoke or have had a 
CABG versus younger pts. At 1 yr, event rates were higher in both subgroups. Significant 
increases in death, stent-related cardiac death and MI were seen in elderly pts, with no 
increase in stent thrombosis (ST) or TAXUS-related TVR for either group. Multivariate 
analysis revealed that thienopyridine termination (<6 months), age, diabetes, cardiogenic 
shock, prior stroke or PCI, acute MI, long lesions and multivessel disease were all 
predictors of death whereas multiple stenting, restenosis, RVD and thienopyridine 
termination were predictors of TVR.
Conclusions: The TAXUS Liberté stent, as used in this real-world registry, has excellent 
overall results in women and the elderly. There were no differences in the 1-yr rates of ST 
or TAXUS-related TVR in either of these pt subsets. 
Table 1: Characteristics and Clinical Outcomes in the OLYMPIA registry by gender and age*.
Overall 
(N=7124)
Female 
(N=1619)
Male 
(N=5505) P-value
Age > 75 
(N=884)
Age ≤ 75 
(N=6240) P-value
Demographics
Age 
[range]
62.3±11.1 
[18, 93]
66.2±10.5 
[18, 93]
61.3±11.0 
[19, 92] <.01
79.3±3.1 
[76, 93]
60.0±9.7 
[18, 75] <.01
Male (%) 77.3 0 100 ns 63.6 79.2 <.01
Cardiac History (%)
Previous PCI 28.4 25.7 29.2 <.01 29.1 28.3 ns
Previous 
Coronary 
Artery Bypass 
Graft (CABG)
10.6 8.1 11.4 <.01 13.5 10.2 <.01
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Known 
Previous MI 37.3 30.1 39.4 <.01 34.8 37.7 ns
Cardiac Risk Factors/Comorbidities (%)
Known 
Smoking 54.5 26.1 62.8 <.01 37.1 56.9 <.01
Known 
Diabetes 
Mellitus
33.4 39.5 31.6 <.01 34.8 33.2 ns
Insulin 9.3 15.1 7.5 <.01 10.1 9.2 ns
Hypertension 66.7 76.5 63.8 <.01 75.9 65.4 <.01
Acute MI 17.8 16.1 18.3 <.01 18.2 17.7 ns
Target Lesion
Reference 
Vessel 
Diameter 
(mm)*
2.9 2.9 2.9 ns 2.9 2.9 ns
Target Lesion 
Length (mm)** 17.8 17.4 17.9 ns 17.6 17.8 ns
AHA/ACC 
class B2/C 
(%)
56.6 55.1 57.1 ns 62.5 55.8 <.01
Severe Lesion 
Calcification 
(%)
4.0 3.9 4.1 ns 7.4 3.6 <.01
12-Month Reviewed Cardiac Events (%)
Death 2.0 2.4 1.9 ns 6.2 1.5 <.01
TAXUS Liberté Stent Related (%)
Composite CE 3.9 4.9 3.7 0.04 6.3 3.6 <.01
Cardiac Death 1.1 1.4 1 ns 3.3 0.8 <.01
MI 0.9 0.9 0.9 ns 1.6 0.8 0.03
TVR 
(per patient) 2.5 3.1 2.4 ns 2.8 2.5 ns
ST (per 
patient) 0.8 0.8 0.8 ns 1.1 0.8 ns
*unadjusted numbers 
**visual estimate
2900-97 Gender-Based Evaluation of XIENCE V Everolimus-
Eluting Coronary Stent System: Clinical and 
Angiographic Results From the SPIRIT III Randomized 
Trial
Alexandra J. Lansky, Mark Midei, William Newman, Mark Sanz, Poornima Sood, Julie 
Doostzadeh, Xiaolu Su, Sherry Cao, Roseann White, Krishnankutty Sudhir, Gregg W. 
Stone, Cardiovascular Research Institute, New York, NY
Background: The SPIRIT III trial was a prospective, single blinded, multicenter US, 2:1 
randomized trial evaluating the safety and efficacy of everolimus-eluting XIENCE™ V 
stents (EES) compared to paclitaxel-eluting TAXUS® stents (PES). In the entire study 
population EES compared to PES resulted in reduced in-segment late loss (LL) at 8 
months and major adverse cardiac events (MACE) at 1 year, with non inferior rates of 
target vessel failure (TVF). Whether these results vary among men and women has not 
been reported.
Methods:  SPIRIT III enrolled 1002 pts (including 687 men and 315 women) undergoing 
PCI in lesions ≤28 mm long with RVD 2.5-3.75 mm. Angiographic follow-up at 8 months 
was pre-specified in the first 564 pts. Clinical and angiographic results were stratified 
according to gender
Results: Consistent with the overall trial, 8 month angiographic LL was numerically lower 
for EES than PES in both men and women (Table). A non significant trend was present 
for lower TVF in women treated with EES compared to PES, due to lower TVR rates with 
EES (3.1% vs. 8.9%). MACE rates for EES were lower in women compared to PES, due 
to less NQMI with EES (2.6% vs. 7.1%). Formal interaction testing showed directionally 
similar treatment effects with EES compared to PES in both men and women.
Conclusions: The beneficial effects of EES compared to PES in reducing angiographic 
LL and MACE are seen in both men and women. Further evaluation of EES in women is 
currently under way in a 2000 female patient registry, XIENCE-SPIRIT WOMEN. 
LL at 8 mo and TVF and MACE at 1 yr ; TVF=cardiac death, MI, or TVR; MACE=cardiac 
death, MI or TLR
Males Females
XIENCE™ V TAXUS® P-Value XIENCE™ V TAXUS
® P-Value
In-segment 
LL @ 
240 d
0.13 mm 
(250)
0.25 
mm(108) 0.0189
0.16 
mm(93) 0.29 mm(50) 0.0996
TVF @ 
1 yr
7.4% 
(34/459)
7.7% 
(16/208) 0.8751
11.3% 
(22/194)
17.9% 
(20/112) 0.1224
MACE @ 
1 yr
5.0% 
(23/459)
7.2% 
(15/208) 0.2804
8.2% 
(16/194)
16.1% 
(18/112) 0.0397
2900-98 Lower Mortality With Drug-Eluting Stent in the “Real 
World” at Two Years
Albert E. Alahmar, Mohammed Andron, Khaled Albouaini, Mohaned Egred, Elved 
Roberts, Billal Patel, Kashif Bashir, Moataz Elkadri, Rodney Stables, Raphael A. Perry, 
Cardiothoracic Centre Liverpool, Liverpool, British Virgin Islands, Royal Liverpool 
University Hospital, Liverpool, British Virgin Islands
Background: Long-term mortality following drug-eluting stent implantation in daily 
practice is still a concern.
Methods: We carried out retrospective analysis of prospectively collected data on All 
patients undergoing PCI with stent implantation at our institution between January 2003 
and December 2004. To account for differences in patient characteristics, logistic regression 
was used to produce a propensity score for DES group membership using age, smoking 
status, New York Heart Association class, diabetes, priority, left main stem, restenotic lesion, 
vessel diameter, and length of lesion. Patients receiving DES were then matched to patients 
receiving bare metal stents (BMS) with identical propensity scores using the greedy match 
technique. We were able to match 777 patients in each group (DES< BMS) which then 
compared with respect to the incidence of Death. Results: During the study period 995 
patients received DES. Of these, 82 patients had combined DES and BMS use and were 
therefore excluded, leaving 913 DES patients compared to 2105 BMS patients. Patients 
who received DES were more likely to be diabetic (p<0.001), restenotic lesions (p<0.001), 
LMS interventions (p<0.001), long lesions (p<0.001), small diameter lesions (p<0.001), and 
AHA C-type lesions (p<0.001). Two years mortality was lower in the DES group before 
(2.0% vs 4.1% p=0.003), and after matching (1.8% vs 4.0% p=0.01).
Conclusions: In our “Real world” series, DES implantation was associated with lower 
moetality compared with BMS. 
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2900-99 Two-Year Survival Advantage in Medicare Patients 
Receiving Sirolimus-Eluting Stents (SES) Compared 
With Bare-Metal Stents (BMS)
Barry F. Uretsky, Dong Zhang, Sharon H. Giordano, Fen Wei Wang, The University of 
Texas Medical Branch, Galveston, TX
Background: Concerns have been raised regarding late mortality from drug -eluting 
stents (DES). We evaluated survival in the first 2 years after DES implantation, specifically 
with the sirolimus eluting stent (SES), Cypher, vs BMS in “real world” older patients using 
the Medicare claims database from May-Dec 2003.
Methods and Results: BMS (n=4149) and SES (n=3418) groups had similar baseline 
characteristics except for small but statistically significant differences with BMS patients 
being somewhat older, having more males and African Americans, and a higher 
percentage of peripheral artery disease and heart failure while SES patients had a 
higher percentage of diabetics and patients with prior revascularization procedures. A 
significant decrease in 2-year mortality using both unadjusted and adjusted analyses 
was observed for SES ( 16.8% BMS vs 10.7% SES, p< 0.0001; hazard ratio 1.65, 95% 
CI 1.5, 1.9). Controlling for comorbidity, extent of disease and other chararacteristics 
by multivariable analysis or by propensity analysis had little impact on these results. 
If analysis was limited to 12-month survivors and 12-24 mortality analyzed, there was 
decreased mortality with SES (6.1% BMS vs 5.0% SES, p=0.05). To understand potential 
interaction of unknown selection biases, Medicare pts from calendar year 2002 (n=6890, 
all BMS) were compared with all 2003 pts (BMS used in 55%). 24-month mortality was 
similar (14.6%, 2002 vs 14.0% 2003), suggesting unidentified selection biases may have 
affected survival results in 2003.
Conclusion: A 2 year survival benefit for SES vs BMS in 2003 was observed, suggesting 
the safety of DES. The similar 2-year survival between 2002 (pre-DES) and 2003 despite 
45% SES use in 2003 suggests unidentified selection biases may have accounted for 
some the survival differences between SES and BMS in 2003.
2900-100 Assessing the Correlation Between In-Stent Neointimal 
Proliferation and Plaque Progression in the Target 
Vessel: An Intravascular Ultrasound Analysis in the 
Drug-Eluting Stent Era
Andre F.l. Brito, Jose de Ribamar Costa, Jr., Alaor M. Cunha, Jr., Fausto Feres, 
Alexandre Abizaid, Ricardo Costa, Rodolfo Staico, Dimytri Siqueira, Luiz Alberto Mattos, 
Amanda Sousa, J Eduardo Sousa, Instituto Dante Pazzanese de Cardiologia, São 
Paulo, Brazil
Background: Local inflammatory response in the treated segment (in-stent and 5 mm 
proximal and distal edges) has been described after PCI resulting in a variable amount 
of neointimal hyperplasia (NIH) formation. Whether this response is limited to the treated 
segment and/or if it correlates with the degree of plaque progression outside the stent 
limits is still to be demonstrated. 
Methods: Between January and March 2006, 36 consecutive unselected patients with 40 
lesions in native coronaries were treated with 45 Zotarolimus-eluting stent (Endeavor™) 
and submitted to IVUS after the procedure and at 6-month follow-up (FU). Segments 
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beyond the 5mm proximal and distal edges of the stent were matched in the baseline and 
FU IVUS for each patient. These segments had their vessel, lumen and plaque volumes 
calculated using a dedicated IVUS software and were correlated to NIH volume in-stent 
at follow-up. After testing the main variables for normality using the Kolmogorov-Smirnov 
Test, Pearson´s correlation test was used to compare the degree of NIH in-stent and 
plaque progression in the matched segments.
Results: Most patients were men (69.5%) and diabetes was detected in 25% of the 
cohort. A total of 69 segments (37 distal and 32proximal to the stent) were properly 
identified and matched at baseline and FU (mean length = 11.1±4.7mm). At FU, % 
of in-stent obstruction was 14.5±14.9 %. Atheromas located proximally to the stent 
markedly progressed more than those located distally to it (plaque volume difference of 
0.6±2.81mm3/mm vs. 0.009 ± 1.5 mm3/mm, p<0.001). However, there was no correlation 
between the amount of NIH in-stent and the degree of plaque progression in the proximal 
(Pearson´s correlation of -0.113; P 0.273), distal (Pearson´s correlation of -0.066; P 
0.379) and both segments (Pearson´s correlation of -0.18; P 0.2).
Conclusion: NIH formation after Endeavor deployment was low and did not correlate 
to plaque progression outside the treated segment. However, the more pronounced 
plaque progression proximal to the treated segment may be a consequence of the more 
aggressive/traumatic manipulation of that area at the time of the stent deployment.
2900-101 Endothelialization Responses to Abluminally-Directed 
Ultrathin Film Stent-Based Paclitaxel Administration to 
the Coronary Artery Wall in Pigs
Toshiro Shinke, Art Rosenthal, Refat Jabara, Nicolas Chronos, Keith Robinson, Saint 
Joseph’s Research Institute, Atlanta, GA, Labcoat Ltd., Galway, Ireland
Purpose: To assess effects of bioabsorbable polymer (D,L polylactic acid (PLA) applied 
abluminally as ultrathin film surface dots) based paclitaxel delivery from stents into porcine 
coronary arteries by scanning electron microscopy (SEM) and histology.
Methods: Vascular responses to PLA coated stent (P), low (L: 5Μg/stent) and high (H: 
10Μg/stent) dose paclitaxel-eluting stents were compared to bare metal stent (BMS). 
Morphological analysis of re-endothelialization was assessed by SEM at 1-mo in 3 pigs. 
Gaps between endothelial cells (ECgap; % images with ≥1 gap/1KX field) and leukocyte 
adhesion to luminal surface (WBC; 0=none to 3=severe) were scored. %area stenosis 
(%AS) and inflammation score (IS: 0-3) were assessed 1-mo and 3-mo in 20 and 9 pigs 
respectively.
Results: 1-mo %AS was slightly lower in H (25.7±3.3%) compared to L (31.0±3.5%), P 
(31.0±3.5%) and BMS (31.1±4.5%), accompanied by higher IS (P=0.001), which were 
abolished at 3-mo. P was indistinguishable from BMS. SEM showed consistent coverage 
of luminal surface with endothelial-like cells in all groups. H and L revealed higher 
ECgap appearance (H: 85%; L: 81%; P: 35%; P=0.005) and higher WBC compared to 
P (P=0.001).
Conclusions: PLA bioabsorbable polymer is biocompatible for stent-based abluminally-
targeted delivery of paclitaxel and endothelialization is complete at 1-mo. Paclitaxel 
exacerbated leukocyte adhesion to the endothelial luminal surface in dose-dependent 
fashion and was associated with interendothelial defects. 
2900-102 Drug-Eluting Stents vs. Bare-Metal Stents for Transplant 
Allograft Vasculopathy
LeRoy E. Rabbani, Anuj Gupta, Mark Apfelbaum, Susheel Kodali, Martin Leon, Jeffrey 
W. Moses, Donna M. Mancini, Columbia University Medical Center, New York, NY
Background: Drug eluting stents (DES) are associated with significant reduction in 
restenosis and target vessel revascularization (TVR) compared with bare metal stents 
(BMS) in patients with native coronary artery disease. The safety and efficacy of DES in 
cardiac transplant allograft vasculopathy (TAV) is not established.
Methods: We performed a retrospective analysis of all patients with TAV at a single 
center undergoing stenting between 1/97 to 9/07. Significant clinical outcomes analyzed 
included (TVR) as well as retransplantation and/or death. BMS patients were followed for 
three years, while DES patients were followed for one year.
Results: 25 patients received 25 bare metal stents; 30 patients received 51 DES 
(paclitaxel 3, sirolimus 48). The average age at transplant was 47 years old (±13) for BMS 
patients and 46 years old (±14) for DES patients. Average time from transplant to stent 
placement was 6.8 years (±3.9) for BMS patients and 8.5 years (±5.4) for DES patients. 
15 DES patients had angiographic follow-up (average follow-up time, 6 months ±3mo); 
3 patients developed in-stent restenosis (20%), 2 patients underwent TVR. Three DES 
patients had definite stent thrombosis (ARC definition). Mortality or retransplantation at 
one year was 16% for BMS patients and 35% for DES patients (p=NS).
Conclusion: Taken together, these data suggest that the use of DES as compared to BMS 
does not appear to reduce mortality or alter the deleterious natural history of TAV. 
2900-103 The Impact of Mandatory Angiographic Follow-up 
on the One-Year Clinical and Angiographic Results 
From Endeavor IV: A Randomized Comparison of the 
Endeavor Drug (ABT-578) Eluting Stent System vs. 
Taxus in De Novo Native Coronary Lesions
Martin B. Leon, Jeffrey Popma, Charlie O’Shaunessy, Paul Overlie, Brent McLaurin, 
Stuart Solomon, Ajay Kirtane, Laura Mauri, Peter Fitzgerald, Kweli Thompson, Columbia 
University Medical Center, New York, NY
Background: While routine angiographic follow up has been demonstrated to impact 
revascularization rates in early bare metal stent (BMS) trials and in drug-eluting (DES) 
vs. BMS trials, the impact of routine follow-up angiography in DES vs. DES trials is less 
understood.
Methods: In the ENDEAVOR IV trial of the Endeavor vs Taxus DES, the first 328 enrolled 
patients (21.2%) underwent protocol-mandated follow up angiography at 8 months; 
outcomes among these patients were compared to those of the subsequent 1200 patients 
with no routine angiographic follow-up.
Results: Trial enrollment was completed in July 2006. The 12 month target lesion 
revascularization rates stratified by assignment to routine angiographic or clinical follow-
up are as follows (see table)
While there was a trend toward reduced TLR with Taxus compared to Endeavor among patients 
undergoing routine angiography, this was not observed in the larger clinical-only follow-up cohort. 
Complete one-year data describing baseline characteristics, procedural and angiographic data 
for these two cohorts of the ENDEAVOR IV trial will be presented in detail.
Conclusions: The low overall rate of protocol-mandated angiographic follow-up in 
the ENDEAVOR IV trial allows assessment of the degree to which protocol-mandated 
angiographic follow-up can impact outcomes in head-to-head DES studies, which has 
implications for future clinical trial designs.
2900-104 The Endeavor Zotarolimus-Eluting Stent in Patients 
With Native Coronary Artery Disease: Safety With 1200 
Patients Followed to Three Years
Laura Mauri, Martin B. Leon, William Wijns, Jean Fajadet, Ian Meredith, Harvard Clinical 
Research Institute, Boston, MA
Background: Clinical efficacy of the Endeavor Drug Eluting Stent (DES) is well 
characterized with low repeat revascularization rates across 5 trials. The long-term safety 
of the Endeavor DES appears promising with low cumulative event rates when compared 
to the Driver BMS however only 675 patients had been followed out to 3 years.
Methods: Clinical outcomes among patients treated with Endeavor DES from the 
ENDEAVOR clinical program were pooled for systematic analysis and compared to the 
control arm of the ENDEAVOR II trial. These trials included ENDEAVOR I; ENDEAVOR II; 
ENDEAVOR II Continued Access Registry; ENDEAVOR III, and ENDEAVOR IV. In these 
collective five trials among patients (n = 2132) receiving the Endeavor DES, diabetes 
mellitus was present in 26.1%, the mean reference vessel diameter was 2.73 mm, and 
the mean lesion length was 14.16 mm.
Results: Cumulative Incidence % (with 675 patients to 1080 days)
(see table)
Conclusion: The earlier pooled analyses of these dataset, with 675 patients followed out 
to 3 years showed an encouraging trend of low cumulative event rates in patients with 
coronary disease of simple and moderate complexity. The 3-year cumulative incidence 
results with approximately 1200 patients receiving the Endeavor DES being followed for 3 
years will be available in March 2008. 
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2900-105 Two-year Outcome After Repeat Intervention for 
Restenosis After Unprotected Left Main Stenting: A 
Report From the French Left Main Taxus Registry
Thierry Lefevre, Beatriz Vaquerizo, Olivier Darremont, Marc Silvestri, Philippe 
Garot, Helen Routledge, Yves Louvard, Pierre Dumas, Marie-Claude Morice, Institut 
Cardiovasculaire Paris Sud, Massy, France
Background: Repeat coronary artery bypass surgery (CABG) is associated with a 
higher complication rate compared to de novo surgery. At present, the outcome of repeat 
PCI for the treatment of restenosis after unprotected left main (LM) stenting in the drug-
eluting stent (DES) era, remains unknown.
Methods: We conducted a retrospective analysis of the long-term outcome of patients 
(Pts) included in the French LM registry who underwent target vessel revascularization 
(TVR).
Results: 291 consecutive Pts were included; acute myocardial infarction (MI) or 
cardiogenic shock were the only exclusion criteria. Pts were 69±11 years old, 77% male, 
29% diabetic, 28% renal failure, 18% had previous or recent MI, 35% acute coronary 
syndrome and 25% 3-vessel disease. Euroscore was 4.8±3.4 (predicted in-hospital 
mortality 6.4±10.5). The provisional T stenting approach (distal LM in 78.4%) was used 
in 92%. Angiographic success was obtained in 99.7%. Two-year follow-up was obtained 
in 99.3%. Overall mortality rate was 9.3% (cardiac in 5.2%). Repeat angiogram was 
performed in 186/291 Pts (64%) at 7.5±4.0 months, 23.6% were symptomatic and 8.6% 
had silent ischaemia. Restenosis was observed in 25/186 (13.4%): 14 in LM stem, (10 in 
distal LM, stent segment, 1 distal to the LM stent and 3 at the LM ostium, unstented), 6 
at ostial LCX, (2 in unstented ostial Cx and 4 in stented ostial Cx), and 5 at ostial LAD (1 
in an unstented ostial LAD and 4 in the stented ostial LAD). In total, TVR was performed 
in 7.9% of cases, 6.5% by re-PCI (all with DES) and 1.4% by CABG). At the time of 
reintervention, 82.6% of Pts were symptomatic (stable angina 52.2%, unstable angina 
13.0%) or had documented silent ischaemia (17.4%). Two years after repeat intervention 
(follow-up completed in 22/23 Pts), 3 Pts (13.6%) had repeated re-intervention (2 by 
re-PCI, 1 by CABG) and 1 (4.5%) died, from pulmonary infection 7 months after the last 
PCI.
Conclusion. Elective ULM PCI using paclitaxel eluting stent with a strategy of provisional 
side branch T stenting in cases of distal LM disease is associated with 7.9%TVR rate at 2 
years. Repeat PCI with DES seems to be safe and effective at 2 years’ follow-up.
2900-106 The Impact of Bifurcation Type and Treatment Strategy 
on the Risk of Stent Thrombosis After Drug-Eluting 
Stent Implantation
Bon-Kwon Koo, Seok-Jae Hwang, Kyeong-Woo Park, In-Ho Chae, Myung Ho Jeong, 
Seung-Jung Park, Hyeon-Cheol Gwon, Ki Bae Seung, Tae-Hoon Ahn, Seung-Jae Tahk, 
Yangsoo Jang, Junghan Yoon, Hyo-Soo Kim, Seoul National University Hospital, Seoul, 
South Korea
Background: Bifurcation lesion is known to be one of the major risk factors for stent 
thrombosis (ST) after drug-eluting stent (DES) implantation. However, whether this is due 
to complex intervention or bifurcation lesion itself increases the risk is not well-defined.
Methods: KoST (Korea Stent Thrombosis) registry was a 10-center prospective registry 
which enrolled ST patients after DES implantation. 98 patients with ST were compared 
with a control group of 1,295 patients from a core center who had up to 18 months of 
clinical follow-up. In this study, the risk of ST was evaluated according to bifurcation 
type (true or pseudo-bifurcation) and treatment modality (no treatment, side branch 
angioplasty only, or side branch stenting) for these lesions.
Results: The pseudo-bifurcation lesion as well as true bifurcation, and non-treated 
bifurcation lesion as well as treated bifurcation had a higher risk of ST when compared 
with non-bifurcation lesion (figure) in logistic regression analyses including variables 
which were found to be independent predictors for stent thrombosis [ACC/AHA lesion 
classification, in-stent restenosis lesion, stent type (Taxus or Cypher), stent diameter, 
stent length and post-procedural minimal luminal diameter]. The risk of ST increased 
linearly as the complexity of bifurcation type and treatment increased.
Conclusions: Bifurcation lesion itself was a risk factor of ST. Any treatment modality 
using DES for any bifurcation lesion resulted in an increased risk of ST.
2900-107 The Effect of Debulking Pre-Drug Eluting Stent for 
Bifurcated Coronary Lesions in Unprotected Left Main 
-Sub Analyses of PERFECT Registry-
Masashi Kimura, Etsuo Tsuchikane, Yuji Oikawa, Tadanori Aizawa, Takahiko Suzuki, 
Toyohashi Heart Center, Toyohashi, Japan, The Cardiovascular Institute, Tokyo, Japan
Background: Percutaneous coronary intervention for bifurcated coronary lesions (BCL) 
using DES alone remains challenging, although drug-eluting stent (DES) significantly 
reduces restenosis and repeated revascularization. The purpose of this study was 
to evaluate the safety and efficacy of plaque debulking with directional coronary 
atherectomy (DCA) before DES implantation for BCL in unprotected left main coronary 
artery (ULMCA).
Methods: Sixty two patients with BCL in ULMCA were enrolled in this prospective 
multicenter registry (PrE Rapamycin eluting stent FlExi-CuT Registry). All patients were 
scheduled to undergo a 9-month coronary angiography. The primary end point was the 
9-month binary angiographic restenosis rate. Secondary end points included procedure-
related events and major adverse cardiac events (MACE) at 1 year.
Results: DCA was performed successfully in all cases without any complications. Simple 
stenting was achieved in all cases. Angiographical findings are shown in Table. No in-
hospital MACEs were observed. The 9-month binary restenosis rates in the main branch 
and side branch were 0% and 0%, respectively. No target lesion revascularization, no 
deaths, no coronary artery bypass grafting, and no myocardial infarction were reported in 
the patients within the first year.
Conclusion: DCA before DES implantation is safe and effective for the treatment of 
ULMCA without complex stenting. These strategies may provide excellent long-term 
outcomes in patients with BCL in ULMCA. 
Main Branch Side Branch
Left Main Circumflex
Pre-procedure
Reference Diameter (mm) 3.38±0.43 2.75±0.69
Minimum Lumen Diameter (mm) 1.38±0.36 1.75±0.62
% Stenosis 59.2±8.4 36.1±16.1
Lesion length (mm) 15.9±8.6 7.6±8.2
Post-procedure
Minimum Lumen Diameter (mm) 3.92±0.43 2.25±0.68
% Stenosis 7.9±13.0 21.1±16.2
Acute Gain (mm) 2.24±0.65 0.39±0.50
Follow up
Minimum Lumen Diameter (mm) 3.12±0.60 2.11±0.54
% Stenosis 10.7±11.7 20.0±15.3
Late Loss (mm) 0.51±0.59 0.13±0.42
2900-108 Cypher or Taxus: Which Is Better for Bifurcation 
Stenting?
Yoshihisa Kinoshita, Osamu Katoh, Tetsuo Matsubara, Mariko Ehara, Yasuyoshi Suzuki, 
Hiroshi Fujita, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Aichi, Japan
Background: The incidence of in-stent restenosis for bifurcation stenting (BS) remains 
high even with drug-eluting stents. We postulated that some of the mechanisms depend 
on polymer damage and stent structure.
Methods: We deployed Cypher and Taxus stents in a silicon “phantom” vessel with a 
3.5mm diameter main branch and a 3.0mm side-branch. Kissing-balloon dilatation 
was then performed, and stent-structure and polymer damage observed using an 
optical microscope, an electron microscope and multi-slice computed tomography. BS 
strategy entailed culotte-stenting, conventional crush-stenting, reverse crush-stenting, 
conventional T-stenting and modified T-stenting.
Results: In Taxus stents, the carina of the bifurcation was not sufficiently covered by 
stent-struts in some BS techniques (Panel A). When the strut was dilated with balloon 
catheter to make side branch access, Taxus stents suffered more damage to structure, 
especially around the carina (Panel B). For both type of stents, polymer damage were 
observed at stent-overlap sites. The degree of damage varied according to BS strategy 
and polymer type. Polymer damage was less marked in Taxus stents, particularly for the 
crush BS technique (Panel C).
Conclusions: When using Taxus stents for BS strategies, the stent may undergo less 
damage to the polymer but the stent may not be suitable for BS on structural grounds. 
2900-109 Simultaneous Kissing Stents to Treat Left Main 
Bifurcation Stenosis
Anjan K. Siotia, Allison Morton, Julian P. Gunn, Sheffield Teaching Hospitals NHS 
Foundation Trust, Sheffield, United Kingdom
Background: There is no single, widely accepted stenting technique used to treat left 
main stem (LMS) bifurcation disease. We recently described a simultaneous kissing 
stents (SKS) technique to treat such disease (Fig-1). We now present our latest results, 
both acute and at medium term clinical follow-up, in a large cohort of patients treated 
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with this technique.
Methods: We treated 100 consecutive patients with unprotected LMS bifurcation disease 
using the SKS technique and Taxus stents. Dual anti-platelet therapy was continued 
lifelong. We recorded clinical status at baseline, in-hospital and at medium term follow-up 
using hospital and catheter laboratory records and telephone contact.
Results: Mean age was 66 (45-88) years, 75% were male, 8% were emergency 
cases, 23% urgent and 69% elective. The mean New York PCI Risk Score was 4.2. The 
procedure was successful in 100% cases. Apart from the LMS, there was 2.0 ± 0.9 vessel 
disease and 1.8 ± 0.8 vessels were successfully treated. There were 4 in-hospital deaths 
all of which were in patients with cardiogenic shock or a recent myocardial infarction. At a 
median follow-up of 20 months, there were 6 more deaths and 6 cases of ischemia-driven 
target lesion revascularisation. 1 patient suffered an ST elevation myocardial infarction.
Conclusions: This is the first substantial series of patients with unprotected LMS 
bifurcation disease treated with SKS technique and it shows that this technique is safe, 
feasible and associated with good medium term clinical results. 
2900-110 First Clinical Experience of “Flower Petal” Stenting: 
A Novel Technique for the Treatment of Bifurcated 
Lesions
Yoshihisa Kinoshita, Osamu Katoh, Tetsuo Matsubara, Etsuo Tsuchikane, Mitsuyasu 
Terashima, Mariko Ehara, Kenya Nasu, Hiroshi Fujita, Takahiko Suzuki, Toyohashi Heart 
Center, t, Japan
Background:The best stenting technique for bifurcated lesions has yet to be defined.
Objective: To report the results of both bench-testing and our first clinical experience with 
this novel technique.
Methods: This technique works by flaring the proximal side of the stent in side branch 
(SB) out like petals (Panel A). We tested it in vitro and the resultant stent-structure 
and stent polymer damage was observed in both main branch (MB) and SB with an 
optical microscope, multi-slice computer tomography, IVUS, endoscope and an electron 
microscope (EM). We also applied this technique in 20 patients and assessed patient 
outcomes up to 9 month prospectively. Drug-eluting stents were used for the bench-tests 
and for all patients.
Result: Bench-testing showed complete coverage of the bifurcation with minimal stent-
layer overlapping (Panel B). There was little polymer damage by EM (Panel C). Procedural 
success was achieved in 19 cases and restenosis occurred in 2 cases. In both restenosis 
cases, “petal” stenting technique was done provisionally after another stent had already 
been deployed in the main branch prior to any stenting of the side-branch. There were no 
incidences of restenosis when we used this technique electively
Conclusions: In terms of damage to the polymer and of ostial strut coverage, this new 
“flower petal stenting” technique may well be superior to other available techniques. 
2900-111 Increased Neointimal Hyperplasia, but not Minimum 
Lumen Area, Is Associated With Restenosis in the 
Side Branch Ostium After Percutaneous Coronary 
Intervention on Bifurcation Lesions
Joo-Yong Hahn, Hyeon-Cheol Gwon, Young Bin Song, Seung Min Choi, Soo Jin Cho, 
Sang Yeub Lee, Seung-Hyuk Choi, Jin-Ho Choi, Sang Hoon Lee, Samsung Medical 
Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background: Restenosis rates are high after percutaneous coronary intervention (PCI) 
on bifurcation lesion, especially at the ostium of the side branch (SB). However, the 
mechanism of restenosis in the SB ostium has not been fully understood.
Methods: We evaluated 84 bifurcation lesions with SB ≥2.5 mm, which were treated 
successfully by provisional T stenting and small protrusion technique using drug-eluting 
stents under intravascular ultrasound (IVUS) guidance. Postintervention IVUS was 
performed in both branches and 9-month angiographic follow-ups were performed. IVUS 
analysis of the SB included 2 distinct locations: SB ostium (<5 mm distal to the neo-
carina), and SB distal stent (≥5 mm distal to the neo-carina).
Results: SB stenting was performed in 56 lesions (67%). Post-procedural MLAs at 
the SB ostium and at the SB distal stent were similar (4.8±1.8 mm2 and 4.8±2.1 mm2 
respectively, p = 0.76). Regarding the SB, angiographic restenosis (diameter stenosis 
≥50%) developed in 8 patients (9%). Of these, 6 cases occurred at the ostium of the 
SB and focal (SB ostium restenosis group). There was no significant difference in post-
procedural MLA at the SB ostium between the SB ostium restenosis group and the SB 
ostium non-restenosis group (4.6±1.8 mm2 versus 4.4±1.7 mm2, p = 0.88). However, 
the SB ostium restenosis group showed a significant larger late lumen loss compared 
with the SB ostium non-restenosis group (1.6±1.0 mm versus 0.3±0.7 mm, p < 0.001). 
Post-procedural MLA did not correlated to late loss in the SB ostium (r = 0.2, p = 0.07). 
In 2-stent group, there was no significant difference in post-procedural minimum stent 
area at the SB ostium between the SB ostium restenosis group and the SB ostium non-
restenosis group (5.4±1.6 mm2 versus 4.8±1.7 mm2, p = 0.49). Again, the SB ostium 
restenosis group showed a significant larger late lumen loss compared with the SB ostium 
non-restenosis group (1.9±1.0 mm versus 0.5±0.7 mm, p < 0.001).
Conclusions: The SB ostium may show a high restenosis rate due to increased 
neointimal hyperplasia rather than small post-procedural MLA.
2900-112 In Hospital Results, One-year and Very Long-
term Follow-up of Drug-eluting Stent Treatment in 
Unprotected Left Main Coronary Artery
Maria Elena Di Salvo, Piera Capranzano, Gian Paolo Ussia, Anna Caggegi, 
Giambattista Barrano, Alessio La Manna, Alfredo Ruggero Galassi, Corrado Tamburino, 
Ferrarotto Hospital, Catania, Italy
Background: Coronary artery bypass graft surgery (CABG) is up to now the treatment 
of choice for unprotected left main artery stenosis (ULM) and it has proven benefit on 
long-term outcomes. The treatment of unprotected left main (ULM) is one of the most 
challenging lesion subset in percutaneous coronary intervention (PCI). Several studies 
on drug eluting stent (DES) showed low mortality and MACE in hospital and at follow-
up, but they reported a limited sample size and a short follow-up duration. We report 
our institutional experience and very long term follow up of patients undergoing LM PCI 
with DES.
Methods: From June 2002 to August 2007, 256 consecutive patients (pts) with ULM 
stenosis were treated with PCI with Sirolimus (28%), Paclitaxel (64% ) or ABT 578 (8%) 
eluting stents in our institution. Mean age was 63 ± 10 y, the ejection fraction was 49 ± 
11%; 88 pts (34%) were diabetic, 162 pts (63%) had unstable angina and 16 pts (6%) had 
acute myocardial infarction. Bifurcation lesion was treated in 130 pts (51%). The clinical 
follow-up was performed at 1, 6 months and every year and angiography follow-up was 
mandatory at 6-8 months.
Results: Procedural success was achieved in 99%. One pt with ostial stenosis had ostial 
recoil at the end of the procedure and one pt for periprocedural acute stent thrombosis 
were referred for coronary artery bypass graft surgery. During hospitalization 3 patients 
(1,2 %) died, one pt for cardiac cause not stent-related. Acute myocardial infarction 
occurred in three patients (1,2 %). At 1 year follow-up (184 pts,72%) 3 pts (1,6%) died, 
one for sudden death, one for not stent-related cause and one died for non cardiac 
disease. AT angiography follow-up was performed on 156 pts (61%), restenosis occurred 
in 12 pts (7,7%) with the need of a new PCI. At long term follow-up (> 1 year) (99 pts, 
39%) 1 pt (1 %) died for sudden death and 2 for chronic cardiac failure (2%);. 6 pts (6 %) 
underwent target lesions revascularization.
Conclusion: In-hospital data of our population show PCI as an effective and therapy with 
low incidence of periprocedural thrombosis, cardiac death and MACE. These results are 
maintained at long term follow-up with only one suspected very late stent thrombosis.
2900-113 The Impact of Restenosis After Percutaneous Treatment 
of Coronary Bifurcation Lesions With Drug-eluting 
Stents
Helen Routledge, Thierry Lefevre, Marie-Claude Morice, Federico De Marco, Beatriz 
Vaquerizo, Mohamed Chettibi, Yves Louvard, Philippe Garot, Institut Cardiovasculaire 
Paris Sud, Massy, France
Background: Despite drug eluting stents (DES), bifurcation coronary disease is 
associated with higher rates of restenosis than that of simple lesions. This may discourage 
choice of an initial percutaneous strategy.
AIm: To investigate the impact of retenosis in patients treated for bifurcation lesions 
with DES.
Methods: Analysis of data from a prospective registry of 477 consecutive patients 
treated with DES and a default provisional side branch (SB) T-stenting strategy.
Results: At 29 (±8) months revascularization involving either of the vessels treated (TVR) 
had been undertaken in 42 patients (8.8%). This involved the index bifurcation in 25 cases 
(5.2% TLR). Treatment of a Medina 0, 0,1 lesion was the only independent predictor of 
TVR. Indications for repeat intervention were stable angina in 48%, silent ischemia in 29% 
and unstable syndromes in 23%.
Of the re-PCI patients, 10% were treated with balloon angioplasty, 64% with a DES in the 
main vessel (MV) 23% with a SB DES and 3% with DES in both branches.
In 37 of 39 patients revascularisation was uncomplicated Two patients died following TVR, 
(1 MI, 1 Tamponade. Re-revascularization occurred in 4.8% of TVR group. The risk of 
death or MI at 2 years was no different in patients who required TLR /TVR.
Conclusion. The need for TLR or TVR at 2-years after using DES and provisional T-stenting 
for bifurcations is low. Restenosis is relatively benign and repeat PCI is associated with a 
high rate of success and a low rate of repeat revascularization. 
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2900-114 Long-term Outcomes of Percutaneous Versus Surgical 
Revascularization for Unprotected Left Main Coronary 
Disease in Diabetic Patients
Seung-Whan Lee, Young-Hak Kim, Duk-Woo Park, Won-Jang Kim, Sang Hyun Kim, Jae 
Hyoung Park, In Hyun Jung, Jeong Hoon Kim, Cheol Whan Lee, Myeong-Ki Hong, Jae-
Joong Kim, Seong-Wook Park, Seung-Jung Park, MAIN-COMPARE Investigators, Asan 
Medical Center, seoul, South Korea
Background: Although diabetes mellitus (DM) is known to be major determinant for 
adverse outcomes in patients undergoing coronary revascularization, data are limited 
about impact of DM on long-term clinical outcomes in patients with revascularization for 
unprotected left main coronary artery (ULMCA) disease.
Methods: Between Jan, 2000 and June, 2006, a total of 747 diabetic patients with 
ULMCA stenosis were enrolled from 12 academic centers in Korea. Percutaneous 
coronary intervention (PCI) and coronary artery bypass grafting (CABG) were performed 
in 341 patients (bare-metal stent: 82, drug-eluting stent [DES]: 259) and 406 patients, 
respectively.
Results: Compared to patients treated with PCI, patients with CABG showed a higher 
incidence of peripheral vascular disease, poor LV function (LVEF<40%), higher Euroscore 
and extra-vessel disease over left main and more presented with acute coronary 
syndrome. After adjustment for difference of baseline characteristics, patients with PCI 
showed a significant increase of target vessel revascularization (TVR) without difference 
for death or Q-wave myocardial infarction (MI) than those with CABG. This trend was 
persistent in comparison between DES and CABG (Table).
Conclusions: In diabetic patients with ULMCA disease, compared with CABG, PCI was 
significantly associated with a subsequent revascularization without increased evidence 
for death or myocardial infarction.
Table. Cumulative 3-year incidence of clinical events 
PCI 
(n=341)
DES 
(n=259)
CABG 
(n=406)
PCI vs. CABG DES vs. CABG
P* Adjusted HR (95% CI) P*
Adjusted HR 
(95% CI)
Death 3.3% 2.3% 5.0% 0.922 0.92 (0.50-1.67) 0.766
0.75 
(0.34-1.63)
Q-MI 0.3% 0.2% 0.6% 0.644 0.16 (0.01-3.0) 0.510
0.35 
(0.03-4.40)
TVR 4.8% 3.9% 0.9% <0.001 26.71 (7.04-101.40) <0.001
17.00 
(4.25-67.99)
Death/Q-MI/
TVR 7.9% 6.0% 6.2% <0.001
2.33 
(1.45-3.74) 0.012
2.07 
(1.24-3.45)
*Log-rank P
2900-115 Percutaneous Treatment of De Novo Coronary 
Bifurcation Lesions With T-stenting or Stenting of 
the Main Branch With Kissing Balloon of the Side 
Branch: Three-year Results From a Large Single-center 
Registry
Miroslaw Ferenc, Heinz-Joachim Buettner, Hans-Peter Bestehorn, Michael Gick, Klaus 
Werner, Thomas Comberg, Juergen Allgeier, Jan Minners, Peter Betz, Piotr Kuebler, 
Franz-Josef Neumann, Heart Center, Bad Krozingen, Germany
Background: PCI of bifurcation lesions may involve stenting of the main branch 
including final kissing balloon of the side branch (single stenting) or stenting of both 
branches. Double stenting is associated with excellent angiographic results immediately 
post procedure, but may expose patients to higher long term risks related to metal burden 
or stent deformation.
Methods: We present 3-year follow-up data from our registry of 1038 consecutive 
patients undergoing percutaneous catheter intervention for de novo bifurcation lesions 
at our institution between January 2002 and September 2005. We treated 656 patients 
with the single stent strategy and 382 patients with stenting of both branches using the 
T-stent technique.
Results: Baseline clinical characteristics were well matched between both groups. Target 
lesion revascularisation (TLR) after three years was performed in 15.1 % of patients 
treated with a single stent and 21.6 % of patients who underwent T-stenting (p=0.006). 
The combined endpoint of death and myocardial infarction (MI) as marker for safety 
was reached by 11 % of patients in the single stenting and 12 % in the T-stenting group 
(p=0.341). Likewise, there was no significant difference in the incidence of death between 
single and T-stent technique (8.9 vs. 7.7 %; p=0.851). Comparing DES with BMS, the 
3-year incidence of TLR was significantly lower with DES (14.8 % vs. 24.6 %, p<0.001); 
we also found a lower 3-year incidence of death and MI in DES as compared with BMS, 
which did not reach statistical significance (10.8 % vs. 12.5 %, p=0.433).
Conclusions: Bifurcation lesions that can be managed with the single stent strategy 
have a lower restenosis rate than lesions treated with T-stenting. Compared with single 
stenting, T-stenting does not increase the 3-year risk of death and MI, regardless of 
whether BMS or DES were implanted. Although there were no significant differences, the 
observed 3-year incidences of death and MI favored DES as compared with BMS.
2900-116 Long-term Clinical Outcomes Between Percutaneous 
Versus Surgical Revascularization for the Treatment 
of Ostial and Shaft Lesions of Unprotected Left Main 
Coronary Artery
Jung Soon Kim, Duk-Woo Park, Young-Hak Kim, Won-Jang Kim, Gyung Jung Kim, 
Jong-Pil Park, Jeong-Woo Lee, Sang Hyun Kim, Seung-Whan Lee, Cheol Whan 
Lee, Myeong-Ki Hong, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park, MAIN-
COMPARE Investigators, Asan Medical Center, seoul, South Korea
Background: The long-term clinical outcomes after percutaneous coronary intervention 
(PCI) versus coronary artery bypass grafting (CABG) has not been known in patients 
with non-bifurcation (ostium and shaft) lesions of unprotected left main coronary artery 
(ULMCA).
Methods: Between Jan, 2000 and June, 2006, a total of 1090 patients with ostium 
and shaft ULMCA stenosis were collected from 12 academic institutions in Korea. 
Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) 
were performed in 577 patients and 513 patients, respectively.
Results: Compared to patients with PCI, patients with CABG were significantly older 
and showed a higher incidence of previous myocardial infarction (MI), peripheral vascular 
disease, hyperlipidemia, poor LV function (LVEF<40%), and high Euroscore (≥6) and 
more presented with acute coronary syndrome. During long-term follow-up of median 35.4 
months, there was no difference of death or Q-wave myocardial infarction (MI) between 
PCI and CABG group. However, patients with PCI showed a significantly higher incidence 
of target vessel revascularization than those with CABG. This trend was persistent in 
comparison between drug-eluting stents and CABG (Table).
Conclusions: There was no difference in death or Q-MI in patients with ostial and shaft 
ULMCA disease with regard to PCI and CABG. However, percutaneous revascularization 
without regard to stent type was significantly associated with target vessel revascularization 
than bypass surgery.
Table. Cumulative 3-year incidence of clinical events 
PCI 
(n=577)
DES 
(n=342)
CABG 
(n=513)
PCI vs. CABG DES vs. CABG
P* Adjusted HR (95% CI) P*
Adjusted HR 
(95% CI)
Death 3.9% 2.3% 3.2% 0.420 1.49 (0.81-2.73) 0.63
1.40 
(0.63-3.12)
Q-MI 0.3% 0.1% 0.3% 0.980 1.80 (0.08-15.11) 0.20
1.00 
(0.01-85.76)
TVR 4.9% 2.5% 0.7% <0.001 19.12 (6.62-55.20) <0.001
10.82 
(3.27-35.83)
Death/Q-MI/
TVR 8.3% 4.6% 4.1% <0.001
3.55 
(2.19-5.77) 0.03
2.28 
(1.32-3.95)
*Log-rank P
DES: drug-eluting stent, Q-MI: Q-wave myocardial infarction, TVR: target vessel 
revascularization
2900-117 Comparison of Long-Term Outcomes Between 
Percutaneous Coronary Intervention Versus Bypass 
Surgery for Treatment of Isolated Unprotected Left Main 
Coronary Artery Disease
Duk-Woo Park, Young-Hak Kim, Won-Jang Kim, Gyung Jung Kim, Jae Hyoung Park, 
Jeong-Woo Lee, Seung-Whan Lee, Cheol Whan Lee, Myeong-Ki Hong, Jae-Joong Kim, 
Seong-Wook Park, Seung-Jung Park, MAIN-COMPARE Investigators, asan medical 
center, seoul, South Korea
Background: The differential long-term outcome of percutaneous coronary intervention 
(PCI) versus coronary artery bypass graft (CABG) surgery is not well known in patients 
with isolated unprotected left main coronary artery (ULMCA) disease.
Methods: Between Jan, 2000 and June, 2006, a total of 354 patients with isolated 
ULMCA stenosis were collected from 12 academic centers in Korea.
Results: Baseline characteristics did not differ between patients treated with PCI versus 
CABG. The mean follow-up period was 969.1 ± 639.9 days in PCI patients and 916.2 ± 
620.3 days in CABG patients.
Conclusions: In patients with isolated ULMCA disease, CABG was associated with 
lower incidence of target vessel revascularization (TVR) compared with PCI. However, 
the difference of TVR was not significant between patients treated with drug-eluting stent 
(DES) versus CABG after adjustment. 
PCI 
overall 
(n=282)
DES 
(n=146)
CABG 
(n=72)
PCI overall vs. 
CABG DES vs. CABG
P*
Adjusted 
HR  
(95% CI)
P* Adjusted HR (95% CI)
Death 4.0% 0.9% 0.8% 0.52 1.75 (0.34-9.13) 0.26 -
Q-MI 0.8% 0% 0.3% 0.96 0.707 (0.06-9.14) 0.23 -
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TVR 8.5% 3.7% 0.3% 0.001 16.613 (2.11-131.0) 0.02
12.84 
(0.95-173.30)
Death/Q-MI/
TVR 11.6% 4.6% 1.1% 0.004
6.137 
(1.77-21.28) 0.27
2.22 
(0.51-9.60)
* Log rank test; ΜΙ=myocardial infarction
2900-118 Unprotected Left Main Coronary Artery Stenting in 
Octogenarians and Patients With Severe Comorbidities: 
A Compasionate or a Clinically Relevant Approach?
Karl Isaaz, Norbert Mayaud, Alexis Cerisier, Michel Lamaud, Christophe Robin, Laure 
Richard, Claude Gerenton, Antoine Da Costa, University of Saint Etienne, Saint Etienne, 
France
Background. Some studies have evaluated unprotected left main (ULM) coronary artery 
stenting (ULMCS) in small subgroups of high-surgical-risk patients (pts) defined by 
an age ≥ 75 years and/or comorbid conditions with a Parsonnet surgical risk score > 
15. Whether ULMCS in even higher risk pts is clinically relevant or only compasionate 
remains unknown. Methods. ULMCS was performed in our center in 29 consecutive pts 
with an age ≥ 80 years and/or a Parsonnet score ≥ 20. Follow-up status was obtained at a 
mean of 37 months (18-96 months). Results. Mean age was 82 ± 9 yrs (54-97 yrs with 21 
pts aged ≥ 80 yrs and 10 aged ≥ 85 yrs), Parsonnet score was 26 ± 8 (13-42); 22/29 (76%) 
had unstable angina, 26/29 (90%) had ≥ 2 vessel disease in addition to ULM, ULM lesion 
was distal in 20/29 (69%). Drug eluting stents were used in 11/29 pts (38%); stenting was 
done on ULM alone in only 4 cases (14%) and on ULM plus 2 or 3 vessels in 19(66%); 
complete revascularization was achieved in 20/29 (69%). In-hospital death occurred in 
2/29 (6.8%) (2 males, 88 and 92 yrs old). In the 27 survivors at hospital discharge (no lost 
pts), death occurred in 9 (33%, 5 non cardiac and 4 cardiac) at 22 ± 18 months (range 
1-54 months). Actuarial survival rates in these 27 pts at 6 and 18 months were 89% and 
85%, respectively. In the subgroup of the 19 pts aged ≥ 80 years, the 18 months actuarial 
survival rate was 84%. Conclusion. Unprotected left main coronary artery stenting can 
be proposed to non surgical candidates at very high risk due to advanced age, including 
octogenarians, or due to severe comorbidities with very high Parsonnet score with 
acceptable immediate and mid-term clinical outcomes. 
2900-119 Favorable Long-Term Outcome Following Drug Eluting 
Stent Implantation in Nonbifurcation Lesions Involving 
Unprotected Left Main Coronary Artery: A Multicenter 
European and Asian Registry
Alaide Chieffo, Young H. Kim, Marco Valgimigli, Thierry Lefevre, Imad Sheiban, Seung J. 
Park, Emanuele Meliga, Beatriz Vaquerizo, Olivier Darremont, Claudio Moretti, Renata 
Rogacka, Matteo Montorfano, Seong W. Park, Dario Sillano, Marie Claude Morice, 
Patrick Serruys, Antonio Colombo, San Raffaele Hospital, Milan, Italy
Background: The presence of a lumen narrowing at the ostium and the body of an 
unprotected LMCA, which does not require bifurcation treatment, is a class I indication to 
surgical revascularization.
Methods: All consecutive patients (pts) who had a stenosis in the ostium and/or the mid-
shaft of an unprotected LMCA (not requiring the treatment of the bifurcation) electively 
treated with percutaneous coronary intervention (PCI) and sirolimus- (SES) or paclitaxel-
eluting (PES) stent in 7 Centres were included in this registry.
Results: A total of 208 patients were analyzed: 107 were treated with SES and 101 
with PES. Almost 60% of the patients had an an Euroscore ≥6 and/or Parsonnet ≥13. 
In 75 (36%) pts IVUS guidance was performed. During hospitalization, zero patients 
experienced a Q wave myocardial infarction (MI) or died, (2.9%) had a non Q wave MI. 
Two patients underwent to coronary artery by-pass grafting ( 1 because of the presence 
of more than 30% residual stenosis after stenting and 1 for procedural complication). 
One patient died 19 days after the procedure because of pulmonary infection. At long 
term clinical follow-up (873±297 days), 10 (4.08%) patients died. Six (2.9%) patients 
were adjudicated as cardiac deaths (5 of these patients died of unknown causes). No 
patient had a definite or probable stent thrombosis, 5 (2.4%) patients had a possible 
stent thrombosis. Eighteen (8.6%) patients had target vessel revascularization (16 re-
PCIs and 2 CABG), of these only 4 (1.9%) patients had a target lesion revascularization. 
Angiographic follow-up was performed in 146 pts (70.2%), restenosis in the left main 
trunk occurred only in 4 (1.9%) patient. Conclusions: PCI with SES or PES implantation 
in non-bifurcation LMCA lesions appears safe with a long-term MACE rate of 11.5 % and 
a restenosis rate of 1.9%.
2900-120 Multicenter International Experience of Unprotected 
Left Main Coronary Artery Percutaneous Coronary 
Intervention with Drug-Eluting Stents in Patients With 
Myocardial Infarction
Michael S. Lee, Imad Sheiban, Giuseppe Biondi Zoccai, Dario Sillano, Jonathan Tobis, 
UCLA Medical Center, Los Angeles, University of Turin, S. Giovanni Battista-Molinette 
Hospital, Turin, Italy
Background: Patients who present with myocardial infarction (MI) and unprotected 
left main coronary artery (ULMCA) disease represent an extremely high-risk subset 
of patients. ULMCA percutaneous coronary intervention (PCI) with drug-eluting stents 
(DES) in MI patients has not been extensively studied. In this retrospective, multicenter, 
international registry, we evaluated the clinical outcomes of ULMCA PCI with DES in MI 
patients.
Methods: From 2002 to 2006, 53 patients who had MI (19 ST-elevation MI and 34 non-
ST-elevation MI) underwent ULMCA PCI with DES.
Results: The mean age was 71 ± 11 years. The mean peak CPK was 1367 ± 1397 U/l. 
Cardiogenic shock was present in 25%. Mean EuroSCORE was 10 ± 8. Distal bifurcation 
was involved in 31 patients (58%). Sirolimus-eluting stents were implanted in 43 patients 
(81%). Angiographic success with TIMI 3 flow was achieved in all patients. Overall in-
hospital major adverse cardiac event (MACE) rate was 9%. In-hospital mortality was 
8% for all patients (16% for ST-elevation MI and 3% for non-ST-elevation MI) all due 
to refractory cardiogenic shock. At one year, the overall MACE rate was 30%, the total 
mortality rate was 15%, and the cardiac mortality rate was 11%. Two patients required 
target vessel revascularization, both of whom had distal bifurcation involvement, and 
subsequently underwent bypass surgery. The definite and probable/possible stent 
thrombosis rates were 0% and 6%, respectively.
Conclusions: Patients with MI and ULMCA disease represent a very high-risk subgroup 
of patients who are critically ill. PCI with DES is technically feasible and appears to be a 
reasonable alternative to surgical revascularization for MI patients with ULMCA disease. 
A randomized trial would be needed to determine the ideal revascularization strategy for 
these patients.
2900-121 Long-Term Outcome of Patients With Distal Versus Non-
Distal Unprotected Left Main Coronary Artery Stenosis 
Treated With Drug Eluting Stents
Andrea Pavei, Guillaume Martin, Jacopo A. Oreglia, Petr Tousek, Faisal Sharif, Bruno 
Farah, Clinique Pasteur, Toulouse, France
Background: Percutaneous coronary intervention (PCI) has been increasingly 
employed to treat unprotected left main coronary artery (ULMCA) stenoses, recently with 
drug eluting stents (DES). To assess the impact of the site of the stenosis (distal vs. non-
distal) on the long-term outcome, we evaluated the patients of our ULMCA PCI registry. 
Methods: 147 consecutive patients with a stenosis of an ULMCA, were electively 
treated with PCI and drug eluting stents (DES) at our center between September 2002 
and September 2006. Results: The mean age was 71 ± 10 years, 120 patients (82%) 
were males, 39 (27%) were diabetic and 62 (42%) had renal failure (creatinine clearance 
< 60mL/min). Eighty-four patients (57%) were treated with sirolimus-eluting stents, 58 
(39%) with paclitaxel-eluting stents and 5 (4%) with zotarolimus-eluting stents. Ninety-four 
patients (64%) had distal ULMCA lesions (group 1) and 53 (36%) had non-distal ULMCA 
lesions (group 2). At baseline, group 1 had a higher prevalence of male sex (88.3% vs. 
69.8% p=0.005) and of previous myocardial infarction (MI) (21.3% vs. 7.5%, p=0.031). 
Procedural success was achieved in all the patients. During hospitalization, no patient 
experienced a Q-wave MI or died. At long-term clinical follow-up (mean 27 ± 13 months), 
15 patients had died: 10 (10.6%) in group 1 and 5 (9.4%) in group 2 (p=0.82). Group 1 
had a higher TLR rate (11.7% vs. 1.9%; p=0,037), but there was no significant difference 
between the two groups concerning the major adverse clinical event (MACE) rate (21.3% 
in group 1 vs. 13.2% in group 2; p=0.22) and the event-free survival (75.5% in group 1 
vs. 62.8% in group 2; p=0.11). At multivariate analysis, distal ULMCA lesions showed a 
trend in predicting TLR occurrences (p=0.056) and cumulative survival analysis showed 
a poorer TLR-free survival in patients with distal LMCA stenoses (log rank p=0.035). 
Conclusion: The majority of our patients had distal ULMCA lesions. At long-term follow-
up, patients with distal and non distal LMCA stenoses had no significant differences in 
mortality and MACE rate, but the presence of a distal lesion was significantly related to 
a worse TLR-free survival.
2900-122 Relationship of Side-Branch Intervention and Drug-
Eluting Stents to Long-Term Outcomes After Coronary 
Bifurcation Stenting
Payman Zamani, Scott Kinlay, Veterans Affairs Boston Healthcare System, West 
Roxbury, MA, Brigham and Women’s Hospital, Boston, MA
Background: Routine side-branch intervention with percutaneous coronary interventions 
(PCI) at bifurcations is controversial. We assessed very long-term clinical outcomes after 
bifurcation PCI according to side-branch intervention and the use of drug-eluting stents 
(DES). 
Methods: We reviewed 160 consecutive cases of de-novo single bifurcation lesions 
treated by PCI in the West Roxbury VA Hospital. Clinical outcomes were followed in 
the nationwide VA VISTA system for in-patient and out-patient encounters up to 4.5 
years after the index event. The primary endpoint was time to any clinical event (death, 
myocardial infarction (MI), any revascularization) using Cox proportional hazards by side 
branch intervention (stent, balloon or no intervention) and use of DES.
Results: Over an average follow-up of 2.3 years (SD=1.3 years), 68 (38%) patients had 
at least one clinical event. The first clinical event included 25 (16%) MIs, 7 (4%) deaths, 6 
(4%) CABGs, 16 (10%) restenosis PCIs, and 6 (4%) non-target lesion PCIs. Side branch 
angioplasty was used in 84 (53%) patients, side branch stenting in 39 (24%) patients, and 
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no side branch intervention in 37 (23%) patients,. DES were used in the main branch in 
73 (46%) patients, and a final kissing balloon angioplasty used in 68 (55%) of patients 
receiving a side branch intervention. On multivariate analysis, the risk of a clinical event 
was significantly higher with increasing age (p=0.024), unstable angina at the index 
presentation (p=0.011) and a prior PCI (p<0.001). Risk was lower with a DES in the 
main vessel (p=0.024) and a final kissing balloon inflation if there was a side branch 
intervention (p=0.013). Long-term risk with side branch balloon angioplasty (HR=0.79, 
95%CI=0.38, 1.65. p=0.53) or no intervention in the side-branch (HR=0.57, 95%CI=0.23, 
1.45. p=0.24) was not different to side branch stenting.
Conclusions: The long-term outcomes with side branch intervention were no better 
than main vessel stenting alone. However, among those having side branch intervention, 
outcomes were better with a final kissing balloon inflation. Patients receiving a DES in the 
main branch had significantly better very long-term outcomes compared to BMS.
2900-123 Preliminary Results of the Novel TMI (TriReme Medical 
Inc.) Antares Side Branch Adaptive System (Antares 
SASTM Stent) for the Treatment of De Novo Coronary 
Bifurcation Lesions
Ricardo A. Costa, Alexandre Abizaid, Andrea Abizaid, Fausto Feres, Rodolfo Staico, 
Luiz A. Mattos, J. Ribamar Costa, Jr., Amanda Sousa, Mary E. Russell, Eitan 
Konstantino, Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil
Background: The Antares SAS stent was designed to facilitate side branch (SB) access, 
improve positioning, and maximize ostial scaffolding. It is comprised of a low profile 6-Fr. 
compatible balloon-expandable stent, and a SB Stabilizing Wire which allows direct SB 
wiring and access after stent deployment into the main vessel (MV), without the need for 
stent re-crossing. Also, there are 4 markers at the device’s “Ostium Preservation” structure 
to improve positioning and complete coverage of the SB ostium (Figure). Methods: 11 
pts/lesions were consecutively enrolled in a single center as a part of a multicenter 
prospective study; 91% of lesions had significant involvement of both branches, and LAD/
Diag. was the prevalent lesion location (73%). Results: Baseline RD was 2.97±0.35mm 
and 2.18±0.37mm, and lesion length was 11.50±2.46mm and 5.03±3.23mm, for the MV 
and SB, respectively. The Antares SAS stent was successfully implanted in 100% (mean 
pressure 13.3±3.0 atm). Single balloon post dilatation was performed in all MVs and in 
82% in SB; 55% had FKB. Stents were implanted in the SB in 2 cases. All pts achievd 
TIMI 3 flow in both branches + <50% DS in the MV and SB access with low residual 
stenosis. There was no in-hospital MACE (death, MI, TLR). At 30-day clinical FU, there 
was 0% MACE. Conclusions: The Antares SAS dedicated stent demonstrated safety 
and excellent acute results; therefore, it may represent an alternative for the treatment of 
bifurcation lesions. Larger studies with long-term FU are warranted. 
2900-124 Midterm Clinical Outcomes From the Intravascular 
Ultrasound Investigation of the Parent Vessel and the 
Side Branch in Coronary Bifurcation Lesions Treated 
With Different Stenting Techniques (INSIDE I) Trial
Ricardo A. Costa, Shinichi Furuichi, Alexandra J. Lansky, Gary S. Mintz, Mateo 
Montorfano, Mauro Carlino, Iassen Michev, Flavio Airoldi, Azeem Latib, Giuseppe 
Sangiogi, Fausto Feres, Rodolfo Staico, Luiz A. Mattos, J. Ribamar Costa, Jr., Antonio 
Colombo, Centro Cuore Columbus & San Raffaele Ospedale, Milan, Italy, Instituto Dante 
Pazzanese de Cardiologia / Cardiovascular Research Foundation, Sao Paulo, Brazil
Background: The INSIDE I trial was a prospective, multicenter, non-randomized study 
designed to evaluate the impact of luminal dimensions and IVUS-guided PCI with DES in 
bifurcation lesions. Methods: From June/06 to April/07, 73 pts (78 lesions) were enrolled 
at 4 clinical centers; 78% of lesions had significant involvement of both branches; LAD/Dg 
was the predominant vessel location (56%), followed by LM stem (33%); and the majority 
of lesions (N=66) were de novo. IVUS imaging was performed in both branches at 
baseline in 81% and at final in 100%. Results: Mean age was 64 yrs, 31% had diabetes, 
32% had previous MI, and 64% had previous revascularization. Forty-one % were treated 
with 1 stent (provisional technique) vs. 59% with 2 stents; FKB was performed in 96%; 
angiographic success (<50% DS in both branches) was achieved in 99%, and procedural 
success (angiographic success without in-hospital MACE) was 90% (6 patients had 
non-Q MI). QCA and IVUS are shown in the Table. At FU (98%, mean time: 7.8±2.4 
months), cardiac death was 1.5%, MI was 3%, TLR was 13% [and was similar among 
lesions treated with 1 (N=4) vs. 2 stents (N=5), p=NS, and overall MACE rate was 23%. 
There was 1 case of stent thrombosis (>30 days). Conclusions: In the INSIDE I trial, SB 
lesion length, vessel size, lesion distribution and vessel remodeling significantly impacted 
the PCI technique for bifurcation DES. At the mid-term FU, MACE was relatively high, 
mainly associated with high rates of TLR, which occur similarly in lesions treated with 
1 vs. 2 stents.
Preliminary QCA and IVUS results
QCA - SB No stent Stent P value IVUS - SB No stent Stent P value
Lesion 
length, 
mm
5.45±1.97 10.17±5.89 0.02
Minimum 
lumen 
area 
(MLA), 
mm2
3.31±1.08 2.77±0.67 0.08
Reference 
diameter, 
mm
2.25±0.44 2.72±0.49 0.009
MLA 
distance 
from SB 
ostium, 
mm
0.00±0.00 0.61±1.16 0.02
MLD, mm 1.10±0.61 1.09±0.49 0.98 Plaque 
“burden” 0.52±0.14 0.56±0.17 0.80
% DS 51.5±27.7 59.0±18.7 0.35 Area of 
stenosis 0.42±0.22 0.44±0.20 0.80
Final Final
MLD 1.91±0.45 2.38±0.51 0.01 MLA, 
mm2 4.32±0.89 5.71±2.13 0.01
% DS 18.8±8.2 17.9±9.0 0.78
MLA at 
5mm 
ostium 
location, 
mm2
4.35±0.96 6.76±2.71 0.0008
2900-125 Analysis of the Long-term Effects of Drug-eluting 
Stents on Coronary Arterial Healing by Virtual 
Histology Intravascular Ultrasound
Takashi Kubo, Akiko Maehara, Gray S. Mintz, Hiroshi Doi, Kenichi Tsujita, Junqing Yang, 
Jian Liu, Carlos Oviedo, Anthony Tam, Harpreet Bharaj, Joelson Guillaume, Richard 
Abendroth, Sinan Biro, Rasha Aaskar, Celia Castellanos, Lokesh Dani, Jeffrey W. 
Moses, Martin B. Leon, D.Geoffrey Vince, M. Pauliina Margolis, Gregg W. Stone, James 
R. Margolis, Cardiovascular Research Foundation, New York
Background: Animal models show impairment of arterial healing after drug-eluting 
stents (DES) compared to bare-metal stents (BMS). Spectral analysis of intravascular 
ultrasound (IVUS), radiofrequency backscattered signals - known as Virtual Histology (VH) 
- offers an opportunity to assess lesion morphology in vivo. Methods and Results: We 
used VH-IVUS to assess long-term (mean=8 months) native artery vascular responses 
after 36 DES implantation compared with 13 BMS. Baseline clinical and grayscale and 
VH-IVUS characteristics were similar between DES and BMS. Although necrotic core 
(NC) volume was not significantly changed during the follow-up period in either group 
(Table), the frequency of NC abutting the lumen (i.e., vulnerable plaque) at follow-up (42% 
vs. 14%, p=0.037) was significantly greater in DES than BMS because of the lack of 
an overlying, protective neointimal hyperplasia in DES-treated lesions. Furthermore, at 
the stent edge the frequency of thin-capped fibroatheromas (TCFAs) decreased in BMS-
treated lesions (27% to 4%, p=0.015) but not in DES (25% to 22%, p=0.695). Conclusion: 
Serial VH-IVUS analysis of DES-treated lesions show a greater frequency of unstable 
lesion morphometry (TCFAs or vulnerable plaques) at follow-up compared to BMS. The 
apparent mechanism is a suppression of the protective neointimal hyperplasia layer 
coupled with a lack of TCFA resolution at stent edges.
Comparison VH-IVUS characteristics between DES and BMS.
DES (n=36) BMS (n=13) p
Stent length, mm 19.3 +/- 7.6 18.5 +/- 7.0 p=0.8
Fibroatheroma at baseline, n (%) 23 (64) 8 (62) p=0.9
Baseline NC volume, mm3 25.8 +/- 18.9 22.5 +/- 17.1 p=0.9
Follow-up NC volume, mm3 27.6 +/- 19.4 25.8 +/- 18.7 p=0.9
ΔNC volume, mm3 2.1 +/- 3.8 3.3 +/- 4.2 p=0.9
2900-126 Single Plane Balloon Sizing of Atrial Septal Defects with 
Intracardiac Echocardiography is an Advantageous 
Alternative to Cineangiography
Thomas Bartel, Thomas Konorza, Verena Barbieri, Raimund Erbel, Otmar Pachinger, 
Silvana Mueller, Medical University Innsbruck, Innsbruck, Austria, West-German Heart 
Center, Essen, Germany
Background: Aiming to develop a safe alternative to conventional quantitative 
cineangiography (QCA) that does not expose patients to radiation, we sought to compare 
intracardiac echocardiography (ICE) and transesophageal echocardiography (TEE) with 
QCA for sizing of atrial septal defects (ASDs).
Methods: In 43 patients (mean age 40±15 years) with ASD, defect size was routinely 
measured by TEE in two perpendicular planes. Prior to percutaneous device closure, native 
ASD size was also determined by ICE. Upon subsequent balloon sizing, the stretched 
balloon diameter was measured by both ICE and QCA. The latter was considered the gold 
standard. QCA measurements were completed in two perpendicular planes whereas ICE 
balloon sizing was completed in just a single standard cut plane.
Results: Conventional QCA-based balloon sizing revealed diameters of 17.5±5.4 mm. 
Both echocardiographic methods underestimated the diameter, but to a different degree: 
TEE 11.8±3.3 mm, p<0.001; ICE sizing of native ASD: 13.5±4.1 mm, p<0.001; single plane 
ICE balloon sizing: 16.9±5.2 mm, p<0.001. ICE-based balloon sizing underestimated 
defect size by les than 1 mm on average (Figure).
Conclusions: Balloon sizing is still indispensable for choosing an adequately sized 
occluder. As a sizing tool, ICE is an accurate alternative to QCA and helps lower radiation 
exposure. With ICE, the occluder should be oversized by about 1 to 2 mm to account for 
the slight underestimation observed with ICE sizing. 
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2900-127 Evolution of plaque composition after statin therapy 
according to plaque stability in patients with acute 
coronary syndrome: A study with intravascular 
ultrasound-virtual histology
Sang-Gon Lee, Eun-Seok Shin, Shin-Jae Kim, Ulsan University Hospital, Ulsan, South 
Korea
Background: Previous trials using intravascular ultrasound(IVUS) have demonstrated 
that the lipid lowering therapy with statin decrease plaque volume and increase plaque 
echogenecity in patients with coronary artery disease. We examined whether statins 
clinically alter the composition of coronary atherosclerotic plaques of humans by in vivo 
IVUS-Virtual Histology(VH) analysis.
Methods: This was a prospective, single-center study to assess the effect of 6 months 
of treatment with statin to induce the change of plaque composition in non-percutaneous 
coronary intervention(PCI) sites of the culprit vessel with <50% diameter stenosis among 
26 patients with acute coronary syndrome(ACS). One target segment was determined in 
a non-PCI site (>5 mm proximal or distal to the PCI site) with a reproducible index side 
branch or from the ostium of target vessel.
Results: In 6 months after statin therapy, no change was demonstrated in mean 
percentage of the lipid core(15.6 ± 7.2% to 13.6 ± 7.9%, p=ns), whereas plaque volume 
and LDL-cholesterol level were significantly reduced. Of 26 patients, four different types of 
atherosclerotic plaque were identified: pathologic intimal thickening(PIT, n=5), fibrocalcific 
atheroma(FC, n=9), fibroatheroma with thick cap(non TCFA, n=3), or fibroatheroma 
without thick cap(TCFA, n=9). There was a significant reduction of lipid core percentage 
only in the type of TCFA (16.7 ± 4.2 % to 9.8 ± 5.7 %, p< 0.05).
Conclusions: IVUS-VH may be useful to evaluate effects of statin on plaque composition 
in vivo. Specifically, percentage of lipid core was significantly reduced in the type of TCFA 
which suggest that the change of plaque composition following statin therapy might be 
different according to plaque stability in patients with ACS.
2900-128 Variable Left Anterior Descending Coronary 
Artery Anatomy in Stress-Induced (Takotsubo) 
Cardiomyopathy
Navin K. Kapur, Ramesh Mazhari, James O. Mudd, Hunter C. Champion, Jon R. Resar, 
Ilan S. Wittstein, Johns Hopkins Hospital, Baltimore, MD
Stress-induced (Takotsubo) cardiomyopathy (SCM) is characterized by mid ventricular 
and apical wall motion abnormalities without obstructive coronary disease. It is unknown 
whether development of the apical ballooning pattern requires the presence of a ‘wrap-
around’ left anterior descending (LAD) artery. The aim of this study was to characterize 
LAD anatomy and flow in patients with SCM. Methods: Coronary angiograms and 
ventriculograms of 75 patients with SCM were compared to 75 case-matched normal 
controls. Coronary dominance, LAD distribution, hemodynamics, and Thrombolysis in 
Myocardial Infarction frame counts (TFC) were compared between groups. Results (Table 
One): No differences in coronary dominance or LAD distribution were observed. Myocardial 
bridging and coronary vasospasm were rare in SCM. TFC were abnormally high in 96% 
of SCM patients; 62% had involvement of all three epicardial vessels. Abnormal TFC 
in the LAD alone was not observed in any SCM patient. Using linear regression, TFC 
in any vessel did not correlate with left ventricular end diastolic pressure (LVEDP) in 
SCM. Conclusion: This study critically analyzes LAD anatomy in SCM. Apical ballooning 
was seen in all SCM patients, irrespective of LAD distribution and flow. Furthermore, 
abnormal LAD flow was not required to develop the apical ballooning pattern. These data 
suggest the pathogenesis of SCM is not due to LAD distribution or single vessel coronary 
dysfunction. Microvascular or myocyte dysfunction may be more likely. 
SCM (n=75) CONTROL (n=75) p-value
Dominance (% 
Incidence)
Right 85% 92% NS
Left 13.30% 6.70% NS
Co-dominant 1.33% 1.33% NS
Vasospasm 4.00% 0% NS
Myocardial Bridging 1.30% 0% NS
LAD Anatomy 
Short 9.30% 8% NS
Conventional 42.70% 52% NS
True-wrap Around 48% 40% NS
TIMI Frame Count 
(frames/sec)
LAD 70.5 +35.7 42.8 +12.3 P<0.00001
Corrected LAD 41.8 +20.9 25.2 +7.2 P<0.00001
LCx 48.5 +17.7 32.1 +7.9 P<0.00001
RCA 42.5 +17 31.8 +10.8 P<0.00001
LV function
LVEF (%) 30.4 +11.5 61.9 +6.6 P<0.00001
LVEDP (mmHg) 23.9 +7.9 16.4 +6.6 P<0.00001
2900-129 Quantitative Multi-Modality Imaging Analysis of a 
Bioabsorbable Poly-L-Lactic Acid Stent Design: A 
comparison between 2- and 3D-QCA, QCU, QOCT and 
QMSCT-CA
Nico Bruining, Shuzou Tanimoto, Masato Otsuka, Annick Weustink, Jurgen Ligthart, 
Sebastiaan de Winter, Carlos van Mieghem, Koen Nieman, Pim de Feijter, Patrick 
Serruys, Erasmus MC, Rotterdam, The Netherlands
Background: 1) To investigate if 3D quantitative techniques are superior to the golden 
standard 2D-QCA and 2) to study the possibility whether non-invasive MSCT could 
potentially be applied in longitudinal studies to evaluate clinical results of a new family of 
bioabsorable drug-eluting stent designs made of poly-l-lactic-acid (PLLA).
Methods: Sixteen patients undergoing primary PTCA were included. After stenting 
(stent length 12mm and diameter 3mm), patients were imaged with standard coronary 
angiography, intravascular ultrasound and optical coherence tomography after which 
quantitative analyses were performed (e.g. 2- and 3D-QCA, Pie Medial, Maastricht 
Netherlands; QCU and QOCT CURAD, Wijk bij Duurstede, Netherlands). Shortly 
thereafter the patients also underwent a MSCT procedure, of which the images were 
quantified by dedicated software (QMSCT-CA, CURAD).
Results: 2D-QCA underestimated stent length, diameters and derived areas, compared 
to the other imaging modalities (p<0.001 in all comparisons). QOCT showed larger 
stent areas compared to QCU and QMSCT-CA (8.86±1.80 vs. 7.10±1.39, p<0.001 and 
7.41±1.78, p=0.003; respectively).
Conclusions: Standard 2D-QCA underestimates absolute stent dimensions. Three-D 
based quantitative analyses techniques can help to evaluate more accurately the results 
of new stent designs. Furthermore, in case of stents made of PLLA, non-invasive QMSCT-
CA could in the near future be considered for longitudinal quantitative assessment of this 
biodegradable stent.
Measured Stent Dimensions
2D-QCA 3D-QCA QCU QMSCT-CA Stent
Length [mm] 9.89±0.93 12.24±0.55 12.46±0.85 11.84±0.24 12
Diameter [mm] 2.86±0.31 3.03±0.25 2.98±0.29 3.05±0.36 3
Area [mm2] 6.50±1.47 7.23±1.17 7.10±1.39 7.41±1.78 7.07
2900-130 Diabetic Patients Had a Higher Frequency of 
Culprit Lesion Thin-Cap Fibroatheroma Compared 
with Nondiabetic Patients Regardless of Clinical 
Presentations: A Virtual Histology-Intravascular 
Ultrasound Analysis
Young Joon Hong, Myung Ho Jeong, Doo Sun Sim, Jong Won Chung, Ju Han Kim, Jae 
Youn Moon, Young Keun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang, 
Chonnam National University Hospital, Gwangju, South Korea
Background:Thin-cap fibroatheroma (TCFA) lesions are the most prevalent substrate 
of plaque rupture. Pathological studies showed diabetic patients had a greater amount 
of macrophage-infiltrated lipid-rich plaque compared with nondiabetic patients. This 
is consistent with a greater probability of plaque rupture in diabetic patients. We used 
virtual histology-intravascular ultrasound (VH-IVUS) to evaluate the plaque composition 
and the incidence of TCFA in diabetic patients (61 diabetic patients vs. 136 non-diabetic 
patients).
Methods: In 196 patients (155 acute coronary syndrome and 42 stable angina), de novo 
coronary lesions were studied and plaque components were analyzed. We classified 
TCFA lesions as focal, necrotic core-rich (≥ 10% of the cross-sectional area) plaques 
being in contact with the lumen; and TCFA definition required a plaque burden ≥ 40%.
Results:The percent necrotic core area was significantly greater at both minimum lumen 
sites (17.3±11.8% vs. 12.6±9.8%, p=0.023) and largest necrotic core sites (30.2±10.8% 
vs. 20.9±9.6%, p<0.001), and the percent necrotic core volume was significantly greater 
(16.5±9.4% vs. 13.8±7.8%, p=0.036) in diabetic patients compared with nondiabetic 
patients. The presence of at least one TCFA (59% vs. 37%, p=0.004) and multiple TCFAs 
(25% vs. 11%, p=0.014) within culprit lesions were significantly higher in diabetic patients 
compared with nondiabetic patients. The presence of at least one TCFA within culprit 
lesions was significantly higher in patients with both acute coronary syndrome (60% vs. 
42%, p=0.035) and stable angina (55% vs. 19%, p=0.026). In the multivariate analysis, 
diabetes mellitus was the only independent predictor of the presence of TCFA (Odds 
ratio=2.179; 95% CI 1.075-4.416, p=0.031).
Conclusions: VH-IVUS analysis demonstrates that diabetic patients had a higher 
frequency of culprit lesion TCFA compared with nondiabetic patients regardless of clinical 
presentations (in both acute coronary syndrome and stable angina).
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2900-131 Identification of Stent Fracture by 64 Slice Multidetector 
Computed Tomographic Angiography 
Harvey S. Hecht, Tandeep Bhatti, Gary Roubin, Lenox Hill Heart & Vascular Institute, 
New York, NY
Background: In the current era, in-stent restenosis (ISR) results from failure of drug 
elution to prevent neointimal hyperplasia. Stent fracture (SF), with lack of exposure of 
the fractured area to drug elution or lumen obstruction by disrupted stent material, is 
an alternative explanation which has not been adequately explored. Catheter based 
angiography (CBA) may not demonstrate SF unless the acquisition is absolutely 
perpendicular to the fracture line. Intravascular ultrasound may be revealing but is not 
used routinely, is invasive, and has not been systematically investigated in this context. 
64 slice multidetector computed tomographic angiography (MDCT) may be ideally suited, 
by virtue of its ability to interrogate stents from a 360 degree perspective and provide 
cross sectional stent images. This study was designed to evaluate the ability of MDCT 
to detect SF. 
Methods: 64 slice MDCT in 300 consecutive stent patients were evaluated. SF was 
diagnosed in either single or overlapped stents by clear separation of struts on both the 
curved and straightened multiplanar reconstruction, with discontinuity of stent structure 
on cross sectional images at the site of separation. CBA was performed in all patients 
with MDCT identified SF.
Results: SF was noted in 9 patients (3.0 %), 7 in the LAD, 1 each in the LCx and RCA. 
4 were single stents and 5 were overlapped. Stent separation was 2.0 + 0.5 mm. In all 
cases, CBA did not reveal SF. Severe (>50%) ISR was present in 3 patients by MDCT, all 
confirmed by CBA, and represented 15.8 % of the total ISR noted in our laboratory. Mild 
(<50%) ISR, confirmed by CBA, was found in 3 patients.
Conclusions: 1) MDCT revealed stent fracture in 3.0 % of stented patients; none were 
apparent on CBA. 2) Stent fracture, in addition to failure of drug elution, may contribute 
to in-stent restenosis; in the absence of significant ISR, more frequent monitoring by 
MDCT may be indicated. 3) Stent fracture should be considered in the evaluation of new 
stent designs.
2900-132 Coronary Plaque Composition of Nonculprit Left Main, 
Assessed by in vivo Intracoronary Ultrasound Radio 
Frequency Data Analysis, is Related to the Severity of 
Coronary Artery Disease
Hong-Seok Lim, So-Yeon Choi, Kyoung-Woo Seo, Hyoung-Mo Yang, Seong-Ill Woo, 
Un-Jung Choi, Jung-Won Hwang, Soo-Jin Kang, Byoung-Joo Choi, Myeong-Ho Yoon, 
Gyo-Seung Hwang, Joon-Han Shin, Seung-Jea Tahk, Ajou University Medical Center, 
Suwon, South Korea
Background: The Identification of subclinical high-risk plaque is important. However, 
there are few data on the clinical significance of nonculprit left main coronary artery (LM) in 
patients with coronary artery disease(CAD). We aimed to assess the relationship between 
plaque composition of nonstenotic LM coronary disease determined by intravascular 
ultrasound virtual histology (IVUS-VH) and severity of coronary artery disease.
Methods: In 83 patients referred for coronary angiogram, a nonculprit LM with 
<50% diameter stenosis was evaluated with IVUS-VH for the in-vivo coronary plaque 
characterization. Tissue maps were reconstructed from radio frequency data using IVUS-
VH software. Cross-sectional measurements, volumetric data of the plaque of LM and the 
volume of 4 different plaque components (fibrous, FI; fibrofatty, FF; dense calcium, DC 
and necrotic core, NC) were compared with the angiographic severity of CAD assessed 
by Gensini scoring system.
Results: Mean Gensini score of the patients was 27±15 and minimal lumen area of LM 
was 16.5±5.4mm2. The average lumen, vessel and plaque volume of the 83 vessels were 
103±70, 153±97 and 50±38mm3, respectively. Mean percentage of the different plaque 
components were 67±10%, FI; 15±9%, FF; 5±5%, DC; and 13±9%, NC. Gensini score 
demonstrated significant positive correlations with the volume% of DC and NC (r=0.392, 
p<0.001; r=0.385, p<0.001, respectively) in the LM plaque. At multivariate regression 
analysis, Gensini score resulted to be an independent predictor of relative necrotic core 
content [β=0.402 (95%CI:0.124, 0.385)], together with age, unstable clinical presentation, 
and presence of diabetes mellitus.
Conclusions: In conclusion, plaque composition of IVUS-VH measurable atherosclerosis 
in nonstenotic LM associated with angiographic severity of CAD. The patients with severe 
CAD had more lipid and calcium content in the LM plaque. We recommend more intensive 
evaluation and treatment for nonculprit LM in the patients with severe CAD.
2900-133 The Predictive Value of Computed Tomography Calcium 
Scores: A Comparison With Quantitative Volumetric 
Intravascular Ultrasound
Teruo Okabe, Gary S. Mintz, Wm. Guy Weigold, Sung Yun Lee, Probal Roy, Daniel 
H. Steinberg, Tina L. Pinto Slottow, Kimberly A. Smith, Rebecca Torguson, Zhenyi 
Xue, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Neil J. Weissman, Joseph 
Lindsay, Ron Waksman, Washington Hospital Center, Washington, DC, Cardiovascular 
Research Foundation, New York, NY
Background: Coronary artery (CA) calcium scoring (CS) by cardiac computed 
tomography (CCT) is used to risk-stratify pts for coronary events.
Methods: We examined the relationship between CACS and intravascular ultrasound 
(IVUS) quantification in 44 pts undergoing CACS 18+23days before IVUS. Volumetric 
IVUS analysis included vessel, lumen, and plaque areas and volume and plaque burden. 
CACS used the Agatson-130 protocol.
Results: There were 106 calcified and 17 non-calcified lesions detected by IVUS. Eighty-
five of the IVUS-calcified lesions (80%) were detected by the CACS protocol, but 38 
lesions (36%) were missed entirely. 14/28 (50%) of the lesions with an IVUS arc of calcium 
below the 25th percentile (51.4°) were detected by CACS vs. 91% of lesions with an IVUS 
arc of calcium >51.4° (p<0.05). Similarly, only 21/36 (58%) lesions <3mm in length were 
detected vs. 91% of lesions >3mm in length (p<0.05). We divided CCT-detected lesions 
into 3 categories: CS <10, 10-400, and >400. Mean plaque burden, lesion length, and arc 
of calcium increased significantly, and minimum lumen area decreased significantly with 
increasing CACS (Table).
Conclusions: Lesion detection using CCT CACS is dependent on both lesion 
morphometry (specifically, the arc and location of calcium) and lesion severity (plaque 
burden, lesion length, and minimum lumen area) as assessed using IVUS.
IVUS vs. CCT CACS
CS<10 
(n=34)
10<CS<400 
(n=64)
CS>400 
(n=8) p-value
Lesion missed by CS 21 0 0 <0.001
Superficial/deep/mixed 4/1/8 34/5/25 1/0/7 0.047/0.7/0.018
Arc of calcium (°) 51.3+21.4 73.8+24.0 104.5+33.8 <0.001
Lesion length (mm) 4.2+4.6 9.5+8.5 24.5+13.8 <0.001
Mean vessel area (mm2) 14.3+6.0 12.8+4.8 16.4+3.7 0.1
Mean lumen area (mm2) 7.3+3.9 5.9+2.5 6.2+1.5 0.08
Minimum lumen area 
(mm2) 6.4+3.8 4.5+2.3 3.2+1.6 0.002
Mean plaque area (mm2) 7.1+3.0 6.9+2.8 10.2+2.4 0.01
Mean plaque burden 0.50+0.10 0.54+0.09 0.61+0.04 0.007
2900-134 Accuracy of Measurement of Stent Strut Thickness by 
Optical Coherence Tomography
Mitsuyasu Terashima, Yoshiaki Nakayama, Yasuyoshi Suzuki, Osamu Katoh, Takahiko 
Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Background: Recently, incomplete stent apposition (ISA) has been reported to be 
associated with stent thrombosis of drug eluting stents. Although optical coherence 
tomography (OCT) can provide detailed structural information due to its higher resolution, 
strong stent surface reflection with typical dorsal shadowing may make it difficult to 
evaluate stent apposition. The aim of this in vitro study is to validate the accuracy of 
measurement of stent strut thickness by OCT for evaluating stent apposition.
Methods: CYPHERTM, EXPRESSTM (platform of TAXUSTM), DRIVERTM (platform of 
ENDEAVORTM), and VISIONTM (platform of XIENCETM) stents were analyzed. Each 
3.5 mm stent was implanted into a polyurethane artery phantom model with a diameter 
of 3.0mm to achieve complete stent apposition using nominal pressure inflation. We 
measured the distance between the strut surface and adjacent vessel surface as strut 
thickness. Every strut on the cross sectional OCT image was analyzed at the proximal, 
mid, and distal segment of each stent.
Results: In total, 84 struts in CYPHERTM, 100 in EXPRESSTM, 120 in DRIVERTM and 
90 in VISIONTM stents were analyzed (Table). The intra- and inter-observer differences 
were low (6 ± 7 Μm and 6 ± 7 Μm). The intra- and inter-observer correlation coefficients 
were high (r = 0.96 Μm and r = 0.96).
Conclusions: Measurement of strut thickness by OCT was accurate. OCT may provide 
precise information of stent apposition.
Stent Strut Thickness
Measured strut 
thickness
Manufacturer’s nominal strut 
thickness Difference
CYPHERTM (Μm) 152 ± 11 153 (0.0055 inch + polymer) -1 ± 11
EXPRESSTM 
(Μm) 119 ± 12 132 (0.0052 inch) -13 ± 12
DRIVERTM (Μm) 88 ± 10 91 (0.0036 inch) -3 ± 10
VISIONTM (Μm) 84 ± 16 81 (0.0032inch) 3 ± 16
2900-135 Safety of Cardiovascular Magnetic Resonance 
Performed Immediately after Primary Percutaneous 
Coronary Intervention for ST-Elevation Myocardial 
Infarction
Julie Cote, Josep Rodes, Bernard Brochu, Santiago Miro, Bernard Noel, Gerald 
Barbeau, Robert Delarochelliere, Olivier Bertrand, Eric Larose, Institut de cardiologie et 
pneumologie, Hopital Laval, Quebec, QC, Canada
Background: After percutaneous coronary intervention (PCI) with stent implantation, 
cardiovascular magnetic resonance (CMR) is usually postponed to prevent theoretical 
stent heating or displacement. However, several studies have demonstrated CMR safety 
performed 3 days after PCI. To better evaluate myocardial perfusion, necrosis and viability 
in the hyperacute phase of ST elevation myocardial infarction (STEMI), it would be useful 
to perform CMR earlier following coronary stenting. We investigated the early and long 
term safety of CMR performed immediately after primary PCI with stenting for STEMI.
Methods: We prospectively studied 128 patients undergoing primary PCI with stent 
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implantation for STEMI. The study group was composed of 64 patients who underwent 
CMR (1.5 Tesla) within 12 hours after primary PCI including 105 stents. The control group, 
also composed of 64 patients, underwent primary PCI without CMR. Adverse events were 
reported during the early in-hospital period as well as during 6-month follow-up.
Results: Patient populations were comparable in both groups. Total ischemic times were 
similar (CMR+ 4.0h, CMR- 5.5h, p=ns), as were peak troponin rise (CMR+ 3.2Μg/L, 
CMR- 2.3Μg/L, p=ns). The median delay between PCI and CMR was 4.8 (interquartile 
range 4.1) hours. Duration of the CMR study was 42 (11) minutes and no adverse events 
occurred during the imaging session. Immediate CMR was not associated with any in-
hospital increase in death, myocardial infarction, urgent revascularization, or bleeding 
(p = ns for each). During 6-month follow-up, CMR performed immediately after primary 
PCI was not associated with a higher rate adverse events compared to primary PCI 
without CMR (respectively MACE 5 vs. 8%, p=0.16; repeat angina 6 vs. 8%, p=0.73; 
rehospitalization for cardiac cause 3 vs. 13%, p=0.05). On Kaplan-Meier estimates, 
event-free survival at 6 months was not decreased by performing CMR immediately after 
primary PCI with stenting.
Conclusion: Cardiovascular magnetic resonance at 1.5 T performed immediately after 
primary PCI with coronary stent implantation has proven early and long-term safety, 
opening the door for improved risk stratification in the hyperacute phase of STEMI.
2900-136 Frequency and Predictors of Troponin-I Elevation After 
Non-Urgent Diagnostic Coronary Angiography: A 
Prospective Study
Shinjiro Miyata, Hisashi Umeda, Tomoyuki Ota, Mitsunori Iwase, Ryoji Ishiki, Haruo 
Inagaki, Hideo Izawa, Toyoaki Murohara, Toyota Memorial Hospital, Toyota, Japan, 
Nagoya University Graduate School of Medicine, Nagoya, Japan
Background: Microembolization during coronary intervention, as reflected by elevated 
cardiac troponin I (cTnI), has been shown to be a common event. However, no reliable 
data to date has definitively demonstrated this issue during coronary angiography (CAG). 
The aim of this study was to identify the incidence and predictors of cTnI elevation after 
CAG.
Methods: A series of 172 consecutive patients undergoing elective CAG because of 
signs of ischemia were prospectively analyzed. Positive cTnI elevation was defined 
as >0.06 ng/ml (2× upper limit of normal) after CAG. The experienced operators were 
defined as the number of CAG >300 cases in their lifetime.
Results: Baseline and post-procedural cTnI levels were 0.025±0.029 ng/ml and 
0.068±0.300 ng/ml, respectively (P=0.066). Consequently, positive cTnI elevation was 
observed in 31 patients (10.3%). (See Table).
In the experienced operators, the frequency of positive cTnI elevation after CAG was 
markedly lower than the inexperienced operators, presumably due to less procedure time 
(32.0±15.3 min vs. 44.0±25.2 min, P=0.001) and contrast volume (172.8±40.4 ml vs. 
209.7±188.5 ml, P=0.017).
Conclusions: The occurrence of mild myocardial injury during CAG might be relatively 
frequent, and associated with gender, left ventricular hypertrophy, and the operator’s 
skill.
Univariate and multivariate predictors of a positive cTnI elevation after CAG
Univariate analysis Multivariate analysis
cTnI (+) 
(n=31)
cTnI (-) 
(n=141) P OR 95%CI P
Procedure time >60 min (%) 26 9 0.007 6.21 1.35-28.5 0.019
Female (%) 48 20 0.001 4.17 1.20-14.52 0.025
Inexperienced oprerator (%) 97 65 <0.001 11.03 1.28-95.06 0.029
Left ventricular hypertrophy 
(%) 48 18 <0.001 3.33
1.07-
10.38 0.038
Diastolic blood pressure 
(mmHg) 77±14 71±17 0.084 1.04 1.00-1.09 0.071
Prior coronary intervention 
(%) 16 38 0.021 0.41 0.09-1.84 0.245
Total cholesterol (mg/dL) 205±41 193±38 0.083 1.01 0.99-1.02 0.458
Preprocedural creatine 
kinase (U/L) 91±64 116±92 0.057 1.00 0.99-1.01 0.554
2900-137 Quantitative Coronary Artery Computed Tomography 
Angiography is Highly Reproducible for Stenosis 
Measurements and for the Quantification of Plaque 
Components
Sarah Rinehart, Hunt Anderson, Jennifer LaCorte, Szilard Voros, Fuqua Heart Center of 
Atlanta, Atlanta, GA
Background. Interobserver agreement for the quantification of stenosis and plaque 
components by CT coronary angiography is unknown.
Methods. We evaluated 184 coronary segments by CTA using a highly standardized 
approach (Vitrea 4.0). 9 pts had a designated study lesion. Two independent observers 
measured each parameter. For study lesions, observers measured % diameter (%DS) and 
area stenosis (%AS), minimal lumen diameter (MLD), minimal lumen area (MLA), calcified 
volume and percent (CaV, %Ca), high-density non-calcified plaque (>30 HU) volume and 
percent (HDNCP-V, %HDNCP) and low-density non-calcified plaque (<30 HU) volume and 
percent (LDNCP-V, %LDNCP). Similar parameters were measured in the left main and the 
proximal, mid and distal LAD, RCA and LCx. Interobserver agreement was determined by 
concordance correlation coefficient (CCC) and Pearson’s p precision (PPP). 
Results. We report CCC, 95% confidence interval and PPP in lesions. %DS: 0.99, 0.99-
1.00, 1.00; %AS: 0.98, 0.93-1.00, 0.98; MLD: 1.00, 1.00-1.00, 1.00; MLA: 1.00, 1.00-1.00, 
1.00; CaV: 1.00, 0.99-1.00, 1.00; %Ca: 1.00, 0.98-1.00, 1.00; HDNCP-V: 0.99, 0.96-1.00, 
0.99; %HDNCP: 1.00, 0.99-1.00, 1.00; LDNCP-V: 0.98, 0.94-1.00, 0.99; %LDNCP: 0.99, 
0.95-1.00, 0.99. Same parameters for the 184 segments are shown in Figure.
Conclusions. Interobserver agreement is remarkably high with our highly standardized 
approach to CorCTA datasets for quantitative measurements of stenosis severity and for 
quantification of plaque components.
2900-138 Measured Vessel-Specific and Lesion-Specific Coronary 
Artery Calcium Scores Significantly Improve Prediction 
of Severely Obstructive Coronary Artery Stenoses
Hunt D. Anderson, Sarah J. Rinehart, Jennifer A. LaCorte, Szilard Voros, Fuqua Heart 
Center of Atlanta, Atlanta, GA
Background: Total coronary artery calcium (CAC) scores (Agatston and volume scores) 
have poor correlation with obstructive (>70%) coronary artery disease (CAD). We 
hypothesized that vessel- and lesion-specific CAC scores are more accurate.
Methods: 44 patients with CAC and invasive angiography (XRA) data were studied. 
Agatston and volume scores were measured individually for each lesion in the four major 
epicardial coronary arteries and the lesion-specific values were recorded. Summation of 
these values resulted in vessel-specific and patient-specific values. Presence or absence 
of obstructive CAD on XRA was recorded for corresponding vessels. CAC values in 
patients with and without obstructive CAD were compared by two-tailed t-test; ROC 
curves were used to evaluate the performance of CAC values in predicting obstructive 
CAD.
Results: Of the 175 vessels included, 27 had obstructive CAD by XRA. Specificity of the 
vessel-specific Agatston score and maximum lesion-specific volume score dramatically 
improved compared to the total Agatston and volume scores (68% to 86% and 68% to 
88%, respectively). AUC of lesion-specific scores was also higher than total scores (0.77 
vs 0.71). Mean scores in patients with and without obstructive CAD and ROC values are 
shown in the Table.
Mean scores in patients without and with obstructive CAD and ROC characteristics
Mean Scores 
(±SEM)
p-value 
(t-test)
Optimal 
Cutpoint
AUC SEM
95% 
Confidence 
Interval
p-Value 
(ROC 
analysis)
Sensitivity Specificity
Total 
Volume 
Score
315.6±89.3 
vs. 
721.7±138.4
0.014 286 0.71 0.08 0.56-0.84 0.0082 77% 68%
Total 
Agatston 
Score
361.1±106.8 
vs. 
870.2±173.3
0.012 335 0.71 0.08 0.56-0.84 0.0078 74% 68%
Vessel-
Specific 
Volume 
Score
92.3±13.8 
vs. 
305.3±53.6
<0.0001 104 0.77 0.06 0.70-0.83 0.0001 73.% 75%
Vessel-
Specific 
Agatston 
Score
107.8±17.0 
vs. 
370.5±67.1
<0.0001 264 0.77 0.06 0.70-0.83 0.0001 62% 86%
Maximum 
Lesion-
Specific 
Volume 
Score
66.1±11.7 
vs. 
210.6±42.0
<0.0001 154 0.77 0.06 0.70-0.83 0.0001 58% 88%
Conclusion: Vessel-and lesion-specific CAC scores are more accurate than total scores 
in predicting obstructive CAD. This novel, simple refinement could increase the accuracy 
of CAC for diagnostic referral.
2900-139 Prediction of major adverse cardiac events after 
percutaneous coronary intervention
Pankaj Madan, MacArthur Elayda, Vei-Vei Lee, James M. Wilson, Texas Heart Institute, 
Houston, TX, Baylor College of Medicine, Houston, TX
Background: Many models have been devised in the past to predict adverse outcomes 
after percutaneous coronary intervention (PCI), but with rapid advancements in this field, 
a new risk prediction model might be needed. The purpose of our study was to identify the 
clinical and angiographic variables associated with adverse cardiac events after PCI and 
construct a simple bed-side tool for risk stratification of the patients.
Methods: Using the Texas Heart Institute research database, we analyzed data from 
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9494 patients who underwent PCI between January 1, 1996 and December 31, 2002 
(i.e. during the bare metal stent era). Predictors of major adverse cardiac events- death, 
myocardial infarction, stroke, and repeat revascularization by emergent coronary artery 
bypass grafting or PCI- were identified by multivariate logistic regression analysis using 
baseline clinical, angiographic and procedural variables. A simple integer score was 
constructed by multiplying β coefficient for each variable by a constant and rounding off 
the result to the nearest integer. The score was validated on 5545 patients undergoing 
PCI from January 1, 2003 to December 31, 2006 (ie. during the drug-eluting stent era).
Results: Multivariate regression analysis identified emergent procedure, urgent 
procedure, unstable angina, acute MI, renal insufficiency, hypertension, congestive heart 
failure, peripheral vascular disease, Type C lesion, presence of thrombus and number 
of stents placed as independent predictors of adverse events after PCI. The model had 
good overall discrimination (Area under the receiver operator characteristic 0.701) and 
the model fitted the validation cohort adequately.
Conclusions: Risk of complications after PCI can be assessed by this simple risk 
assessment tool, which may permit comparisons between different operators as well as 
different hospitals
2900-140 Nationwide Trends in the Utilization of Percutaneous 
coronary Intervention (PCI) in the United States.
Mohammad Reza Movahed, Mehrtash Hashemzadeh, Mazen Jamal, University of 
Arizona Sarver Heart Center and Southern Arizona VA Health Care System, Tucson, AZ
Background: To evaluate nationwide trends in the utilization of Percutaneous Coronary 
Intervention (PCI) in the past in comparison to recent years, we used a large data base 
from 1988 to 2004.
Methods: The Nationwide Inpatient Sample (NIS) database was utilized to calculate 
the age-adjusted rate for PCI from 1988 to 2004. Specific ICD-9-CM codes for all PCIs 
were used to compile the data. Patient demographic data was also analyzed from the 
database.
Results: The NIS database contained 1,747,736 patients who had PCI performed 
from 1988 to 2004. The mean age for these patients was 63.75 ± 11.07 years old. Male 
underwent PCI twice than female (male: 66.27, female 33.73). From 1988, the age-
adjusted rate for all PCI gradually increased to more than double until 2001 [(80.39 per 
100,000 (95%CI=71.86-88.92) in 1988 and 243.85 per 100,000 (95%CI=221.31-266.39, 
p<0.01) in 2001] but remained unchanged until end of the study in 2004 (232.17 per 
100,000 (95%CI=211.69-252.66) in 2004, see figure).
Conclusion: The utilization of PCI has dramatically increased to more than double from 
1988 to 2001 but remained unchanged thereafter. The reason for the lack of steady 
increase in PCI rate in the recent years is not known. It could be related to the approval of 
drug eluting stents or secondary to aggressive lipid lowering treatments. 
2900-141 Nationwide Trends in the Utilization of Multi vessel 
Percutaneous Coronary Intervention (MPCI) in the 
United States.
Mohammad Reza Movahed, Mehrtash Hashemzadeh, Mazen Jamal, University of 
Arizona Sarver Heart Center and Southern Arizona VA Health Care System, Tucson, AZ
Background: To evaluate nationwide trends in the utilization of Multi Vessel Percutaneous 
Coronary Intervention (MPCI) in the past in comparison to recent years, we used a large 
data base from 1988 to 2004.
Method: The Nationwide Inpatient Sample (NIS) database was utilized to calculate the 
age-adjusted rate for PCI from 1988 to 2004. Specific ICD-9-CM codes for Multi vessel 
PCI were used to compile the data. Patient demographic data was also analyzed from 
the database.
Results: The NIS database contained 241,319 patients who had MPCI performed 
from 1988 to 2004. The mean age for these patients was 64.89 ± 11.84 years old. Male 
underwent MPCI at the double rate in comparison to female (male: 67.87, female 32.13). 
From 1988, the age-adjusted rate for MPCI gradually increased to more than 3 times in 
1998 [(6.62 per 100,000 (95%CI=5.92-7.33) in 1988 and 23.92 per 100,000 (95%CI=21.62-
26.22, p<0.001) in 1998] and accelerated to more than 6 time than original rate at the end of 
the study in 2004 (41.50 per 100,000 (95%CI=37.84-45.16) in 2004, see figure).
Conclusion: The utilization of multi vessel PCI has dramatically increased to more 
than 6 times from 1988 to 2004 with acceleration in the recent years. The cause of 
this acceleration is most likely related to advancement in the percutaneous coronary 
interventional techniques. 
2900-142 Deadly Quartet of Clinical Factors Among Patients With 
Diabetes Mellitus Undergoing Saphenous Vein Graft 
Interventions
Rajendra H. Mehta, Emily Honeycutt, Linda K. Shaw, Michael H. Sketch, Jr., Duke 
University Medical Center, Durham, NC, Duke Clinical Research Institute, Durham, NC
Background: Less data exist on the long-term outcomes of patients with diabetes mellitus 
(DM) undergoing saphenous vein graft (SVG) interventions. Accordingly, our goals were to 
evaluate the long-term outcomes and identify baseline factors associated with decrease 
survival in DM patients undergoing SVG interventions. Methods: We analyzed 1160 
patients undergoing SVG interventions from the Duke Cardiovascular Disease Database 
(1986-2003). Cox proportional hazards modeling was used to identify predictors of long-
term death. The most significant model predictors were then used to construct a decision 
tree providing unadjusted Kaplan-Meier survival estimates at the median follow-up of 4 
years. Results: DM was present in 437 (37.7%) patients undergoing SVG interventions. 
Median survival was significantly lower in DM versus non-DM patients (66.7% vs. 81.9%, 
p<0.0001). A clinical decision tree depicting baseline features and survival in DM patients 
is shown in Figure. While 88% of patients without heart rate >/=80, heart failure, renal 
insufficiency or hypertension survived to 4 years, those with all these 4 factors had 100% 
mortality. Conclusion: Long-term survival of DM patients undergoing SVG interventions 
is significantly lower than non-DM patients with one-third of these individuals dying at 4 
years. We identify a ‘deadly quartet’ of clinical risk factors associated with extremely poor 
4-year survival (100% mortality) in diabetics undergoing SVG interventions that may help 
physician in risk stratifying and counseling these patients. 
2900-143 Sex Differences in Clinical Presentation and 
Angiographic Data in Acute Coronary Syndromes
Jeffrey S. Berger, Dianne Gallup, Matthew Roe, Christopher B. Granger, Paul W. 
Armstrong, R. John Simes, Harvey D. White, Frans Van de Werf, Eric J. Topol, Robert 
A. Harrington, Robert M. Califf, Richard C. Becker, Pamela S. Douglas, Duke Clinical 
Research Institute, Durham, NC
Background: Although sex differences exist in acute coronary syndromes (ACS), their 
origins remain unclear. Limited data exist on angiographic severity between women and 
men across the full clinical spectrum of ACS. We investigated the relationship between 
sex and angiographic characteristics using a large database spanning the 3 major 
categories of ACS.
Methods: Data from patients who underwent cardiac catheterization in 11 independent 
randomized ACS trials from 1993 to 2006 were pooled. This included 35,128 patients 
(20,352 with ST-segment elevation myocardial infarction [STEMI], 6743 with non-STEMI 
[NSTEMI], and 8,033 with unstable angina [UA]), of whom 9,399 (27%) were women.
Results: Across the spectrum of ACS, women were older with a higher prevalence of 
hypertension, hyperlipidemia, diabetes, and heart failure. Conversely, men had a greater 
history of smoking, prior myocardial infarction and bypass surgery. Angiographic severity 
differed by sex across the spectrum of ACS (Table). Compared to men, women were 
more likely to have non-obstructive disease and less likely to have multi-vessel disease 
regardless of ACS presentation type. Whereas 27% of women with UA (vs 14% in men) 
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had no coronary obstruction this sex differential progressively decreased across the ACS 
spectrum. Importantly, the prevalence of single-vessel disease differed according to type 
of ACS.
Conclusions: Sex-based differences exist in clinical presentation and angiographic 
severity according to type of ACS. Appreciating these differences in clinical syndromes and 
anatomy may provide useful mechanistic insights into the pathogenesis of ACS in women 
and men, which may ultimately translate into improved patient care and outcomes. 
Women Men P Value
All ACS 9,399 (27%) 25,729 (73%)
No obstructive disease 14.6 8.3 <0.01
Single-vessel disease 38 38 0.63
Multi-vessel disease 48 54 <0.01
STEMI 4,788 (24%) 15,564 (76%)
No obstructive disease 8.8 7.6 <0.01
Single-vessel disease 46 43 <0.01
Multi-vessel disease 45 49 <0.01
NSTEMI 1,772 (26%) 10,307 (74%)
No obstructive disease 10 5 <0.01
Single-vessel disease 32 30 0.07
Multi-vessel disease 58 65 <0.01
UA 2839 (35%) 5194 (65%)
No obstructive disease 27 14 <0.01
Single-vessel disease 28 29 0.49
Multi-vessel disease 45 58 <0.01
2900-144 Improving STEMI Care in Eastern Pennsylvania: The 
Lehigh Valley Hospital and Health Network MI-ALERT 
Program
J. Patrick Kleaveland, Bruce Feldman, David Cox, Richard MacKenzie, Stephen Palmer, 
David Richardson, Jeffrey Snyder, Gerald Pytlewski, James Reed, Michael Rossi, 
Lehigh Valley Hospital, Allentown, PA
Background: Primary percutaneous coronary intervention (PCI) is the preferred 
treatment for ST-elevation myocardial infarction (STEMI) patients. National registries 
indicate this goal is not consistently achieved and that longer door to balloon times (DBT) 
are associated with increased mortality. Lehigh Valley Hospital and Health Network 
(LVHHN) has developed a local and regional MI-ALERT program to facilitate treatment of 
STEMI patients in eastern Pennsylvania. The MI-ALERT protocol with preferred strategy 
of primary PCI was developed at two local PCI centers in 2000 and expanded to 6 
regional non-PCI hospitals facilitating urgent transfer in 2004.
Objective: To compare DBT and hospital mortality in STEMI patients enrolled in the 
LVHHN local versus regional MI-ALERT program.
Methods: Retrospective chart review of 578 MI-ALERT STEMI patients who had PCI 
at LVHHN from 4-1-04 to 5-31-07 was performed. DBT was defined as time of first ED 
contact (local or regional) to initial balloon inflation in minutes (m). Results are presented 
as median (range). Key elements of the MI-ALERT protocol include rapid ECG, a single 
phone call to activate all MI-ALERT personnel, and burst paging to notify cath lab staff. 
Statistical analyses were made using chi-square, t-test and Mann-Whitney.
Results: A total of 578 consecutive STEMI patients were enrolled. 453 local MI- ALERT 
patients had median DBT of 75m (28-239) compared to median DBT of 109m (63-209) 
for 125 regional MI ALERT patients (p<.0001). 80% of local DBT were <90m and 68% 
of regional DBT were <120m, which compare favorably to the NRMI Registry where only 
29% of local DBT were <90m and only 16% of transfer PCI patients had DBT <120m. 
Despite a much shorter DBT for the local MI-ALERT patients, there was no difference in 
local (2.4%) versus regional (2.4%) hospital mortality.
Conclusion: The LVHHN MI-ALERT Program has lead to improved treatment of STEMI 
patients who present locally and to regional non-PCI hospitals within a 60 mile radius. 
New strategies to improve DTB for local and regional STEMI patients involving activation 
of the MI-ALERT system by EMS personnel en route to hospital are presently being 
evaluated.
2900-145 PCI Complication Rate Decline: 1999-2002 versus 
2003-2006
Ioannis A. Stathopoulos, Marcelo Jimenez, EJ Kwak, Monica Losquadro, Georgia 
Panagopoulos, Howard Cohen, Sriram Iyer, Carlos Ruiz, Gary Roubin, Kirk Garratt, 
Lenox Hill Hospital, New York, NY, New York Hospital Queens, Flushing, NY
Background: Technical improvements permit the performance of PCIs reliably and safely. 
Yet, adverse events during such procedures have not been eliminated. Our objective was 
to assess current rates of complications from PCI in “the real world”, as well as changes, 
from 1999 to 2006.
Methods: Prospectively collected data were abstracted from the New York State 
PCI Report forms and review of the QI office database. The reported complications 
from 23,399 consecutive PCIs performed in our institution during an eight year period 
(1/1/1999-12/31/2006) were recorded.The complication rates between the earlier period 
(1999-2002) versus the most recent period (2003-2006) were compared using the Z-test 
for two proportions.
Results: Complications occurred in 3.36 % of PCIs. The following complication rates 
were found: one month death rate 0.6 %, death in the catheterization suite 0.047 %, 
stent thrombosis (one month) 0.53 % , presumed stent thrombosis (one month) 0.82 %, 
MI (either Q or non-Q wave) 0.74 %, emergent cardiac surgery 0.15 %, stroke 0.29 %, 
cardiac perforation 0.29 %, retroperitoneal bleeding 0.18 %, acute renal failure 0.28 %, 
need for hemodialysis 0.17 %, one month composite endpoint (CEP) (death, myocardial 
infarction, stent thrombosis, stroke, or emergent cardiac surgery) 1.8 % and one month 
composite endpoint excluding stent thrombosis (CEPnoST) 1.26 %. Left main artery 
dissection complicated 0.087 % of PCIs and four patients experienced aortic dissection.
When the complication rates between the earlier period (1999-2002) versus the most 
recent period (2003-2006) were compared, significant decline was found for the total 
number of complications, CEP, CEPnoST, stroke, MI, and vascular complications (figures 
1 and 2 and table 1).
Conclusions: The one month composite end point, whether inclusive (CEP) or exclusive 
(CEPnoST) of stent thrombosis, declined significantly over the last four years. Overall 
PCI complication rate declined over the last four years of the study, although rates of 
death, stent thrombosis, need for emergent cardiac surgery and cardiac perforation did 
not. Current rates of PCI complications remain low. 
Table 1. PCI complication rate: Early (1999-2002) vs Recent period (2003-2006)
Complication Absolute difference z value p value CI %
Stroke 0.002 3.34 < 0.001 0.001 - 0.004
Any MI 0.005 4.84 < 0.001 0.003 - 0.008
Vascular 0.004 3.52 < 0.001 0.002 - 0.006
CEP 0.007 4.26 < 0.001 0.004 - 0.011
CEPnoST 0.009 5.41 < 0.001 0.006 - 0.012
Any complication 0.013 5.48 < 0.001 0.008 - 0.018
2900-146 Is High Sensitivity C-Reactive Protein Associated 
With Early or Late Cardiovascular Events Following 
Percutaneous Coronary Intervention?
Tina L. Pinto Slottow, Daniel H. Steinberg, Probal Roy, Teruo Okabe, Saquib Samee, 
Zhenyi Xue, Kimberly Smith, Rebecca Torguson, Joseph Lindsay, Augusto D. Pichard, 
Lowell Satler, William O. Suddath, Kenneth Kent, Ron Waksman, Washington Hospital 
Center, Washington, DC
Background: High-sensitivity C-reactive protein (hsCRP) has been shown to be an 
independent marker of vascular risk in primary and secondary prevention populations. 
Stratification by levels of <1, 1-3, and 3-10, and >10 mg/L has correlated with risk of 
myocardial infarction (MI), stroke, and cardiovascular death.
Methods: 1341 consecutive patients who underwent percutaneous coronary intervention 
(PCI) between April 2003 and August 2007 were stratified by baseline hsCRP levels. 305 
had a hsCRP <1, 406 between 1 and 3, 400 between 3 and 10, and 230 >10. Death, MI, 
and target vessel revascularization were examined at 30 days and 1 year following PCI.
Results: Baseline demographics were similar except in the CRP ≥10 group where 
patients were more likely to be female, have a history of diabetes, smoking, renal disease, 
and heart failure, and present with acute MI. (p<0.001) Outcomes at 30 days and 1 year 
revealed no difference in MI or revascularization among groups. There appeared to be 
a trend towards increased all-cause death at 1 year in the highest hsCRP group, but 
after performing an adjusted regression analysis that accounted for MI during admission, 
cardiogenic shock, and history of diabetes, smoking, renal disease, and heart failure, 
there was no significant difference in all-cause death at 1 year (adjusted p value=0.054) 
(Table)
Conclusions: Higher hsCRP levels were not independently associated with increased 
risk of cardiovascular events or mortality following PCI in an unrestricted population. 
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hsCRP <1 1 to <3 3 to <10 ≥10
Patient Characteristics n=305 n=406 n=400 n=230 p value
Baseline hsCRP 0.56±0.25 1.85±0.57 5.49±1.96 52.47±86.44 <0.001
30 Day Outcome (%) n=305 n=406 n=400 n=230 p value
All-cause death 0.3 0.2 1.0 1.7 0.142
Cardiac death 0.3 0 0.3 0.9 0.174
Myocardial infarction 0.3 0 0.3 0.9 0.174
TVR 1.6 0.5 1.5 0.4 0.299
1 Year Outcome (%) n=303 n=404 n=395 n=226 p value
All-cause death 1.3 2.0 3.5 5.8 0.012
Cardiac death 0.7 0.5 1.5 1.8 0.302
Myocardial infarction 2.0 0.8 1.8 1.8 0.437
TVR 9.6 8.8 7.9 8.6 0.882
Adjusted Outcome (%) n=303 n=404 n=395 n=226 p value
All-cause death at 1 year 1.3 2.0 3.5 5.8 0.054
2900-147 Funnel Plots for Comparing Performance of PCI 
Performing Hospitals and Cardiologists: A More 
Meaningful Presentation of the New York State PCI 
Hospital Mortality Data
Babu Kunadian, Joel Dunning, Anthony P. Roberts, Robert Morley, Darragh Twomey, Mark 
A. de Belder, The James Cook University Hospital, Middlesbrough, United Kingdom
Background: The New York State Department of Health reports individual hospital and 
operator outcome data for PCI in a tabular form to allow them to examine their quality of 
care. However funnel plots are the display method of choice for institutional and operator 
comparison.
Methods: The risk adjusted mortality rates for 48 hospitals and cardiologists performing 
PCI were used to generate funnel plots (with control limits at 3 and 2 sigma). Separate 
plots were derived for emergency and non-emergency PCI procedures.
Results: 149,888 patients underwent PCI procedures between January 1, 2002 and 
December 31, 2004.The risk-adjusted hospital mortality rates for all PCI patients ranged 
from 0% to 1.37%. The funnel plot shows the adjusted rate for each site against number 
of cases treated, displayed as a scatter plot and compared to the binomial funnel plot 
calculated around the mean for all cases reported. The risk adjusted mortality rates of all 
hospitals were within 3 sigma upper control limits. The risk-adjusted mortality rates were 
above or on the upper warning limit (2 sigma control limits) for 3 hospitals, and below 2 
sigma control limits for 4 hospitals. 
Conclusion: The funnel plot is an accurate, risk adjusted means of identifying units 
whose results diverge significantly from the population mean. Funnel plots allow visual 
comparison of data derived from multiple health-care units. Variation is readily identified 
permitting hospitals and cardiologists to appraise their practices and data quality. 
2900-148 Trends in the Association Between Age and In-Hospital 
Mortality Following PCI: Data From the NCDR
Mandeep Singh, Eric Peterson, Matthew Roe, Fang-Shu Ou, John Spertus, John Rumsfeld, 
H Vernon Anderson, Lloyd Klein, David Holmes, Jr., NCDR, Washington DC, DC
Background: Temporal trends and contemporary data on the association between age 
and outcome of percutaneous coronary interventions (PCI) are lacking. We aimed to 
determine the in-hospital mortality of various age groups in the National Cardiovascular 
Database Registry (NCDR) and to evaluate the temporal trends.
Methods and Results: In-hospital mortality following PCI on 1,410,069 patients from 
2001-2006 was evaluated, age-stratified into 4 groups, Group 1 (age<40, n=25,679), 
Group 2 (40-59, n=496,204), Group 3 (60-79, n=732,574), and Group 4 (≥80, n=155,612). 
Overall in-hospital mortality was 1.22%, and was 0.60%, 0.59%, 1.26%, and 3.16% in 
groups 1 to 4 respectively, P<0.0001. Overall temporal improvement per calendar year in 
the unadjusted and risk-adjusted in-hospital mortality following PCI was noted in all the 4 
groups (Fig), however, it was significant only in older age groups, group 3 (OR 0.95, 95% 
CI 0.93, 0.97) and group 4 (OR 0.95, 95% CI 0.93, 0.97). While relative mortality reduction 
was greatest in young patients, absolute mortality reduction was greatest in the elderly.
Conclusions: In-hospital mortality following PCI has fallen for all age groups over the 
last six years; with the largest magnitude reductions seen among octogenarians. 
2900-149 Different Risk of Different Outcome Events After 
Percutaneous Coronary Interventions - A 15-Year 
Follow-up From the Swedish Angiography and 
Angioplasty Registry (SCAAR)
Axel Åkerblom, Stefan James, Tage Nilsson, Per Albertsson, Peter Eriksson, Hans 
Ohlsson, Ulf Stenestrand, Bo Lagerqvist, Uppsala Clinical Research Centre, Uppsala, 
Sweden, University Hospital, Uppsala, Sweden
Background: To investigate long term outcome regarding different outcome events after 
percutaneous coronary intervention (PCI) in a real world setting.
Methods: The Swedish angiography and angioplasty registry (SCAAR) is a continuous 
national registry covering all Swedish patients undergoing coronary angiography and 
percutaneous coronary interventions in Sweden. A complete 15-year follow-up of patients 
treated between 1989 and 2006 was obtained by merging with other national registries 
of death, myocardial infarction, coronary artery by pass surgery and hospital discharge 
diagnoses. Only the first intervention during the study period was included.
Results: 67 000 procedures were included in the analysis. The re-intervention rate was 
almost 20% the initial year post PCI and thereafter app. 2 % annually. After 15 years 50% 
of patients had undergone a new intervention (40% PCI and 10% with by pass surgery), 
almost 30% had experienced a myocardial infarction and 10% had suffered from stroke. 
Mortality increased continuously and reached almost 40% after 15 years.
Conclusions: This large real world registry demonstrates the natural course after PCI 
with a high risk of other manifestations of cardiovascular disease after very long term 
follow-up.
2900-150 Procedural And Clinical Outcomes Of Percutaneous 
Coronary Intervention for Ostial Lesions in proximal 
coronary arteries.
Freeman Melanie, David Clark, Han S. Lim, Stephen J. Duffy, Nick Andrianopoulos, 
Angela Brennan, Kerrie Charter, James Shaw, Martin Sebastian, Andrew E. Ajani, Chris 
Reid, Mark Horrigan, Farouque Omar, Austin Hospital, Melbourne, Australia
Background: Ostial lesions (OL) are a difficult subset associated with suboptimal 
outcomes after percutaneous coronary intervention (PCI). However, data from 
contemporary practice is limited.
Methods: There were 1714 consecutive patients who underwent PCI for proximal 
lesions of the left anterior descending, left circumflex and right coronary arteries, who 
were prospectively enrolled in the Melbourne Interventional Group Registry (February 
2004 - December 2006). We compared clinical and procedural data in 109 patients 
undergoing PCI for OL with 1605 patients with proximal non-ostial (NO) lesions. Left main 
and bifurcation lesions were excluded.
Results: The mean age (69±11 vs. 65±12 years; p = 0.001) and proportion of women 
(39% vs. 28%; p = 0.021) were greater in the OL group. Other baseline characteristics 
were similar. Stents were more frequently deployed in the NO group (95% vs. 87%; p = 
0.005). Drug-eluting stents were deployed more often in the OL group (66% vs. 48%; 
p<0.0001). There was no significant difference in frequency of procedural success, in-
hospital death, bleeding or urgent unplanned reintervention. Unplanned coronary artery 
bypass grafting was more frequent in the OL group (4.8% vs. 1.0%; p=0.007). There was 
no difference in 30-day major adverse cardiac events (MACE, 8.7% OL versus 7.0% 
NO, p= 0.548), and target lesion revascularization (2.9% vs. 4.9%, p= 0.233), however, 
12-month MACE was higher in the OL group (29% vs. 16%; p=0.036), largely driven by 
target vessel revascularisation.
Conclusion: PCI for OL is associated with similar 30-day clinical outcomes, but worse 12-
month outcomes than for NO lesions. OL continue to present significant challenges.
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2900-151 Impact of Prior CABG on Door-to-Balloon Time and 
In-Hospital Outcomes: A Report From the National 
Cardiovascular Data Registry (NCDR)
Michael S. Kim, Tracy Y. Wang, David Dai, Andrew J. Klein, Eric D. Peterson, John S. 
Rumsfeld, John C. Messenger, University of Colorado Health Sciences Center, Aurora, 
CO, Duke Clinical Research Institute, Durham, NC
Background: Intense focus has been placed on strategies to reduce door-to-balloon 
(DTB) time in patients undergoing primary PCI for ST-elevation myocardial infarction 
(STEMI). Despite the use of DTB time as a national performance measure, the impact of 
prior CABG surgery on DTB time is unknown.
Methods: We analyzed 77,166 patients who had primary PCI for STEMI from 2004-
2007 in the ACC/SCAI National Cardiovascular Data Registry (NCDR). The median and 
distribution of DTB time in patients with and without prior CABG were analyzed. Logistic 
General Estimating Equation models were used to evaluate in-hospital mortality, adjusting 
for differences in baseline patient characteristics.
Results: During the study period, 4601 (5.8%) patients undergoing primary PCI for 
STEMI had a history of CABG. Median DTB time was significantly longer in patients with 
prior CABG (113 vs. 98 minutes; p < 0.0001). In addition, the highest proportion of patients 
with prior CABG had DTB times of > 120 minutes (46.1%), while the highest proportion of 
patients without prior CABG had DTB times of < 90 minutes (43.3%) (Figure). However, 
in-hospital risk-adjusted mortality was not statistically different between the two groups 
(OR= 1.07; 95% CI 0.91-1.25).
Conclusion: Prior CABG was associated with prolonged DTB time in patients undergoing 
primary PCI. This finding did not translate into higher in-hospital risk-adjusted mortality, 
yet could substantially impact performance measurement depending on the case mix for 
a given hospital. 
2900-152 Publication of the COURAGE Trial Resulted in Fewer 
Patients Referred for Coronary Angiography: Results of 
a Multicenter Study
Atman P. Shah, Grace Nam, Edward Toggart, Ramin Ebrahimi, Harbor-UCLA Medical 
Center, Torrance, CA, West Los Angeles VA, Los Angeles, CA
Background: The recent publication of the COURAGE Trial has received a great deal of 
attention in the press by suggesting that medical therapy is equivalent to percutaneous 
coronary intervention (PCI) in patients with stable angina. Our study sought to investigate 
whether the publication of the COURAGE Trial has led to a decrease in the number of 
coronary angiograms (CA) and PCIs in 4 Southern California academic institutions.
Methods: We retrospectively analyzed the number of CAs and PCIs performed at 
four institutions performed during the period between 4/1/2005 to 8/31/2005 (Group 
1); 4/1/2006 to 8/31/2006 (Group 2); and 4/1/2007 to 8/31/2007 (Group 3). Differences 
between the groups were compared using repeated measures ANOVA and were 
considered significant if the p value was < 0.05.
Results: In Group 1, there were 1397 CAs and 623 PCIs (44.6% PCI); Group two had 
1549 CAs and 788 PCIs (50.9% PCI), and Group 3 had 1091 CAs and 594 PCIs (54.5% 
PCI). Compared to Groups 1 & 2, Group 3 had significantly fewer CAs (p<0.01). Group 3 
had a 9.9% increase in the number of PCIs compared to Group 1 (p<0.01), and a 3.6% 
increase compared to Group 2 (p<0.02).
Conclusions: The COURAGE Trial and the widespread attention it received may be 
responsible for some decline in the number of CAs being performed. Our study revealed 
an increase in the percentage of PCI’s as a ratio of the total procedures suggesting a 
higher likelihood of intervention in those patients undergoing CA. These preliminary 
results need to be validated by larger trials. 
2900-153 Generalizability of a Quality-Assurance Model Towards 
Performance of Percutaneous Coronary Interventions 
at Sites without On-site Surgery
Mandeep Singh, Charanjit Rihal, Bernard Gersh, Ryan Lennon, Henry Ting, Charles Cagin, 
Ripudamanjit Singh, Joshua Slusser, David Holmes, Jr., Mayo Clinic, Rochester, MN
Background: Data on outcomes of percutaneous coronary interventions (PCI) at 
centers without on-site surgery are largely limited to small, single center registries. We 
hypothesize that the model of care previous used in one Mayo Health System Hospital 
(MHS) without on-site surgery can deliver optimal results towards performance of PCI 
in another hospital. We, herein, report the results of PCI program from two community 
hospitals without on-site surgery.
Methods: We used a model initially tested at Immanuel St. Joseph’s Hospital (ISJ) for 
the conduct of PCI. The quality assurance model included a valid peer-review process, 
meeting minimum volume threshold standards for the operators, a fully equipped cardiac 
catheterization laboratory facility, participation in a PCI database, and strict protocol for 
case selection and transfers. In-hospital mortality, Q-wave myocardial infarction, and need 
for emergency CABG were analyzed and compared with a facility with on-site surgery.
We evaluated the in-hospital outcomes of 928 PCI (737 elective) performed at Franciscan 
Skemp (FSH), La Crosse, WI and 1175 PCI (877 elective) at ISJ, Mankato, MN, a 
hospital without on-site surgery whose model of care was adopted by FSH. The cases 
were compared to one-to-one matched controls from procedures performed at St. Mary’s 
Hospital (SMH) in Rochester, Minnesota, which has on-site surgical capability. Baseline 
clinical characteristics were well balanced between cases and controls.
Results:  Within elective procedures, the procedural success and major in-hospital 
adverse cardiovascular outcomes at sites with and without on-site surgery were similar 
(Table). No patients at MHS undergoing elective PCI required emergent transfer for cardiac 
surgery. Results in patients undergoing primary PCI for acute myocardial infarction were 
also similar between cases and controls (data not shown).
Conclusions: In one of the largest studies, adoption of a quality assurance model 
demonstrated similar clinical outcomes for both elective PCI and primary PCI at two 
community hospitals without onsite cardiac surgery as compared with those at a tertiary 
center with onsite cardiac surgery.
In-Hospital Events
FSH 
N=737
ISJ 
N=877
SMH 
N=1614 P
Age 64 ± 12 65 ± 12 65 ± 12 0.49
Diabetes 28% 26% 28% 0.5
Procedural success 98% 99% 97% .19
Mortality 0.1% 0.3% 0.2% 1.0
QMI 0.3% 0.3% 0.2% 0.48
Emergent CABG<24 hr 0 0 0.2% 0.041
2900-154 Lower Socioeconomic Status Is Independently 
Predictive Of Major Adverse Cardiac Events Post-
Percutaneous Coronary Intervention In An Open 
Cohort Of Public Health System Patients
Sandeep Nathan, Amit P. Amin, Steve Attanasio, Ravilla Mahidhar, Sirikarn Napan, 
Sameer Kadri, Maria N. Orig, Russell F. Kelly, Rush University Medical Center, Chicago, 
IL, Cook County Hospital, Chicago, IL
Background: Disparities in healthcare and cardiovascular outcomes are evident in lower 
socioeconomic status (SES) patients (pts). Very limited data exist however, addressing 
post-percutaneous coronary intervention (PCI) outcomes in the low SES population.
Methods: 1,410 consecutive pts undergoing PCI at a large public health system (PHS) 
hospital were analyzed as an open cohort. Pts were included if complete clinical and 
procedural data were available at entry. SES was assessed via a validated proxy measure: 
geographic household income determination. Pts were dichotomized into above and 
below median income groups and followed for occurrence of MACE (death, MI, urgent 
TVR). Multivariate models were constructed and survival data were analyzed via Kaplan-
Meier analysis and Log-rank test.
Results: 1,410 pts meeting inclusion criteria (57±9.9 yrs, 68.4% male, 37.8% DM) 
underwent PCI for STEMI (17.1%), NSTEMI (27.9%), unstable angina (26.0%) or stable 
CAD (29.1%) over 56 mos. Clinical follow-up was obtained in 97.2% (n=1370, mean 1.7 
yrs ± 1.3 yrs) and was similar in both groups. Computed median income was $38,044. Pts 
below the median income evidenced significantly greater MACE rates than those above 
the median income after adjustment for all risk and therapy covariates [Figure. 1].
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Conclusions: Lower SES was a powerful independent predictor of increased long-
term MACE. This novel finding persisted after adjustment for risk, therapy and medical 
compliance, and warrants further investigation.
2900-155 Outcomes in African American versus non-African 
American Patients following Percutaneous Coronary 
Intervention With Drug Eluting Stents
Daniel H. Steinberg, Michael A. Gaglia, Jr., Rebecca Torguson, Tina L. Pinto Slottow, 
Probal Roy, Teruo Okabe, Saquib Samee, Kimberly A. Smith, Zhenyi Xue, William O. 
Suddath, Kenneth M. Kent, Lowell F. Satler, Augusto D. Pichard, Joseph Lindsay, Ron 
Waksman, Washington Hospital Center, Washington, DC
Background: Previous research has suggested that African American (AA) patients 
experience adverse cardiac outcomes following percutaneous coronary intervention 
(PCI).
Methods: We identified 1123 AA patients referred for PCI and compared them to 3966 
non-AA patients. Patients were followed for one year with regard to major adverse 
cardiovascular events (MACE) including death, q-wave myocardial infarction (MI) and 
target vessel revascularization. We performed multivariate Cox proportional hazards 
regression to adjust for confounding variables and assess the contribution of African-
American race to one year outcomes.
Results: At one year AA patients experienced significantly higher rates of overall MACE 
(15.9% AA vs. 10.0% non-AA, p<0.001) as well as each individual component of death 
(7.1% AA vs. 4.5% non-AA, p<0.001), q-wave MI (3.7% vs. 1.6%, p<0.001) and TLR (8.2% 
AA vs. 5.1% non-AA, p<0.001). Stent thrombosis was also higher in the AA population at 
one year (2.8% AA vs. 0.7% non-AA, p<0.001). After multivariate analysis, AA remained 
a highly significant predictor of MACE (HR 1.3, 95% CI 1.1 - 1.6, p=0.003). AA did not 
predict stent thrombosis on multivariate analysis, but there was a trend toward increased 
thrombosis with decreased thienopyridine compliance.
Conclusions: After controlling for comorbidities with multivariable analysis, AA remains 
a highly significant and independent predictor of MACE following PCI. 
2900-156 Low Incidence of Stent Thrombosis in Asian Races: 
Multicenter Registry in Asia 3 Years Follow-Up Result
Sunao Nakamura, Shotaro Nakamura, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan 
Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, 
Chiba, Japan, Konyang University Hospital, Daejeon, South Korea
Background: There are limited data about stent thrombosis which is rare but devastating 
complication after drug-eluting stent (DES) implantation in unselected patients with a 
variety of coronary lesions. The aim of this study was to evaluate the frequency, 
predictors and the clinical outcome of stent thrombosis after DES implantation and bare 
metal stent (BMS) implantation in Asian races. Method: A total of 14,577 consecutive 
patients who underwent successful DES implantation (8,809 patients, 62% of the lesion 
with Sirolimus-eluting stent: SES, 38% of the lesion with paclitaxel-eluting stent: PES) 
and BMS implantation (5,768 patients) in 5 Asian high volume PCI center during March 
2002 to March 2004 were included in this study. We evaluate the frequency, predictor and 
clinical outcome of stent thrombosis in our multi-center registry of Asian races. Results: 
At a mean follow-up of 40.5±14.6 months in DES and 44.8±16.4 months in BMS. The 
cumulative incidence of stent thrombosis were subacute stent thrombosis (SAT): 0.5% 
with DES and 0.6% with BMS, late stent thrombosis (LAST): 0.2% with DES and no 
with BMS, very late stent thrombosis (VLAST): 0.4% per 2 year with DES and no BMS. 
Independent predictors of stent thrombosis are bifurcation lesion (OR=1.90, 95% CI: 1.83 
to 24.24, p=0.01) and ejection fraction (OR=0.90, 95% CI: 0.86 to 0.94, p=0.03). Only 0.2 
% of the patients were died because of the myocardial infarction after stent thrombosis in 
both groups. Conclusions: The incidence of stent thrombosis in Asian races is relatively 
low (0.5 % with DES and 0.6% with BMS of SAT, 0.2% increase per year with DES of late 
stent thrombosis) at mean follow-up more than 3 years. Particular attention will need to 
be directed to this complication when the patients have bifurcation lesions or low ejection 
fraction.
2900-157 Trends in the Incidence Rate and Outcomes of Primary 
ST-Segment Elevation Myocardial Infarction Among 
Medicare Beneficiaries: 2000 Through 2006
Aaron D. Kugelmass, David J. Cohen, Phillip P. Brown, Matthew R. Reynolds, Steven 
D. Culler, April W. Simon, Cardiac Data Solutions, Inc., Atlanta, GA, Emory University 
Rollins School of Public Health, Atlanta, GA
Background: This study reports annual national trends in incidence rates, survival rates, 
and Medicare program spending for treating Medicare beneficiaries (MB) experiencing a 
primary ST-segment elevation Myocardial Infarction (STEMI).
Methods: A retrospective analysis was conducted using annual MedPAR data files for 
fiscal years (FY) 2000 through 2006. The study sample consists of all MB hospitalized with 
a primary diagnosis of STEMI. Incidence rates were the number of admissions in each 
FY per 1,000 MB. Survival rates were the observed proportion of MB discharged alive. 
Reimbursement was the mean reimbursement for all STEMI hospitalizations during each 
FY. Program savings were calculated as the difference between actual reimbursement in 
the FY and the amount the Medicare program would have spent if the incidence rate of 
STEMI admissions had remained at the FY2000 level.
Results: Between 2000 and 2006, the number of hospitalizations for STEMI among MB 
decreased by 38%, with a 32% reduction (p<0.001) in per capita incidence. This has been 
accompanied by a 3.1% improvement (p=0.001) in in-hospital survival rate. The final rows 
of the table summarize the fiscal impact of the decline in STEMI incidence rate on the 
Medicare program hospital expenditures.
Conclusions: There has been a significant increase in survival rates for STEMI 
admissions, and a decrease in the incidence rate of STEMI admissions resulting in 
total cumulative program savings of $3.84 billion over the past six years in the Medicare 
program. 
2000 2001 2002 2003 2004 2005 2006
STEMI 
Hospitalization 170,154 160,400 153,822 144,457 131,616 117,723 105,915
STEMI 
Hospitalization 
Per 1,000 
Enrollees
4.3 4.1 3.8 3.5 3.2 2.8 2.5
Survival Rates 85.8% 85.9% 86.4% 86.9% 87.2% 87.6% 88.5%
Medicare 
Program 
Expenditures:
Average Hospital 
Reimbursement 
for Patients 
with a Primary 
Diagnosis 
of STEMI 
(Regardless 
of Treatment 
Received)
$11,578 $12,174 $13,141 $13,720 $14,172 $15,061 $15,945
Actual Annual 
Medicare Cost in 
Billions $
$1.97 $1.95 $2.02 $1.98 $187 $1.77 $1.69
Expected Annual 
Medicare Cost in 
Billions $
$1.97 $2.09 $2.31 $2.44 $2.56 $2.76 $2.96
Annual Savings 
from Decrease 
in STEMI 
Hospitalizations 
per 1,000 
Enrollees in 
Billions $
$0 $0.136 $0.294 $0.457 $0.691 $0.989 $1.275
Cumulative 
Savings in 
Billions $
$0 $0.136 $0.430 $0.887 $1.578 $2.567 $3.842
2900-158 Percutaneous Coronary Intervention and 30-Day 
Mortality: The British Columbia PCI Risk Score
Jaap N. Hambuger, Simon J. Walsh, Lillian Ding, Zhi Tan, Min Gao, Karin H. Humphries, 
Dewey Evans, Ronald Carere, Anthony Y. Fung, Richard R. Mildenberger, Gerald J. 
Simkus, John G. Webb, Christopher E. Buller, University of British Columbia, Vancouver, 
BC, Canada, Provincial Health Services Authority, Vancouver, BC, Canada
Background: Predictors of 30-day mortality are commonly used to aid the management 
of cardiac surgical patients. There is a need for an equivalent risk-score for 30-day 
mortality for percutaneous coronary intervention (PCI) patients to allow direct comparison 
between the 2 different methods of revascularization.
Methods: The British Columbia Cardiac Registry (BCCR) is a population-based registry 
that collects information on all PCI procedures performed in British Columbia (BC). We 
used data from the BCCR to construct a calculator that predicts mortality risk for patients 
undergoing PCI.
Results: A total of 32,899 BC residents had PCI performed during the years 2000 - 
2005. These patients were divided into a training set (n= 26350, PCI between 2000 - 
2004) and validation set (n = 6549, PCI in 2005). Univariate predictors of mortality were 
identified. Multivariable logistic regression analysis was performed on the training set to 
develop a statistical model for prediction of 30-day mortality. This model was tested in 
the validation set. Variables that were objective and available before PCI were included 
in the final risk score calculator. These included: age, gender, emergency procedure, left 
main disease, 3-vessel disease, left ventricular ejection fraction (LVEF) <30%, LVEF 30-
50%, LV assessment clinically contraindicated, heart failure, critical pre-procedure state, 
April 2008 
B60  ABSTRACTS - SCAI-ACCi2 Interventional E-Abstracts   
S
C
A
I-A
C
C
i2
 I
nt
er
ve
nt
io
na
l E
-A
bs
tr
ac
ts
ST-elevation MI (STEMI) ongoing, recurrent STEMI, other acute coronary syndrome and 
renal failure. The 30-day mortality for the overall population was 1.5% (n = 500). The 
area under the ROC curve for the training set was 90.2%. The Hosmer and Lemeshow 
p-value was 0.84 indicating no evidence of lack of fit for the model. Corresponding values 
for the validation set were 91.1% and 0.12 indicating that the model also performed well 
in this group.
Conclusions: We describe a large, contemporary cohort of consecutive patients 
undergoing PCI with complete follow-up for 30-day mortality. A robust, validated model of 
30-day mortality after PCI was used to construct a risk calculator, the BC-PCI risk score. 
The risk score will be presented in detail at the meeting.
2900-159 Epidemiology of Cardiogenic Shock Requiring 
Intensive Care Admission in Olmsted County, 
Minnesota
Amir H. Shoja, Rodrigo Cartin-Ceba, Mohammed Ahmed, Jaise Poulose, Girish Mour, 
Javier Cabello-Garza, Harpreet Suri, Ognjen Gajic, Daryl Kor, Mayo Epidemiology 
and Translational Research in Intensive Care (M.E.T.R.I.C.), Mayo Clinic College of 
Medicine, Rochester, MN
Background: While the incidence of Cardiogenic Shock (CS) following an acute coronary 
syndrome has been described, the epidemiology of all-cause CS requiring an Intensive 
Care Unit (ICU) admission is not, to our knowledge, known. The purpose of this study was 
to evaluate the epidemiology of CS in residents of Olmsted county, MN.
Methods: This was a retrospective cohort study of all Olmsted County residents admitted 
to the ICU’s of Mayo Clinic, Rochester, MN. This is the only center capable of providing 
continuous ICU services for patient’s in this demographic. A random quarter sample of 
the population was selected for analysis. We excluded patients who denied research 
authorization, were less than 18 years of age and who needed vasoactive support in 
the immediate post-cardiopulmonary bypass period. Those with prior withdrawal of care 
orders or a “mixed” distributive and CS picture were also excluded.
CS was defined as a patient having 1. A shock index >1 or Systolic Blood Pressue (SBP) 
persistently <90 mmHg or need for vasoactive infusions to maintain a SBP >90 mmHg, 2. 
Evidence of end organ hypoperfusion and 3. Evidence of elevated filling pressures.
Results: The adult population of Olmsted County in 2006 was 100,716. During this one 
year evaluation, 88 patients developed 100 episodes of CS.
Median age of the patients with CS was 76 (IQR 63.5-81) of which 64% were females. 
The median BMI was 25.2 (IQR 22.7-34.1). The all cause in-hospital mortality following 
CS was 45% (95%CI 35-65).
CS was caused by NSTEMI in 40%, STEMI in 20% and other causes (arrhythmias, 
valvular disease, decompensated heart failure) in the remaining 40%.
The cumulative incidence of CS was 99 episodes (95%CI 68-147) per 100000 person-
years at risk. This translates to one episode of CS for every 1007 patient years. For a 
national life expectancy of 77.9 years, approximately one in 13 patients would develop 
CS in the course of his or her life in Olmsted county.
Conclusions: The incidence of cardiogenic shock in the community appears to be 
higher than previously reported. This may be explained by our use of more sensitive 
shock criteria. The in-hospital mortality was lower than expected, possibly due to recent 
improvements in our therapeutic approach.
2900-160 Treatment of Patients Previously Deemed 
“Unrevascularizable” Often Includes Revascularization
Gregory W. Barsness, Linda Tesmer, Ryan J. Lennon, Mayo Clinic, Rochester, MN
Background: There is a growing population of patients with severe ischemic chest pain 
who are considered poor candidates for traditional revascularization. These patients 
are often referred to as “no option” or “refractory angina” patients, although the specific 
characterization is ill-defined, making determination of long-term outcome and comparison 
of treatment strategies difficult. We studied long-term outcome in severely symptomatic 
patients referred to a tertiary center for treatment of chronic unrevascularizable coronary 
disease.
Methods: Clinical characteristics, symptoms and follow-up events were recorded at 
baseline and at 6 month intervals in 200 consecutive patients with demonstrable coronary 
disease and CCS class 3 or 4 angina consenting to follow-up. All patients were on optimal 
medical therapy and deemed unrevascularizable by a referring cardiologist due to 
comorbidities and/or unfavorable coronary anatomy.
Results: Patients were elderly (median 68 yrs), primarily men (80%), with a history of 
diabetes (44%), hypertension (76%), tobacco use (54%), heart failure (20%), MI (58%), 
and prior PCI (67%), CABG (83%), TMR (5%) and/or heart transplantation (1%). Mean 
LVEF was 50±14%. Initial treatment included traditional revascularization (3% PCI, 2% 
CABG), TMR (1%), ECP (63%) or continued medical therapy (30%). At 1 year, events 
included MI (10%), CVA (1%), urgent revascularization (11%) and death (5.5%), resulting 
in a 1-year event-free survival of 77%. By 1 year, 15.5% of patients in this cohort underwent 
PCI and/or CABG. Of patients selected to undergo early elective revascularization, there 
were no deaths at a median of 3 years follow-up.
Conclusions: Patients with symptomatic coronary artery disease deemed to be 
unrevascularizable by experienced cardiologists may, in fact, be candidates for traditional 
revascularization. While this referral cohort included many who are at high risk for 
subsequent non-fatal coronary events, overall mortality was low and did not seem to 
be increased in those selected for elective revascularization. Further effort is needed 
to better define appropriate invasive and non-invasive strategies for patients labeled 
“unrevascularizable.”
2900-161 The Impact of Systemic Inflammation on Heat 
Production in Non-Culprit Lesions.
Konstantinos Toutouzas, Maria Drakopoulou, John Karabelas, Sophia Vaina, Maria 
Riga, Christodoulos Stefanadis, 1st Department of Cardiology, Univesity of Athens, 
Athens, Greece
Background: Coronary artery disease is related to enhanced systemic and diffuse 
coronary inflammation. Though, the impact of systemic inflammation on non-culprit 
lesions (NCL) has not been extensively investigated. We studied: 1) the relation between 
local plaque temperature and C-reactive protein (CRP), 2) the impact of diabetes (DM) 
and 3) statin intake on NCL heat production.
Methods: We included 40 patients (pts) with stable angina (SA) and 47 with acute 
coronary syndrome (ACS), who underwent percutaneous coronary intervention in the 
CL and had a second intermediate NCL. Systemic inflammation was assessed by CRP. 
Temperature difference (ΔT) was calculated by subtracting the proximal vessel wall 
temperature from the maximal one at the NCL.
Results: Pts with ACS had higher ΔT (0.10±0.07 vs. 0.05±0.05oC, p<0.01) and CRP 
(1.19±1.06 vs. 0.46±0.35mg/dL, p<0.01) than SA pts. Pts with DM (n=30) had higher ΔΤ 
than non-DM (0.10±0.08 vs. 0.06±0.05°C, p=0.01). Statin intake (n=40) lowered ΔΤ (ACS: 
0.06±0.04 vs. 0.12±0.07°C, p<0.01; SA: 0.04±0.04 vs. 0.08±0.07°C, p=0.02). There was 
a linear correlation of ΔT and CRP in the study population (figure) and in the ACS and 
SA groups (R=0.44, p<0.001, R=0.34, p=0.01, R=0.41, p=0.01 respectively). Multivariate 
analysis showed CRP and DM as independent predictors of ΔΤ.
Conclusions: Pts with ACS have increased NCL heat production compared to SA pts, 
possibly due to enhanced systemic inflammatory activation. Statin intake has a beneficial 
effect on NCL heat production.
2900-162 Risk and Clinical Predictors for Patients with Unstable 
Angina and Non-ST Segment Elevation Myocardial 
Infarction Post Early Percutaneous Coronary 
Intervention.
Eric Chong, Shen Liang, Kian Keong Poh, Huay Cheem Tan, The Heart Institute, 
National University Hospital, Singapore, Singapore, Biostatistics Unit, National 
University, Singapore
Background: TIMI score has been used to predict outcomes in patients with unstable 
angina (UAP) and non-ST elevation myocardial infarction (NSTEMI). We aim to look 
for clinical predictors for patients in this group undergoing early percutanous coronary 
intervention (PCI).
Methods: A cohort of 3822 patients presented with UAP/NSTEMI from June 1996 to 
March 2007 to our center were recruited. All patients underwent PCI within the same 
admission. We analyzed the various clinic predictors for prediction of major adverse 
cardiac events (MACE) and death at 1 month and 6 month.
Results: Median age was 56(22-97), 78.1% was men, 34.5%% diabetics, 58.8% had 
hypertension. Coronary lesions involving left main and proximal left anterior descending 
artery was 27.6%., 36.1% had NSTEMI. 
Clinical predictors Death at 1 
month
Death at 6 
month
MACE at 1 
month
MACE at 6 
month
Odds ratio 
(p value)
Odds ratio 
(p value)
Odds ratio 
(p value)
Odds ratio 
(p value)
Age (> 75 years) 2.03 (p=0.279)
5.5 
(p=0.001)
2.21 
(p=0.042)
1.69 
(p=0.049)
Gender (Female) 2.49 (p=0.031)
2.98 
(p=0.001)
1.93 
(p=0.002)
1.63 
(p=0.001)
Diabetes 1.89 (p=0.131)
1.79 
(p=0.095)
2.20 
(p<0.001)
1.51 
(p=0.003)
Anemia (Hemoglobulin < 
11g/dl)
3.86 
(p=0.027)
8.47 
(p<0.001)
2.40 
(p=0.007)
2.03 
(p=0.003)
Baseline Renal Impairment 
(Creatinine > 1.5 mg/dl)
6.0 
(p=0.001)
7.38 
(p<0.001)
1.75 
(p=0.149)
1.54 
(p=0.108)
Development of contrast 
induced nephropathy (CIN)
7.37 
p=0.019
5.80 
(p=0.005)
2.43 
(p=0.05)
1.67 
(p=0.116)
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Other clinical parameters including hypertension, smoking, hyperlipidemia and type of 
stent used (Bare metal vs. Drug eluting vs. endothelial progenitor capture cell stents) did 
not show significant difference in the clinical outcome in this cohort.
Conclusion: Elderly female diabetics with anemia and chronic renal impairment are high 
risk patients presenting with UAP/NSTEMI undergoing PCI. Development of CIN has 
significant adverse impact on the clinical outcomes in these patients.
2900-163 The Effect of Percutaneous Coronary Intervention on 
Inflammatory Response and Endothelial Progenitor 
Cell Recruitment
Rajeev Garg, Armando Tellez, Carlos Alviar, Neal S. Kleiman, Eli I. Lev, The Methodist 
hospital Research Institute, Houston, TX, University of Missouri, Columbia, MO
Background: Vascular interventions for athero-thrombotic disease, such as percutaneous 
coronary intervention (PCI) lead to endothelial damage and cause a potent inflammatory 
response. Endothelial progenitor cells (EPC) have been shown to have a prominent 
role in re-endothelializtion and the repair process following vascular injury. Studies have 
implicated a role for the chemokine, stromal-cell-derived factor-1 alpha (SDF1-alpha), 
secreted from platelets and smooth muscle cells in the recruitment of circulating EPCs 
to sites of vascular injury. However, the relationship between the inflammatory response, 
SDF1-alpha and EPC levels following PCI is not known.
Methods: We enrolled one hundred patients (Mean age 65.5 yrs ± 10.9, 32% females) 
- 20 patients with NSTEMI, 27 patients with unstable angina and 53 patients with stable 
angina who underwent PCI with stenting. EPC levels were measured by counting colony 
forming units (CFU) only in the 20 NSTEMI patients while SDF1-alpha levels and hs CRP 
levels were measured in all 100 patients by enzyme-linked immunosorbent assay and 
automated hsCRP using equal diagnostic reagent respectively. All three markers were 
measured in blood samples drawn both pre and 24 hours post PCI.
Results: EPC colonies increased from 9.6 colonies per million cells before PCI to 13.2 
colonies per million cells after PCI (37% increase, p=0.03). Circulating SDF1-alpha levels 
increased mildly from 1707.1 +/- 480.4 pg/ml prior to PCI to 1758.6 +/- 500.7 pg/ml after 
PCI. (3% increase, p=0.0425). There was a 95% increase in the levels of hs-CRP (Pre 
PCI - 4.5 +/- 5.3 mg/L vs. Post PCI - 8.8 +/- 9.5 mg/L; p = 0.0004).
Conclusions: We compared the levels of three markers involved in vascular response 
to injury (EPC, hs-CRP and SDF1-alpha) before and early after the procedure. Our study 
showed that the relative numbers of all these markers increased following PCI. A robust 
rise in hs-CRP levels in our study suggests that PCI induced a potent inflammatory 
response. This combined with a proportional increase in the levels of EPCs and SDF 
1-alpha post PCI suggests the possibility that this potent inflammatory response induced 
by PCI may be associated with EPC recruitment to the site of arterial injury.
2900-164 Emergent Percutaneous Coronary Intervention 
in Resuscitated Patients After Cardiac Arrest is 
Associated with Improved Survival at 30 Days but not 
at 180 Days
Atman P. Shah, Grace Nam, William J. French, James T. Niemann, Harbor-UCLA 
Medical Center, Torrance, CA
Background: The outcome of resuscitated patients after cardiac arrest complicating 
acute myocardial infarction (AMI) remains poor. Recent data suggests the potential 
benefit of early myocardial reperfusion with percutaneous coronary intervention (PCI). 
The purpose of this study was to determine if there is a benefit to early PCI in the high risk 
patients who present after successful resuscitation after cardiac arrest that is complicated 
by AMI.
Methods: From 1998 to 2006, a retrospective study was performed on 108 patients (64% 
men, mean age 57.9+/-11.2 years) who were admitted to a large, academic, tertiary care 
hospital after successful resuscitation for cardiac arrest complicating AMI. 79 patients 
(73.1%) underwent emergent PCI and 29 received standard medical care. Survival at 30 
days and 180 days were compared between the two groups.
Results: There were no differences in baseline characteristics. Of the 79 patients 
who underwent PCI, 77 (97.5%) had successful procedures. At 30 days, survival was 
improved in the PCI group [42% (n=34) vs. 17.2% (n=5), p=0.031]. At 6 months, there was 
no difference in survival between the two groups [11.4% (n=9) vs. 6.9% (n=2); p=0.54].
Conclusions: Early PCI in patients successfully resuscitated after cardiac arrest with 
AMI is associated with improved 30 day survival. However, this survival advantage was 
not maintained at 6 months. Further studies are needed to determine the role of specific 
clinical predictors and to assess potential clinical outcomes. 
2900-165 Culprit Vessel Primary Percutaneous Coronary 
Intervention for ST Elevation Myocardial Infarction: 
Shorter Door to Balloon Time
Stacy H. Graham, Robert J. Applegate, Sanjay K. Gandhi, Matthew T. Sacrinty, Talal T. 
Baki, Renato M. Santos, William C. Little, Michael A. Kutcher, Wake Forest University 
School of Medicine, Winston-Salem, NC
Background. Shorter door-to-balloon for ST elevation myocardial infarction (STEMI) 
treatment is associated with better outcomes, and is generally achieved by shortening 
the door to vascular access time. Whether procedural improvements can shorten, the 
vascular access to balloon time has not been examined. We hypothesized that by first 
performing culprit vessel primary percutaneous coronary intervention (PCI) for STEMI, 
and then completing coronary angiography we would shorten door-to-balloon times.
Methods. Door-to-balloon was assessed in 50 patients who underwent initial PCI of the 
culprit vessel for STEMI at Wake Forest University Baptist Medical Center and 85 patients 
who underwent traditional complete coronary angiography followed by PCI for STEMI. All 
other treatment strategies were used similarly in both groups.
Results. Procedural success was 100% in both groups. See Figure for time intervals. 
92% of the culprit PCI group had a door-to-balloon time <90 minutes, compared to 76% 
in the traditional group, p=0.023. Subsequent planned revascularization procedures were 
infrequent and similar in both groups.
Conclusions. Performing PCI of the culprit vessel for STEMI as initial treatment resulted 
in a significant decrease in the door-to-balloon time compared to traditional coronary 
angiography followed by PCI without sacrificing subsequent cardiac care.
2900-166 20 Years Follow-Up Results Of Pulmonary Balloon 
Valvuloplasty In Adults And The Fate Of Concomitant 
Infundibular Stenosis And Tricuspid Regurgitation
Mohamed Eid Fawzy, Adil Osman, Souad El Amraoui, Omar Nowayhed, Iman Ibrahim, 
Shabir Shah, King Faisal Specialist Hospital, Riyadh, Saudi Arabia
Background: The goal of this study was to evaluate the long term (up to 20 years) 
outcome of pulmonary balloon valvuloplasty (PBV) for severe pulmonary valve stenosis 
(PS) in adults, and to determine its effects on concomitant severe infundibular stenosis 
and severe tricuspid regurgitation (TR).
Methods: PBV was performed in 90 consecutive patients (49 women) mean age 23 
±9; years with severe congenital PS. Clinical and echocardiographic assessment were 
performed 2-20 years (mean 11± 3.3) after PBV. Repeat cardiac catheterization was 
performed 6-24 months after PBV in 43 patients who had concomitant moderate to 
severe infundibular stenosis (infundibular gradient ≥ 30 mm Hg).
Results: There were no immediate or late deaths. The mean catheter peak pulmonary 
gradient (PG) before and immediately after PBV was 105 ± 39 and 34 ± 26 (p <0.0001). 
The right ventricular pressure was 125 ± 38 and 59 ± 21 (p <0.0001) mm Hg, respectively. 
The infundibular gradient (in 43 patients) immediately after PBV was 42.9 ± 24.8 (30 - 
113) mm Hg and regressed at repeated catheterization to 13.5 ± 8.3 mm Hg (P < 0.0001). 
Doppler PG before PBV and at one year and long term follow-up was 91 ± 33 (range 
36 - 200), 28 ± 12 (p < 0.0001) and 26 ± 11 mm Hg (p = 0.2), respectively. New mild 
pulmonary regurgitation (PR) was noted in 24 patients (28%) after PBV. Significant TR in 
seven patients either regressed or disappeared after PBV.
Conclusions: Long term results up to 20 years of PBV in adults are excellent. Severe 
infundibular stenosis and severe TR regressed after successful PBV. No restenosis was 
encountered after successful PBV.
2900-168 The Gender Difference in No Reflow Phenomenon in 
Patients with ST segments elevation acute myocardial 
infarction
Kodlipet C. Dharmashankar, Ihab B. Abdalrahman, Qasim Raza, Richard L. Berg, 
Shereif H. Rezkalla, Robert A. Kloner, Marshfield Clinic and Marshfield clinic research 
Foundation, Marshfield, WI
Background: The gender difference is established in epicardial coronary artery disease. 
However, it is not known whether or not there is any difference in coronary microcirculation 
and the occurrence of no reflow (NRF) phenomenon between the sexes.
Methods: All patients with ST elevation acute myocardial infarction (STEMI) admitted to 
a tertiary referral hospital from May 2001 to October 2005 who underwent percutaneous 
coronary intervention were reviewed. Patients with previous coronary artery bypass 
surgery and patients with unsuccessful intervention were excluded. NRF was diagnosed 
by using myocardial blush grade and TIMI flow score by a single reader blinded to the 
patients’ clinical data.
Results: Three hundred fifty patients met the inclusion criteria and form the basis of 
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the study. The prevalence of cardiac risk factors was comparable in those with normal 
flow and those with NRF. Male patients were more likely to develop NRF (table 1.) It was 
also observed that the presence of thrombus at the time of intervention was not different 
between males and females with 46% of male patients and 40% of female patients having 
thrombus. (P =0.28). 
Table 1. Gender Difference in NRF
Myocardial Blush TIMI Flow
Gender Normal flow NRF Normal flow NRF Total
Female 51 (52.04%) 47 (47.96%) 74 (75.51%) 24 (24.49%) 98
Male 100 (39.68%) 152 (60.32%) 165 (65.48%) 87 (34.52%) 252
151 199 239 111 350
Fisher’s exact test 
Two-sided p= 0.0412
Fisher’s exact test 
Two-sided p= 0.0745
Conclusions: Male gender is a strong risk factor for development of NRF and that 
difference did not appear to be related to the presence of angiographically visible 
thrombus. These results are the first to demonstrate a gender difference in the coronary 
microcirculation following reperfusion therapy for STEMI.
2900-169 Clinical Implications of the Choice of Therapy for 
Patients with Rheumatoid Arthritis and Lupus after 
Acute Myocardial Infarction
Joji J. Varghese, Sushma Koneru, Steven L. Scaife, Whitney Zahnd, Syeda Rumman, 
Mark L. Francis, Southern Illinois University School of Medicine, Springfield, IL
Background:
European studies have shown that rheumatoid arthritis (RA) patients have excessive 
risk of cardiovascular death after myocardial infarction (MI) and were less likely to 
receive percutaneous coronary intervention (PCI). The differential use of coronary 
revascularization procedures and its clinical implications in patients with RA and systemic 
lupus erythematosus (SLE) are unknown in United States.
Methods:
Using Nationwide Inpatient Sample (2003-2004), we analyzed all patients admitted with 
diagnosis of MI. After adjusting for confounding factors which include age, gender, race, 
Charlson comorbidity index, hypertension, diabetes, hyperlipidemia, income, insurance, 
rural/urban residency, elective admission, and weekend admission, we examined 
patients with RA or SLE to determine the adjusted odds ratio of medical therapy, PCI 
and coronary artery bypass graft (CABG) compared to patients without RA or SLE.We 
then compared inhospital mortality of RA and SLE patients treated with medical therapy, 
PCI and CABG.
Results:
Adjusted Odds Ratio for Choice of Therapy and In-Hospital Mortality (95% Confidence 
Intervals)
Medical Therapy 
(n=119069)
CABG 
(n=29206)
PTCA 
(n=72599)
Choice of therapy for RA 0.68 (0.61-0.76) 0.96 (0.81-1.13)
1.63 (1.45-
1.83)
Choice of therapy for SLE 0.99 (0.81-1.21) 0.64 (0.45-0.9) 1.31 (1.06-1.61)
In-hospital mortality for RA 0.92 (0.78-1.09) 0.79 (0.41-1.52)
0.38 (0.23-
0.62)
In-hospital mortality for 
SLE 0.97 (0.69-1.36)
0.27 (0.04-
2.08)
1.01 (0.54-
1.88)
Conclusions: In United States, RA and SLE patients with acute myocardial infarction 
were more likely to recieve coronary revascularization procedures especially PCI. 
Furthermore, this treatment pattern appears to be justified since in-hospital mortality of 
RA patients undergoing PCI is significantly better than patients without RA.
2900-170 Inflammation/Lipid Score May Outperform Timi Score 
in Acute Myocardial Infarction Treated by Primary 
Intervention.
Jaroslaw D. Kasprzak, Katarzyna Kolodziej, Jan Z. Peruga, Michal Kidawa, Jaroslaw 
Drozdz, Maria Krzeminska-Pakula, II Chair of Cardiology, Medical University of Lodz, 
Lodz, Poland
Background. Novel inflammatory and neurohumoral markers are potential prognostic factors 
after acute coronary syndromes. The aim of the study was to reassess the prognostic model 
after the first myocardial infarction (MI) treated with primary PCI (pPCI).
Methods. 85 patients (20 females) aged 61±9 years admitted with first ST-elevation MI 
and treated with pPCI. Laboratory panel extended with IL-1, IL-10, MCP-1, sFASl, NT-
proBNP, fibrinogen and CRP were sampled prior to intervention. Patients were followed-
up with regard to the occurrence of death, MI or ventricular fibrillation during 12 month 
follow-up period.
Results. 27% pts reached the composite endpoint. We defined univariate predictors 
of 1-year prognosis: IL-10 (p=0.0014), HDL-cholesterol (OR=7.5; 95% CI 1.9-30.1, 
p=0,0001), creatine kinase (CK, p=0.007)) and CK-MB (p=0.05), left ventricular ejection 
fraction (p=0.026), TIMI risk score (p=0.027) and white blood count/WBC (P=0.029). In 
multivariate logistic regression model (86% correct, p=0,001) the independent prognostic 
factors were: HDL-cholesterol; HR=0,89 (0,81-0,98), p=0,0001; IL-10; HR=1,392 (1,01-
1,96), p=0,014, and WBC; HR=1,39 (1,03-1,88), p=0,038. A prognostic score based on 
3 factors: HDL<31,2 mg/dl, IL-10>0.4pg/ml, WBC>10800/mm³ yielded Kaplan-Meier’s 
HR=10.4 (p<0.0001) when 2 or 3 factors were present (event rate 0%, 17% and 80% for 
scores 0, 1 and 2or3, resp.). TIMI score at optimal ROC-defined threshold>3 offered low 
HR=2.37 (p=0.028).
Conclusions. A simple prognostic score including white cell count, HDL-cholesterol 
and interleukin-10 concentration enabled optimized risk stratification and outperformed 
TIMI risk score in this study. These variables may better predict prognosis in patients 
reperfused with primary percutaneous intervention than Antman’s TIMI score. 
2900-171 Direct LV Dynamics During Primary Angioplasty for 
Anterior ST-Elevation Myocardial Infarction and Follow Up
Maurice Remmelink, Krischan D. Sjauw, José P. Henriques, Karel T. Koch, Marije M. Vis, 
René J. van der Schaaf, Jan G. Tijssen, Robbert J. de Winter, Jan J. Piek, Jan Baan, Jr., 
Academic Medical Center - University of Amsterdam, Amsterdam, The Netherlands
Background: We studied direct changes in left ventricular (LV) dynamics during primary 
percutaneous coronary intervention (PCI) and after a recovery period of 4 months, by 
pressure-volume (PV) loops.
Methods: Thirteen consecutive patients (8 males, mean age 60±11 years) were 
studied, who presented with their first acute anterior ST-segment elevation myocardial 
infarction within 6 hours after onset of symptoms (CK-MBmax 215±116 Μg/L), and in 
whom angiography revealed an occluded left anterior descending artery. A pressure-
conductance catheter was placed in the LV after which primary PCI was performed 
successfully. The patients were re-catheterized at 3 days and 4 months.
Results: Before PCI, patients had depressed LV contractility, as indicated by a decreased 
ejection fraction (EF) 41±17%, an increased end-diastolic pressure (EDP) and volume 
(EDV), and end-systolic volume (ESV). Immediately after successful reperfusion with 
TIMI 3 flow, EDP decreased by 9±5 mm Hg (p=0.007), while ESV and EDV showed 
a decrease after 3 days by 26±15 mL (p=0.009) and 38±23 mL (p=0.01), respectively, 
with a concomitant increase in EF by 14±5% (p=0.001). At 4 months EDV increased 
by 41±29 mL (p=0.02), while ESV and EF remained unchanged, indicating dilatation 
with a relatively preserved contractility. Levels of NT-proBNP increased up to 3 days and 
returned close to normal at 4 months. Conclusion: Coronary reperfusion during primary 
PCI directly reduces LV end-diastolic pressure, indicating an immediate partial relief of 
the stunned myocardium, which is followed by an increased contractile function at 3 days. 
At 4 months contractile function was relatively preserved, despite myocardial dilatation.
2900-172 Physician Experience Significantly Modifies The Effect 
of Hospital Primary Angioplasty Volume on In-Hospital 
Mortality
Vankeepuram S. Srinivas, Elana Koss, E.Scott Monrad, Susan Hailperin, Michael 
Alderman, Montefiore Medical Center, New York, NY, Albert Einstein College of 
Medicine, New York, NY
Background: An inverse relationship between volume and outcome has been described 
for both hospitals and physicians during primary angioplasty (PA). However, whether 
physician experience of PA offsets the risk related to low volume hospitals and vice versa 
is not known.
Methods and Results: Using the 2000-2002 New York State PCI reporting system, 
we calculated the independent and joint effects of hospital, physician volume on risk-
adjusted mortality in 7321 patients undergoing PA using logistic regression analyses. In 
these analysis, high volume hospitals (performing >50 PA/yr) and high volume physicians 
(>10 PA/yr)hospital and physician volumes were compared to their respective low volume 
counterparts after adjustment for underlying risk using the New York state PCI risk 
score.
Results: PA by high volume hospitals (OR 0.53; 95% CI 0.34 - 0.81) and by high volume 
physicians (0.66; 0.48 - 0.92) was independently associated with lower odds of mortality. In 
a logistic regression model of hospital and physician volume adjusted for underlying risk, 
the product interaction term for hospital and physician volume was significant with wald 
chi2 of 417; P=0.02. Compared to PA in high volume hospitals by high volume physicians 
as reference, PA by low volume physicians in low volume hospitals was associated with 
significantly higher odds of mortality (1.72; 1.04 - 2.85). Similarly, even within high volume 
hospitals, PA by high volume physicians was associated with significantly better outcomes 
compared to low volume physicians (OR 0.58; 95% CI 0.39-0.86)
Conclusions: A significant interaction exists between hospital and physician volume 
of PA such that the effect of low hospital volume on outcome is significantly modified by 
physician experience. These results would support the use of minimum volume thresholds 
for both hospitals and physicians performing PA.
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2900-173 Impact of Round-the-Clock In-House Interventional 
Cardiologist on Door-to-Balloon Time in STEMI Patients
Mohamed Djelmami-Hani, Angela Schlemm, Suhail Allaqaband, Tanvir Bajwa, Aurora 
Sinai/Aurora St. Luke’s Med Ctrs, Univ Wisconsin School of Med and Public Health-
MCC, Milwaukee, WI
Background: Prompt revascularization in ST-elevation myocardial infarction (STEMI) 
decreases infarct size and mortality. ACC/AHA recommends a goal of door-to-balloon 
time (D2B) <90 minutes in STEMI. We report the impact of round-the-clock in-house 
interventional cardiology team (24/7) on D2B time in our tertiary care hospital since April 
2004.
Methods: Data was prospectively collected on all consecutive patients who presented to 
emergency room with STEMI and underwent primary percutaneous coronary intervention. 
We compared D2B time during the 2 years prior to 24/7 coverage (Pre 24/7) with D2B 
time for the 2 years since we started 24/7 (Post 24/7).
Results: In 587 patients (297 Pre 24/7 and 290 Post 24/7) mean D2B improved from 
131.1± 281 min Pre 24/7 to 65.9±33.6 min Post 24/7 (p<0.0001). The target D2B <90 
min was achieved in 39% of the Pre 24/7group and 85.2% of the Post 24/7 group 
(p<0.0001).
Conclusions: Round-the-clock in-house coverage by catheterization laboratory staff and 
interventional cardiologist results in a significant improvement in door-to-balloon time.
2900-174 Intra Aortic Balloon Pumping Ineffective Against 
Systemic Inflammatory Activation During Myocardial 
Infarction Related Cardiogenic Shock
Justin Carter, Roland Prondzinsky, Henning Lemm, Michael Swyter, Nikolas Wegener, 
Susanne Unverzagt, Axel Schlitt, Ute Buerke, Martin Russ, Karl Werdan, Michael 
Buerke, Martin Luther University, Halle (Saale), Germany
Background: In patients with myocardial infarction complicated by cardiogenic shock 
(MI-CS) the use of IABP is recommended. MI-CS causes a systemic inflammatory 
response syndrome (SIRS) leading to further impaired hemodynamics and multi-organ 
dysfunction syndrome (MODS). This inflammatory response could be improved (by 
improvement of shock hemodynamics) or worsened (by exposure of the circulation to 
foreign material) with IABP use. No randomized clinical trial has examined whether IABP 
improves SIRS in MI-CS. We hypothesised that IABP use would ameliorate systemic 
inflammatory activation in MI-CS. The present IABP-shock-trial was a monocentric, 
randomized, controlled, prospective, parallel treatment trial to examine the role of IABP in 
treating MODS and inflammation in PCI treated patients with MI-CS.
Methods. Forty consecutive patients with acute MI-CS were randomised to receive therapy 
with or without IABP (for ≥48hr) in addition to PCI centred care. APACHE II scores and 
inflammatory markers (Leukocyte count, IL-6, TNFα, and CRP levels) were measured at 
enrolment and daily for 4 days. 
Results. The study population mean age was 64±1.9 years, 52% were mechanically 
ventilated, the mean LVEF was 27±2.1% and 28 day survival was 67%. The global 
mean APACHE II score was 20.4±2.7 (illustrating the severity of disease) but was not 
significantly affected by use of IABP. IL-6 levels were raised in both groups, illustrating 
systemic inflammatory activation in MI-CS but levels remained elevated (500ng/ml mean) 
and were not affected by IABP use. Similarly, the other markers of inflammation were 
unaffected by the implementation of IABP therapy.
Conclusion. Although IABP therapy may exert pro- or anti-inflammatory influences, given 
the present data, we conclude that IABP use does not significantly improve markers 
of systemic inflammation or the development of SIRS / MODS in PCI treated MI-CS 
patients. 
2900-175 Long-Term Clinical Outcome and Stent Thrombosis of 
Paclitaxel-Eluting Stent versus Sirolimus-Eluting Stent 
in Primary Percutaneous Intervention: multicenter 
registry in Korea
Seong-Wook Park, Seung-Whan Lee, Won-Jang Kim, Duk-Woo Park, Young-Hak Kim, 
Cheol Whan Lee, Myeong-Ki Hong, Jae-Joong Kim, Jae-Hwan Lee, Jae Hyeong Park, 
In-Whan Seong, Hyun Sook Kim, Jae-Ki Ko, Jei Keon Chae, Seung-Jung Park, Asan 
Medical Center, Seoul, South Korea
Background: To compare long-term (3-year) safety and efficacy of paclitaxel eluting 
stents (PES) versus sirolimus eluting stents (SES) for the treatment of acute ST elevation 
myocardial infarction.
Methods:The 549 consecutive patients were treated with PES (n=187) or SES (n=362) in 
the setting of primary percutaneous coronary intervention for acute myocardial infarction 
in this multicenter registry. Thirty-day and long-term clinical outcomes (28±10 months) 
were clinically assessed. The primary endpoint was incidence of stent thrombosis and 
major adverse cardiac events (MACE) including all cause mortality, myocardial infarction 
(MI), and target lesion revasularization (TLR). We applied a classification of stent 
thrombosis set by the Academic Research Consortium (ARC).
Results:Both group had similar clinical and angiographic characteristics. At 30 days, the 
rate of all cause mortality (4.3% for PES and 4.1% for SES, p = 0.941) and MI (2.1% for 
PES and 1.4% for SES, p =0.498) was similar between groups. Angiographic restenosis 
was significantly lower in SES (6.0% vs. PES, 14.4%; p=0.006). During the 3-year follow-
up, no significant differences were seen between groups in terms of death (7.9% for 
PES and 6.5% for SES, p = 0.893), MI (3.9% vs. 3.4%, p = 0.562), TLR (8.3% vs. 6.4%, 
p = 0.318) and MACE (15.9% vs. 12.8%, HR 1.24; 95% CI, 0.72-2.13; p=0.441). Stent 
thrombosis (overall cumulative incidence; 1.9% at 30 days, 2.4% at 1 year, 2.6% at 2 
years, and 3.3% at 3 years) occurred in 2.8% for PES versus 3.6% for SES during the 
3-year follow-up (HR 0.95; 95% CI, 0.29-3.10; p=0.788). Late stent thrombosis (> 1 
month) occurred in 0.6% for PES versus 2.2% for SES (p=0.259).
Conclusions:Despite significant reduction of angiographic restenosis in SES versus 
PES, no differences were seen in MACE and incidence of stent thrombosis between PES 
and SES for the treatment of acute myocardial infarction during 3-year follow-up.
2900-176 Myocardial Perfusion Grade (MPG) After Late Infarct 
Artery Recanalization Predicts Global and Regional 
LV Function at One Year; Analysis From the Total 
Occlusion Study of Canada-2
Terje K. Steigen, Vinod Jorapur, Christopher E. Buller, Warren J. Cantor, Boban Thomas, 
James M. Rankin, John G. Webb, Bruce Barton, Deborah J. Atchison, Gervasio A. 
Lamas, Judith S. Hochman, G. B. John Mancini, Vladimir Dzavik, Vancouver General 
Hospital, Vancouver, BC, Canada, University Health Network, Toronto, ON, Canada
Background:TOSCA-2 is an NHLBI-funded substudy of the Occluded Artery Trial (OAT), 
an international randomized trial of PCI for occluded IRAs 3-28 days post-MI. TOSCA-2 
obtained paired ventriculograms at baseline and 1 year post-PCI, providing a unique 
opportunity to evaluate the association between myocardial perfusion grade (MPG) 
and global and regional functional recovery at one year following successful late IRA 
recanalization.
Methods:MPG was evaluable in 157 patients assigned to PCI (TIMI MPG scheme: 0- no 
blush, 1-stain, 2- slow entry/exit, 3-normal). Angiographic parameters, including MPG, 
were evaluated in a core lab.
Results:Lower blush grade post-PCI (MPG 0/1, n=33, 22 %) predicted lower LV ejection 
fraction (EF), higher end-systolic volume index (ESVI) and lower wall motion index (WMI) 
at one year (Table). In a logistic model days from MI to randomization (trend; OR 1.109 
per day, 95% CI 1.019-1.206; p=0.017) and baseline ESVI (significant; OR 1.316, 95% CI 
1.112-1.556; p=0.001) were positively related to MPG 0/1 at one year. For this analysis, 
p<0.01 was considered significant.
Conclusions:MPG is often preserved following late IRA recanalization and preserved 
MPG is significantly related to better global and segmental indices of LV function at 1 year. 
These observations extend prior analyses undertaken in acute MI settings indicating that 
MPG may represent preserved microvascular integrity and myocardial viability.
Outcome at One 
Year Post PCI MPG
Parameter Estimate 
(Effect of Baseline 
MPG 0/1)
SEM t Value Pr > |t|
WMI Baseline MPG 0/1 -0.64 0.20 -3.27 0.0014
EF Baseline MPG 0/1 -4.00 1.74 -2.30 0.0233
ESVI Baseline MPG 0/1 -6.32 2.68 -2.36 0.0209
2900-177 Time Delay to Treatment and Long-term Outcome 
After Primary Angioplasty for ST-Segment Elevation 
Myocardial Infarction: A DANAMI-2 Substudy
Michael Maeng, Michael Maeng, Leif S. Mortensen, Torsten T. Nielsen, Henning R. 
Andersen, Aarhus University Hospital, Skejby, Aarhus, Denmark
Background: In patients with ST-segment elevation myocardial infarction (STEMI) 
treated with primary percutaneous coronary intervention (pPCI) early reperfusion is 
believed to improve left ventricular systolic function and reduce mortality. However, long-
term (>1 year) data are lacking.
Methods: In the DANAMI-2 study 686 patients were treated with pPCI. Long-term 
mortality was obtained during three years follow-up. We grouped the patients according 
to symptom-to-ballon time <3 hours (early, n=223), 3-5 hours (intermediate, n=282) and 
≥5 hours (late, n=181). These groups were compared using a Cox proportional hazards 
regression model adjusted for significant baseline differences between the groups. Left 
ventricular systolic ejection fraction (LVEF) was estimated prior to discharge during index 
hospitalization.
Results: There was no long-term mortality difference between the early and intermediate 
groups. The unadjusted mortality hazard ratio (HR) for symptom-to-balloon time ≥5 hours 
was highly significant (HR 2.36, 95% Confidence Intervals (CI) 1.51-3.67, p=0.0002) but 
after adjustment for differences in baseline characteristics only a trend remained (HR 
1.55, 95% CI 0.98-2.44, p=0.063). There was a significant mortality interaction between 
age and time delay (p=0.047); the younger the patient the greater was the survival benefit 
of symptom-to-balloon time <5 hours. Symptom-to-balloon time was positively associated 
an LVEF >40 (early 80.3%, intermediate 77.2%, late 66.9%, p=0.036) and increased 
postPCI TIMI-3 flow (early 86.5%, intermediate 80.9%, late 75.7%, p=0.020).
Conclusions: A symptom-to-balloon time < 5 hours is associated with improved three-
year survival in STEMI patients treated with pPCI. This long-term survival benefit is age-
dependent and associated with improved left ventricular function and improved postPCI 
coronary flow.
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2900-178 Early Initiation of Statins Immediately after Acute 
Myocardial Infarction Improves Mid-Term Clinical 
Outcomes 
Young Joon Hong, Myung Ho Jeong, Doo Sun Sim, Jong Won Chung, Ju Han Kim, Jae 
Youn Moon, Young Keun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang, 
Chonnam National University Hospital, Gwangju, South Korea
Background:Effects of early initiation of statins in patients with acute myocardial 
infarction (AMI) on secondary cardiac events remain unclear. The aim of this study was to 
evaluate the beneficial effects of early initiation of statins on mid-term clinical events after 
AMI in a real-world setting.
Methods: Between October, 2005 and December 2006, 621 patients with AMI (439 
ST segment elevation MI and 182 non-ST segment elevation MI) were registered and 
followed prospectively. Early initiation of statins was defined as prescription during 
hospitalization (statin group: 545 patients), and the control group was not prescribed 
statins during hospitalization or at discharge (76 patients). The primary end point was 
6-month mortality rate. 
Results:During 6-month follow-up, 22 patients died (3.5%), including 7 patients from the 
control group (9.2%) and 15 patients from the statin group (2.8%) (p=0.004). 6-month 
follow-up major adverse cardiac events (including cardiac death, MI, and target lesion 
revascularization) occurred less frequently in patients who were taken early statin therapy 
compared with patients who were not taken statin therapy [statin group: 78 (14.3%) vs. 
control group: 18 (23.7%), p=0.034]. Baseline high-sensitivity C-reactive protein (hs-CRP) 
was significantly higher in died patients compared with live patients (12.8±10.2 mg/dl 
vs. 2.1±3.0 mg/dl, p<0.001). Multivariate logistic regression analysis showed that early 
initiation of statin therapy and baseline hs-CRP level were the independent predictors 
of 6-month mortality [Hazard ratio (HR); 0.078, 95% CI; 0.008-0.808, p=0.032, and 
HR=1.314; 95% CI; 1.149-1.501, p<0.001, respectively).
Conclusions:
In this analysis of 621 AMI patients, high inflammatory status is associated with poor 
prognosis, and early initiation of statins after AMI could decrease mid-term mortality rate.
2900-179 Local Leukocyte Elastase Release at Site of Occlusive 
Plaque Rupture Predicts Downstream Microvascular 
Reperfusion Injury and Impaired Left Ventricular 
Function in ST Elevation Myocardial Infarction
Mark Nallaratnam, Tessa Mocatta, Catriona Marshall, David Smyth, Christine 
Winterbourn, John Elliott, Mark Richards, Anthony J. Kettle, Dougal R. McClean, 
Christchurch Hospital, Christchurch, New Zealand, University of Otago, Christchurch, 
New Zealand
Background: Leukocyte elastase (LE) is a serine protease released from granules 
of activated neutrophils and associated with extracellular matrix breakdown and up-
regulation of cytokines and metalloproteinases. High levels of LE have also been found 
in monocyte/ macrophages in morphologically vulnerable atheromatous plaques. We 
hypothesized that increased leukocyte activation locally at site of coronary plaque rupture 
may help predict a subgroup of patients that have impaired microvascular reperfusion 
following successful primary percutaneous coronary intervention (PCI) for ST elevation 
myocardial infarction (STEMI).
Methods: We enrolled STEMI patients presenting within 12 hours about to undergo 
primary PCI. Following informed consent, samples were obtained from the coronary 
artery (CA) at site of occlusive plaque rupture pre (CApre) and post coronary angioplasty 
and stenting (CApost)using a multi-functioning probing catheter (BSC, Natwick, NJ). ΔCA 
= CApre - CApost was calculated to differentiate local release from basal coronary levels. 
ST segment resolution (STR)was measured on 12 lead ECG and left ventricular ejection 
fraction (LVEF) by 2D echocardiography 24 hours post and at 6 months. Plasma LE was 
measured by ELISA (IDK, Bensheim, Germany).
Results: Following informed consent, 34 patients with STEMI were enrolled. 32% 
anterior MI, 94% Final TIMI 3 flow, 42% with STR >70%. LE was higher at CApre 50.2 ng/
ml(IQ 29.2-74.3) compared to systemic 25.5ng/ml(IQ:21.8-36.2), p=0.001 
Correlations ΔCA Leukocyte Elastase
Systemic 
Leukocyte 
ElastaseBaseline TIMI 0-1 (n=18) Baseline all TIMI Flow (n=34)
%STR r= -0.59** r= -0.36* r= -0.23 (ns)
24 hour LVEF r= -0.53* r= -0.38* r= 0.02 (ns)
6month LVEF r= -0.71** r= -0.273(ns) r= 0.26 (ns)
*p<0.05; **p<0.01 Spearmans Rank Order Correlation
Conclusion: Increased leukocyte elastase release locally at site of occlusive coronary 
plaque rupture, but not systemically, predicts downstream microvascular reperfusion 
injury and medium term LV myocardial dysfunction. Strategies to target intra-coronary 
leukocyte elastase and downstream products of activation may help improve outcome in 
patients undergoing primary PCI for STEMI.
2900-180 Predictors of Slow Flow During Primary Percutaneous 
Coronary Intervention
Jang-Ho Bae, Taek-Geun Kwon, Dae-Woo Hyun, Charanjit S. Rihal, Amir Lerman, 
Konyang University Hospital, Daejeon, South Korea, Mayo Clinic, Rochester, MN
Background: Slow flow phenomenon is a serious complication of percutaneous 
coronary intervention (PCI) and associated with poor prognosis. We sought to evaluate 
the characteristics of lesions predisposing to slow/no-reflow phenomenon during primary 
PCI in patients presenting with acute myocardial infarction.
Methods: The study subjects consisted of 57 consecutive patients (mean 58.5±14.5 
years old, 45 males) who underwent primary PCI for acute myocardial infarction and 
intravascular ultrasound-virtual histology (IVUS-VH) examination. Slow flow was defined 
as ≤ thrombolysis in myocardial infarction grade 2 after PCI.
Results: Slow flow was developed in 12 patients (8 males). Patients with slow flow was 
likely to be older (67.5±13.8 yrs old vs. 56.2±13.9 yrs old, p=0.015), had more cardiogenic 
shock (16.7% vs. 2.2%, p=0.046), larger fibrofatty volume over the entire lesion length 
(36.7±25.5mm3 vs. 18.0±18.6mm3, p=0.006), higher remodeling index (1.10±0.17 vs. 
0.99±0.16, p=0.043), larger plaque area (16.2±5.4mm2 vs. 12.5±4.9mm2, p=0.025), 
fibrous area(8.0±3.3mm2 vs. 5.4±3.0mm2, p=0.014), and fibrofatty area (2.7±2.2mm2 
vs. 1.3±1.6mm2, p=0.016) at the minimal lumen site than those without slow flow (37 
males). Multivariate analysis revealed that the fibrofatty volume over the entire lesion 
length was the only independent factor (beta=0.359, 95% confidence interval 0.002 to 
0.012, p=0.006) for slow flow during primary PCI.
Conclusions: This study suggests that slow flow may be dependent on the tissue 
characterization (fibrofatty volume) of the underlying lesion at the time of the primary PCI 
for acute myocardial infarction.
2900-181 One -Year Clinical Follow-Up of Endothelial Progenitor 
Cell Capture Stent versus Uncoated Stent in Patients 
Undergoing Primary Percutaneous Coronary 
Intervention for Acute Myocardial Infarction
Yian-Ping Lee, Edgar Tay, Melissa Co, Wee-Tiong Yeo, Chi-Hang Lee, Adrian Low, 
Swee Guan Teo, Jimmy Lim, Ing Han Lim, Yean Teng Lim, Huay Cheem Tan, National 
University Hospital, Singapore, Singapore
Background: The endothelial progenitor cell (EPC) capture stent is a bioengineered R 
stent with immobilized antibodies on its stent struts which allows for capture of circulating 
EPCs to promote rapid endothelization. We compare the mid-term efficacy and safety of 
this novel stent with bare metal stent in patients with ST-elevation myocardial infarction 
(STEMI) undergoing primary percutaneous coronary intervention (PCI).
Methods: Between January 2005 to September 2006, 234 consecutive patients 
presenting to our centre with STEMI and who underwent primary PCI with either EPC 
or bare metal stents were enrolled. The primary study end point was target vessel failure 
(death, recurrent MI or target vessel revascularization) at 1 year.
Results: The 2 groups were comparable in baseline demographic characteristics with 
males of 88.5% and diabetics 31.2%. The mean stent length deployed of EPC vs bare 
metal stents were 20.5±5.1mm and 23.2±6.8 mm respectively (p<0.001). At 1 year, the 
primary end point was similar between the 2 groups (12.0% vs 11.3%, p=0.88). There was 
no significant difference in the rate of death (2.6% vs 5.7%, p=0.24), reinfarction (2.6% vs 
2.8%, p=1.00) or target vessel revascularization (6.8% vs 2.8%, p=0.17). The rate of late 
stent thrombosis (0.9% vs 1.9%, p=0.50) was also similar.
Conclusion: The use of EPC capture stent in patients with STEMI undergoing primary PCI 
have comparable 1-year clinical outcomes with bare metal stents.
Table. Clinical Events at 1 Year 
Event
EPC  
Stent  
(N=120)
Bare Metal Stent  
(N=114) P Value
number (percent)
Target-vessel failure 14 (12.0) 12 (11.3) 0.88
Clinically driven target vessel revascularization 8 (6.8) 3 (2.8) 0.17
Death 3 (2.6) 6 (5.7) 0.24
Cardiac causes 3 (2.6) 3 (2.9) 1.00
Noncardiac causes 0 3 (2.9) 0.07
Recurrent MI 3 (2.6) 3 (2.8) 0.90
Stent thrombosis 1 (0.9) 2 (1.9) 0.50
Acute 0 0
Subacute 0 1 (1.0) 0.29
Late 1 (0.9) 1 (1.0) 0.94
2900-182 Drug-eluting Stents and Acute Myocardial Infarction: 
Experience from the TAXUS ARRIVE Registry Program
John M. Lasala, David Cox, Marc Schweiger, Donald Jenny, Nicholas Davakis, Stephen 
Mascioli, Donald Baim, Washington University School of Medicine Cardiovascular 
Division, St. Louis, MO, Lehigh Valley Heart Specialists, Allentown, PA
Background: Patients (pts) with acute myocardial infarction (AMI) may have more 
adverse events after treatment than pts undergoing elective intervention. The risks when 
using drug-eluting stents (DES) are not well understood. Therefore, we examined pts in 
the ARRIVE program with all types of AMI.
Methods: In ARRIVE 1 and 2, investigators at 99 US sites collected safety and clinical 
outcomes data for pts receiving TAXUS Express2 Paclitaxel-eluting stents in routine 
clinical practice.
Results: AMI pts comprised 12.5% (n=917) of the total 7,307 pt cohort. Their baseline 
characteristics were similar to the overall study population in most respects, but the 
prevalence of prior intervention and diabetes were lower, while prior MI and smoking 
were higher. AMI pts had significantly higher mortality (p=0.03), MI (p<0.01) and stent 
thrombosis (ST, p<0.01) at 1 yr with no difference in reintervention when compared to 
2,641 pts treated for “simple” non-AMI indications. Independent predictors of outcomes 
at 2 yrs will be presented.
Conclusions: AMI pts treated with the TAXUS Express stent show comparable anti-
restenotic benefits but have more death, MI and ST than Simple Use pts. This pattern 
has been reported with bare metal stents and a recent meta-analysis of AMI patients 
April 2008
   ABSTRACTS - SCAI-ACCi2 Interventional E-Abstracts B65 
S
C
A
I-A
C
C
i2
 Interventional E
-A
bstracts
treated with DES found reduced reintervention with no difference in death or ST rates. 
Large, adequately powered randomized trials are needed to demonstrate the net long 
term safety and efficacy of the TAXUS stent in this pt subset. 
Table 1: Characteristics and clinical outcomes in ARRIVE 1 and 2 pooled data: overall 
and AMI patient subgroup
Characteristic Overall Study Population (n=7307)
AMI Patients 
(n=917)
Age (yrs) 64.3±11.7 62.1±12.9
Male (%) 67.3 66.6
Diabetes (%) 31.5 24.0
Insulin-treated (%) 10.2 8.7
Hypertension (%) 75.8 63.4
Previous PCI (%) 36.6 20.6
Previous CABG (%) 20.0 9.9
Previous MI (%) 36.1 66.4
Known Smoker (%) 23.3 37.0
RVD (mm) 3.0±0.4 3.1±0.5
Lesion Length (mm) 15.7±9.2 16.6±9.5
Outcomes** 0-1 year (n=6979) 1-2 years (n=2280)***
Simple Use* 
(n=2641)
AMI 
(n=917) p-value
Simple 
Use 
(n=874)
AMI 
(n=254) p-value
All Death (%) 2.3 3.7 0.03 3.6 6.7 0.04
Cardiac Death (%) 1.3 2.6 0.02 1.7 3.6 0.11
MI (%) 1.4 2.9 <0.01 3.0 5.3 0.09
Re-intervention (%) 4.8 5.6 0.37 7.9 8.9 0.63
ST (ARC def/prob, 
total; %) 0.9 2.7 <0.01 2.1 4.9 0.21
*Simple use excludes patients with baseline AMI, left main, graft, chronic total 
occlusion, in-stent restenosis, failed brachytherapy, bifurcation, ostial, severe tortuosity, 
multivessel stenting, moderate/severe calcification, RVD<2.5mm, RVD>3.75mm, lesion 
length>28mm, cardiogenic shock, renal dysfunction. 
**events adjudicated by an independent Clinical Events Committee 
***ARRIVE 1 only, data available for ARRIVE 2 at time of presentation
2900-183 Four-Year Follow-Up Patients with ST-Segment 
Elevation Acute Myocardial Infarction Treated with 
Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent: 
Multicenter Registry in Asia
Sunao Nakamura, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan Udayachalerm, Damras 
Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, Chiba, Japan, Konyang 
University Hospital, Daejeon, South Korea
Background: Previous clinical study utilizing Sirolimus-eluting stent (SES) and Paclitaxel-
eluting stent (PES) in simple coronary lesions demonstrated an impressive reduction in 
intimal hyperplasia and restenosis. However, clinical efficacy of SES and PES in treating 
patients with ST-segment elevation myocardial infarction (STEMI) has not been validated. 
Methods: We assessed baseline clinical and angiographic characteristics, in-hospital and 
12, 24 and 36-month major adverse cardiac events (MACE) in 1,838 consecutive STEMI 
patients who received on SES, PES or bare metal stents (BMS) without cardiogenic 
shock undergoing emergent PCI. Results: The baseline clinical characteristics between 
3 groups were similar. See table for the clinical results. Conclusion: Implantation of SES 
and PES in STEMI patients is not associated with any risk of adverse in-hospital events, 
and reduced the need for repeat PCI at follow-up. 
BMS SES PES p
Number of patients 388 843 607 -
In-hospital Clinical success (%) 98.5 98.8 99.0 NS
Death (%) 1.0 0.8 1.0 NS
Stent thrombosis (%) 0.5 0 0 NS
30 days to 12 mo Death (%) 0.5 0.2 0.3 NS
Angiographic restenosis (%) 16.0 3.8* 4.9* 0.01
Repeat PCI (%) 10.8 3.0* 4.9* 0.01
Stent thrombosis (%) 0 0.2 0.3 NS
30 days to 36 mo Death (%) 0.8 0.8 0.5 NS
Angiographic restenosis (%) 17.5 5.3* 5.9* 0.01
Repeat PCI (%) 11.9 3.8* 5.9* 0.01
Stent thrombosis (%) 0 1.2 0.3 NS
30 days to 48 mo Death (%) 1.0 1.1 0.2 NS
Angiographic restenosis (%) 17.8 5.3* 6.1* 0.01
Repeat PCI (%) 11.9 4.0* 6.1* 0.01
Stent thrombosis (%) 0 1.2 0.2 NS
2900-184 Primary Coronary Intervention Without On-site Surgery 
vs. Thrombolysis: A Rural Facility Cost Analysis
Dane E. Sobek, Jennifer L. Kack, Blair D. Erb, Jr., Bozeman Deaconess Hospital, 
Bozeman, MT, Cardiology Consultants of Bozeman, PC, Bozeman, MT
Background: The current recommended approach to the ST elevation myocardial 
infarction (STEMI) patient at facilities without on-site cardiac surgery (non-SOS) is 
thrombolysis with urgent transfer to the nearest SOS facility. Many non-SOS facilities across 
the country currently offer primary percutaneous coronary intervention (PCI) despite the 
current recommendations. Previous studies have generally shown good angiographic 
and clinical outcomes in this setting. The cost of the two approaches, however, is rarely 
discussed. We compare overall medical care costs for STEMI patients receiving primary 
PCI at our rural non-SOS facility to estimated costs for lysis and transfer.
Methods: Hospital charges for all STEMI patients, identified by hospital DRG, who 
underwent primary PCI during 2006 in an 85 bed rural non-SOS hospital. The nearest 
SOS facility is 150 miles away requiring helicopter transport. Cost for the lysis and transfer 
approach were calculated by adding emergency room costs (hourly rate for a 2 hour visit), 
thrombolytic (tPA) administration costs (by CPT Code), and helicopter flight costs (based 
on a 300 mile roundtrip) to the assumed similar costs for PCI at the nearest SOS facility.
Results: In 2006, 25 primary PCIs were performed for STEMI. Mean door-to-balloon time 
was 69.6 minutes (12 - 146 minutes). Six (24%) of STEMI patients were in cardiogenic 
shock. Two patients underwent an induced hypothermia protocol for sudden cardiac 
death. Survival-to-discharge and 30 day survival rates were 100%. There were no major 
cardiovascular complications. Average hospital charges per STEMI patient was $34,971 
($18,397 - $57,572). The estimated cost for the lysis and transfer approach per patient 
was significantly higher at $49,629 ($33,055 - $72,230) (p=0.05). The estimated cost in 
health care dollars for STEMI care was decreased by 42% ($14,658) per patient with the 
primary PCI approach.
Conclusions: Initiation of a primary PCI program in a rural non-SOS community hospital 
resulted in a significant cost savings for acute STEMI care compared to thrombolysis 
and transfer. Clinical outcomes were not compromised, and PCI may have resulted in 
improved outcomes in patients with cardiogenic shock.
2900-185 Late Recovery of Myocardial Reperfusion 24 Hours 
After a Primary PCI Predicts Long Term Outcomes.
Jorge L. Szarfer, Miguel A. Riccitelli, Patricia Arce, Alejandro García Escudero, Gerardo 
Gigena, Federico Blanco, Rodrigo Blanco, Andrea Rodriguez, Roberto Neme, Ricardo 
Sarmiento, Luis A. Vidal, Hospital Argerich Hemodinamia, Buenos Aires, Argentina
Late Recovery of Myocardial Reperfusion 24 Hours After a Primary PCI Predicts Long 
Term Outcomes
Background: The lack of Myocardial Reperfusion immediately after a primary PCI 
predicts worst long term outcomes. The effect of 24 hours (Hs) Myocardial Reperfusion 
Recovery accessed by Myocardial Blush Recovery (MBR) on long term Left Ventricular 
Function (LVF) and mortality is unknown. The aim of the study is to evaluate if Late (24 hs) 
MBR affects LVF evaluated 6 months (m.) after the procedure and 1 year survival.
Methods: End diastolic (EDV), end systolic (ESV) volumes and Ejection Fraction (EF) 
angiographicaly assessed through the area-length method, were prospectively evaluated 
pre procedure and 6 m. after a Primary PCI, in 405 consecutive patients (P.) performed 
<12 hs. of symptoms onset. The corrected Timi Frame Count (cTFC) and Myocardial 
Blush (MB) according to the 0-3 grades described by Gibson were evaluated immediately 
and 24 hs. after Primary PCI. Patients were allocated to 3 groups according to the post 
procedure and 24 hs. MB: No reperfusion Group (NR): MB 0-1 immediately after and 
24 hs (44p); Late reperfusion Group (LR) MB 0-1 immediately after and 2-3 at 24 hs 
(53p); Early reperfusion Group (ER) MB 2-3 immediately and 24 hs. after (308p).99.5% of 
patient have completed follow up period.
Results: Cardiac death:
LR: 6/53 p. Vs. NR: 14/44 p. RR: 2.81 (CI 95%:1.18-6.70) p<0.02.
ER:10/308 p Vs. LR 6/53 p. RR: 3.49 (1.32-9.19) p<0.02.
ER:10/308 p. Vs. NR: 14/44 p. RR: 9.80(4.64-20) p<0.001.
NR Basal NR 6 m. LR Basal LR 6 m. ER Basal ER 6 m.
EDV 83.5±27 86.2±29 P= NS 75.1±18 81.2±22 p=0.22 78.8±21 85-1±23 p<0.002
ESV 48.8±26 49.1±27 P= NS 43.6±14
37.0±19 
p<0.001 42.4±17 37.5±18 p<0.01
EF % 43.1±16 45±15 P= NS 40.8±14 55.0±13 p<0.001 46.5±12 57.1±12 p<0.001
cTFC 33±17 39±25 P= NS 42±28 21±12 p<0.001 22.1±9 19.6±13 p<0.001
Conclusions: Late Recovery of Myocardial Reperfusion improves long term LVF 
to similar levels achieved at the Early Reperfusion group, and could define a group of 
patients with intermediate prognostic risk at 1 year follow up.
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2900-186 Identifying the Factors That Prolong Door-to-Balloon 
Time in Primary Percutaneous Coronary Intervention 
After Hours
Natesh Lingam, Henry Kim, Christine Swanson, Muhammad Arida, Hrishikesh Iyengar, 
Adam Greenbaum, Akshay Khandelwal, Abdul Arabi, Mayra Guerrero, W Douglas 
Weaver, Aaron Kugelmass, Henry Ford Hospital, Detroit, MI
Background: Primary percutaneous coronary intervention (PPCI) is the preferred 
treatment for acute ST elevation myocardial infarction (STEMI). Shorter door-to-balloon 
times (DTB) are associated with improved outcomes. It is known that DTB vary by time of 
day and day of week, with longer DTB after hours. This study seeks to identify processes 
and factors that impact the timeliness of PPCI after hours.
Methods: This is a prospectively collected data registry of 171 STEMI patients who 
underwent PPCI between 08/2003 and 12/2006. The study population was divided into 
two cohorts: weekday (6AM - 6 PM) versus after hours. After hours included holidays, 
weekends and weeknights. The following variables were studied: emergency department 
(ED) arrival to 1st electrocardiogram, electrocardiogram to catheterization laboratory (CL) 
activation, CL arrival to sheath access, sheath access to 1st balloon inflation, CL arrival 
to 1st balloon inflation. Unpaired t-tests for different variables between each group were 
analyzed.
Results: 
Variables Weekday N = 86
After 
Hours 
N = 85
p Value
Median DTB (minutes) 75 107
DTB <90 minutes (percentage) 71 31
ED Arrival to 1st Electrocardiogram (mean in 
minutes) 13.47 11.58 Not Significant
Electrocardiogram to CL Activation (mean in 
minutes) 19.68 15.90 Not Significant
CL Arrival to Sheath Access (mean in minutes) 12.09 16.25 p<0.0001
Sheath Access to 1st Balloon Inflation (mean in 
minutes) 20.22 23.53 Not Significant
CL Arrival to 1st Balloon Inflation (mean in 
minutes) 32.29 39.52 p=0.0145
Conclusion: After hours presentation of STEMI is common, and their DTB times are 
worse. Although not reaching statistical significance, ED response times are actually 
better after hours. CL metrics are significantly worse after hours, primarily related to 
preprocedure performance, although procedure times are also longer. Improving DTB 
after hours requires CL focused solutions that could include, faster staff response times, 
24-hour CL staffing or cross-training of non-CL staff.
2900-187 Quality of myocardial reperfusion according to 
ischemic time and infarcted territory
Fernando A. Cura, Samir Jozami, Lucio Padilla, Mariano Albertal, Marcelo Trivi, Jorge 
Thierer, Pablo Perez Baliño, Jorge Belardi, on behalf of the PREMIAR Investigators, 
Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
Background:The relationship of the ischemic time to primary angioplasty and the quality 
of myocardial reperfusion according to infarcted territory among patients with ST-segment 
elevation myocardial infarction (STEMI) is unclear.
Methods: This study comprised 140 patients with STEMI within 12 hours from symptom 
onset undergoing primary angioplasty from the Protection of Distal Embolization in High-
Risk Patients with Acute ST-Segment Elevation Myocardial Infarction Trial (PREMIAR) 
clinical trial. ST-segment resolution (STR) at 60 minutes was analyzed by an independent 
corelab using a continuous ST monitoring. Patients were divided in anterior (n=76) and 
non-anterior (n=64) location according to quartiles in 4 groups (<90, 90-148, 148-241 
and 241-635 minutes).
Results: Although there was no significant decrement in the extent of STR with the 
ischemic time in the entire population (74%, 51%, 72%, and 51%, respectively, p=ns), 
patients with anterior location have a significant reduction in the extent of STR after 90 
minutes (p=0.005).
Conclusions: Patients with anterior STEMI appear to have a stronger impact of 
ischemic time on the quality of myocardial reperfusion compared to patients with non-
anterior location. Efforts to reduce time to reperfusion should be emphasize among this 
high risk group of patients. 
2900-188 Predictors for lack of reperfusion after primary 
angioplasty in ST-elevation acute myocardial infarction 
Fernando A. Cura, Mariano Albertal, Lucio Padilla, Pablo Perez Baliño, Samir Jozami, 
Marcelo Trivi, Jorge Thierer, Jorge Belardi, on behalf of the PREMIAR Investigators, on 
behalf of the PREMIAR Investigators, Instituto Cardiovascular de Buenos Aires, Buenos 
Aires, Argentina
Background: Primary percutaneous coronary intervention (PCI) is limited by lack of 
achievement of myocardial reperfusion in a substantial proportion of patients. The 
predictors of lack of complete ST-segment deviation resolution, a surrogate of reperfusion, 
are unknown.
Methods: This study prospectively included 140 patients from the PREMIAR trial that 
evaluated the role of filter-based distal protection during PCI in patients with acute ST-
segment elevation myocardial infarction (STEMI) at high-risk of embolic events (including 
only patients with baseline TIMI 0-2-flow). The primary endpoint was the rate of complete 
resolution (>70%) at 60 minutes using continuous holter monitoring of ST-segment 
resolution. Multivariate predictors of lack of complete ST-segment resolution were 
assessed by logistic regression modeling.
Results: Complete resolution of ST-segment deviation 60-minutes after PCI occurred 
in 53 patients (37%) while non-complete resolution in 82 patients (63%) with a 30-day 
combined rate of mortality and/or worsened heart failure of 7.3 % and 15.1%, respectively 
(p=0.12). Univariate analysis showed that patients with suboptimal myocardial reperfusion 
had a higher rate of anterior location (81.1% vs 37.8%, p= 0.001), diabetics (26.4% vs 
15.8%, p= 0.13), time from symptom onset to PCI (minutes) (217+-167 vs 182+-134, 
p= 0.19), heart rate (81.1+-20.2 vs 70.5+-15.4, p= <0.001), Killip class >1 (30.2% vs 
17.1%, p= 0.07), while a lower rate of current smokers (24.5% vs 51.2%, p=0.002). 
Multivariate analysis showed that the presence of anterior location (OR 7.25, CI 95% 
3.1- 16.9, p<0.001) correlated with lack of complete reperfusion while the use of GP IIbIIIa 
blockers (OR 11.7, CI 95% 2.1- 64.8, p=0.005) and smoking (OR 4.63, CI 95% 1.67- 12.7, 
p=0.003) correlated with complete reperfusion.
Conclusions: There is a significant proportion of patients with lack of complete 
myocardial reperfusion at the tissue level who are associated with a poor outcome. The 
presence of anterior myocardial infarction correlates with incomplete reperfusion while 
smoking habits and the use of GP IIbIIIa inhibitors are associated with a more profound 
myocardial reperfusion after PCI.
2900-189 Pretreatment with statins gives better frame count in 
the culprit artery after primary PCI for acute MI.
waleed Y. kadro, Maya Turkmani, Hussam Eddin Alrahim, Dana Kadro, Lubaba 
Fayyoumi, Ali Dbs, The Golden Cardiovascular Center, Damascus, Syrian Arab Republic
Background: Primary PCI has been established as the best treatment for acute MI when 
it is used appropriately. It is known to give better TIMI III flow and better frame count when 
compared with thrombolytics. Adjunctive therapies with primary PCI are still controversial. 
We report the effect of pretreatment with statins on the TIMI frame count in the culprit 
artery after successful PCI.
Methods: We calculated the TIMI frame count in the culprit artery after successful 
primary PCI in 44 patients who presented to our center with acute MI. The mean door 
to balloon time was 98±12 minutes. All patients received 325 mg of aspirn and 600mg 
loading dose of clopidogril. GP IIb/IIIa inhibitors were used in all cases together with 
heparin adjusted dose. Stent usage was 100%. No thrombectomy device was used in any 
of these cases. TIMI III flow after stenting was achieved in all culprit arteries. 21 patients 
(group 1) were on statins therapy before admission. The other 23 patients (group2) were 
not receiving statins.
Results: The mean corrected TIMI frame count in the culprit artery post PCI was 
18.34±3.16 frames in group 1 and 29.73±3.92 in group 2 (p=0.02).
Conclusions: Pretreatment with statins gives faster flow after successful primary 
PCI in acute MI. This can be attributed to that statin therapy can cause: improvement 
in endothelial dysfunction, decreased production of free radicals, reduced platelet 
aggregation and reduced production of inflammatory mediators and adhesion molecules. 
Since this is a retrospective observation a larger prospective randomized study can be 
done.
2900-190 Comparison of Eighteen-Month Clinical Outcomes 
of Endothelial Progenitor Cell Capture Stent versus 
Sirolimus-Eluting Bioabsorbable Polymer-Coated 
Stent versus Bare Metal Stents In Patients Undergoing 
Primary Percutaneous Coronary Intervention for Acute 
Myocardial Infarction
Eric Chong, Ronald Chi Hang Lee, Shen Liang, Adrian Low, Swee Guan Teo, Kian 
Keong Poh, Huay Cheem Tan, The Heart Institute National University Hospital, 
Singapore, Singapore, Biostatistics Unit National University, Singapore, Singapore
Background: Endothelial progenitor cell (EPC) capture stent (Genous™, OrbusNeich), 
is designed to promote rapid endothelization and is potentially useful in patients 
undergoing primary percutaneous coronary intervention (PPCI) for acute ST-segment 
elevation myocardial infarction (STEMI). We compare its clinical efficacy and safety with a 
sirolimus-eluting (SES) bioabsorbable polymer-coated stent (Cura™, OrbusNeich) and a 
bare metal stent (BMS) (Liberte™, Boston scientific) in patients with STEMI.
Methodology: All patients presented to our center with STEMI and received PPCI 
with either EPC, SES or BMS stents between Jan 2004 and June 2006 were enrolled 
in the cohort study. The study endpoints were major adverse cardiac events (MACE) 
defined as composite end point of death, myocardial infarction (MI) and target vessel 
revascularization (TVR) at 18 months.
Results: A total of 365 patients (EPC=95, SES=53, BMS 218) were enrolled. Baseline 
demographics in terms of age, gender, diabetes mellitus, baseline renal impairment, pre-
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discharge left ventricular ejection fraction, cardiogenic shock were comparable among the 
3 groups. Procedural success rate was high at a mean of 99.5%. Post-procedural TIMI 
3 flow was achieved in EPC 91.6%, SES 96.2% and BMS 88.5%. The MACE results at 
18-months were shown: 
Events EPC (n=95)
SES 
(n=53)
BMS 
(n=218) p value
MACE (%) 13(13.7%) 8(15.1%) 35(16.1%) 0.865
Death (%) 9(9.5%) 2(3.8%) 25(11.5%) 0.208
Non-fatal MI (%) 1(1.1%) 1(1.9%) 4(1.8%) 0.916
TVR 3(3.2%) 5(9.4%) 6(2.8%) 0.070
Acute stent thrombosis 1 (1%) 0 (0%) 0 (0%)
Subacute stent thrombosis (SAT) 0 (0%) 0 (0%) 0 (0%)
Late stent thrombosis (LST) 0 (0%) 0 (0%) 2 (0.9%)
Conclusion: The MACE rates among patients who underwent PPCI were similar in all 
3 stent groups at 18 months follow-up. There was no difference in TVR rate and stent 
thrombosis remains a low event occurrence.
2900-191 Impact of advanced age on the safety and effectiveness 
of bivalirudin in patients with acute myocardial 
infarction undergoing primary angioplasty: The 
HORIZONS AMI trial
Dariusz Dudek, Krzyszto Zmudka, Bernhard Witzenbichler, Giulio Guagliumi, Jan Z. 
Peruga, Bruce R. Brodie, Ran Kornowski, Franz Hartmann, Martin Mockel, Andrzej 
Ochala, Helen Parise, Roxana Mehran, Gregg W. Stone, Columbia University Medical 
Center/Cardiovascular Research Foundation, New York, NY
Background. In the HORIZONS AMI trial, bivalirudin monotherapy (Biv) compared 
to unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) resulted in 
reduced rates of major bleeding, comparable composite major adverse cardiovascular 
events (MACE) (though with decreased cardiac mortality), and enhanced freedom from 
net adverse clinical events (NACE) in pts with AMI undergoing primary PCI. Whether the 
beneficial effects of Biv are independent of age, an important determinate of outcomes 
after primary PCI, has not been reported.
Methods and Results. A total of 3602 pts at 123 centers in 11 countries with AMI 
undergoing primary PCI were randomized to Biv (n=1800) vs. UFH+GPI (n=1802) and 
followed for 30 days. Outcomes were analyzed according to age above or below the 
median of 60.2 years. In the entire study population, Biv compared to UFH+GPI resulted 
in a 40% reduction in major bleeding (4.9% vs. 8.3%, P<0.0001), similar MACE (5.4% vs. 
5.5%, P=1.0), and a 24% reduction in NACE (9.2% vs. 12.1%, P=0.006). Compared to 
young pts, elderly patients had greater rates of major bleeding (8.6% vs. 4.6%, P<0.0001), 
MACE (7.1% vs. 3.8%, P<0.0001) and NACE (14.0% vs. 7.4%, P<0.0001). As shown 
in the table, the impact of Biv was independent of age (interaction P value for these 3 
endpoints = 0.26, 0.26, and 0.99 respectively).
Conclusions. In patients with AMI undergoing primary PCI, Biv monotherapy significantly 
reduces major bleeding and net adverse clinical events, effects which are independent 
of age. 
Age ≤60.2 years (n=1808) Age >60.2 years (n=1794)
Biv 
mono
UFH+GPI RR [95%CI] Biv 
mono
UFH+GPI RR [95%CI]
Major 
bleeding 3.0% 6.2%
0.49 [0.31, 
0.76] 7.0% 10.3%
0.68 [0.50, 
0.92]
MACE* 4.2% 3.4% 1.25 [0.78, 1.99] 6.7% 7.5%
0.89 [0.64, 
1.25]
NACE** 6.4% 8.4% 0.76 [0.55, 1.06] 12.2% 15.7%
0.78 [0.62, 
0.98]
* MACE = death, reinfarction, ischemic TVR or stroke; 
**NACE (Net Adverse Clinical Events) = MACE or major bleeding
2900-192 Impact of diabetes mellitus on the safety and 
effectiveness of bivalirudin in patients with acute 
myocardial infarction undergoing primary angioplasty: 
The HORIZONS AMI trial
Bernhard Witzenbichler, Giulio Guagliumi, Martin Desaga, Janusz Kochman, Dennis 
Nilsen, Ariel Finkelstein, Morris Mosseri, Helen Parise, Roxana Mehran, Gregg W. 
Stone, Columbia University Medical Center/Cardiovascular Research Foundation, New 
York, NY
Background. In the HORIZONS AMI trial, bivalirudin monotherapy (Biv) compared to 
unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) resulted in reduced 
rates of major bleeding, comparable composite major adverse cardiovascular events 
(MACE) (although with decreased cardiac mortality), and enhanced freedom from net 
adverse clinical events (NACE) in pts with AMI undergoing primary PCI. Whether the 
beneficial effects of Biv are independent of diabetic status has not been reported.
Methods and Results. A total of 3602 pts at 123 centers in 11 countries with AMI undergoing 
primary PCI were randomized to Biv (n=1800) vs. UFH+GPI (n=1802) and followed for 
30 days. Outcomes were analyzed according to the presence of known diabetes mellitus 
(DM) at the time of admission. In the entire study population, Biv compared to UFH+GPI 
resulted in a 40% reduction in major bleeding (4.9% vs. 8.3%, P<0.0001), similar MACE 
(5.4% vs. 5.5%, P=1.0), and a 24% reduction in NACE (9.2% vs. 12.1%, P=0.006). 
Compared to pts without DM, those with DM (n=593; 16.4%) had greater rates of major 
bleeding (8.8% vs. 6.2%, P=0.02), MACE (8.1% vs. 5.0%, P=0.004) and NACE (14.2% vs. 
10.0%, P=0.004). The impact of Biv was independent of DM (interaction P value for these 
3 endpoints = 0.22, 0.10, and 0.90 respectively) (Table).
Conclusions. In pts with AMI undergoing primary PCI, Biv monotherapy significantly 
reduces major bleeding and net adverse clinical events, effects which are independent 
of diabetic status. 
No diabetes (n=3006) Diabetes (n=593)
Biv 
mono
UFH+GPI RR [95%CI] Biv 
mono
UFH+GPI RR [95%CI]
Major 
bleeding 4.4% 8.0%
0.55 [0.41, 
0.74] 7.8% 9.6%
0.81 [0.48, 
1.38]
MACE* 5.3% 4.6% 1.14 [0.83, 1.56] 6.4% 9.6%
0.67 [0.38, 
1.17]
NACE** 8.6% 11.4% 0.60 [0.61, 0.94] 12.5% 15.7%
0.79 [0.53, 
1.19]
* MACE = death, reinfarction, ischemic TVR or stroke; 
**NACE (Net Adverse Clinical Events) = MACE or major bleeding
2900-193 Safety and effectiveness of bivalirudin in patients 
with acute myocardial infarction undergoing primary 
angioplasty: The HORIZONS AMI trial
Gregg W. Stone, Bernhard Witzenbichler, Giulio Guagliumi, Jan Peruga, Bruce Brodie, 
Dariusz Dudek, Ran Kornowski, Franz Hartmann, George Dangas, Ajay Kirtane, S. 
Chiu Wong, Helen Parise, Roxana Mehran, Columbia University Medical Center/
Cardiovascular Research Foundation, New York, NY
Background. In patients with stable angina and NSTEMI, bivalirudin (Biv) monotherapy 
has been shown to result in similar rates of composite ischemia as unfractionated 
heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI), while significantly reducing 
major bleeding. Whether Biv has comparable safety and efficacy in patients with STEMI 
undergoing primary PCI in AMI is unknown
Methods and Results. A total of 3602 pts at 123 centers in 11 countries with AMI within 
12 hrs of symptom onset undergoing primary PCI were randomized to Biv (n=1800) vs. 
UFH+GPI (n=1802) and followed for 30 days. Following angiography, primary PCI was 
performed in 3,340 pts (92.7%). Among these pts, baseline characteristics were well 
matched for age (median 60.1 yrs), gender (23% women), diabetes (16.3%), LAD PCI 
(40.7%), door to balloon time (median 99 mins), stent use (99.5%), TIMI-3 pre (18.7%) 
and TIMI-3 post (91.6%). Procedural GPI were used in 97.7% of UFH+GPI pts vs. 7.5% 
of Biv pts for bail-out. Thirty day results among pts undergoing PCI appear in the Table. 
Cardiac mortality 30 days after PCI occurred in 1.8% of Biv pts vs. 2.8% of UFH+GPI pts 
(RR [95%CI] = 0.63 [0.40, 0.99], P=0.049).
Conclusions. In patients with AMI undergoing primary PCI, at 30 days Biv monotherapy 
compared to UFH+GPI significantly reduces major bleeding and net adverse clinical 
events, including cardiac mortality. 
30 Day Event Rates Biv mono (n=1678)
UFH+GPI 
(n=1662) RR [95%CI] P value
Major bleeding (non 
CABG) 5.1% 8.5%
0.59 [0.46, 
0.77] <0.0001
MACE* 5.4% 5.4% 0.99 [0.75, 1.32] 1.0
Net adverse clinical 
events** 9.2% 12.2%
0.75 [0.62, 
0.92] 0.005
*Death, reinfarction, stroke or ischemic TVR. **Major bleeding or MACE
2900-194 Impact of gender on the safety and effectiveness of 
bivalirudin in patients with acute myocardial infarction 
undergoing primary angioplasty: The HORIZONS AMI trial
Liliana Grinfeld, Jorge Belardi, Alexandra Lansky, Bernhard Witzenbichler, Giulio 
Guagliumi, Krzyszto Zmudka, Martin Mockel, Andrzej Ochala, Witkowski Ruzyllo, Helen 
Parise, Roxana Mehran, Gregg W. Stone, Trials ArgeNtine Group Organization (TANGO) 
Coordinating Center, Buenos Aires, Argentina
Background. In the HORIZONS AMI trial, bivalirudin monotherapy (Biv) compared 
to unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) resulted in 
reduced rates of major bleeding, comparable composite major adverse cardiovascular 
events (MACE) (though with decreased cardiac mortality), and enhanced freedom from 
net adverse clinical events (NACE) in pts with AMI undergoing primary PCI. Whether the 
beneficial effects of bivalirudin are present in women, a high risk group after primary PCI 
in AMI, has not been reported.
Methods and Results. A total of 3602 pts at 123 centers in 11 countries with AMI undergoing 
primary PCI were randomized to Biv (n=1800) vs. UFH+GPI (n=1802) and followed for 30 
days. In the entire study population, Biv compared to UFH+GPI resulted in a 40% reduction 
in major bleeding (4.9% vs. 8.3%, P<0.0001), similar MACE (5.4% vs. 5.5%, P=1.0), and 
a 24% reduction in NACE (9.2% vs. 12.1%, P=0.006). Compared to men, women (n=842; 
23.4%) had greater rates of major bleeding (10.0% vs. 5.6%, P=0.xx), MACE (7.4% vs. 
4.9%, P=0.007) and NACE (15.6% vs. 9.2%, P<0.0001). Outcomes were analyzed 
according to gender. As shown in the table, the impact of Biv was independent of gender 
(interaction P value for these 3 endpoints = 0.99, 0.93, and 0.98 respectively).
Conclusions. In patients with AMI undergoing primary PCI, Biv monotherapy significantly 
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reduces major bleeding and net adverse clinical events, effects which are consistent in 
women and men. 
Male (n=2760) Female (n=842)
Biv 
mono
UFH+GPI RR [95%CI] Biv 
mono
UFH+GPI RR [95%CI]
Major 
bleeding 4.2% 7.0%
0.60 [0.43, 
0.82] 7.5% 12.3%
0.61 [0.40, 
0.93]
MACE* 4.9% 4.9% 1.00 [0.72, 1.39] 7.3% 7.4%
0.98 [0.61, 
1.58]
NACE** 7.9% 10.4% 0.76 [0.60, 0.96] 13.6% 17.4%
0.78 [0.57, 
1.07]
* MACE = death, reinfarction, ischemic TVR or stroke; 
**NACE (Net Adverse Clinical Events) = MACE or major bleeding
2900-195 Pre-Hospital 1/2-dose Fibrinolytic Therapy Coupled 
with Immediate PCI vs Primary PCI in Diabetics: AMICO 
Registry
H. Vernon Anderson, Ali E. Denktas, Timothy D. Henry, Holger Thiele, Stefano D. 
Sdringola, Nathaniel W. Niles, Raymond G. McKay, Richard W. Smalling, University of 
Texas Health Science Center Houston, Houston, TX
Background: Early treatment of ST-elevation myocardial infarction (STEMI) is not firmly 
established. Both fibrinolysis and primary PCI (PPCI) are advocated, yet time and transfer 
issues make definitive strategies elusive. Patients (pts) with diabetes are known to be at 
higher risk from STEMI, and clarity in early treatment options is especially needed.
Methods: The Alliance for Myocardial Infarction Care Optimization (AMICO) is a 
consortium of 5 high volume PCI centers. By local protocols, pts with STEMI may 
receive pre-hospital 1/2-dose fibrinolytic therapy coupled with transport to the center for 
immediate PCI (FAST-PCI). Our registry tracks and compares these pts with other STEMI 
pts at these centers treated with PPCI. For the period 1/1/2001-12/31/2006 we compared 
1200 FAST-PCI pts with 1669 PPCI pts. We tested the hypothesis that STEMI pts with 
diabetes would have superior outcomes with FAST-PCI compared to PPCI.
Results: There were 223 (19%) FAST-PCI pts with diabetes, and 352 (21%) in PPCI 
group. 1st-medical-contact-to-balloon times were longer for FAST-PCI compared to PPCI 
(mean 196 min vs 166 min, p=0.012). Despite this, mortality at 30 days was significantly 
lower in diabetics treated with FAST-PCI compared to PPCI (5.8% vs 11.6%, p=0.01) 
and was more similar to non-diabetics. Also, non-diabetic pts had lower mortality with 
FAST-PCI.
Conclusions: STEMI pts with diabetes benefitted from a strategy of pre-hospital 1/2-
dose fibrinolytic therapy coupled with immediate PCI instead of PPCI.
2900-196 Culprit-lesion Revascularization versus Complete 
Revascularization in Patients with Acute Myocardial 
Infarction Undergoing Primary Percutaneous Coronary 
Intervention with Drug-eluting Stents
Zhe Jin, Seung-Woon Rha, Kang-yin Chen, Yoshiyasu Minami, Jin Oh Na, Soon Yong 
Suh, Cheol Ung Choi, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, 
Dong Joo Oh, Myung Ho Jeong, Korea University Guro Hospital, seoul, South Korea, 
Chonnam National University Hospital, GwangJu
Background: Treatment guideline of STEMI has recommended opening the culprit 
infarct-related artery when primary PCI is required to patients (pts) with muti-vessel 
disease (MVD). The safety and efficacy of these two different PCI strategies of AMI with 
MVD in the DES era are largely unknown.
Methods: Study population is consisted of a total 1116 STEMI pts with MVD underwent 
primary PCI with DES enrolled in the Korean Acute Myocardial Infarction Registry 
(KAMIR) from Jan 2005 to Dec 2006. The pts were divided into two groups according 
to PCI strategy: Culprit-lesion revascularization group (Group 1, n=905) and Complete 
revascularization group (Group 2, n=215). In-hospital and 6-month clinical outcomes were 
compared between the two groups.
Results: The baseline and angiographic characteristics were similar between the two 
groups except that history of coronary heart disease was more common in Group 1 
(10.3% vs. 5.4%, P= 0.025). The procedural success rate and in-hospital mortality were 
similar between the two groups (0.4% vs. 1.4%, P=0.111, 91.5% vs. 92.1%, P=0.846, 
respectively). At 6-month follow up, the survival and freedom from MACEs was higher in 
Group 1 due to the incidence of TLR was higher in Group 2 (Table).
Conclusion: Culprit-lesion revascularization strategy (infarct-related artery only) showed 
better midterm clinical outcomes compared with those of complete revascularization 
strategy in AMI pts with MVD requiring multivessel angioplasty in the DES era.
Table. Clinical Outcomes at 6-month 
Variables, n (%)
Culprit-lesion 
Revascularization 
Group 
(Group 1, n=901 pts)
Complete 
Revascularization Group 
(Group 2, n=215 pts)
P value
All MACE 37 (4.1) 17 (7.9) 0.020
Total Death 19 (2.1) 7 (3.3) 0.316
Repeat-PCI 9 (1.0) 9 (4.2) 0.001
AMI 5 (0.6) 0 (0) 0.274
CABG 4 (0.4) 1 (0.5) 1.000
2900-197 Increased Endothelial Cell Mobility Following 
Stabilization of Hypoxia-Inducible Factor- Steps 
Towards Therapeutic Angiogenesis
Damian J. Kelly, Jasmin Mecinovic, Kamal Chitkara, Christopher J. Schofield, Anthony 
H. Gershlick, University of Leicester, Leicester, United Kingdom, University of Oxford, 
Oxford, United Kingdom
Background: Chronic total coronary occlusions (CTOs) are often resistant to treatment 
by percutaneous intervention. Clinical trials of therapeutic angiogenesis with systemic 
administration of protein growth factors such as Vascular Endothelial Growth Factor 
(VEGF) have been negative. Hypoxia-inducible factor (HIF) binds DNA sequences within 
the hypoxia response elements of multiple target genes involved in angiogenesis. In 
humans the proteolytic stability of HIF is regulated via oxygen-dependent hydroxylases. 
We investigated the effect of a prolyl-4-hydroxylase inhibitor, Di-methyl oxalyl glycine 
(DMOG), on endothelial cell mobility and tube-formation in a matrigel-based angiogenesis 
assay with a view to developing a stent-based angiogenic treatment for CTOs.
Methods: EHy926 human umbilical vein endothelial cells were cultured in Dulbecco’s 
medium with 2% HAT and 2% FBS. 72 wells of a 96-well plate were inoculated with 
40,000 cells per well, passage 4/5, over 50Μl of reduced growth-factor matrigel. 100Μl 
of culture medium was added with 125ΜM DMOG, 250Μg VEGF or 125ΜM Glycine 
(control). 160ΜM of a specific VEGF receptor inhibitor (VI) was added to alternate wells. 
Wells were photographed at 4, 8, 16, 24, 36 and 48 hours for evidence of cell migration. 
Blinded off-line digital image analysis using a 10x10 overlay-grid was performed to 
measure the proportion of grids squares containing ≥1 branching structure (GSB%).
Results: Minimal tube-like structures were present at 8 hours. By 16 hours DMOG culture 
produced similar GSB% to VEGF but more than control, Mean (SD): DMOG 38.7(3.6), 
VEGF 33.4(4.6), p=0.60; Control 4(1.7), p=0.012. Addition of VI reduced mean GSB% 
at 16 hrs in DMOG culture to 30.3(2.5), p=0.038; and abolished migration under VEGF 
culture, GSB% 0.5(0.7). Cell migration was complete in all cultures by 36 hours.
Conclusions: DMOG accelerates and enhances endothelial cell migration and tube-
formation in matrigel culture. This effect is in part mediated via VEGF. We are currently 
investigating the effect on antegrade collateral formation of stent-loaded HIF-stabilizing 
compounds in a novel porcine percutaneous model of coronary occlusion.
2900-198 The Protective Role of Human Coronary Collaterals: 
Prevention of QT Time Prolongation During Ischemia
Pascal Meier, Steffen Gloekler, Stefano De Marchi, Rainer Zbinden, Stephan Windecker, 
Bernhard Meier, Etienne Delacretaz, Christian Seiler, University Hospital, Bern, 
Switzerland
Background: Arrhythmogenesis during early myocardial ischemia is not well understood. 
Changes in action potential duration of ischemic regions may be important. The coronary 
collateral function has a beneficial role regarding all-cause and cardiac mortality. The aim 
of this study was to investigate the effect of acute ischemia on QT time and the protective 
influence of the coronary collateral function.
Methods: A total of 150 patients (mean age 63±11 years, 38 female) referred to our 
hospital for coronary angiography were prospectively included in this study. An ECG was 
recorded at baseline and during a 1-minute balloon occlusion. QT interval was measured 
in lead II before, at the end of and after a 1-minute balloon occlusion of a coronary vessel. 
QT time was corrected according to Bazzet’s formula (QTc). Collateral flow index (CFI; 
no unit) expressing collateral flow relative to normal anterograde flow was determined by 
pressure guide wires using mean aortic, central venous and occlusive coronary wedge 
pressure.
Results: During occlusion of the left coronary artery (left anterior descending (LAD) or 
left circumflex artery (LCX)), QTc increased from 426ms±35 to 444±37; p<0.001. QTc 
was not influenced by occlusion of the right coronary artery RCA. Collateral flow index 
was inversely correlated with QTc prolongation during occlusion of the left coronary 
artery (r=0.286, p=0.0028). In a multivariate regression analysis including CFI, gender, 
medication and cardiovascular risk factors, CFI was the only independent predictor of 
QTc change during vessel occlusion (p=0.0271).
Conclusion: Myocardial ischemia leads to QT prolongation during a controlled one-
minute occlusion of the left but not the right coronary artery. QT prolongation is negatively 
correlated to collateral function indicating a protective mechanism of human coronary 
collaterals against cardiac death.
2900-199 Device Selection Guidelines for Transcatheter Closure 
of the Patent Ductus Arteriosus
Todd M. Gudausky, Russel Hirsch, Philip R. Khoury, Robert H. Beekman, III, Cincinnati 
Children’s Hospital Medical Center, Cincinnati, OH
Introduction: A variety of devices are available for transcatheter closure of the patent 
ductus arteriosus (PDA) but no guidelines exist to guide operator device choice. 
Therefore, to provide guidelines for device selection we retrospectively evaluated two 
consecutive closure strategies utilized in 132 patients at our center between January 
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2000 and June 2005.
Methods: Strategy A (N=64; January 2000 to May 2003) utilized Gianturco coils only. 
Strategy B (N=68; June 2003 to June 2005) utilized a single Gianturco coil for the PDA 
with minimal diameter ≤1mm (n=28) and an Amplatzer Ductal Occluder (ADO) if the PDA 
diameter exceeded 1mm (n=40). Success was defined as complete occlusion on a follow-
up echocardiogram.
Results: 
Strategy A Strategy B p value
Subjects (N) 64 68
Age (years) 5.5 ± 7.1 4.1 ± 4.0 0.16
Weight (kg) 21.6 ± 19.0 17.9 ±16.5 0.24
PDA diameter (mm) 1.7 ± 0.9 1.6 ± 1.0 0.55
PDA length (mm) 8.9 ± 3.9 9.3 ± 3.6 0.54
Fluoroscopy Time (min) 11.0 ± 9.4 13.5 ± 6.8 0.09
Procedure Time (min) 104.9 ± 42.2 97.9 ± 22.0 0.24
Total Contrast (mL/kg) 2.9 ± 1.3 3.5 ± 1.9 0.02
Device Embolization (N) 9/64 4/68 0.07
Follow up Interval (days) 273 ± 245 199 ± 150 0.10
Success (N) 32/44 57/58 <0.0001
(Mean + standard deviation)
Stepwise logistic regression analysis identified closure strategy (OR 85.9, 95% CI 5.6-
999), PDA diameter (OR 0.3, 95% CI 0.1-0.7) and PDA length (OR 0.8, 95% CI 0.6-1.0) 
as the only significant predictors of closure success.
Conclusion: A transcatheter closure strategy (B) consisting of a single Gianturco coil for 
PDA <1mm and an ADO for any larger sized PDA achieves superior outcomes compared 
to the use of coils alone. This strategy did not result in a clinically significant increase in 
contrast dose or fluoroscopy time.
2900-200 Echocardiographic Assessment of Diastolic 
Function in Patients with Thin Filament Hypertrophic 
Cardiomyopathy
Shaji C. Menon, J. Martijn Bos, Melissa Will, Benjamin W. Eidem, Steve R. Ommen, 
Michael J. Ackerman, Mayo Clinic, Rochester, MN
Background:Hypertrophic cardiomyopathy (HCM) is the most common heritable 
cardiovascular disease and is underscored by genetic and phenotypic heterogeneity. 
Compared to thick filament HCM which is secondary to mutations in beta myosin heavy 
chain and myosin binding protein C, thin filament HCM due to mutations in the troponin 
complex, alpha tropomyosin, and actin is much less common. There is little data detailing 
the echo phenotype of patients with thin filament HCM.
Methods:Among 1025 consecutively enrolled, unrelated patients with HCM evaluated 
at Mayo Clinic, echo and clinical data were reviewed and blinded to genotype for the 37 
patients with thin filament HCM (troponin T, troponin I, troponin C, alpha tropomyosin, and 
actin). Assessment of diastolic function, including myocardial tissue Doppler and left atrial 
volume indices, was evaluated and graded using standard echo criteria.
Results:Nearly two-thirds of the patients with thin filament HCM had mutations involving 
the troponin complex: troponin T (13), troponin I (12), and troponin C (4). The median 
age at diagnosis was 36 yrs (2-70 yrs) with a median age at evaluation of 44.5 yrs (9-79 
yrs). The mean septal thickness was 21 mm (13-45 mm) and over half (20/37) were non-
obstructive. Sixteen patients (43%) were in NYHA class III or IV. Echo data consistent with 
elevated LV filling pressures and restrictive filling patterns were present in 93% of patients. 
Both mean left atrial volume index = 48 ml/m2 (normal < 28 ml/m2) and tissue Doppler 
data (mean septal E/E’ = 16) were consistent with elevated LV filling pressure as well as 
impaired myocardial relaxation (septal E’= 0.06 m/s). Septal myectomy was performed 
in 9 patients (24%) and alcohol septal ablation in 4 (11%). Histopathology of myectomy 
specimens revealed severe hypertrophy with mild-moderate myocardial disarray.
Conclusions:Less than half the patients seeking medical attention for thin filament HCM 
had obstructive disease and only one-third have required septal reduction therapies. 
Clinically significant diastolic dysfunction with elevated LV filling pressure and abnormal 
myocardial relaxation are hallmarks of thin filament HCM and likely contribute to their 
clinical symptoms.
2900-201 Covered Versus Bare Stent Forpercutaneous Treatment 
of Aortic Coarctation. 
gianfranco butera, Luciane Piazza, Massimo Chessa, Raul Abella, Santi Trimarchi, 
Diana Negura, Claudio Bussadori, Eduardo Bossone, Mario Carminati, Policlinico San 
Donato IRCCS, san donato milanese, Italy
Background: Bare stents have been used in patients with congenital heart diseases 
and large series are reported in literature. However, even with these stents, complications 
may occur. Covered stents have been recently introduced for the treatment of aortic 
coarctation. We aimed to compare results and complications between bare stents and 
covered stents.
Methods and patients: Between January 2000 and June 2007, 104 consecutive patients 
(median age 15 years, range 6-66 years, 64 males) underwent cardiac catheterization 
for native or recurrent coarctation of the aorta. Seventy-two had native aortic coarctation, 
while 32 had recoarctation. Procedures were performed under general anhestesia. The 
following stents were used: Palmaz stents, Genesis stents, Cheatham-Platinum, covered 
Cheatham-Platinum. Bare stents were used in 71 patients, while covered stents were 
used in 33 subjects.
Results: There were no differences for age, gender, native coarctation/recoarctation rate, 
mean drop of peak systolic gradient, increase of diameter of coarcted segment, mean 
fluoroscopy and procedure times, between the two groups (BS: bare stents group vs CS: 
covered stents group).Stents were placed in the correct position in all subjects in both 
groups. Long-sheath used for stent implantation was larger in CS group compared to BS 
group (median 12 vs 10 French; p=0.01). Total complication rate was higher in BS (12% 
vs 0%; p=0.03). The following complications occurred in BS group: early post-procedural 
death due to acute aortic dissection in 1 patient, stent embolization in 3 subjects, femoral 
artery pseudo-aneueysm needing vascular surgery in 3 pts, early periaortic hematoma 
in 1 pt, aneurysm formation during follow-up in 2 subjects.Follow-up was longer for BS 
(median 38 vs 13 months; p=0.04). A total of 6 subjects (4 in the BS group and 2 subjects 
in the CS group) needed re-dilation during follow-up. Finally, 10 subjects in BS (14%) and 
9 in CS (27%) needed anti-hypertensive drugs during follow-up (p=0.14 ).
Conclusions: Covered CP stents are promising tools for the treatment of aortic 
coarctation. They appears to be safer than bare metal stents. Long-term follow-up data 
are needed.
2900-202 OUTCOME AND COMPLICATIONS OF PERCUTANEOUS 
PERI-MEMEBRANOUS VSD CLOSURE, MEDTERM 
FOLLOW-UP
Mansour AlJufan, Ahmed AlOmrani, Walid Hassan, Abdenasser Drighil, Mohamed 
Khayyat, Saud AlOufi, Zohair AlHalees, King Faisal Specialist Hospital and Research 
Center, Riyadh, Saudi Arabia
Background: The safety, efficacy and indications of peri-membranous (PM) ventricular 
septal defect (VSD) percutaneous device closure are under scrutiny in as a primary 
therapy for PM VSDs. There have been encouraging reports of the initial experience with 
the Amplatzer device; however, this has been hindered by reports of conduction system 
disturbances, to the extent of elective pause of the procedure
Methods: Retrospective analysis of all patients who successfully underwent (PM) VSD 
Amplatzer device closure in our institution, between May 2002 and July 2006. All patients 
were followed up with ECGs and echocardiograms. The mean FU duration was 20.3 ± 
11.3 (9-48) months.
Results: We implanted 51 devices in 51 Patients, 25 males, and 26 females. Mean age 
(10.2 ±7.5) years, with mean weight 28.6 ± 15.7 Kg. During catheterization, the average 
QP/QS was 1.9 ± 0.6, mean PA pressure was 18.5 ± 4.1 mmHg, and PVR was 1.04 
± 0.5 Wood units. The mean VSD size by transesophageal echocardiography (TEE) 
was 7.2 ± 2.5 mm, and mean device size was 8 ± 2 mm. The mean QRS duration, pre 
device implantation was 88.3 ± 16.8 ms. One patient developed complete heart block 
immediately after, and needed permanent pacemaker, five patients developed right 
bundle branch block, three patients noticed to have trivial to mild AR on follow-up, and 
one device had to be removed surgically because of severe tricuspid regurgitation. Left 
ventricular end-diastolic diameter decreased from 44.1 ± 6.82 mm to 42.6 ± 6.0 mm after. 
There was no immediate or late mortality. There was immediate complete closure in 41 
(80%) patients, and 49 (96%) late complete closure.
Conclusions: Amplatzer PM VSD device closure is feasible, effective and safe, but not 
free of complications. Careful patient’s selection, refinement of the technique, device, 
hardware and further miniaturizing could expand the use, safety and the effectiveness of 
PM VSD device closure. Our relatively low rate of conduction system disturbance could 
be related to precise device sizing
2900-203 Pulmonary Valvuloplasty in Adults Using the 
InoueBalloon Catheter
Hung Manh Pham, Hieu Lan Nguyen, Quang Ngoc Nguyen, Hung Minh Nguyen, Loi 
Doan Do, Viet Lan Nguyen, Khai Gia Pham, Vietnam Heart Insitute, Hanoi, Viet Nam, 
Hanoi Medical School, Hanoi, Viet Nam
Background: Although pulmonary valvular stenosis is not uncommon in adults. There 
are few reports of percutaneous pulmonary valvuloplasty in adults, especially using 
Inoue balloon. OBJECTIVES: This report describes the experience in adult patients 
undergoing Pulmonary valvuloplasty using Inoue balloon and evaluates its effectiveness 
and tolerance.
Methods: Over an 7-year period (2000-2006), pulmonary valvuloplasty using Inoue 
balloon was considered in 65 adult patients [39 men, 26 women; mean age 28.0 years 
± standard deviation (SD) 10.3; range 16-53 years] with congenital pulmonary valve 
stenosis. Twenty-five patients were asymptomatic with pulmonary systolic murmurs, 
although 40 patients presented with dyspnea. Before the procedure, the peak-to-peak 
transpulmonary valve gradient was 91±40 mmHg SD, with a mean right ventricular 
systolic pressure of 107±41 mmHg SD.
Results: The procedure was technically successful in all patients but one (98.46%). One 
falure because balloon could not pass throught pulmonary orifice valve due to very tight 
valve stenosis. Among all patients with technical success all tolerated well and free of 
major complications. The mean right ventricular systolic pressure and the pulmonary 
valvular peak-to-peak systolic gradient decreased from 107±41 to 56±19 mm Hg (p = 
0.001) and 91±40 to 21±7 mm Hg (p = 0.0002), respectively. An infundibular peak-to-peak 
systolic gradient either developed (n = 13) or increased (n = 17). None of these patients 
were treated with beta-adrenergic blockers before or after the valvuloplasty. Incontrast, 
this gradient decreased or did not develop in the remain patients who were on beta- 
blokers before procedures. All patients underwent echo follow up study for 6 - 60 months 
(mean 24) after treatment, and had no evidence of valvular restenosis. The mean right 
ventricular systolic pressure and the mean infundibular peak-to-peak systolic gradient 
decreased, compared to the values immediately after valvuloplasty (56 to 47 mm Hg, p = 
0.03, and 28 to 10 mm Hg, p = 0.03, respectively).
Conclusions: The study suggests that pulmonary valvuloplasty in adults using the Inoue 
balloon catheter technique is feasible, safe, and effective.
April 2008 
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2900-204 Preferred Management Strategies for Uncomplicated 
Atrial Septal Defects: A Physician Survey
Matthew J. Gillespie, Jonathan R. Kaltman, Stacey Kaltman, Mark D. Levin, Paul 
Stephens, Jr., Christopher J. Petit, Susan Schachtner, Jonathan J. Rome, The Children’s 
Hospital of Philadelphia, Philadelphia, PA, Children’s National Medical Center, 
Washington DC, DC
Background: Transcatheter closure (TCC) and surgical closure (SC) of uncomplicated 
secundum atrial septal defects (ASD) are equivalent in terms of published success rates, 
and low mortality rates. The purpose of this study was to determine physician treatment 
preferences for uncomplicated ASD closure in the current era, and to identify factors that 
influence preferences.
Methods: We performed an anonymous online survey of pediatric cardiologists in three 
geographic areas in the United States. Doctors were queried on personal demographics, 
treatment preference, risk perceptions, and knowledge of morbidity and mortality rates.
Results: The survey was completed by 61 (62%) of the 98 recipients. The majority 
practice in academic centers (89%), 55% have been in practice for >10 yrs, and 37% 
have a subspecialty interest in echocardiography (Echo). TCC was preferred over SC 
by 87% while 13% preferred SC. Echo interest was associated with preferring SC (p = 
0.006), but no other demographic variables were significant. Doctors who preferred SC 
reported a lower incidence of mortality for SC (0.10 ± 0.00 vs. 0.15 ± 0.15 %; p = 0.03) 
and a higher incidence of complications for TCC (3.0 ± 1.9 vs. 1.3 ± 1.5 %; p = 0.03) 
compared to those who prefer TCC. Those who preferred SC differed from those who 
preferred TCC in reporting the “most concerning” potential complication for ASD closure 
(p = 0.02). Device erosion was the most concerning complication for 85% who preferred 
SC vs. 15% who preferred TCC. Those who preferred TCC were most concerned about 
“unforeseen long term risks” (30%) and “death on the OR table” (26%). ASD closure 
related complications were reported by 40%. Eighty-three percent who reported a TCC 
related complication in a pt preferred TCC, while only 11% whose pts had an SC related 
complication preferred SC (p =0.01).
Conclusions: The majority of pediatric cardiologists surveyed prefer TCC to SC for 
treatment of ASD. Those who prefer SC were more likely Echo doctors, and reported 
higher incidence of complication with TCC than those who prefer TCC. Device erosion is 
the major concern of those who prefer SC.
2900-205 Transcatheter Device Closure of Patent Foramen Ovale 
in Patients With Cryptogenic Stroke Secondary to 
Presumed Paradoxical Embolism
Monique A. Ford, Guy S. Reeder, Ryan J. Lennon, Daniel J. Crusan, Robert D. Brown, 
Jr., George W. Petty, Allison Cabalka, Frank Cetta, Donald J. Hagler, Mayo Clinic, 
Rochester, MN
Background: The role of device closure of patent foramen ovale (PFO) in preventing 
recurrent cryptogenic stroke and transient ischemic attacks (TIA’s) remains highly 
controversial. We reviewed our experience with transcatheter device closure of PFO’s 
in selected patients after cryptogenic stroke or TIA to determine procedural safety and 
efficacy. We measured recurrent event rates and determined risk factors for recurrent 
stroke or TIA in this population.
Methods: Between December 2001 and June 2006, 402 patients at Mayo Clinic 
Rochester underwent transcatheter device closure of a patent PFO for cryptogenic 
stroke, TIA or peripheral embolization. Baseline characteristics, procedural details and 
complications were reviewed. Kaplan-Meier methods were used to estimate recurrent 
event rates. Simple Cox models were then used to identify risk factors for these recurrent 
events.
Results: We included 353 patients who presented with cryptogenic stroke (n=235) or 
TIA (n=128) in this analysis. The mean age was 53.4 years and 59% were male. The 
procedural complication rate was 2.8% and included atrial fibrillation (n=2), atrial flutter 
(n=2), cardiac perforation with tamponade (n=1), femoral bleed (n=1) and protamine 
reaction (n=1). There were no procedural deaths. The mean follow-up was 36 months 
(interquartile range 24 to 48 months). None of the 10 patients with residual shunts at 
follow up had recurrent events. Twenty recurrent events occurred in 17 patients: 7 strokes, 
7 TIA’s, 3 peripheral embolizations. The recurrence rate at 1 year was 0.6% for stroke and 
0.9% for TIA. At 4 years, the recurrence rate for stroke was 2.5% and 1.7% for TIA. Risk 
factors for recurrent events were hypertension (p=0.03), diabetes (p=0.001), right atrial 
pressure (p=0.002), pulmonary artery systolic pressure (p=0.001) and wedge pressure 
(p= <0.001). Neither residual shunts nor hypercoagulable states were associated with 
recurrent events.
Conclusions: Transcatheter device closure of PFO is safe and effective. Recurrence 
rates of stroke or TIA are low. Predictors of recurrent events include conventional stroke 
risk factors and elevated intracardiac pressures. Residual shunt is not associated with 
recurrent events.
2900-206 Mid-Term Follow-up After Transluminal Alcohol Septal 
Ablation of Hypertrophic Obstructive Cardiomyopathy. 
A Real World Study
Kamaldeep Chawla, Thierry Lefevre, Marie-Claude Morice, Aleem Khand, Ivan Laurent, 
Marie-Christine Malergue, Bertrand Cormier, Institut Cardiovasculaire Paris Sud, Massy, 
France
Introduction: Transluminal alcohol septal ablation (TASH) is now an alternative to surgery 
in patients (pts) with hypertrophic obstructive cardiomyopathy (HOCM). It is associated 
with good acute and mid-tem results and an acceptable risk of atrio-ventricular bloch 
(AVB) requiring permanent pace maker (PM). To optimize the technique, perprocedural 
echo-guidance (ECHO) is recommended.
Objective: Assess the mid-term clinical outcome of TASH with systematic echographic 
guidance in the real world.
Method and Results:104 pts with symptomatic HOCM despite optimal treatment were 
prospectively enrolled. They were aged 56+17 years, 24% had a family history of HOCM, 
8% previous syncope, 27% previous PM, 2% defibrillator, NYHA class 2.8+0.7. The septal 
thickness pre-procedure was 23±4 mm and basal gradient 97±48 mmHg. Injection of 
2.1+0.8 ml of ethanol under ECHO was performed in 1.6+0.4 septal branches. Gradient 
decreased to 20+22 mmHg (p<0.001). Except conduction disturbance, no complications 
were observed during the procedure. Temporary PM was necessary in 25 % of cases 
and became definitive in 6%. The maximal CPK elevation after TASH was 1146+412 IU. 
Total hospital stay was 7.1+2.2 days (intensive care unit 5.2+1.9 days). In-hospital death 
occurred in 2 cases (1.9%) at day 2 (ventricular arrhythmia) and day 3 (atrio-ventricular 
block).
Follow-up was obtained in 98% of cases at 38+22 months. After hospital discharge, 2.8% 
of patients had PM implantation. Fonctional class was 1.1+0.3 (p<0.001). Eight death 
occurred, 6 cardiac (1 endocarditis, 2 sudden deaths, 3 heart failure) and 2 non cardiac.
The Kaplan Meier survival curve is shown in the figure.
Conclusion: TASH using systematic ECHO is associated with a high rate of mid-term 
clinical success and a relatively low risk of irreversible AVB. The annual risk of cardiac 
death (1.5%) after successful TASH seems to be reasonable in this high risk population.
 
2900-207 Presence of Atrial Septal Aneurysm does not Increase 
the Risk of Recurrent Thrombo-embolic Events in 
Patients Following Transcatheter Patent Foramen Ovale 
Closure
Abha Khandelwal, Christian Spies, Ines Timmermann, Rainer Schräder, Rush 
University Medical Center, Chicago, IL, Cardioangiologisches Centrum Bethanien/
Markuskrankenhaus, Frankfurt, Germany
Background: Atrial septal aneurysms (ASA) are a potential risk factor for recurrent 
cryptogenic thromboembolic events (TE) following patent foramen ovale (PFO). However, 
results regarding its significance for recurrent TE are conflicting. We evaluated in a 
large patient population whether the presence of ASA at baseline influences the risk for 
recurrent TE.
Methods: We included patients (pts) who underwent PFO closure from 2/1994 until 
9/2007. Pts were required to have at least one cryptogenic TE (stroke, transitory ischemic 
attack (TIA), or peripheral embolism) prior to PFO closure. Groups were stratified 
according to presence of ASA.
Results: A total of 862 pts underwent PFO closure, of which 380 had an ASA (44%). 
Median age was 51 years (range 17-83). Median follow-up time after PFO closure was 20 
months (range 0-162). Thirty five recurrent TE (TIA=20, stroke=15) in 33 pts were noted in 
2065 cumulative follow up years (annual incidence=1.6%). Baseline characteristics were 
similar between pts with and without ASA. Fourteen of 390 pts with ASA had a recurrent 
TE (3.6%) compared to 19 out of 472 pts without ASA (4.0%, p=0.32). Annual incidence 
of recurrent TE was also similar in pts with ASA (1.8%) compared to those without ASA 
(1.6%; p=0.45) (figure). There was no difference in frequency of residual shunts between 
pts with and without ASA (both 11%, p=0.51).
Conclusions: In this large patient collective, ASA does not influence the frequency of 
recurrent TE in pts following PFO closure for cryptogenic TE events. 
April 2008
   ABSTRACTS - SCAI-ACCi2 Interventional E-Abstracts B71 
S
C
A
I-A
C
C
i2
 Interventional E
-A
bstracts
2900-208 Transcatheter Patent Foramen Ovale Closure is 
Associated with Increased Occurrence of Atrial 
Fibrillation
Abha Khandelwal, Christian Spies, Ines Timmermanns, Rainer Schräder, Rush 
University Medical Center, Chicago, IL, Cardioangiologisches Centrum Bethanien/
Markuskrankenhaus, Frankfurt, Germany
Background: An increase in arrhythmias, specifically atrial fibrillation (AF) is a concern 
in patients (pts) following transcatheter closure of patent foramen ovale (PFO) following 
cryptogenic thromboembolic events (TE). Estimating the AF incidence following PFO 
closure has been difficult. We evaluated the frequency of AF following PFO closure.
Methods: We evaluated all pts who underwent PFO closure at our institution from 2/1994 
until 9/2007. Pts were required to have at least one cryptogenic TE (Cerebrovascular 
accident (CVA), transient ischemic attack (TIA), or peripheral embolism) prior to PFO 
closure.
Results: During the 13 year period 862 pts underwent PFO closure. Median age was 51 
years (range 17-83). Two hundred and fifty five patients had hypertension (30%) and 56 
pts had coronary artery disease (CAD) (5.5%). Median follow-up time after PFO closure 
was 20 months (range 0-162). New onset AF was noted in 58 pts (6.7 %); with 2065 
cumulative follow up years this translates into an annual incidence of 2.8%. During follow 
up 21 pts complained of palpitations (2.4%) and 7 patients of dyspnea (0.8%), of which 
only 6 were found to have AF on Holter monitoring. When comparing pts with and without 
new onset AF, there was no difference in the prevalence of hypertension (31% vs. 29%, 
p=0.653), CAD (5.1% vs. 5.5%, p=0.891) and residual shunt (13% vs. 9%, p=0.134).
Conclusion: AF frequency following PFO closure in pts with cryptogenic TE is mildly 
increased compared to an age matched population, where the annual incidence has 
been estimated to be 1-1.5%. Importantly, pts only rarely had symptomatic AF following 
PFO closure.
2900-209 Single Pediatric Center Experience With Multiple Device 
Implantation for Complex Secundum Atrial Septal 
Defects
Matthew Bramlet, Mark Hoyer, Indiana University, Riley Hospital for Children, 
Indianapolis, IN
Background:  Limited pediatric information exists regarding the safety and efficacy 
of using multiple devices for secundum atrial septal defects (ASD) when more than 
one defect is present. We analyzed the efficacy and complications of placing multiple 
transcatheter devices to correct complex ASD in a primarily pediatric population. 
Methods: Cath lab, echo, and clinical data were reviewed for 238 patients who underwent 
device closure of secundum ASD from 2001 to present at a single pediatric center. Of 
those requiring multiple devices (n = 15), outcomes regarding residual shunting and 
complications were assessed.
Results: A total of 238 patients (mean age 12 yrs; 80% < 18 yrs) underwent transcatheter 
ASD closure. 34 of the 238 (14%) had multiple ASD, but only 15 received multiple devices 
(2 devices in 14 and 3 devices in 1). The mean age and weight (12 yrs; 38 kg) represent 
a younger population than previously reported for use of multiple devices. Only 3 patients 
were older than 15 yrs, with a median age of 9 yrs (range 2-31). There was no compromise 
or obstruction to surrounding structures, including mitral valve, right pulmonary vein, and 
coronary sinus, and no device embolization or erosion was noted. A tiny thrombus was 
observed on the right sided screw of one device with no clinical sequelae. One patient 
(age 31 yrs) died at home 30 days post procedure from cardiac tamponade. Autopsy 
revealed 200 ml serosanguineous pericardial fluid, and all 3 devices were intact and in 
stable position without evidence of erosion. Latest available echo follow-up for the group 
revealed functional resolution of atrial level shunting in all patients. 5 patients (36%) still 
showed evidence of flow around a device 1 day later; all but one had no residual atrial 
shunt by 1 month, and the remaining patient had complete resolution of residual shunt 
at 7 months.
Conclusions:
Multiple devices can safely and effectively be implanted in the pediatric population to 
close complex ASD.
2900-210 ATRIAL SEPTAL REPAIR IMPROVES SHUNT 
ASSOCIATED MIGRAINE: FIRST EVER CASE-
CONTROL STUDY
Gian Paolo Anzola, Marco Berti, Francesco Casilli, Eustaquio Onorato, S. Orsola 
Hospital, Fatebenefratelli, Brescia, Italy
Background and purpose: Transcatheter closure of patent foramen (PFO) ovale has 
been reported to improve migraine in patients with cerebrovascular disorders in non-
controlled studies. The aim of the study was to compare the course of migraine assessed 
prospectively over a 12 month period in symptomatic (for cerebrovascular disease) 
and asymptomatic patients undergoing PFO closure and in patients with PFO treated 
medically.
Methods: Twenty-three stroke symptomatic (SS; 39±10 years of age; males/females 
[M/F] 5/18) and 27 stroke asymptomatic (SA; 40±12 years of age; M/F 5/22) patients with 
migraine underwent PFO closure. Twenty-seven patients with migraine and PFO (controls 
[CTRLS]; 36±11 years of age; M/F 4/23) were followed up medically. Migraine severity 
was assessed at baseline with a scale that takes into account the frequency, duration, 
and intensity of the attacks and the occurrence of aura (score range 0 to 10). Six months 
later, the patients were given a structured diary to annotate monthly with the same scale 
the characteristics of the attacks for the next 6 months. By the end of 1 year, the migraine 
score was averaged for the last 6 months.
Results: Baseline severity of migraine did not differ between groups (6.3 to 6.1 and 
6.7 in SS, SA, and CTRLS groups, respectively). At the 1-year assessment, the overall 
migraine score had significantly improved by 3.7 and 2.8 points in SS and SA, respectively 
(P<0.001 on repeated-measure ANOVA), whereas it had non significantly worsened by 
0.1 points in CTRLS. Multiple linear regression analysis showed that the improvement 
in SS and SA was independent of migraine type, age, and cerebrovascular risk factors. 
Twenty-one of 21 patients with migraine with aura in the CTRLS group still had aura at 
the end of follow-up, whereas only 3 of 14 among SA and 4 of 19 among SS continued to 
have migraine preceded by aura (P<0.0001 on Fisher exact test).
Conclusions: Compared with medical treatment, closure of PFO brings about a 
significant overall improvement in migraine. This seems to occur irrespective of migraine 
type and of previous cerebrovascular disease. In addition to the overall improvement, in 
migraine with aura, the occurrence of aura is dramatically reduced.
2900-211 Computed Tomography Angiography is More 
Accurate than Transesophageal Echocardiography 
in Determining Atrial Septal Defect Size and Device 
Failure During Percutaneous Closure of Atrial Septal 
Defects
William L. Discepolo, Atman P. Shah, Naser Ahmadi, David M. Shavelle, William J. 
French, Matthew J. Budoff, Harbor-UCLA Medical Center, Torrance, CA
Background: Percutaneous closure (PC) of atrial septal defects (ASD) is an alternative 
to surgical closure. This study compared transesophageal echocardiography (TEE) to 
computed tomography angiography (CTA) in assessing ASD size and to predict device 
failure (DF).
Methods: We performed a retrospective study of patients with symptomatic ASDs 
presenting at an academic hospital. Patients underwent CTA (GE 64 Slice), TEE, and 
cardiac catheterization. Suitable defects were referred for PC. The measurements 
provided by CTA and TEE were compared to fluid-filled balloon (FFB) sizing at PC, and 
eventual device selection. DF was defined as failure of device deployment or device 
embolization.
Results: Between May 1999 and December 2005, 10 patients (38+/-12 years, 60% 
female) with ASDs had a CTA, TEE, and FFB and underwent PC. The coefficient of 
variation (CV%) for size between TEE and FFB measurements was 7.2% (Bland Altman 
Model (BAM), ratio 1.10, 95% CI 0.89-1.32) and between CTA and FFB was 4.6% (BAM, 
ratio 1.03, 95% CI 0.9-1.17). The correlation between the FFB measurement and CTA 
was closer [R value 0.9 (p=0.004)] than FFB and TEE [R value 0.79 (p=0.005)]. CTA 
accurately predicted defect size and DF (n=2) compared to TEE [CTA: OR 2.76 (95% CI 
1.2-4.1, p=0.03); TEE: OR 1.6 (95% CI 0.9-8.3, p=0.3)].
Conclusions: While TEE is still important during the procedure, CTA is more accurate 
that TEE in determining ASD size and in selection of appropriately sized ASD closure 
device and may be the test of choice prior to PC of ASD. 
2900-212 A Novel SeptRx PFO Closure System: Results of the 
First in Man Trial
Nicolas Majunke, Wibke Zimmermann, Corinna Heinisch, Nina Wunderlich, Horst 
Sievert, CardioVascular Center, Frankfurt, Germany
Background: Percutaneous closure of Patent Foramen Ovale (PFO) to prevent 
paradoxical embolism is successfully performed with different devices for many years. 
However, all the commonly used devices leave a relatively large amount of material in 
the right and left atrium which can cause early and late complications. The SeptRx device 
is designed to fit in the pocket of the PFO and to leave minimal material in the right and 
left atrium.
Methods: From July 2006 till May 2007 13 patients (29- 68 years, mean 52 ± 13) with a 
history of cryptogenic stroke or TIA were treated using the SeptRx PFO closure system. 
All patients received 100 mg aspirin and 75 mg clopidogrel for at least 6 month. Follow 
up was carried out at one and six month post- procedure including clinical exam, ECG, 
Transesophageal Echocardiography (TEE) and Transcranial Doppler (TCD).
Results: In 11 of the 13 patients the SeptRx device was successfully placed. The mean 
PFO diameter was 7,6 mm (4,9 - 11,3 mm), mean fluoroscopy time was 9,3 min (4,1 - 
33,5 min), the mean procedure time was 42 min (11 - 52 min). There were no peri- or 
post- procedure related adverse events. After 30 days 6 of 11 PFOs were closed and at 
the 6 months follow-up PFO closure was achieved in 100% of the patients.
Conclusions: This initial experience demonstrates that PFO closure using the SeptRx 
system is technically feasible and safe. The 6 month follow up showed excellent results 
with complete closure of all PFOs.
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2900-213 Posture-Dependence Of Right-To-Left Shunt Across The 
Patent Foramen Ovale: A Contrast Transcranial Doppler 
Evaluation
Gian Paolo Anzola, Marco Berti, Francesco Casilli, Eustaquio Onorato, S. Orsola 
Hospital, Fatebenefratelli, Brescia, Italy
Purpose: Patent foramen ovale (PFO) has been associated with embolic events secondary 
to paradoxical embolism and, more recently, also with migraine with aura. The aim of our 
paper was to evaluate if the posture changes the amount of RLS across the PFO thus 
enhancing the likelihood of paradoxical embolism to the left heart chambers. Methods: In 
a consecutive series of 26 patients (M/F= 6/20, age 44±14) with PFO, we used contrast-
enhanced transcranial Doppler (c-TCD) to assess the bubble load in the right middle 
cerebral artery during normal breathing both in standing and in recumbent position. Half 
the pts were first tested while standing, half were tested in the reversed order. Data were 
analyzed with a repeated measure ANOVA with position (horizontal versus vertical) as 
within pts and order of testing (first while horizontal versus first while vertical) as between 
subjects factors. Results: The position factor was statistically significant (F= 6587, P= 
0.017) with an average of 12 and 29 bubbles detected during recumbent and standing 
position, respectively. The effect was independent of the testing order. Fourteen pts 
showed an increase in the bubble number from the horizontal to the upright position, 7 
exhibited the same number, whereas in 5 the amount of shunt decreased on standing. 
Conclusions: The amount of permanent RLS is posture-dependent in pts with PFO to an 
extent that may be variable between one individual and the other. Our results differ from 
previous reports in which the examination from supine to sitting resulted in a decrease of 
the median bubble count. We hypothesized that in upright position the neighbour vessels 
(aorta and pulmonary artery) may exert a traction on the components of the tunnel-like 
PFO thus increasing the amount of RLS. It is conceivable that other factors, such as heart 
rate and stroke volume may influence the results of the c-TCD examination. Testing in 
upright position may thus be warranted in those cases in whom the usual assessment 
performed with the subject in horizontal position yields doubtful or inconclusive results.
2900-214 Anatomy of Patent Foramen Ovale in Patients With 
Migraine Versus Stroke
Arif A. Khan, Mark Spence, Michael Mullen, Royal Brompton Hospital, London, United 
Kingdom
Background: Patent foramen ovalve (PFO) has been implicated in transient ischemic 
attack (TIA), cryptogenic stroke (CS) and migraine (M). It is not known whether is there 
any difference in anatomy of PFO between migraine and stroke or TIA patients. This study 
assessed differences in shunt size and anatomy in patients with TIA/CS and Migraine 
undergoing device closure.
Methods: PFO shunt size was assessed by transthoracic contrast echocardiogram at 
rest and during valsalva based on the highest number of contrast bubbles seen in the left 
heart. G 0; 0, G 1; <10/frame, G 2; 10-20/frame, G3; >20/frame. Defect size and length 
were determined by inflation of a balloon. The sites of constraint of the balloon allowed 
identification of the entrance (E1), exit (E2) and length (L). 
Results:We reviewed all patients referred for percutaneous PFO closure for CS/TIA 
(n=40, 15= female) or severe migraine with aura (n=36, 24=female) mainly enrolled for 
MIST (Migraine Intervention with STARFlex Technology) study. There was no difference 
in shunt size, frequency of an aneurysm or size of the PFO in patients with CS/TIA 
compared to those with M. There was a trend towards increased frequency of long-
tunnels in the TIA/CS group
Conclusions: Our data demonstrate no significant differences in physiological 
and anatomical parameters in patients with TIA/CS and M that would impact on the 
effectiveness of device closure of PFOs. Balloon assessment of PFOs enhances the 
understanding of PFO morphology. 
Migraine with aura (n=36) TIA/CS (n=40) p value
Shunt size
G 0 0 1 NS
G1 1 4 NS
G 3 30 31 NS
Aneurysm(%) 33% 35% NS
E1(mm) 7.8 8.5 0.37
E2 (mm) 7.5 8 0.47
PFO tunnel length (mm) 2.2 3.3 0.04
Waist (mm) 6.8 7.4 0.47
2900-215 To Assess the Clinical Impactof Percutaneous Atrial 
Septal Defect Closure in the Older Population
Arif A. Khan, Jule Tan, Mark Spence, Michael Mullen, Royal Brompton Hospital, London, 
United Kingdom
Background: Atrial septal defect (ASD) is accounting for 10% of all congenital cardiac 
defects. The benefit of ASD closure in elderly is not well established we therefore aimed to 
prospectively assess the clinical status and functional class of patients after ASD device 
closure. 
Methods: A prospective study of all consecutive patients age 40 or more who underwent 
device closure of secundum ASD between April 2004 and August 2006. Investigations 
including ANP and BNP levels, 12 lead ECG, Chest X ray, transthoracic echocardiogram, 
6 MWT, and quality of life questionnaire (SF36v2) performed prior to and at 6 weeks and 
1 year after the procedure.
Results: 23 patients had percutneous device closure of ASD. Mean age was 69 year 
(range 43 - 93 years). Mean ASD size was 20 mm (range 13 to 30 mm) and mean device 
size was 24 mm (range 10 to 36 mm). At 1 year, NYHA class improved (p=0.004) in 18 
patients with also significant improvement in 6MWT distance (p=0.001) and physical but 
not mental health score on the SF36v2 (p= 0.004). There were no major complications. 
Following ASD closure there was a increase in LV diastolic dimension (pre procedure 
42 mm and 48 mm at 1 yr, p=0.0002), long axis function (DTIs mm pre procedure 14, 
9 at 1 yr, p= 0.009), and stroke volume but only a trend towards reduction in right heart 
dimensions.
Conclusions: Our results demonstrate significant improvements in symptoms and 
functional ability in elderly due to improvement in LV hemodynamics. These data support 
ASD closure at an advanced age.
Pre device 6 weeks 1 yr p value
ANP 21 28 17 0.03
BNP 43 55 32 0.13
Mental Health score (SF36v2) 46 47 53 0.13
Physical Health score (SF46v2) 47 48 53 0.004
6 MWT distance (m) 400 458 470 0.001
LVEDD(mm) 42 48 49 0.0002
LVEF(%) 66 81 82 0.01
DTI LV s 14 8 9 0.009
2900-216 Improvement in Myocardial Perfusion With Chronic 
Total Coronary Artery Occlusion Revascularization
Tapas Ghose, Steven Marso, Vivek Goswami, Kevin Kennedy, John House, J. Aaron 
Grantham, Barry Rutherford, Mid-America Heart Institute, Kansas City, MO
Background: The benefits of revascularization for chronic total coronary occlusion 
(CTO) have been shown to improve longevity but, there is a paucity of data regarding 
improvements in myocardial perfusion as assessed by radionuclide imaging.
Methods: Using a 20 segment model, the Sum Stress Scores (SSS) were examined for 
238 patients 12 months before and after attempted CTO revascularization. Ischemia was 
stratified to normal (SSS < 4), mildly abnormal (SSS 5-8), moderately abnormal (SSS 
9-12), and severely abnormal (SSS > 13) and changes in myocardial perfusion were 
analyzed after adjustments for age, gender, and prior revascularization.
Results: Overall, there was a significant improvement in myocardial perfusion with CTO 
revascularization (median SSS before, 14; median SSS after, 7; p = <0.001). Patients 
were also analyzed by stratum as shown in Figure 1. 
Conclusions: Opening CTO decreases ischemic burden in patients with at least 
moderate ischemia and increases ischemic burden in patients with normal myocardial 
perfusion. These data support that myocardial perfusion imaging should be used in 
screening CTO candidates.
2900-217 Serum Retinol Binding Protein 4 and HbA1C level is 
associated with Target Lesion Revascularization in 
Type II Diabetes after Drug Eluting Stent Implantation
Yun Seok Choi, Wook-Sung Chung, Chul-Soo Park, Jeong-Hwan Park, Soo-Sung Oh, 
Dong-Hyeon Lee, Jong-Min Lee, Pum-Joon Kim, Sang-Hyun Ihm, Hee-Yul Kim, Yong-
Seog Oh, Ho-Joong Youn, Ki-Bae Seung, Jae-Hyung Kim, The Catholic University of 
Korea, SEOUL, South Korea
Background: Retinol Binding Protein 4 (RBP4), a novel marker of insulin resistance and 
a key regulatory adipokine of Glucose Transporter 4 (GLUT 4) is predictive of vascular 
complication in type 2 diabetes. We examined the association between RBP 4 or glycemic 
control determined by pre and post procedural hemoglobin A1c (HbA1c) level and target 
lesion revascularization rate(TLR) in diabetic patients Methods: 90 patients(mean age 
: mean age=64±8 years, M:F=41:49, Cypher: Taxus= 65:25) who underwent PCI and 
six month angiographic follow up were divided into two groups(TLR and no TLR group). 
Serum RBP 4 concentrations just before procedure and at the time of follow up coronary 
angiogram were measured by ELISA method. Optimal glycemic control was defined as 
HbA1c≤7%, and serum adiponectin and hsCRP levels were also compared between two 
groups respectively. Results: 1. Among the 90 patients, TLR at follow up was 12.2%. 
2.Serum RBP 4 level just before PCI was significantly higher in TLR group than no TLR 
group (40.5±5.9ug/ml vs 26.7±1.6ug/ml, p=0.008) 3. Serum RBP 4 at follow up was 
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not different between two groups (36.6±7.7 ug/ml vs 52.7±4.7 ug/ml) 4. Patients with 
HbA1c>7% showed significantly higher TLR rate than those with HbA1c≤7% (17% vs. 
11%, p=0.001). 5. Serum adiponectin, hsCRP and stent length did not show significant 
difference between two groups but the stent diameter was significantly smaller in TLR 
than no TLR group(3.0±0.5mm vs 3.1±0.3mm, p=0.02). 6. In a multiple logistic regression 
analysis, serum RBP 4 elevation at the index intervention was a significant independent 
predictor for TLR (odds ratio 1.08, 95% confidence interval 1.02 to 1.14; p=0.006). 
Conclusion: In diabetic patients undergoing elective PCI, improving insulin resistance and 
obtaining optimal glycemic control might be important to reduce TLR
2900-218 Incidence and Treatment Outcomes of Chronic Total 
Occlusions: A Report From the 2000-2001 New York 
State Angioplasty Registry
Christopher L. F. Gade, Robert M. Minutello, Dmitriy N. Feldman, Geoffrey Bergman, 
Nichole Polin, S. Chiu Wong, NY Presbyterian Hospital-Cornell Medical Center, New 
York, NY
Background: Despite continued enthusiasm in the treatment of chronic total occlusions, 
their prevalence, recanalization attempts and peri-procedural outcomes are not well 
defined.
Methods: Using the 2000-2001 New York State Angioplasty Registry, we evaluated the 
prevalence of chronic total occlusion (CTO) and compared in-hospital clinical outcomes 
in patients undergoing percutaneous coronary interventions (PCI) of CTO vs. non-CTO 
lesions.
Results: Of the 82,140 patients undergoing angioplasty, 18,758 patients (22.8%) had 
at least one total occlusion in their main epicardial coronary arteries or major branches. 
After excluding patients with a history of CABG, this figure drops to 13.4% of all patients. 
Only 6.3% of all angioplasties were performed on total occlusion lesions. Compared to 
patients with non-CTO interventions, patients undergoing CTO PCI were older, more 
likely to be males, smokers, have lower left ventricular ejection fractions and a have a 
higher incidence of multi-vessel disease. The procedural success rate of PCI of CTO 
lesions was 73.5% compared to 97.0% in non-CTO lesions. Patients with PCI of CTO in 
their LAD artery had a significantly higher angiographic success rate than PCI of CTOs 
involving the RCA or LCX (77.1% vs. 72.2% vs. 69.3% respectively; P value for LAD vs. 
RCA=0.002, LAD vs. LCX<0.001, LCX vs. RCA=0.119). Patients with CTO had higher in-
hospital major adverse cardiac and cerebral events (MACCE) (0.9% vs. 0.6%, p=0.028). 
Multivariate regression analysis showed attempted PCI of a CTO was an independent 
predictor of MACCE (OR=1.7, 95% CI=1.2-2.3.79, p=0.004) and trended toward being a 
predictor of in-hospital mortality (OR=1.6, 95% CI=0.97-2.58, p=0.064).
Conclusions: In this comprehensive registry analysis involving a broad spectrum of 
clinical practices in New York State during a 2-year period, both the incidence and the 
treatment attempts of CTO lesions are considerably lower than previously reported. 
Importantly, patients undergoing PCI of a total occlusion have higher rates of in-hospital 
adverse events than patients with non-CTO interventions.
2900-219 Drug-Eluting Stents for the Treatment of Chronic Total 
Occlusion: A Comparison with Sirolimus, Paclitaxel, 
Zotarolimus, Tacrolimus-Eluting and EPC Capture 
Stent: Multicenter Registry in Asia
Sunao Nakamura, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan Udayachalerm, Damras 
Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, Chiba, Japan, Konyang 
University Hospital, Daejeon, South Korea
Aim: The aim of this study is to compare the safety and efficacy of Sirolimus, Paclitaxel, 
Zotarolimus, Tacrolimus-eluting stent and EPC capture stent on the outcome of patients 
with chronic total occlusion. Methods: A prospective analysis of 1149 patients with 1255 
CTOs (396 SES, 526 PES, 177 ZES, 115 TES, 41 ECS) in five high volume Asian centers 
after successful recanalization of CTO was performed. The study endpoints were 30 
days and 9 months major adverse cardiac events, 9 months angiographic restenosis and 
target lesion revascularization. Results: See table for clinical results. Conclusion: The 
use of drug-eluting stents in patients with CTO was safe with low acute complication. 
Patients treated with SES showed lesser rate of restenosis compared with other drug-
eluting stents. 
SES PES ZES TES ECS
Number of patients/lesions 365/396 482/526 154/177 109/115 39/41
LAD/LCX/RCA (%) 54/26/20 52/22/26 89/138/50 70/23/22 21/9/9
Procedural success (%) 100 100 100 100 100
MACE at 30 days (%) 0 0.4 0.6 0.9 0
Proximal reference diameter (mean: mm) 2.86 2.80 2.83 2.89 2.90
Minimum lumen diameter post procedure 
(mean: mm) 2.65 2.54 2.59 2.62 2.60
Minimum lumen diameter at 9 months 
(mean: mm) 2.55 2.33 2.09 2.29 2.34
Restenosis rate at 9 months (%) 4.0* 6.7 12.3 11.0 12.8
TLR at 9 months (%) 3.6* 6.7 10.4 8.2 10.3
MACE at 9 months (%) 3.6* 6.7 10.4 9.2 10.3
*p<0.05 vs ZES, TES
2900-220 The Effect of Drug-Eluting Stents on Clinical and 
Angiographic Outcomes in Diabetic Patients: 
Multicenter Registry in Asia
Sunao Nakamura, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan Udayachalerm, Damras 
Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, Chiba, Japan, Konyang 
University Hospital, Daejeon, South Korea
Aim: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), 
Paclitaxel (PES), Zotarolimus (ZES) and Tacrolimus-eluting stent (TES) on the outcome 
of percutaneous coronary intervention in patients with diabetes mellitus (DM). Methods: 
A prospective analysis of 1240 patients with DM (SES 508, PES 420, ZES 204, TES 
108) in five high volume Asian centers after successful stenting was performed. The 
study endpoints were major adverse cardiac events (MACE) at 30 days, 9 months and 
restenosis rate and target lesion revascularization (TLR) at 9 months. Results: See table 
for clinical results. Conclusion: The use of drug-eluting stents in patient with DM was safe 
with low acute complication. Patients treated with SES showed lesser rate of restenosis 
compared with other drug-eluting stents. 
SES PES ZES TES
Number of patients 508 420 204 108
Multivessel disease (%) 78.5 72.6 76.5 74.1
MACE at 30 days (%) 0.8 1.2 1.0 0.9
Lesion length (mean: mm) 25.8 23.9 28.3 26.5
Lesion type: % of B2, C (%) 45.3 47.4 52.0 54.6
Reference diameter (mean: mm) 2.75 2.69 2.73 2.68
Minimum lumen diameter post procedure (mean: mm) 2.72 2.66 2.70 2.63
Minimum lumen diameter at 9 months (mean: mm) 2.54 2.38 2.08 1.98
Restenosis rate at 9 months (%) 7.9* 12.6 16.2 13.0
TLR at 9 months (%) 6.5* 10.7 13.7 11.1
*p<0.05 vs ZES, TES
2900-221 Determining the Hardness of the Proximal and Distal 
caps of Chronic Total Occlusions on 64-slice CT for the 
Retrograde Approach
Kazuhiro Ashida, Masahiko Ochiai, Shigeo Saito, Koichi Hoshimoto, Yuki Mikoshiba, 
Naoei Isomura, Hiroshi Araki, Chiaki Obara, Showa University Northern Yokohama 
Hospital, Yokohama-shi, Kanagawa, Japan
Background: Recently, the retrograde approach has been used to cross of chronic 
total occlusions (CTOs). One of the differences between the antegrade and retrograde 
approaches is the hardness of plaque at the site of CTO, but little is known about 
differences in the hardness of these lesions.
Methods: Eighteen consecutive patients with CTO awaiting PCI underwent 64-slice 
CT scanning between February and September 2007. We assessed the CT values of 
the proximal cap (PC) and distal cap (DC) of each CTO on the CT scans. We obtained 
accurate data on the duration of occlusion (DO) in 7 patients, and we investigated the 
relationship between DO and PC or DC hardness in these patients.
Results: All CTOs were successfully revascularized via the retrograde approach 
(n=16), or via the antegrade approach (n=2) in the patients without suitable collaterals 
for retrograde manipulation. The PC had a significantly higher CT value than the DC 
(578±217 vs. 292±135, p=0.0006). The CT value of the PC showed a significant correlation 
with DO (r=0.963, p<0.0001), although the CT value of the DC was not correlated with 
DO (r=0.379, n.s.).
Conclusions: From our data, the proximal cap of a CTO has harder plaque than the 
distal cap. A longer DO is not associated with the hardness of plaque in the DC, but is 
correlated with harder plaque in the PC. If the retrograde approach is available, a high 
success rate of crossing CTOs (without the guide wire taking the wrong course because 
of hard plaque) can be expected.
2900-222 Clinical and Angiographic Predictors for Successful 
and Unsuccessful Percutaneous Revascularization of 
Coronary Chronic Total Occlusions
Kotaro Obunai, George D. Dangas, Jeffrey W. Moses, Somjot Brar, Michael B. Collins, 
Edward M. Kreps, Anuj Gupta, Satya R. Atmakuri, Sudhi Tyagi, Martin B. Leon, Gregg 
W. Stone, Roxana Mehran, New York Presbyterian-Columbia University Medical Center, 
New York, NY
Background: Previous studies of PCI of chronic total occlusions (CTO) have reported 
angiographic features that correlate with enhanced ability to successfully cross a CTO. 
However, these predictors have not been validated in the current era with improved CTO 
techniques and equipments.
Methods: In a prospective PCI database, we identified 379 consecutive pts with 395 
totally occluded native coronary vessels who underwent PCI of CTO between January 
2005 and January 2007; the majority of pts were referred to our institution after failed 
attempts of CTO recanalization. Contralateral injections, multiple guidewires and 
retrograde techniques were used when indicated. Baseline angiograms of CTO 
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procedures were analyzed by QCA.
Results: Guidewire recanalization and successful PCI was achieved in 284 (72%) CTO 
vessels. Pts in the successful group had less likelihood of previous history of CABG (18% 
vs. 34%, p=0.001), shorter CTO length (18.9±12. mm vs. 26.9±14.63mm, p<0.001), lower 
prevalence of non-tapered stump (14% vs. 26%, p=0.01), absence of a side branch at 
CTO site (25% vs. 42%, p=0.01), lower rates of multiple occlusions in a vessel (5% vs. 
16%, p=0.001), and less evidence of severe calcification by fluoroscopy (19% vs. 45%, 
p<0.001). There was no significant difference in presence of bridging collaterals (27% 
vs. 34%, p=0.23) between the two groups. Multivariate analysis identified independent 
predictors of unsuccessful PCI of CTO: longer CTO length (OR 1.06 per 1mm increase, 
95% CI 1.03-1.09, p<0.01), severe calcification (OR 4.54, 95% CI 2.40-8.56, p<0.01), 
multiple occlusions in a vessel (OR 3.22, 95% CI 1.13-9.19, p=0.03), and presence of a 
side branch at the target site (OR 2.81, 95% CI 1.45-4.96, p<0.01).
Conclusions: In this large contemporary CTO cohort, greater lesion length, severe 
calcification, multiple occlusion sites in a vessel, and presence of a side branch at the 
target site, predicted unsuccessful recanalization. Unlike historical reports, our study 
indicates that presence of bridging collaterals or a non-tapered stump should no longer 
discourage a CTO attempt from technical point of view. This observation may improve 
patient selection for CTO PCI.
2900-223 Left Ventricular Dysfunction is Not a Predictor of Peri-
Procedural Complications in Patients Undergoing 
Carotid Artery Stenting
Rajesh Maddikunta, Raaid Museitif, Mohamed Djelmami-Hani, Fareed Shaikh, Jayant 
Khitha, Shahid Qamar, Mohammed Taha, Adnan Nazir, Abdul Rauf Sheikh, Adnan 
Aquil, Wendy Schmidt, Alfred J. Anderson, Arvind Ahuja, Suhail Allaqaband, Mark 
W. Mewissen, Tanvir Bajwa, Aurora Sinai/Aurora St. Luke’s Med Ctrs, Univ Wisconsin 
School of Med and Public Health-MCC, Milwaukee, WI
Background: Carotid artery stenting (CAS), with the use of embolic protection device 
(EPD), is a minimally invasive alternative to carotid endarterectomy in high-risk patients. 
In patients with left ventricular systolic dysfunction (LVSD), short-term outcomes of death 
and non-fatal stroke have been shown to be excellent, however, long-term results are not 
well established.
Methods: From January 2000 to April 2007, 202 patients underwent 216 CAS. They had 
either symptomatic carotid artery stenosis ≥ 50% of luminal diameter or asymptomatic 
stenosis ≥ 80%. These procedures were carried out as part of various study protocols 
at our institution. All patients had independent neurological evaluation pre and post 
procedure. We identified patients with severe LVSD (left ventricular ejection fraction 
(LVEF) <30%) and compared them with a cohort of patients with normal LVEF.
Results: 34% of the patients had LVSD. Rate of death and non-fatal strokes were similar 
at 30 days between the two groups (2.8% vs. 4.5%, p=ns). On one-year follow-up, there 
were no new ipsilateral strokes, however, in patients with severe LVSD, the rate of death 
was 47% compared to only 9% with normal LVEF. (Kaplan-Meier curve, significance level, 
p<0.01.)
Conclusions: Patients with severe LVSD who undergo CAS with EPD have a similar 
outcome at 30 days when compared to patients with normal LVEF. However, long-term 
outcome remains poor in such patients, mainly due to non-neurologic deaths.
2900-224 A Simplified Criteria for Determining Stroke Potential by 
TEE; Could it Herald an Earlier Septal Closure Policy?
Robert W. W. Biederman, Mark Doyle, Allegheny General Hospital, The Gerald McGinnis 
Cardiovascular Institute, Pittsburgh, PA
Introduction Multiple observations regarding the causality of PFO and stroke have been 
made focusing on defining stroke likelihood based on age, risk factors, septal redundancy, 
PFO size and transmitted bubble counts.
Hypothesis The anatomic relationship between the primum and secundum septum is 
directly related to PFO presence.
Methods 250 consecutive pts referred for either TIA/CVA evaluation (Group 1) or all 
others (Group 2) underwent TEE. The septal morphology in those with and without PFO 
was defined by the septal ‘track’ formation. A track was defined as a clear passageway 
between the septum primum and secundum and classified as either Absent (obliterated 
or obscured fossa ovale by the adjacent septal tissue; Type A), Intermediate (<1cm long 
and <0.25 cm wide; Type B) or Present (>1cm long and >0.25cm wide; Type C).
Results In Group 1 (37 pts) 3 (8%) were Type A, 5 (15%) were Type B and 29 (78%) were 
Type C. Of these 25pts (67%) had a PFO: 3(12%) Type A, 2(8%) Type B, and 20 (80%) 
Type C. In Group 2 (202 pts) 143 (71%) were Type A, 49 (24%) were Type B, and 10 (5%) 
were Type C. Of these, only 10 pts (5%) had PFO’s: 0 Type A, 4/10 (40%) Type B, and 6/10 
(60%) Type C. When excluding Type A pts (only 3 PFOs), the odds ratio of having a PFO 
in Type C vs. B was 16 (5.4-47.4). The presence of the septal track formation (Type C) 
was a stronger predictor of PFO formation and initial referral for TIA/CVA evaluation than 
was an atrial septal aneurysm (p<0.05). Larger, bidirectional shunts were predominantly 
16/30pts (53%), present in Type C pts in whom 13/20 (65%) were in Group 1 pts; odds 
ratio for bidirectional shunt in Type C vs. Type B was 12.5 (1.4-112).
Conclusions Atrial septum morphology defined by the presence of a long inner atrial track 
(>1cm long and >0.25cm wide; Type C septum) showed high predilection for: a) PFO 
presence b) highly associated with TIA/CVA pts c) not typically present in those referred 
for other reasons d) predicted larger, bidirectional shunts, especially in the young. The 
presence of a septal track between the primum and secundum septum appears to be a 
strong predictor of PFO presence helping to prognosticate those in whom future stroke 
potential is high, potentially leading to earlier referral for prophylactic closure.
2900-225 Predictors of Cardiac Death or MI Following Carotid 
Stenting: Insights from the Cordis Carotid Stent 
Collaborative
Herbert D. Aronow, Dennis Donohoe, Robert Safian, Rodney Raabe, John Nicholas, 
Greg Boxberger, Jeffrey Hull, Maurice Solis, Larry Shindelman, Hong Wang, Michigan 
Heart, P.C., Ann Arbor, MI, Cordis Corporation, Warren, NJ
Background: The risk of myocardial infarction (MI) appears to be greater following 
carotid endarterectomy than carotid stenting in high-surgical risk patients. Nevertheless, 
MI still occurs following 1-2% of carotid stent procedures.
Methods: We pooled data from 4 Cordis-sponsored carotid stent trials (n=2104), 
including the Continued Access Registry, CASES, SAPPHIRE and ADVANCE to identify 
predictors of cardiac death or MI within 30 days of the procedure.
Results: Overall, median age was 74 years, 37% were women and 34% had a history 
of prior MI. The composite outcome, cardiac death or MI occurred in 35 (1.7%) patients 
during this interval. Cardiac death occurred in 13 (0.6%) and MI in 25 (1.2%) patients. 
Q-wave and non-Q-wave MI occurred in 2 (0.2%) and 23 (1.1%) patients, respectively. In 
a logistic regression model (Table) including baseline and procedural variables, significant 
positive multivariable predictors of 30-day cardiac death/MI included development of a 
new neurological deficit during the procedure, need for IV nitroglycerin during or after 
carotid stenting, stenting an eccentric lesion, renal insufficiency, female gender and 
diabetes.
Conclusion: In this pooled trial analysis, a number of clinical and procedural factors 
predicted higher risk of cardiac death or MI during the 30 days following a carotid stent 
procedure. Identification of such predictors may help guide appropriate patient selection 
and optimize performance of these procedures. 
Predictors of Cardiac Death or MI at 30 
Days Coefficient
Standard 
Error
Odds 
Ratio p-Value
New neurological deficit during procedure 2.090 0.490 8.09 <0.001
Need for IV nitroglycerin during/after the 
procedure 0.902 0.362 2.46 0.013
Eccentric lesion -0.774 0.362 0.46 0.032
Renal insufficiency 1.067 0.508 2.91 0.036
Male gender -0.617 0.354 0.540 0.082
Diabetes mellitus 0.613 0.354 1.84 0.083
2900-226 Carotid artery stenting in elderly patients
Paul TL Chiam, Gary S. Roubin, Sriram S. Iyer, Daniel E. Soffer, Christina Brennan, Jiri 
J. Vitek, Lenox Hill Heart and Vascular Institute, New York, NY
Background: Carotid stenting (CS) is evolving as an alternative to carotid endarterectomy 
(CEA).
Age has been shown to be a predictor of neurological complications even with distal 
protection. In the CREST lead-in phase, octogenarians had an elevated 30-day stroke or 
death rate of 12.1% vs 4.0% in younger patients.
We postulated that if certain anatomical and clinical markers such as excessive tortuosity 
(including arch anatomy), heavy concentric calcification of the lesion and decreased 
cerebral reserve were avoided, CS could be safely performed in the elderly. This study 
was done to determine if experienced operators could perform CS in the elderly with 
acceptable complication rates.
Methods: From Aug 2003 to Jun 2007, 128 patients aged ≥ 80 yrs underwent 139 CS 
procedures at the Lenox Hill Heart and Vascular Institute. Patients were candidates if they 
had symptomatic stenosis ≥ 50% or asymptomatic stenosis ≥ 70%. All had carotid and 
cerebral angiography to determine anatomic suitability. Demographic and outcome data 
were collected prospectively. A NIH stroke scale was performed by a neurologist, before 
and 24-hours after the procedure.
Results: Mean age was 83.2 yrs (80-95 yrs). Risk factors and characteristics were: males 
61.9%, symptomatic 24.5%, post CEA restenosis 7.9%, contralateral ICA occlusion 
5.8%, DM 25.2%, hypertension 87.1%, dyslipidemia 84.2%, smoker 50.3%, CAD 65.5%, 
previous CABG 26.6%.
There were no MIs or intracranial hemorrhage. One patient had amaurosis fugax. There 
were 2 minor strokes and 3 major stroke or death in-hospital (3.6%). One major stroke 
occurred after emergency CEA for an irretrievable malfunctioned investigational distal 
filter (since withdrawn).
All had 30-day follow up. One additional patient had a TIA. Two of the 3 major strokes died; 
no further events occurred. The 30-day stroke or death rate was 3.6% and major stroke 
or death rate was 2.2%.
Conclusion: CS in the elderly can be performed safely with an acceptable adverse event 
rate, providing experienced operators use careful patient selection and refined techniques. 
CS may be an option for carotid revascularization in these patients.
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2900-227 Identifying the High Endovascular Risk Patient with 
Carotid Stenosis: An analysis from the Cordis Carotid 
Stent Collaborative
Herbert D. Aronow, Dennis Donohoe, Luis Queral, Joseph Andriole, Fred Leya, David 
Weatherford, Robert Hibbard, John R. Laird, Jonathan Altschuler, Hong Wang, Michigan 
Heart, P.C., Ann Arbor, MI, Cordis Corporation, Warren, NJ
Background: Comorbid and anatomic characteristics that portend higher procedural 
risk are well defined for carotid endarterectomy (CEA) but not for carotid stenting.
Methods: We pooled data from 4 Cordis-sponsored carotid stent trials (n=2104), 
including the Continued Access Registry, CASES, SAPPHIRE and ADVANCE to identify 
predictors of neurological death, stroke or transient ischemic attack (TIA) within 30 days 
of the procedure.
Results: Overall, median age was 74 years, 37% were women, 29% had prior TIA and 
28% previous stroke. The composite outcome, neurological death, stroke or TIA occurred 
in 160 (7.6%) patients during this interval. Neurological death occurred in 9 (0.4%), any 
stroke in 87 (4.1%) and TIA in 78 (3.7%) patients. Major ipsilateral, minor ipsilateral, major 
non-ipsilateral and minor non-ipsilateral stroke occurred in 30, 43, 5 and 12 patients, 
respectively. In a logistic regression model, significant multivariable predictors of 30-day 
neurological death/stroke/TIA included development of a neurological deficit during the 
procedure, angiographically visible thrombus in a symptomatic patient, GP IIb/IIIa inhibitor 
use during the procedure, recent stroke and increasing age (Table).
Conclusion: A number of clinical and procedural factors predict higher risk of neurological 
death, stroke or TIA within 30 days of a carotid stent procedure. Identification of such 
predictors may help guide appropriate patient selection and optimize performance of 
these procedures. 
Predictors of Neurological Death or Stroke 
at 30 Days Coefficient
Standard 
Error
Odds 
Ratio p-Value
New neurological deficit during the 
procedure 3.618 0.315 37.27 <0.001
Use of a GP IIb/IIIa inhibitor during the 
procedure 1.621 0.319 5.06 <0.001
Increasing age (per year) 0.044 0.011 1.04 <0.001
Stroke within 180 days before procedure 0.796 0.231 2.22 <0.001
Neurological symptoms within 180 days 
and thrombus 2.288 0.766 9.86 0.003
2900-228 Safety of Carotid Artery Stent Placement in the Elderly
Carlos A. Velez, Christopher J. White, John P. Reilly, Stephen R. Ramee, Tyrone J. 
Collins, J. Stephen Jenkins, Ochsner Clinic Foundation, New Orleans, LA
Background: Endovascular intervention of the carotid arteries is being evaluated as an 
alternative to carotid endarterectomy (CEA) for stroke prevention. Successful adoption 
of carotid artery stenting (CAS) depends on being able to perform the procedure safely 
enough to generate a cumulative stroke prevention benefit over time. Conflicting results 
regarding the safety of CAS in the elderly have been reported raising concerns about its 
periprocedural safety. We report our 13 year experience for CAS in patients ≥ 80 years 
of age.
Methods: Between 1994 and 2007, 811 CAS procedures were performed at the Ochsner 
Clinic Foundation. Elderly patients (≥ 80 years of age) accounted for 128 (16%) of those 
procedures. All patients underwent independent neurologic examination before and after 
the CAS procedure. A dedicated database was developed and analyzed for data on in-
hospital and 30-day major adverse cardiac and cerebrovascular events (MACCE).
Results: Complete data was available for analysis in 99 CAS procedures performed in 
92 consecutive patients ≥ 80 years of age. The average age was 82.7 ± 2.7 years. Almost 
half (45%) were female and 38% were symptomatic. One-third of the elderly patients 
had anatomical high surgical risk conditions including prior endarterectomy (23%) and 
contra-lateral carotid artery occlusion in 10%. The procedure success rate was 100%. 
Embolic protection was used in 52%. Self-expanding stents were used in 92%. The 30-
day MACCE was 3% [n = 3] all in symptomatic patients {death (1%), Q-MI (0%) major 
stroke (0%) and minor stroke (2%)}.
Conclusions: We report a low MACCE rate with independent neurological assessment, 
in a patient population that has been reported to be at increased risk for CAS 
complications. Our excellent outcomes were despite the 52% use of embolic protection. 
We believe that experienced CAS operators and careful patient selection were critical to 
our success. Our data suggests that carefully selected elderly patients can undergo CAS 
with periprocedural mortality and morbidity within the current guidelines.
2900-229 Ischemia Postconditioning Protects Skeletal Muscle 
from Reperfusion Injury Through Calreticulin-regulated 
Calcineurin Pathway in Rat Hind Limb
Xu-Dong Wu, Zhen-Ying Zhang, Xiu-Hua Liu, Xiao-Sun Guo, Feng-Ying Liu, Chinese 
PLA General Hospital, Beijing, People’s Republic of China
Background:Reperfusion therapy is the gold standard in treatment for acute limb 
ischemia. Sudden restoration of blood flow to the ischemic skeletal muscle may, 
however, also cause reperfusion injury. Ischemic preconditioning (IPC) and ischemic 
postconditioning (I-postC) are endogenous protective mechanisms capable of protecting 
the ischemic tissue from I/R injury. I-postC has been demonstrated in multiple species 
in reducing infarct size and preserving endothelial function to an extent comparable to 
IPC. The fact that I-postC can be applied after a prolonged period of ischemia offers a 
novel approach to protection. The present study was designed to investigate the effects of 
I-postC on ischemic/reperfusion (I/R) injury and its signal pathway.
Methods: In vivo study: Wistar rats were divided into three groups (n=16) as follows: (1) 
I/R group: Hind limb I/R was induced by clamping right femoral artery for 4 h followed by 
24 h reperfusion, (2) I-postC group: After 4 h of right femoral artery occlusion, reperfusion 
was initiated for 1 min of reperfusion followed by 1 min of reocclusion, repeated for three 
cycles, then subjected to 24 h reperfusion. (3) IPC group: the right femoral artery was 
occluded for 5 min followed by 5 min of reperfusion, repeated for three cycles, before the 
4 h of prolonged occlusion. (4) Sham rats underwent the same surgical procedure without 
ligation. Lactate dehydrogenase (LDH) activity in blood plasma, Wet/Dry ratio (W/D) and 
ultramicrostructure of skeletal muscle were detected on 12 h or 24 h after reperfusion. The 
expression of calreticulin (CRT) and Calcineurin(CaN) in skeletal muscle were detected 
by Western blotting. In vitro study: Cultured skeletal muscle cells (SMCs) from neonatal 
Wistar rats were divided into six groups (n=4) as follows: (1) hypoxia/reoxygenation(H/R) 
group: Culttured SMCs were placed into the hypoxia chamberfor 2 h to induce hypoxia 
followed by reoxygenation (for 24 h). (2) hypoxia postconditioning (H-postC) group: SMCs 
were directly exposed to hypoxia (for 2 h) followed by 3 cycles of brief reoxygenation (5 
min) and hypoxia (5 min) to induce H-postC. Then SMCs were incubated in cell incubator 
for 24 h to induce sustained reoxygenation. (3) Hypoxic preconditioning (HPC) group: 
SMC were placed into the hypoxia chamber for 20 min to induce HPC prior to H/R. 
(4) Cyclosporine A(CsA)+ H-postC group: SMCs were preincubated with CsA (a CaN 
inhibitor, (10 Μmol/L) prior to H-postC. (5) CsA+ H/R group: SMCs were preincubated 
with CsA prior to H/R. (6) Control group: SMCs were incubated in cell incubator for 24 h. 
Survival and apoptosis rate of SMCs were measured by Annexin V and PI FACS analysis. 
Western blot was used to detect the expression of CRT and CaN.
Results:In In vivo experiment, compared with I/R group, I-postC significantly decreased 
LDH leakage, W/D ratio and ultramicrostructure damage induced by I/R I-postC 
upregulated CRT expression to 4-fold (reperfusion 12 h)and 102% (reperfusion 24 
h) compared with I/R group (P<0.05). The expression of CaN increased to 196% 
(reperfusion 12 h) and 63% (reperfusion 24 h) respectively (P<0.05). In in vitro study, 
H-postC attenuated H/R-induced apoptosis and induced upregulation of CRT and CaN, 
compared with H/R group. CaN inhibitor CsA abolished H-postC induced cytoprotection 
and up-regulation of CaN without affected CRT expression.
Conclusions: Both in vivo and in vitro results indicated that I-postC can protect the 
skeletal muscle against I/R injury, which has similar protection effects with IPC. CRT is 
involved in I-postC-induced SMCs protection through CaN signaling pathway.
2900-230 Results From the International Registry of the 
AngioSculpt Scoring Balloon Catheter for the Treatment 
of Infra-popliteal Disease
R. Stefan Kiesz, Dierk Scheinert, Patrick J. Peeters, Marc Bosiers, Gerry O’Sullivan, 
Sherif Sultan, Mark A. Turco, William A. Gray, John R. Laird, Amir Malik, Mark W. 
Mewissen, Rajesh Dave, Tony S. Das, Thomas C. Piemonte, Puneet Khanna, Gary 
Gershony, Northeast Methodist Hospital, San Antonio, TX, John Muir Medical Center, 
Walnut Creek, CA
Background: The AngioSculpt (ASC) device incorporates a flexible nitinol scoring 
element containing 3 rectangular spiral struts which encircle a balloon to create focal 
concentration of the dilating force. The ASC was designed to treat complex lesions 
and to avoid slippage during deployment. Methods: Pts scheduled for percutaneous 
intervention of infra-popliteal arteries or planned amputation and with a reference vessel 
diameter of 1.5-3.5 mm were included. Results: A total of 93 pts (age 71.1±11.4 yrs, 
males 62.4%) and 131 lesions were treated at 16 clinical sites. Of these, 74 pts (79.6%) 
presented with critical limb ischemia (Rutherford Class ≥4). The ASC was successfully 
deployed in 99.2% (130/131) of lesions attempted and was used without stenting in 
88.6% (116/131). Lesions were complex, including total occlusions in 14.5%, moderate/
severe calcification in 54.2%, length 28.6±34.1 mm (range 4-200 mm), bifurcation in 
16.8% and ostial in 15.3%. There was no significant device slippage and no perforations. 
Post-ASC dissections occurred in only thirteen (9.9%) lesions and were minor or resolved 
with stenting. In 17 pts initially referred for amputation, treatment with the ASC resulted in 
limb salvage. Angiographic results are shown in the table. 
Pre-ASC Post-ASC Post-Stent
RVD (mm) 
DS (%) 
MLD (mm)
2.98±0.67 
85.84±11.57 
0.53±0.49
-- 
12.17±16.81 
2.75±0.67
-- 
7.00±10.48 
3.30±0.86
DS=diameter stenosis, MLD=minimum luminal diameter, RVD=reference vessel 
diameter
Conclusions: The AngioSculpt is highly effective in a broad range of complex lesions, 
in most cases as sole therapy, is associated with a very low complication rate and avoids 
device slippage during deployment. Follow-up studies are underway to assess the long 
term efficacy of this promising new technology.
2900-231 Stent Fracture Does Not Affect the Long Term Patency 
in the Superficial Femoral Artery in the New Stent Era
Osamu Iida, Shinsuke Nanto, Masaaki Uematsu, Takakazu Morozumi, Tetsuya 
Watanabe, Masaki Awata, Toshinari Onishi, Fusako Sera, Hitoshi Minamiguchi, Hirokuni 
Akahori, Masamichi Yano, Kuniyasu Ikeoka, Shin Okamoto, Nobuaki Tanaka, Haruyo 
Yasui, Seiki Nagata, Kansai Rosai Hospital, Amagasaki, Japan
Background: Stent fracture in the superficial femoral artery (SFA) has been related to 
poor long term patency. Although a new nitinol stent has been introduced to reduce stent 
fracture and restenosis in the SFA, whether stent fracture of the new stent still influences 
long-term patency remains unclear.
Methods: We studied 90 SFA lesions that underwent provisional stenting with a recently 
developed nitinol stent (Smart, J&J) in consecutive 77patients who gave consent to 
receive follow-up arteriography (12±4 months later). Morphology of the stent fracture 
was classified based on the Cardiovascular Institute of the South Nitinol Stent Fracture 
classification system, evaluated by X-ray with multiple projections. Relation between 
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follow-up restenosis (> 50% angiographic stenosis or peak systolic velocity ratio > 2.5 by 
Doppler ultrasound) and angiographic morphology of the fracture was explored.
Results: Stent fracture occurred in 28% lesions (25/90). Angiographic restenosis rate 
at follow-up was 24% (22/90). Restenosis rate neither correlated with the stent fracture 
(log-rank test, p = 0.36, Figure) nor with stent fracture morphology (I= 35%, 6/17; II= 50%, 
2/4; III= 0%, 0/2; None = 22%, 14/65, P=0.5).
Conclusion: Stent fracture and fracture morphology of the new generation nitinol stent did 
not affect the long term patency following superficial femoral artery stenting. 
2900-232 VIABAHN Stent-Graft for Percutaneous 
Revascularization of Long, Complex Lesions (TASC 
C/D) of Superficial Femoral Artery
Mohamed Djelmami-Hani, Raaid Museitif, Mohammed Taha, Nadder Chadda, 
Abedlazim Hashim, Sepideh Kazemi, Anjan Gupta, Ramagopal Tumuluri, Yoseph 
Shalev, Suhail Allaqaband, Tanvir Bajwa, Aurora Sinai/Aurora St. Luke’s Med Ctrs, Univ 
Wisconsin School of Med and Public Health-MCC, Milwaukee, WI
Background: Endovascular intervention for femoropopliteal occlusive disease poses a 
challenge due to a significant restenosis rate. We evaluated the primary and secondary 
patency rate of VIABAHN stent-graft (W. L. Gore, Flagstaff, AZ) in patients with long, high-
grade de novo superficial femoral artery (SFA) lesions.
Methods: From August 2004 to March 2007, 123 patients at our institution underwent 
a total of 132 endovascular interventions for de novo, TASC grade C or D, SFA lesions, 
using VIABAHN stent-graft. All patients were discharged on ASA and clopidogrel. Patients 
were followed clinically and with duplex scans at 1, 3, 6 and 12 months postprocedure and 
longer, if clinically indicated. In-stent restenosis on duplex scan was defined as a lumen 
loss of ≥50% and confirmed with angiography.
Results: Mean age was 65 ±13 (59% male). Prevalence of diabetes, hypertension, 
renal failure, smoking and dyslipidemia was 45.5%, 82.1%, 27.6%, 36.6, and 72.3% 
respectively. Clinical presentation was Fontaine class IIb in 74.8%, class III in 4% and 
class IV in 21.2%. Lesions were TASC class C in 71% and D in 46.2% with a mean length 
of 21±10.9 cm. The initial technical success was 100%. All patients had at least 2-vessel 
run-off. Patency rates are shown in the graph.
Conclusions: Percutaneous revascularization of de novo, long and high-grade SFA 
lesions/occlusions with VIABAHN stent-graft is safe, feasible with excellent long-term 
patency. 
2900-233 Routine Stent Implantation Versus Percutaneous 
Transluminal Angioplasty in Femoropopliteal Artery 
Disease: A Meta-Analysis of Randomized Controlled 
Trials
Christos Kasapis, Peter K. Henke, Stanley J. Chetcuti, Gerald C. Koenig, John E. 
Rectenwald, P. Michael Grossman, Hitinder S. Gurm, University of Michigan Health 
System, Division of Cardiovascular Medicine, Ann Arbor, MI
Background: Clinical trials comparing routine stent (ST) implantation with percutaneous 
angioplasty (PTA) for superficial femoral-popliteal artery (SFPA) disease have produced 
conflicting results. We performed a systematic meta-analysis of randomized controlled 
trials comparing ST vs. PTA in symptomatic SFPA disease.
Methods: We searched the MEDLINE, Embase, ISI Web of Knowledge, Current 
Contents, International Pharmaceutical Abstracts databases, and the Cochrane Central 
Register of Controlled Trials up to August 31, 2007. We calculated the summary odds 
ratio (OR) for immediate technical success, restenosis and target vessel revascularization 
(TVR) using fixed-effect models.
Results: Data from nine randomized controlled trials (1,146 patients) were pooled. 
Patients were randomized to ST (N=627 limbs) or PTA with provisional stenting (N=618 
limbs). The follow up period varied from 9-24 months. The immediate technical success 
was higher in patients treated with ST (OR=4.79, 95% CI 1.99-11.52, p<0.001) with 9% 
of the PTA patients undergoing stenting, because of suboptimal PTA result. There was a 
non-significant trend for lower restenosis in the ST group (OR=2.02, 95% CI 0.92-4.45, 
P=0.081), but no difference in the need for TVR (OR 1.01, 95% CI 0.75-1.4, P = 0.92).
Conclusions: Despite the higher immediate success, routine stenting for SFPA disease 
was not associated with a reduction in rate of restenosis or TVR. Our data do not support 
use of routine stenting for SFPA lesions.
2900-234 Preventing Lower Extremity Distal Embolization During 
Percutaneous Interventions Using Embolic Filter 
Protection: Results of the PROTECT Registry
Nicolas W. Shammas, Eric Dippel, Denise Coiner, Gail Shammas, Laura Gayton, 
Midwest Cardiovascular Research Foundation, Davenport, IA
Background: Atheroembolization has been frequently noted during endovascular 
interventions of the coronaries, vein grafts, carotids, renals and lower extremity vessels.
In this single center prospective registry we evaluate the effectiveness of embolic filter 
protection (EFP) in patients undergoing peripheral interventions.
Methods:Patients were included if they were able to provide informed consent and 
had an infrainguinal lesion that met one or more of the following angiographic criteria: a. 
moderate or severe calcification of any length, b. total occlusions of any length, c. presence 
of a filling defect, d. irregular appearing lesions at least 30 mm in length, e. smooth lesion 
at least 50 mm in length. The primary angiographic outcome was to evaluate the EFP 
ability in capturing macro debris in the lower extremities and prevent visible embolization, 
slow flow and loss of a distal tibial runoff. Clinically significant macrodebris was defined 
as more or equal 2 mm in its longest axis
Results:Forty patients were enrolled in the PROTECT registry. One Filter was used per 
patient. The total number of vessels treated with EFP is 57 (denovo 43, restenotic 14). The 
Spider Filter (EV3) (n=35) and the EmboShield (Abbott) (n=15) were utilized. Forty four 
vessels (group A) were treated with percutaneous angioplasty with (n=33) and without 
stenting (n=11) and the remainder 13 vessels (Group B) were treated with the SilverHawk 
(Foxhollow) atherectomy and adjunctive balloon angioplasty. Macroembolization occurred 
in 53% of vessels treated (44% clinically significant), 39% in group A and 100% in group 
B. All filters were retrieved successfully with no complications. One patient had side 
branch embolization. In another patient the filter was overfilled resulting in no distal flow 
and had to be retrieved with subsequent distal tibial embolization when the procedure 
was continued without EFP.
Conclusions:Macroembolization is very frequent in patients undergoing PPI of the LE 
particularly with the use of the SilverHawk atherectomy device. EFP appears to be very 
effective in capturing macrodebris and its use is associated with good acute angiographic 
outcome.
2900-235 Platelet Activation During Renal Artery Stenting
Steven Haller, Grant Reed, Pamela Brewster, David Kennedy, Jason Wu, Mark W. 
Burket, William Colyer, Christopher J. Cooper, University of Toledo Medical Center, 
Toledo, OH
Background: Platelet activation leading to thrombus formation is a well-described 
complication of coronary revascularization. Whether it occurs in the setting of renal 
artery revascularization is unknown. Additionally, the effect of embolic protection devices 
(EPD) and glycoprotein inhibitors (GP2b3a) on platelet activation in renal intervention 
is unknown. Upon activation of platelets, CD40L is translocated to the platelet surface, 
cleaved, producing a soluble fragment.
Methods: One hundred patients enrolled at 7 centers undergoing renal artery stenting 
were randomized to an EPD, Angioguard, or double-blind use of abciximab, in a 2x2 
design. Platelet activation was assessed by measuring plasma levels of soluble CD40 
ligand (CD40L). Blood samples were collected at baseline, immediate post, and 24hr 
post procedure. Statistical analysis was performed on matched pairs (n=84). A natural log 
transformation was performed to normalize the data.
Results: In all patients that received an EPD, CD40L levels rose slightly (p=ns) 
immediately following stenting, and returned to baseline levels at 24hrs. Twenty four % of 
EPDs (10/42) had platelet rich emboli captured. In these patients with platelet thrombus 
CD40L rose significantly. CD40L declined with abciximab immediately post (5.6 ± 0.6 vs 
4.9 ± 0.8 pg/ml, p<0.001), and persisted at 24hrs (5.6 ± 0.6 vs 5.1 ± 0.4 pg/ml, p<0.01). 
Patients randomized to both an EPD and abciximab showed a significant decrease in 
CD40L immediately following the procedure (5.6 ± 0.7 vs 5.0 ± 1.0 pg/ml, p<0.01) and 
had a significant increase in MDRD GFR following the procedure (48.6 ± 18.8 vs 66.2 ± 
25.4 mL/min per 1.73m2, p<0.01). The other groups did not improve.
Conclusions: Platelet activation and embolization of platelet rich thrombi is common 
during renal artery stenting. In this setting abciximab effectively inhibits platelet activation. 
Combining an EPD with a GP2b3a inhibitor provides additional protection against acute 
platelet activation, thrombus embolization, and may improve renal function.
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2900-236 Renal Artery Stenosis and Proximal Tubular Injury
Grant Reed, Katherine Hoetzl, Steven Haller, Pamela Brewster, Joseph I. Shapiro, 
Christopher J. Cooper, University of Toledo Medical Center, Toledo, OH
Background: Atherosclerotic renal artery stenosis (RAS) is associated with renal 
dysfunction in many patients. However, the mechanisms of renal injury are not well 
understood. In patients with proximal tubular injury N-acetyl-β-D-glucosaminidase (NAG), 
and β-2-Microglobulin (B2M) levels increase in the urine because of increased release 
and impaired reabsorbtion respectively. The present study evaluated proximal tubular 
function in patients undergoing renal artery stenting.
Methods: As a sub-study of the RESIST clinical trial 100 patients enrolled at 7 centers 
undergoing renal artery stenting were randomized to an embolic protection device (EPD), 
Angioguard, or a GP2b3a inhibitor, abciximab, in a 2x2 design. Urine was collected at 
baseline, 24hrs, and 1 month post procedure. Statistical analysis was performed on 
the natural log transformed data of matched pairs. NAG and B2M were corrected for 
creatinine.
Results: A substantial proportion of patients (54/86 [63%]) have evidence of proximal 
tubular dysfunction prior to revascularization. Elevated levels of NAG and B2M were 
highly correlated with overall renal function (MDRD GFR, p<0.05). After stenting tubular 
function appeared to worsen acutely at 24 hours (NAG, -0.2 ± 1.0 vs 0.1 ± 1.1 Μg/L, 
P<0.05, and B2M, -8.4 ± 4.3 vs -7.8 ± 4.5 Μg/L, p=0.2). No change in tubular function 
was seen with an EPD, whereas without an EPD there was a trend towards worsening 
tubular injury at 24hrs (B2M, -9.0 ± 4.2 vs -7.0 ± 4.5 Μg/L, p<0.05). Contrast dose did not 
have an effect on NAG or B2M.
Conclusion: Abnormalities of the proximal kidney tubule are important contributors to 
renal dysfunction in patients with renal artery stenosis, and may worsen 24hrs following 
revascularization. This effect may be lessened with the use of an EPD.
2900-237 CASES-PMS Carotid Artery Stenting with Emboli 
Protection Surveillance Study: Outcomes at 1-Year 
Theodore Schreiber, William Bachinsky, Peter Faries, David Lewis, Steve Tyndall, 
Sherwood Dixon, Amit Patel, Christopher Cates, Peter Soukas, Charles Daly, Dennis 
Donohoe, Harper University Hospital, Detroit, MI
Background: CASES-PMS, a multi-center, prospective, single-arm, surveillance study 
assessed safety and efficacy outcomes of carotid artery stenting (CAS) using the Cordis 
PRECISE® Nitinol Stent and ANGIOGUARD®XP Emboli Capture Guidewire, when 
performed by physicians with varied experience in CAS utilizing a formal training program.
Methods: High surgical-risk patients with de novo atherosclerotic or post-endarterectomy 
restenotic lesions in native carotid arteries were enrolled. Inclusion and exclusion criteria 
matched those of the SAPPHIRE trial. Primary endpoint was composite 30-day major 
adverse events (MAE) including death, any stroke, or myocardial infarction.
Results: A total of 1,493 patients were enrolled at 73 sites from September 24, 2004 
through October 7, 2005. 30-day results have been reported previously. At 1-year, Kaplan-
Meier analysis of all stroke and death to 30-days plus ipsilateral stroke between 31 to 360 
days with CASES-PMS (5.4%) was similar to rates seen with the SAPPHIRE trial stent 
cohort (5.5%). There were no significant differences in outcomes at 1 year by symptom 
status or high-risk status, however, octogenarians did have a significantly higher event 
rate compared with younger patients.
Conclusions: The durability of carotid artery stenting in high surgical-risk patients seen 
in the SAPPHIRE trial has been reproduced with CASES-PMS. Subgroup analyses in 
this study suggest that proper patient selection criteria for CAS and operator experience 
may help reduce event rates in patient subsets that are typically at higher risk for adverse 
events after carotid artery stenting. 
Safety Measure and 
Other Clinical Events to 360 
Days
All 
Patients 
(N=1493 
Patients)
Training 
Level 1 
(N=918 
Patients)
Training 
Level 2 
(N=352 
Patients)
Training 
Level 3 
(N=223 
Patients)
MAE1 (Death, MI, Stroke within 
30 days and 
Death and Ipsilateral Stroke from 
31-360 days)
11.8% 
(176/1493)
11.1% 
(102/918)
12.2% 
(43/352)
13.9% 
(31/223)
MAE2 (Death, MI, Stroke within 
30 days and Ipsilateral Stroke 
from 31-360 days)
6.0% 
(90/1493)
5.8% 
(53/918)
6.5% 
(23/352)
6.3% 
(14/223)
Death 7.6% (114/1493)
7.1% 
(65/918)
8.2% 
(29/352)
9.0% 
(20/223)
Myocardial Infarction (Q Wave 
and Non-Q Wave)
3.2% 
(48/1493)
3.7% 
(34/918) 2.0% (7/352) 3.1% (7/223)
Stroke 5.8% (86/1493)
5.6% 
(51/918)
6.5% 
(23/352)
5.4% 
(12/223)
Major Ipsilateral Stroke 1.8% (27/1493)
1.7% 
(16/918) 2.3% (8/352) 1.3% (3/223)
Major Non-Ipsilateral Stroke 0.7% (10/1493) 0.5% (5/918) 1.1% (4/352) 0.4% (1/223)
Minor Ipsilateral Stroke 2.4% (36/1493)
2.2% 
(20/918) 2.3% (8/352) 3.6% (8/223)
Minor Non-Ipsilateral Stroke 1.3% (20/1493)
1.4% 
(13/918) 1.4% (5/352) 0.9% (2/223)
TIA 4.5% (67/1493)
3.6% 
(33/918)
4.8% 
(17/352)
7.6% 
(17/223)
All TVR 0.9% (14/1493) 0.8% (7/918) 1.4% (5/352) 0.9% (2/223)
Stent Thrombosis 0.3% (5/1493) 0.3% (3/918) 0.6% (2/352) 0.0% (0/223)
Major Bleeding 3.5% (53/1493)
3.5% 
(32/918)
3.1% 
(11/352)
4.5% 
(10/223)
Major Vascular Complications 4.0% (60/1493)
3.5% 
(32/918)
4.3% 
(15/352)
5.8% 
(13/223)
2900-238 Long-Term Durability of Endoluminal Stenting 
for Obstructive Lesions of the Subclavian Artery: 
Multicenter Registry in Japan
Sunao Nakamura, Eiji Tada, Kensuke Fujiwara, Osamu Kakuda, Naoyuki Kurita, Mizuki 
Hirose, Shotaro Nakamura, Satoko Tahara, Koji Hozawa, Hitoshi Nakamura, Kazutoshi 
Yamamoto, Seiji Otani, Nobuyuki Makishima, Jun Koyama, New Tokyo Hospital, Chiba, 
Japan, Chiba Central Medical Center, Chiba, Japan
Background: Obstructive lesions of the subclavian artery can result in arm claudication, 
symptoms of subclavian steal. Aim: To evaluate the safety, efficacy and durability of 
endovascular stenting for treating 405 obstructive lesions of subclavian artery. Methods: 
We performed 405 cases of endoluminal stenting for 383 patients (272 males, 67±13 
years). All procedures were performed with Palmaz stents (272 cases) and Wall stents 
(133 cases), 262 cases (64.7%) were used transradial approach. Indications for stenting 
were arm claudication in 219 cases, subclavian steal syndrome in 90 cases and 
myocardial ischemia secondary to compromised flow through internal mammary grafts 
in 74 cases. Results: Procedural success (defined as abolition of pressure gradient 
across the aorta and subclavian artery and a residual diameter stenosis <20% without 
major complications was achieved in 380 patients (99.2%). Only one patient had a major 
complication (mediastinum hemorrhage due to subclavian artery rupture). Baseline 
diameter stenosis was reduced from 88.9% to 12.9±9.2%, mean systolic pressure 
difference was reduced 45.9±14.8 mmHg to 4.7±4.9 mmHg (p<0.01). There was no 
cerebral or distal embolization. In 320 of 383 patients (83.6%) we performed, follow-up 
angiography ranged from 6 months to 9 years (mean, 56.8 months). Primary angiographic 
patency at 5 years was 99% (only 3 restenosis: 1.0%). Conclusions: Endoluminal 
stenting of the subclavian artery is safe and effective with high technical success and 
these clinical benefits are durable at least 5 years.
2900-239 Differences in Nitinol Stent Characteristics for Clinical 
Decision Making
Bruce H. Gray, Anthony Ragheb, Greenville Hospital System University Medical Center, 
Greenville, SC, Medical Institute (Cook), Lafayette, IN
Background: There are a variety of nitinol stents available for use. Nitinol stents are not 
all the same, yet the clinician is provided little information besides selective marketing 
data. The purpose of this study was to compare some key characteristics of nitinol stents 
that may impact their ability to meet physiologic demands. Methods: The evaluations 
were performed using controlled test methods, and the various devices were tested under 
the same conditions. The table below summarizes the results.
Results: 
Stent 
 
 
 
Property
Abbott 
Xpert™
Bard® 
Luminexx™
Boston 
Scientific 
Sentinol™
COOK® 
Zilver®
Cordis® 
S.M.A.R.T. ®
Edwards 
Lifesciences 
Lifestent NT
EV3® 
Protégé® 
Everflex™
Guidant/
Abbott 
Absolute™
 
Mean 
Value
Maximum 
Radial 
Force (N/
mm)
0.69 0.86 0.66 0.72 0.91 0.71 0.75 0.54 0.73
Axial 
Stiffness 
(N/mm)
0.061 0.136 0.110 0.035 0.094 0.016 0.071 0.017 0.068
Torsional 
Stiffness 
(N/Degree 
Rotation)
1.15 3.62 1.59 0.65 2.43 0.70 1.08 0.40 1.45
Bending 
Stiffness 
(N[[ 
Unsupported 
Character - 
&#903; ]]mm/
mm)
0.69 2.28 1.32 0.84 1.50 0.315 0.59 0.29 0.98
Kink 
Radius 
(mm)
13.0 16.0 23.5 8.5 16.0 8.5 23.5 19.0 16.0
Surface 
Finish  
(1 - 3, 
where 
1= poor 
and 3= 
excellent)
2.5 1 2.5 2.5 2.5 2.5 2 3 2.3
Visibility  
(Grayscale 
Contrast)
51 205 88 179 109 134 89 154 126
Conclusions: In the absence of comparative randomized trials, some clinical decisions 
may be hypothesized from these results. Stents with maximal radial force tend to give up 
axial flexibility, which may predispose them to fracture under physiologic loading
(e.g., superficial femoral artery). Stents with the lowest kink radius (8.5 mm) may be the 
most resistant to kinking in arteries that undergo substantial bending (e.g., popliteal artery). 
Stents with poor surface finish may be more likely to fracture at areas of imperfection. No 
one stent manifests ideal characteristics. Therefore, stents should be selected with key 
characteristics that are best suited for the demands of the implant location.
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2900-240 Endovascular Exclusion of Popliteal Arterial 
Aneurysms with Stent-Grafts - A Prospective, Single 
Center Experience.
Gary M. Idelchik, Leo Simpson, Kathryn G. Dougherty, Edwardo Hernandez, Ali 
Mortazavi, Neil E. Strickman, Zvonimir Krajcer, Texas Heart Institute at St. Luke’s 
Episcopal Hospital, Houston, TX, Baylor College of Medicine, Houston, TX
Background: Untreated popliteal artery aneurysms (PAAs) are associated with 
significant morbidity secondary to thrombosis and thromboembolization that may lead to 
limb loss. Due to the considerable morbidity and mortality related to surgical PAA repair, 
especially in symptomatic patients, we sought to determine the efficacy of percutaneously 
treating PAAs using self-expanding stent grafts.
Methods: Between October 2000 to September 2007, 32 patients underwent successful 
endovascular exclusion of 36 PAAs.
Results: Thirty-three (91.7%) of the aneurysms were secondary to atherosclerotic disease, 
with three aneurysms occurring at sites of previous directional atherectomy. Twenty-nine 
PAAs (80.5%) were symptomatic and 4 patients presented with PAA-associated venous 
occlusion and thrombosis. Twenty-eight (77.8%) of the treated aneurysms had associated 
mural thrombus. The mean aneurysm diameter was 22.9 ± 16.2 mm. The mean lesion 
length was 98.6 ± 102.1 mm (range 15 to 422.3 mm). Average stent grafts implanted 
per aneurysm treated was 1.9 ± 0.4, with a mean length of stent per lesion of 198.6 ± 
105.3 mm (range of 50 to 450 mm). A total of 60 stent grafts were used, of which 15 
were Wallgraft stents and 45 were Viabahn stents. All PAAs were successfully excluded. 
There were no device-associated complications, failures or deaths. Three (8.3%) patients 
had access site hematomas, one (2.7%) requiring surgical repair. Thrombosis occurred 
in two (5.6%) stent grafts at 24 hours and successfully recannalized. The mean length 
of hospitalization was 1.4 ± 1 days. Average follow-up was 35.4 ± 32.1 months. Primary 
and secondary patency rates at 3 and 6 months were 94.4% and 100%, and 93.9% and 
100%, respectively. One and 2-year primary and secondary patency rates were 89.3% 
and 96.4%, and 70.6% and 94.1%, respectively. In the patients with ≥ 5 years of follow-up, 
primary and secondary patency rates were 85.7% and 100%, respectively. There were no 
endoleaks, aneurysmal ruptures or limb-loss at follow-up.
Conclusions: Percutaneous self-expanding stent graft exclusion of PAAs is safe and 
effective, with primary and secondary patency rates comparable to surgical repair.
2900-241 Effects of Endovascular Stent-Graft Repair and Medical 
Therapy on True and False Lumen Volume in Type B 
Aortic Dissection
Sebastian Huptas, Holger Eggebrecht, Hilmar Kuehl, Ulf Herold, Heinz G. Jakob, 
Rajendra H. Metha, Raimund Erbel, University of Duisburg-Essen, West-German Heart 
Center, Cardiology Department, Essen, Germany
Background: Endovascular aortic repair (EVAR) aims at non-surgical reconstruction of 
type B aortic dissection (AD). Obliteration of false lumen (FL) perfusion by implantation 
of a membrane-covered stent-graft across the proximal entry tear is hypothesized to 
facilitate aortic remodeling characterized by FL thrombosis and enlargement of the true 
lumen (TL). So far, a comprehensive analysis of the remodeling process in comparison 
with conventional management is, however, missing.
Methods and Results: Serial contrast-enhanced computed tomography (CT) aortic scans 
of 27 type B-AD patients (60±13 years) were analyzed; 17 of these underwent EVAR, 
while 10 patients received medical therapy. Volumes of TL and FL on CT performed at 
baseline and at follow-up (14±6 months) were quantified by 3-dimensional reconstruction 
from the origin of the left subclavian artery to the abdominal aortic bifurcation. EVAR 
resulted in a significant immediate gain in TL volume (pre-EVAR 132±56ml vs. 164±51ml 
post-EVAR, p<0.001), which increased further to 220±68ml at follow-up (p<0.001 vs. 
baseline). In contrast, in the medical therapy group there was only minimal increase in 
TL volume during the follow-up period (113±34ml to 120±41ml, p=0.195). In the EVAR 
group, FL volume decreased overtime (257±147ml at baseline to 252±144ml immediate 
post EVAR to 178±140ml at follow-up, p<0.001). No significant change in FL volume 
was observed in the medical therapy patients. Total aortic volume remained similar in the 
EVAR group overtime (389±164ml to 400±167ml at follow-up, p=ns), but increased in 
the medical group (372±141ml to 396±164 ml at follow-up, p<0.05). This increase in the 
medical therapy group was due to an enlargement of the thoracic rather than abdominal 
aorta.
Conclusions: We demonstrate that EVAR for type B-AD results in a significant increase 
of TL and a decrease in FL volumes, not only acutely but also overtime at follow-up due to 
continued remodelling processes. Our data provides insight into the potential mechanism 
of therapeutic benefit of EVAR over medical therapy in type B-AD that remains to be 
confirmed in randomized clinical trial. 
2900-242 Outcome of Carotid Artery Stenting in Female versus 
Male Patients: A Gender Analysis of The CAPTURE-2 
Registry
Heidar Arjomand, William Gray, Alan Hymanson, Lawrence Petrovich, Patty LaBlanc, 
Firas Alani, Satish Surabhi, Sheldon Goldberg, Daniel McCormick, York Hospital, York, 
ME, Hahnemann University Hospital, Philadelphia, PA
Background:  Based on available data, female patients undergoing carotid 
endarterectomy (CEA) have worse outcome compared to male patients. There is limited 
comparative data on the outcome of carotid artery stenting (CAS) in female versus male 
patients.
Methods:  We evaluated the outcome of CAS with embolic protection device (EPD) in 801 
female patients as compared to 1269 male patients enrolled in the CAPTURE-2 clinical 
Registry (Carotid RX Acculink/Accunet Post-Approval Trial to Uncover Unanticipated 
and Rare Events). The primary endpoint of this analysis was the cumulative incidence of 
death, stroke, or MI at one-month follow-up.
Results: Mean age was 73 years in both groups. Other baseline clinical characteristics 
were also similar in both groups. High-risk features in female and male patients, 
respectively, included age > 80 years (23.9% vs 23.0%), CHF (16.6% vs 17.3%), and 
unfavorable CEA anatomy (19.5% vs 21.2%). Individual one-month event rate is shown in 
the table. Composite one-month event rate was 4.4% in female and 4.0% in male patients 
(95% CI: -2.5% to 1.6%).
Conclusions: In contrast to CEA, Carotid artery stenting with EPD has similarly good 
outcomes in female and male patients.
CAPTURE-2: One-Month Event Rate in Female vs Male Patients
Event Female ( n = 801) Male (n = 1269)
Death 0.6% 1.0%
Stroke 3.5% 3.2%
MI 0.8% 0.2%
Death & Stroke 3.7% 3.9%
Death, Stroke, & MI 4.4% 4.0%
2900-243 The Effect of Renal Artery Stenting on Left Ventricular 
Diastolic Function
Osami Kawarada, Yoshiaki Yokoi, Kazushi Takemoto, Shinichi Higashiue, Nobuyuki 
Morioka, Kishiwada Tokushukai Hospital, Kishiwada, Osaka, Japan
Background: No previous studies have evaluated left ventricular diastolic function in 
renal artery stenosis (RAS). We investigated the severity of diastolic dysfunction in RAS, 
and the effect of renal artery stenting on diastolic function.
Methods: A total of 41 patients with 48 lesions that underwent primary renal artery 
stenting were prospectively included. We echocardiographically assessed diastolic 
function as well as systolic function before and after renal artery stenting. Diastolic 
function measurements included peak early diastolic mitral inflow velocity (E), peak late 
diastolic mitral inflow velocity (A), the E/A ratio, early filling deceleration time (DT), peak 
early mitral annular velocity (E’) and the E/E’ ratio.
Results: E/E’ significantly (p<0.001) improved from 13.4±5.8 to 11.3±3.6 pre and post 
stenting, and remained significantly (p<0.001) decreased to 10.8±2.7 at mean follow-up 
of 5.7±3.9 months, whereas ejection fraction and wall motion score index remained no 
changed. E velocity, A velocity and E/A decreased significantly after stenting compared 
with before stenting whereas DT remained no changed. When the E/E’ ratio was of a 
higher value, renal artery stenting was more beneficial. Subjects with improvement in 
hypertension and cardiac disturbance syndrome following renal artery stenting had 
significant higher baseline E/E’ ratio than those without clinical improvement.
Conclusions:  Renal artery stenting can contribute to an improvement in left ventricular 
diastolic dysfunction for RAS patients. Patients with pre-existing severe diastolic 
dysfunction are more likely to benefit from renal artery stenting. An enthusiastic evaluation 
of diastolic function in RAS patients is warranted.
2900-244 Drug-Eluting Stents versus Bare Metal Stents in 
Saphenous Vein Grafts at 2 Years
Robert J. Applegate, Matthew T. Sacrinty, Michael A. Kutcher, Sanjay K. Gandhi, Renato M. 
Santos, William C. Little, Wake Forest University School of Medicine, Winston-Salem, NC
Background: Drug-eluting stents (DES) reduce restenosis compared to bare metal 
stents (BMS) in native coronary arteries. Recent data suggest that DES efficacy and 
safety in SVGs may be lower than with BMS. However, long term (>2 year) outcomes of 
DES in SVGs in routine clinical practice is limited.
Methods: 212 pts. at Wake Forest Baptist Medical Center between 4/02 and 4/05 
underwent PCI of SVGs including 123 pts. with BMS and 89 pts. with DES. Clinical 
outcomes at 2 years were retrospectively reviewed.
Results: The baseline clinical characteristics of the two groups were similar. Procedural 
characteristics were also similar, except that embolic protection was used in 58% of BMS 
and 46% of DES cases, p=0.093. Anti-platelet therapy was similar in both groups at 2 
years, with 50% using dual anti-platelet therapy. The hazard ratio at 2 years for DES 
compared to BMS for target vessel revascularization was 0.66 (0.32-1.38); for non-fatal 
MI was 0.26 (0.09-0.78); for all cause death was 0.55 (0.27-1.12); for stent thrombosis 
was 0.44 (0.09-2.20); and for non-fatal MI or death was 0.42 (0.22-0.79). The Kaplan-
Meier plot of non-fatal MI or death is shown in the figure.
Conclusions: In this study of routine clinical practice, use of DES for PCI of SVGs was 
associated with lower need for repeat revascularization and non-fatal MI or death, with a 
similar incidence of stent thrombosis at 2 years. Thus, DES in SVGs have similar clinical 
efficacy as in native coronary arteries.
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2900-245 Histopathological Features in Primary PCI: a Large 
Single-Center Thrombectomy Study
Miranda C. Kramer, Allard C. van der Wal, Karel T. Koch, Johanna P. Ploegmakers, Rene 
J. van der Schaaf, Jan Baan, Jr., Marije M. Vis, Jose P. Henriques, Jan J. Piek, Robbert 
J. de Winter, Academic Medical Center, Amsterdam, The Netherlands
Background: ST-elevation myocardial infarction is mostly due to plaque rupture or erosion 
and subsequent intracoronary occlusive thrombosis at the onset of symptoms. However, 
a heterogeneous composition in terms of thrombus age has been described suggesting a 
discrepancy between the time of onset of the thrombotic process and the occurrence of acute 
clinical symptoms. We aimed to describe the pathohistological characteristics of thrombectomy 
material obtained in a large cohort of STEMI-patients treated with primary PCI.
Methods and Results: Intracoronary thrombectomy during primary PCI was performed 
in 1381 consecutive STEMI patients between August 2001 and September 2007. Patients 
were eligible if there was evidence of acute myocardial infarction with ≥ 2 mm ST elevation 
in 2 or more contiguous leads and symptoms of < 12 hours’ duration. We used two different 
thrombectomy catheters; the Rescue® and the Export® catheter and one proximal 
protection device; the Proxis® device. In 1307 of the patients (95%) thrombectomy was 
performed successfully and in 983 of these patients (75%) intracoronary-derived material 
was obtained. Thrombus age was classified as fresh (< 1 day), lytic (1 to 5 days) and 
organized (> 5 days), according to accepted definitions. We identified thrombus material 
in 936 patients (95%) and thrombus age could be classified in 916 of these patients. 
Thrombus older than 1 day was found in 369 of these patients (40%). Both thrombus and 
plaque components were found in 356 patients (36%) and only plaque components were 
found in 31 of the patients (3%). 
Conclusions: This large single-center thrombectomy study confirms and extends our 
previous observation that in a significant proportion of the STEMI patients (40%) an acute 
coronary occlusion appears to be the final stage in a series of successive thrombotic 
events in the preceding days or weeks.
2900-246 Validation of Model Predicting 30-day Major Adverse 
Cardiac Events in Saphenous Vein Graft Percutaneous 
Coronary Intervention
Alanna Coolong, A. James O’Malley, Donald S. Baim, Richard E. Kuntz, Donald E. 
Cutlip, Laura Mauri, Brigham and Women’s Hospital, Boston, MA, Harvard Clinical 
Research Institute, Boston, MA
Background: Saphenous vein graft (SVG) percutaneous coronary intervention (PCI) 
is associated with a high risk of peri-procedural morbidity. The use of embolic protection 
devices (EPD) has been shown to reduce 30-day major adverse cardiac events (MACE) 
by ~40%. A pooled analysis of 3,958 patients enrolled in 5 randomized, controlled trials 
and one registry evaluating EPDs found angiographic measures of plaque burden to be 
the most potent predictors of adverse outcome. We attempted to confirm the predictive 
value of this multivariable model using an external dataset.
Methods: A multivariable logistic regression model predicting 30d MACE in SVG PCI 
was developed by combining patient data (N=3,958) from trials of EPD in SVG (SAFER, 
FIRE, CAPTIVE, SPIDER, and PROXIMAL randomized, controlled trials and the 
BLAZE II registry). The model identified estimated plaque volume, SVG degeneration 
score, presence of thrombus, age, tobacco use, and glycoprotein IIb/IIIa inhibitor use 
as independent predictors of 30d MACE. Patients enrolled in the PRIDE randomized, 
controlled trial (N=693) and ASPIRE registry (N=113) of the TriActiv EPD in SVG were 
pooled to form an independent validation cohort. The multivariable logistic regression 
model was applied to the validation cohort and a goodness-of-fit estimate was performed 
using the Hosmer-Lemeshow statistic on ordered deciles.
Results: The Hosmer-Lemeshow test statistic was 4.75 (p=0.78) signifying good fit of the 
original model in this independent trial dataset.
Conclusions: A prediction model for 30d MACE in SVG PCI from 3958 patients was 
successfully validated in an independent dataset of 806 patients, confirming its reliability 
in predicting patient outcomes across devices and trials. This model may serve to develop 
a method to evaluate new EPDs against risk-adjusted models in future studies.
2900-247 Impact Of Atrial Fibrillation On The Immediate And 
Long Term Results Of Mitral Balloon Valvuloplasty In 
531 Consecutive Patients
Mohamed Eid Fawzy, Walid Hassan, Adil Osman, Manzoor Memon, Iman Ibrahim, Souad 
El Amraoui, Abdulmoniem El Dali, King Faisal Specialist Hospital, Riyadh, Saudi Arabia
Background: The aim of this study was to assess the effect of AF on the immediate and 
long-term results of mitral balloon valvuloplasty (MBV) in 531 consecutive patients with MS.
Methods: The immediate and long-term (up to 17.8 years) clinical and echocardiographic 
results of MBV of 71 patients with AF at baseline were prospectively collected and 
compared with those of 460 patients in normal sinus rhythm (NSR).
Results: Patients in AF were older 42 ± 12 vs. 30 ± 10 years (P < 0.0001), had high 
echocardiographic score (echo score) 8.45 ± 1.14 vs. 7.95 ± 1 (P = 0.005) and MBV 
resulted in inferior immediate and long-term results as reflected in smaller immediate 
mitral valve area (MVA) 1.89 ± 0.23 cm2 vs. 2.0 ± 0.39 cm2 (P = 0.005) and smaller 
follow-up MVA (1.49 ± 0.39 vs. 1.6 ± 0.4) (P = 0.037), higher restenosis rate 44% vs. 30% 
(P = 0.012). Actuarial freedom from restenosis at 10, 15 years for patients in AF were 
67 ± 6%, 34 ± 8% vs. 77 ± 2%, 46 ± 4% (P = 0.069) respectively, echo score > 8. (P < 
0.0001) age (P = 0.018), NYHA functional class (P = 0.03) were identified as predictors 
of restenosis. Lower survival, the actuarial survival rate at 10 and 15 years were 96 ± 2%, 
72 ± 11% vs. 99 ± 1%, 96 ± 1% (P < 0.0001) respectively and lower event free survival at 
10, 15 years 72 ± 1%, 40 ± 9% vs. 89 ± 1%, 55 ± 4% (P = 0.025) respectively echo score 
> 8 was identified as predictors of combined events (P < 0.0001) at follow-up.
Conclusions: AF has a negative impact on the immediate and long-term outcome after 
MBV. However, the presence of AF is a marker for clinical and morphologic features 
associated with inferior results after MBV.
2900-248 The QuantumCor RF Device: An Alternative To 
Surgical MVR
Richard R. Heuser, Thomas Witzell, Duane Dickens, Patricia A. Takeda, David Allie, 
Michael Caskey, Affiliated Cardiologists of Arizona, Phoenix, AZ, University of Arizona, 
Tucson, AZ
Background: Ischemic mitral regurgitation (MR) is a common problem occurring in up 
to 74% of all myocardial infarctions and results in harmful ventricular remodeling and 
increased morbidity and mortality. The QuantumCor (TM) device uses radiofrequency 
(RF) energy at sub-ablative temperatures to produce contraction of the mitral valve 
annulus and theoretically reduces mitral regurgitation.
Methods: Sixteen healthy sheep (six with naturally-occurring MR) had RF energy 
applied for a mean of 60 seconds at sub-ablative temperatures to replicate a surgical 
mitral annular ring. Four segments of the posterior mitral valve annulus were heated 
while on cardiopulmonary support via a left thoracotomy with access via the left atrial 
appendage. Seven sheep were followed chronically. Two developed systemic infection 
after 30 day follow-up.
Results: All sheep were immediately studied with either intracardiac echocardiography or 
by direct circumferential measurement of the mitral annulus before and after RF therapy. 
The mean anterior-posterior (AP) annular distance was reduced by a mean of 5.75 ± 0.86 
mm (23.8% reduction) (p<0.001). The six sheep with non-ischemic mitral regurgitation 
had the MR eliminated. Acute histopathology (HP) demonstrated no damage to valve 
leaflets, the coronary sinus, or coronary arteries. At 90 days, the AP distance continued 
to be reduced in the five surviving sheep (mean 6.0 ± 2.5mm reduction) (p<0.001). The 
treatment effect was preserved at 180 day follow-up with a mean reduction in the AP 
annular diameter of 8.03 ± 1.4mm (p=0.2). Chronic HP continued to show no valve, 
coronary sinus or coronary artery damage.
Conclusions: In a sheep model, RF energy applied at sub-ablative temperatures in 
four quadrants of the posterior mitral valve annulus can reduce the anteroposterior 
and circumferential annular distance significantly and eliminate non-ischemic MR. The 
annular contraction occurs immediately and appears to be durable without extra annular 
HP damage. This technique could be used either as an alternative to surgical ring 
annuloplasty or potentially as a novel percutaneous method of mitral valve annuloplasty.
2900-249 Stability of Mitral Valve Area and Gradient Following 
Percutaneous Repair of Mitral Regurgitation with the 
MitraClip Device
Howard C. Herrmann, Saibal Kar, Peter Fail, Jason Rogers, Andrew Wang, Andrew 
Berke, Paul Kramer, S. Chiu Wong, Scott Lim, Elyse Foster, Don Glower, Ted Feldman, 
on behalf of the EVEREST Investigators, Hospital of the University of Pennsylvania, 
Philadelphia, PA
Background: Percutaneous repair of mitral regurgitation (MR) by leaflet apposition 
with the MitraClip® device (Evalve, Inc.) is undergoing evaluation. To detect LV inflow 
obstruction, we measured mitral valve area (MVA) and transmitral gradient (MVG) before 
and following repair.
Methods: 104 patients with moderate to severe or severe MR received one Clip (n=64), 
two Clips (n=30), or no Clip (n=10). Echocardiography was performed at baseline, pre-
discharge, and at 12 months. Mean (+SD) MVA by planimetry and pressure half-time 
(PHT) and MVG by Doppler were compared using paired patient data.
Results: MVG increased slightly with treatment (1.8 + 0.9 to 4.1 + 2.2 mmHg, p<0.0001), 
and fell slightly from discharge to 12 months (4.2 + 2.4 to 3.3 + 1.7 mmHg, p<0.001). MVA 
by planimetry showed an expected decrease after Clip repair (6.0 + 1.3 to 3.5 + 1.1 cm2, 
p<0.0001), no change from discharge to 12 months (3.5 + 1.3 to 3.4 + 0.9 cm2, p=NS), 
and no differences between patients who received one vs. two Clips (Figure). MVA by 
PHT showed similar results over time with a smaller MVA than by planimetry that also 
remained stable to 12 months (cm2): 4.0 + 0.8 (baseline), 2.9 + 1.2 (discharge), 2.8 + 
0.9 (12 month).
Conclusions: 1) Echocardiography demonstrates an expected decrease in MVA after 
percutaneous MitraClip repair without clinically significant mitral obstruction. 2) There is 
no significant difference in MVA or MVG between one and two Clips, and no evidence of 
progressive mitral inflow obstruction from discharge to 12 months. 
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2900-250 18 Years Clinical And Echocardiographic Follow-
up Results Of Mitral Balloon Valvuloplasty In 531 
Consecutive Patients And Predictors of Long-Term 
Outcome
Mohamed Eid Fawzy, Adil Osman, Omar Nowayhed, Souad El Amraoui, Shabir Shah, 
Iman Ibrahim, Abdulmoniem El Dali, King Faisal Specialist Hospital, Riyadh, Saudi 
Arabia
Background: Long-term echocardiographic follow-up studies of mitral balloon 
valvuloplasty (MBV) are scarce. The aim of this study was to assess the long term results 
(up to 18 years) of MBV and to identify predictors of restenosis and event-free survival.
Methods: We report the immediate and long term clinical and echocardiographic results 
in 531 consecutive patients, (385 female) mean age 31 ± 11 years, who underwent 
successful MBV for severe mitral stenosis (MS) and were followed up for 1.5 - 18 (mean 
8.5 ± 4.8) years after MBV.
Results: Mitral valve area (MVA) increased from 0.92 ± 0.17 to 1.95 ± 0.29 cm2 (P < 
0.0001. Restenosis occurred in 165 (31%) patients and it was less frequent in patients 
with low echo echo score (MES ≤ 8) (19%). Actuarial freedom from restenosis at 10, 15, 
18 years were (77 ± 2, 46 ± 3%, 18 ± 4%) respectively, and were significantly higher in 
patients with (MES ≤ 8) (86 ± 2%, 62 ± 4%, 30 ± 7%) respectively (P < 0.001). Event-free 
survival (death, redo MBV, MVR, NYHA Functional Class III or IV) at 10, 15, 18 years 
were 88 ± 1%, 54 ± 4%, 21 ± 5% respectively, and were significantly higher for patients 
with (MES ≤ 8) 92 ± 1%, 67 ± 4%, 38 ± 8% respectively (P < 0.001). Cox regression 
analysis identified MES > 8 (P < 0.0001), female gender (P = 0.021) as predictors of 
restenosis and MES ≤ 8 (P < 0.0001), as predictors of event free survival.
Conclusions: MBV provides excellent long-term results for selected patients with MS. 
The long-term outcome of this procedure can be predicted from baseline clinical and 
echocardiographic characteristics of the mitral valve.
2900-251 Percutaneous Mitral Valvuloplasty During Pregnancy
Hung Manh Pham, Hieu Lan Nguyen, Quang Ngoc Nguyen, Loi Doan Do, Viet Lan 
Nguyen, Khai Gia Pham, Vietnam Heart Insitute, Hanoi, Viet Nam, Hanoi Medical 
School, Hanoi, Viet Nam
Background: Circulatory changes in gestation, a hyperdynamic adaptive state in 
general, cause an additional burden on the cardiovascular system of women with 
rheumatic mitral stenosis (MS). Percutaneous Mitral Valvuloplasty (PMV) has emerged 
as an effective nonsurgical technique for the treatment of patients with symptomatic MS 
during pregnancy.
Methods: From November 1999 to Dec. 2006, 75 pregnant women (among 4200 PMV 
patients) were performed PMV using Inoue balloon at Vietnam Heart Institute. The 
transthoracic echocardiography was used in combination with intermittent fluoroscopy 
to limit the radiation exposure time. A detailed clinical, echocardiographic, hemodynamic 
assessment was analyzed pre, post procedure, at every 3 months for the first year and 
at 6-month interval thereafter. The pregnancy and newborn babies outcomes were also 
followed.
Results: MS pregnant women were 27,6 years old on average (ranged 22-42) and the 
mean length of pregnancy was 24,2 ± 5,6 weeks. Echo score of mitral valve was 7,1 ± 2,3. 
The procedure was technically successful in all cases without any complications. The total 
mean duration of the procedure was 35,25 ± 14,28 min and that of fluoroscopy 2,55 ± 1,28 
min (from 1 min 59 sec to 3 min 15 sec). The fluoroscopy time was significantly shorter 
than that of usual patients not using echo guided (2 min 23 sec vs. 7 min 23 sec, p< 0,01). 
The mitral valve area increased from 0,7 ± 0,3 to 1,9 ± 0,4 cm2 (on 2D echocardiography) 
and from 0,8 ± 0,4 to 2,0 ± 0,4 cm2 (on PHT) (p< 0.01). A reduction in mean transmitral 
valve gradient (MVG) was from 22 ± 6 to 8 ± 2 mmHg. There were no maternal or fetal 
deaths. All patients delivered at full term but 4 (without major complications), 34 vaginally 
and 41 by caesarean section. After average 36 months follow-up (range, 3 to 60) all 
children had normal growth.
Conclusions: During pregnancy, Percutaneous Mitral Valvuloplasty could be considered 
as the treatment of choice of severe pliable mitral stenosis which are refractory to medical 
treatment. Using echocardiography guided can reduce the fluoroscopy time.
2900-252 PERCUTANEOUS AORTIC VALVES: Predicting 
Appropriate Size
Vasilis Babaliaros, David Liff, Edward Chen, Jason Rogers, Ryan Brown, Vinod 
Thourani, Robert Guyton, Stamatios Lerakis, Arthur Stillman, Paolo Raggi, Jennifer 
Cheesborough, Jacob Green, Peter Block, Emory University Hospital, Atlanta, GA, 
University of California, Davis, Sacramento, CA
Background: Exact sizing of percutaneous aortic heart valves (PHV) is not clear.
Methods: Patients (pts, n=33) with aortic stenosis (< 1.0cm2) scheduled for surgical 
valve replacement were enrolled. Pre-operative echo measurements were made by TTE 
and TEE. Valve calcification was classified by Computed Tomography (Calcium scoring) 
as mild (<1500), moderate (<5000) or heavy (≥ 5000 Agatston Units). Intra-operative 
balloon aortic valvuloplasty (BAV) was performed (8 pts with ≥2 different balloon sizes), 
and intra-balloon pressure recorded at BAV and on a sterile table. The difference (push 
back pressure) quantified apposition between balloon and annulus. Surgical annulus was 
measured by cylindrical sizers after leaflets were resected.
Results: Mild, moderate and heavy calcification was seen in 24, 55 and 21% of pts. Push 
back pressure (≥0.2atm) was generated in 15/16 vs 4/17 pts when the balloon diameter > 
surgical annulus (FIGURE) and 12/13 vs 8/20 pts when balloon diameter > TEE annulus 
+ 2mm (not related to calcium score). Leaflet dehiscence occurred in 2 pts (bicuspid, 
balloon 3mm ≥ annulus). Annulus size was underestimated by TTE and TEE (p<0.05) 
compared to surgery: TTE=21.5±1.8mm, TEE=22.0±1.6mm, Surgical=23.2±1.9mm (20-
27mm, mode 22mm).
Conclusions: Balloon oversizing the annulus is important to generate push back 
pressure (apposition) regardless of leaflet calcium. TEE consistently underestimates 
surgical annulus size. These data suggest a strategy of PHV sizing > 2mm above TEE 
annulus. 
2900-253 Gender differences in Procedural and Clinical 
Outcomes after Percutaenous Balloon Mitral 
Valvuloplasty
Hani Jneid, Ignacio Cruz-Gonzalez, Maria Sanchez-Ledesman, Juan Pal Otero, 
Santiago Vigo, Roberto J. Cubeddu, Andrew O. Maree, Igor F. Palacios, Massachusetts 
General Hospital, b, MA
Background: Few studies examined the outcomes of percutaneous balloon mitral 
valvuloplasty (PMV) among men and women. Methods: We compared procedural 
success, complications and long-term clinical outcomes between 839 consecutive women 
and 176 consecutive men undergoing a first PMV procedure for mitral stenosis (MS) at 
a single center between 1986 and 2005. The PMV procedure was performed using the 
trans-septal antegrade approach and either the double-balloon or Inoue technique. We 
compared outcomes and measures first without adjustment and then after adjustment of 
11 clinical, hemodynamic and mitral valve morphological variables. Results: Men had 
higher baseline echocardiographic score and pre-procedural MV area (MVA: 0.9±0.3 vs. 
1.0±0.3, P =0.002) than women, and were less likely to undergo PMV with the Inoue 
technique (36 vs. 24%, P= 0.003). Men had lower incidence of severe post-PMV mitral 
regurgitation (4.0 vs. 9.4%, P = 0.02), higher PMV success rate (83 vs. 69%, P 0.001) 
and higher likelihood to achieve a post-PMV MVA ≥ 1.5 cm2 (87 vs. 74%, P =0.001). After 
multivariate adjustment, men remained more likely to achieve PMV success and larger 
post-procedural MVA, and had no differences in procedural and in-hospital complications 
compared with women. Men were also less likely to undergo MV surgery and more likely 
to have redo-PMV during long-term follow-up (Table 1). Conclusions: Men undergoing a 
first PMV procedure for MS have better immediate and long-term outcomes.
Table 1. 
Outcome/Measure
Men vs. Women  
Odds/Risk Ratio  
(95% CI)
P value
PMV procedure variables
PMV success (Post PMV MVA ≥ 1.5 cm2 and MR 
< 3) 2.16 (1.29-3.60) 0.003
Post-PMV MVA increase ≥ 50% 1.78 (1.04-3.11) 0.03
Post-PMV MVA ≥ 1.5 cm2 2.35 (1.32-4.17) 0.003
Severe post-procedural MR ≥ 3+ 0.42 (0.17-1.02) 0.06
In-hospital Outcomes
Procedure-related death 0.91 (0.20-4.11) 0.9
Total in-hospital death 1.52 (0.27-8.45) 0.6
Emergent MV surgery 1.39 (0.26-7.34) 0.7
Total in-hospital surgery 0.32 (0.07-1.47) 0.3
Cardiac Tamponade 0.64 (0.06-6.27) 0.7
Stroke 0.92 (0.23-3.61) 0.9
Heart block 1.21 (0.11-13.26) 0.9
Long-term Outcomes
Death 1.16 (0.75-1.8) 0.5
MV surgery 0.62 (0.41-0.95) 0.03
Redo PMV 2.07 (1.02-4.19) 0.04
Combined clinical end point (death + redo-PMV+ 
MV surgery) 1.01 (0.76-1.3) 0.9
2900-254 Quality of Life Improvements Following Transcatheter 
Aortic Valve Replacement: Results From the REVIVAL II 
Feasibility Study
Matthew R. Reynolds, Jeffrey W. Moses, Lars G. Svensson, Joshua Walczak, Ronna 
Berezin, David J. Cohen, for the REVIVAL II Investigators, Beth Israel Deaconess 
Medical Center, Boston, MA, Mid-America Heart Institute, Kansas City, MO
Background: The feasibility of treating aortic stenosis (AS) with a catheter-mounted 
valve prosthesis has recently been shown. The aim of the present study was to measure 
changes in quality of life (QOL) following treatment of AS with the Edwards SAPIEN™ 
transcatheter heart valve.
Methods: In the REVIVAL II study, 75 patients aged ≥70 years with critical AS (valve 
area ≤0.7 cm2) considered unacceptable for surgery underwent attempted placement 
of the study valve. The valve was delivered by a transfemoral, retrograde aortic or trans-
apical antegrade approach via a limited thoracotomy. General and disease-specific QOL 
were assessed using the Short Form-12 (SF-12) and Kansas City Cardiomyopathy 
Questionnaire (KCCQ), at baseline, 30 days, 6 and 12 months. Follow-up scores were 
compared with baseline scores in pairwise manner.
Results: The mean age was 83±6 years. At baseline, physical health and cardiac-specific 
QOL were markedly impaired (see Table). At 30 days, statistically significant improvement 
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in the KCCQ summary score was seen, but not in the summary scores of the SF-12. At 
6 months, significant improvements were seen in all 3 scales. Study follow-up is ongoing, 
with 12 month results expected in early 2008.
Conclusions: In an elderly cohort of non-surgical candidates with critical AS, successful 
transcatheter aortic valve replacement was associated with large, clinically meaningful 
improvements in QOL over 6 months. 
Baseline 
(N=75)
30 Days 
(N=62)
P-value 
(Baseline - 30d)
6 Months 
(N=36)
P-value 
(Baseline - 6 Months)
SF-12/ Physical 30.8±8.3 33.3±8.9 0.06* 36.9±9.9 0.001
SF-12/ Mental 46.7±10.4 44.8±10.6 0.53* 52.7±8.7 0.01*
KCCQ 38.6±21.0 54.8±25.0 <.001 70.3±20.7 <.001
Scores = mean ± s.d. *p-value from sign test; others from paired t-tests
2900-255 Prevalence of Diastolic Trans-mitral Valve Gradient in 
Patients with Severe Calcific Aortic Stenosis
Gerald Yong, Aman Ali, Ted Feldman, Evanston Northwestern Healthcare, Evanston, IL
Background: During antegrade balloon aortic valvuloplasty (BAV), transmitral valve 
pressure gradients (MVG) were noted frequently on hemodynamic assessment.
Aim: Determine the prevalence and significance of a diastolic MVG in patients with aortic 
stenosis (AS) and no diagnosed mitral valve stenosis.
Method: Retrospective chart review of patients with severe non-rheumatic AS undergoing 
antegrade BAV. During antegrade BAV, direct left atrial (LA) and left ventricular (LV) 
pressure measurements were obtained allowing for accurate assessment of MVG. 
Significant MVG is defined as a LA-LV gradient of ≥5mmHg.
Results: 82 BAV patients were reviewed (mean age 84 years, Euroscore ≥6 in 100%). 
MVG ranged from 0 to 14mmHg, with mean 5.0+3.5mmHg. A significant MVG was seen 
in 54.9%, and was associated with significantly higher LA mean pressure, pulmonary 
arterial (PA) mean pressure and PA systolic pressure at baseline and post-BAV (see 
table). A weak but statistically significant correlation was seen between MVG and baseline 
LA mean pressure (r=.65, p<.001), PA systolic (r=.49, p<.001) and PA mean pressures 
(r=.41, p<.001). There was no association with cardiovascular risk factors, with presence 
or severity of mitral annular calcification (visually assessed on cinefluroscopy) or with the 
presence of mitral regurgitation.
Conclusion: A significant MVG is common in elderly patients with severe AS. It is 
associated with higher LA and PA pressures. The clinical significance of this finding is 
yet to be determined.
LA and PA Pressures, in mmHg; Mean (Standard Deviation)
LA-LV≥5mmHg LA-LV≤5mmHg p-value
BASELINE
LA mean pressure 16.8 (6.6) 26.0 (6.0) <0.001
PA mean pressure 28.0 (11.4) 37.7 (10.4) <0.001
PA systolic pressure 43.1 (16.5) 59.3 (14.7) <0.001
POST-BAV
LA mean pressure 14.9 (5.9) 22.5 (7.7) <0.001
PA mean pressure 30.9 (8.8) 38.6 (9.4) 0.012
PA systolic pressure 50.6 (16.5) 63.5 (13.8) 0.009
2900-256 Bicuspid Aortic Valve in athletes : an echocardiographic 
follow up . 
Laura Stefani, Sr., Roberto Mercuri, Jr., Loira Toncelli, Sr., Vlentina Di Tante, Jr., Maria 
Concetta Robertina Vono, Sr., Giorgio Galanti, Sr., Sport Medicine Cenyter, Florence, Italy
Background : Bicuspid aortic valve (BAV) is a common congenital cardiac disease in the 
general population and in athletes. Data on the cardiac parameters are available in non 
-athletic BAV population . Though BAV is compatible with sports activity, the impact that 
regular training may have on the heart has not yet been investigated. We followed up with 
echocardiography a group of competitive athletes with BAV matched with tricuspid aortic 
valve ( TAV) group .
Methods: A group of 120 consecutive athletes diagnosed with BAV were followed 
from January 1999 to December 2005 with yearly echocardiographic evaluations. 60 
of these athletes had a full 5 years of follow up. The protocol study was performed at 
the University Teaching Hospital Specialist Clinic of Florence( Italy) . Results: After five 
years, BAV athletes showed significant progression of left ventricular dimensions and 
aortic diameters ( tab1) despite the values maintain within the range of the general non-
athletic BAV populations described in previous studies. In TAV athletes, the aortic and 
left ventricle dimensions did not increase significantly, and remained within physiological 
range. Conclusions: There is a significant progressive increase in aorta and left 
ventricular measurements in competitive BAV athletes as compared to TAV athletes. The 
rate of the progression in BAV athletes is similar to that in the non-athletic BAV population. 
Sports activity does not have a deleterious impact on cardiac morphology in athletes with 
asymptomatic BAV.
Tab 1 
BAV=60 Year 1 Year 2 Year 3 Year 4 Year 5 P
Aoan 29.30 ± 5.57 30.33 ± 7.87 31.00 ± 7.85 32.03 ± 5.29 32.40 ± 4.79 <0.001
Aos 33.80 ± 5.27 34.47± 6.12 36.32 ± 5.52 36.17 ± 5.28 36.27± 5.57 <0.001
AOj 31.67 ± 5.27 31.71± 5.13 32.95 ± 4.95 33.54 ± 4.69 34.93 ± 5.00 <0.001
PAA 31.75 ± 5.70 31.59 ± 6.22 33.27 ± 5.37 33.63 ± 5.71 35.67 ± 5.76 <0.001
LVDD mm 50.86 ± 6.11 51.16 ± 6.25 51.68± 5.64 53.03 ± 5.57 53.70 ±4.84 <0.001
LVSD mm 32.48 ± 5.41 32.50 ± 4.78 32.63± 4.56 33.93 ± 5.14 34.57± 4.72 <0.001
EF% 64.70±5.01 63.90± 5.02 64.67 ± 4.79 63.78±5.4 64.33±4.79 NS
2900-257 Presence of Significant PAD in Patients Assessed for 
Percutaneous Aortic Valve Replacememt. Implications 
for Feasibility of the Transfemoral Approach
Srikanth Sola, Vikram Kurra, Lars Svensson, Murat Tuzcu, Samir Kapadia, Roy 
Greenberg, Eric Roselli, Sandra Halliburton, Paul Schoenhagen, Cleveland Clinic, 
Cleveland, OH
Background: Percutaneous aortic valve replacement (PAVR) is an emerging treatment 
option for selected patients with advanced aortic stenosis (AS) and may be done from 
a transfemoral or transapical approach. The prevalence of significant peripheral arterial 
disease (PAD)/unsuitable iliofemoral anatomy in this high-risk population is unknown. We 
evaluated the utility of cardiac multi-detector computed tomography (MDCT) in identifying 
suitable candidates for a transfemoral approach to PAVR.
Methods: We evaluated consecutive patients with calcific AS who were referred for 
PAVR. Patients with known peripheral vascular disease were excluded. All patients were 
scanned on a Siemens Definition Dual Source MDCT scanner after receiving iodinated 
contrast. Images of the chest, abdomen, and pelvis to the level of the mid thigh were 
reconstructed at 3 mm slice thickness to evaluate the aorta and iliofemoral vessels. The 
common iliac, external iliac, and common femoral arteries were evaluated for minimal 
luminal diameter < 8 mm, severe calcification, presence of dense calcification at the iliac 
bifurcation, and angulation of the external iliac to the common and internal iliac arteries.
Results: 45 patients (82±7 years, 55% male) were enrolled. The mean luminal diameter 
of the common iliac, external iliac, and common femoral arteries were 11.2±1.7 mm, 
8.9±1.1 mm, and 9.4±1.0 mm, respectively. 10 patients had a minimal luminal diameter 
of < 8 mm and were excluded from the transfemoral approach. An additional 5 patients 
had adequate luminal diameters of the iliofemoral arteries but had severe circumferential 
(>60%) calcification or severe calcification at the external-internal iliac bifurcation that 
made a transfemoral approach unsuitable. In all, 15 of 45 patients (33%) were excluded 
from a transfemoral approach due to unsuitable iliofemoral anatomy.
Conclusions: PAD is common in the high-risk patient population currently evaluated 
for PAVR. Cardiac MDCT is useful to identify patients who are suitable candidates for 
a transfemoral approach to PAVR and allows preprocedural planning of arterial access 
strategies.
2900-258 Balloon valvuloplasty for native isolated rheumatic 
tricuspid stenosis
Sunil V. Sathe, Manuel Durairaj, Rituparna Shinde, Chandrashekhar Makhale, Shirish 
MS Hiremath, Archana Sathe, Siddarth Gadage, Rajiv B. Sethi, Purvez Grant, Grant 
Medical Foundation, Ruby Hall Clinic, Pune, India
Background: Incidence of native rheumatic tricuspid stenosis has been found to vary 
from 5-30% in clinical and pathological studies in cases of rheumatic valvular heart 
disease. Coexisting tricuspid stenosis in patients with significant mitral stenosis is 
often treated with concurrent balloon tricuspid valvuloplasty. Isolated balloon tricuspid 
valvuloplasty without hemodynamically significant mitral stenosis has not been reported 
extensively. We performed isolated balloon tricuspid valvuloplasty for rheumatic tricuspid 
stenosis in 12 cases.
Methods: We performed balloon tricuspid valvuloplasty in 12 cases of isolated rheumatic 
tricuspid stenosis. 8/12 cases were previously treated with balloon mitral valvuloplasty , 2 
had mitral valve replacement and 2 had open mitral valvotomy. All had mild to moderate 
mitral valve disease not requiring intervention . Inoue balloon was used in 8 cases. We 
used Mansfield double balloon with double length wire in right pulmonary artery in 4 
patients. Results: Good immediate results obtained in all cases. The mean gradient 
across the tricuspid valve reduced from 11mm +/- 2.2 mmHg to 1.6 +/- 0.7 mmHg after 
balloon tricuspid valvuloplasty. Conclusions: Isolated balloon tricuspid valvuloplasty 
for rheumatic tricuspid stenosis is feasible and provides good reduction in the gradient 
across the tricuspid valve. With improving longevity following mitral valve intervention, this 
subgroup should be recognized and appropriately treated.
2900-259 N-Acetylcysteine Enhanced Angiographic Contrast 
Provides Cardiorenal Protection
Markus Meyer, Martin LeWinter, Stephen Bell, Zengyi Chen, Donald Selby, Dinender K. 
Singla, Harold L. Dauermann, University of Vermont College of Medicine, Burlington, VT
Background: We hypothesized that intracoronary administration of N-Acetylcysteine 
(NAC) mixed with a radiographic contrast agent could provide both cardiac and renal 
protection in a pig model of ischemia-reperfusion.
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Methods: Twelve pigs underwent coronary angiography followed by one hour of a mid left 
anterior descending artery (LAD) balloon occlusion. Each pig received a total of 200mL of 
intracoronary angiographic Iopamidol contrast. In seven animals, NAC (11.3mg/mL) was 
added to the contrast. The following end points were analyzed 24 hours after restoration 
of blood flow: area of myocardium at risk for myocardial infarction (MI), infarct size and 
morphology, apoptosis, ventricular arrhythmias and renal function.
Results: Intra-coronary administration of NAC enhanced contrast alone did not result 
in arrhythmias or hemodynamic instability. There was no significant difference in the 
area at risk between control animals receiving contrast-only (C) and animals receiving 
NAC enhanced contrast (C-NAC). In comparison, MI size in C-NAC treated animals was 
significantly smaller compared with the controls (8.2±2.3% of ventricular weight versus 
13.9±4.5%, p<0.05). In the control group 92 percent of the area at risk demonstrated a MI 
compared with 45 percent in the C-NAC group (p<0.001). MIs in the C-NAC group were 
mottled in appearance, whereas MIs in the controls were homogenous and had a discrete 
border zone (MI circumference/ MI area index 3.2±0.5 versus 1.9±0.2, p<0.001). This 
observation may explain a higher incidence of peri-procedural ventricular arrhythmias 
in the C-NAC group (C-NAC: 6/7 animals; C: 1/5 animals). In addition, histological 
comparison of C-NAC versus C revealed that apoptosis in the area at risk was 20-fold 
reduced in C-NAC myocardium. At 24 hours after contrast exposure, intracoronary C-NAC 
administration blunted the rise in serum creatinine levels from 37 percent in the control 
group to 15 percent in the C-NAC group (p<0.05).
Conclusions: N-Acetylcysteine enhanced contrast medium reduced MI size by about 
50 percent and protected renal function in a pig model of ischemia and reperfusion. This 
strategy might be beneficial in patients undergoing coronary interventions.
2900-260 White Blood Cell Count Is an Independent Predictor 
of Contrast-induced Nephropathy After Coronary 
Angiography
Annunziata Nusca, Faisal Shaikh, Antonio Abbate, Evelyn Goudreau, Michael Cowley, 
Germano Di Sciascio, George Vetrovec, Virginia Commonwealth University, Richmond, VA
Background: Inflammation may play a central role in the pathophysiology of contrast-
induced nephropathy (CIN) and white blood cell (WBC) count has been demonstrated 
as an unfavorable prognostic indicator in patients with chronic renal failure. The aim of 
this study was to determine the predictive value of pre-procedural WBC count for the 
incidence of CIN in a selected population of high-risk patients with pre-existing renal 
dysfunction or diabetes.
Methods: We selected a cohort of 466 patients with pre-existing chronic kidney disease 
defined as an estimated glomerular filtration rate (eGFR) <60ml/min/1.73m2, who 
underwent coronary angiography. GFR was estimated by applying the Levey Modified 
Modification of Diet in Renal Disease (MDRD) formula. CIN was defined as in increase 
of > 25% or > 0.5mg/dl in baseline serum creatinine occurring within 72 hours after the 
procedure. WBC count quartiles of distribution were used and a pre-specified cutoff of 
11.7x103 cells/mm3 (upper limit of normal for local laboratory) was also considered.
Results: The incidence of CIN was 21% in the entire population. Patients that sustained 
CIN included more likely to be diabetic, have CHF, as well as have a higher baseline serum 
creatinine and lower eGFR (p < 0.05). Considering WBC count quartiles, a significant 
trend towards an increase in the incidence of CIN was observed with increasing WBC 
counts, from 14% in the lowest quartile to 27% in the highest quartile (P for trend = 
0.014, RR for quartile IV Versus quartile I =1.95 [95% CI 1.13-3.35]). When we used a 
pre-specified cutoff of 11.7x103 cells/mm3, the incidence of CIN was 19% in patients with 
WBC count < 11.7x103 cells/mm3 and 34% in patients with WBC > 11.7x103 cells/mm3 
(p=0.008; RR =1.78 [95% CI 1.18-2.63]) Diabetes, CHF, baseline serum creatinine and 
WBC quartiles (p=0.006) were independent predictors of CIN.
Conclusions: The current study shows for the first time that WBC count, a readily available 
systemic marker of inflammation, is an independent predictor for the development of CIN 
in patients with chronic kidney disease undergoing coronary angiography.
2900-262 Safety and Diagnostic Efficacy of Iodixanol vs 
Iopromide in Patients with Renal Insufficiency 
Undergoing Coronary Angiography: A Randomized, 
Controlled Trial
Bin Nie, Wan-jun Cheng, Yan-fang Li, Zheng Cao, Qing Yang, Ying-xin Zhao, Yong-he 
Guo, Yu-jie Zhou, Beijing Anzhen hospital, Beijing, People’s Republic of China
Background: With the growing number of indications for contrast-enhanced procedures, 
the safety and efficacy of contrast media (CM) have come under increased scrutiny. 
This study was undertaken to compare the renal safety, as well as cardiac impact and 
diagnostic quality, of the iso-osmolar CM iodixanol and the low-osmolar CM iopromide in 
patients with renal insufficiency undergoing coronary angiography. 
Methods: In this single-center, prospective study, 208 patients with renal insufficiency 
were randomized to iodixanol (n=106) or iopromide (n=102) as the CM for coronary 
angiography. The primary end point was the incidence of contrast-induced nephropathy 
(CIN). Secondary end points were the frequency of early major adverse cardiac 
events (MACE) and the quality of diagnostic information produced during the coronary 
angiography.
Results: CIN incidence was significantly lower with iodixanol than iopromide (5.7% vs 
16.7%; p=0.011). Baseline SCr (OR 2.21, 95% CI 1.25 to 3.47; p=0.031), iopromide use 
(OR 2.56, 95% CI 1.18 to 5.76; p=0.024), and CM volume (OR 2.01, 95% CI 1.01 to 
3.21; p=0.038) were identified as independent risk factors for CIN in this population. The 
composite MACE outcome favored iodixanol (1.9% vs 8.8%; P=0.025). The quality of 
diagnostic information from the 2 CM was similar (p=0.354).
Conclusions: Findings for this study population at high risk of CIN and undergoing 
coronary angiography suggest that the iso-osmolar CM iodixanol is associated with less 
nephrotoxicity and fewer cardiovascular-related complications than the low-osmolar CM 
iopromide, with no apparent difference in diagnostic quality.
2900-263 Long-term Clinical Outcomes and Stent Thrombosis 
Rates of Sirolimus-eluting Versus Bare-metal Stents 
in Patients with End-stage Renal Disease; Results 
of Korean Multicenter Angioplasty Team (KOMATE) 
Registry
Byoung-Keuk Kim, Sungjin Oh, Dong Woon Jeon, Jung-Sun Kim, Donghoon Choi, 
Yangsoo Jang, Bum-Kee Hong, Hyuk Moon Kwon, Seung-Whan Lee, Choong Won 
Goh, Kihwan Kwon, Sung Kee Ryu, Joo Young Yang, National Health Insurance 
Corporation Ilsan Hospital, Goyang-si, South Korea
Background: Although sirolimus-eluting stents (SES) have been shown to markedly 
reduce restenosis, there are still controversies about the safety issues in high-risk 
patients. The aim of this study is to compare long-term outcomes and stent thrombosis 
(ST) rates in patients with end-stage renal disease (ESRD) following SES versus bare-
metal stent (BMS) implantation.
Methods:Between 2003 and 2005, a total 58 patient (80 lesions) with ESRD undergoing 
SES implantation (SES-ESRD group) were enrolled and compared with 50 patients 
(54 lesions) with ESRD receiving BMS (BMS-ESRD group) in a Korean Multicenter 
Angioplasty Team (KOMATE) Registry. We assessed the incidences of major adverse 
cardiac events [MACE; death, myocardial infarction (MI), target-vessel revascularization 
(TVR)] and ST, by Academic Research Consortium definition, of the 2 groups.
Results:Although SES-ESRD group had more diabetes and longer lesion length with 
smaller vessel diameter, 1-year MACE rate of this group was significantly lower than 
that of BMS-ESRD group (See Table). However, during the long-term follow-up (mean; 
34.1±9.9 months), there were no statistical differences in the mortality, overall MACE, 
and cumulative 3-year MACE-free survival rates between the 2 groups. The incidences of 
definite or probable ST were similar between both groups (See Table).
Conclusions: The use of SES did not increase the risks of death, overall MACE, and ST 
in patients with ESRD during the long-term follow-up, as compared with BMS. 
SES-ESRD group 
(n=58)
BMS-ESRD group 
(n=50) P-value
Diabetes (%) 79 60 0.041
Lesion length, mm 26.0 ± 7.9 19.8 ± 9.0 0.001
Vessel diameter, mm 2.83 ± 0.53 3.11 ± 0.43 0.001
1-year MACE rate (%) 12.5 30.0 0.031
Overall-MACE rate (%) 31.0 40.0 0.419
- Death (%) 17.2 20.1 0.792
- MI (%) 3.4 2.0 0.951
- TVR (%) 10.3 22.0 0.112
ST rate (%) 13.8 14.0 (%) 1.000
Definite or probable ST rates (%) 8.6 6.0 0.722
2900-264 Iloprost prevents Contrast-Induced Nephropathy in 
high-risk patients undergoing a coronary procedure. 
Results of a randomized study.
Konstantinos S. Spargias, Elias Andreanides, Angeliki Gouziouta, Eftihia Demeruti, 
Athanasios Manginas, Gregory Pavlides, Vassilios Voudris, Dennis Cokkinis, Onassis 
Cardiac Surgery Centre, Athens, Greece
Background: The prevention of contrast-induced nephropathy (CIN), which accounts for 
considerable morbidity and mortality, remains a vexing problem. Contrast-induced renal 
vasoconstriction is believed to play a pivotal role in the CIN mechanism. The aim of this 
study was to examine the efficacy of the prostacyclin analogue iloprost in preventing CIN 
in high-risk patients undergoing a coronary procedure.
Methods: Consecutive patients (n=205) undergoing coronary angiography and/or 
intervention who had a serum creatinine concentration ≥1.4 mg/dL were randomized to 
receive intravenous iloprost at 1 ng/kg/min or placebo, beginning 30-90 minutes before 
and terminating 4 hours after the procedure. Intravenous hydration with 1.5ml/kg/h normal 
saline was started in all patients at least 4 hours before contrast exposure and continued 
for at least 12 h after the procedure. CIN was defined by an absolute increase of serum 
creatinine ≥0.5 mg/dL or a relative increase of ≥25% measured 2 to 5 days after the 
procedure.
Results: One patient randomized to placebo died before contrast exposure. No cases 
of CIN requiring renal replacement therapy occurred during follow-up. The mean volume 
of contrast agent used in the study patients was 234±110 ml. CIN occurred in 8 of the 
102 patients (8%) in the iloprost group and in 24 of the 103 patients (23%) in the placebo 
group (OR 0.28; 95% CI 0.12 to 0.66, p=0.003). The mean serum creatinine concentration 
increased significantly in the placebo group (from 1.59±0.49 to 1.73±0.66 mg/dL, p=0.001) 
but not in the iloprost group (from 1.63±0.49 to 1.66±0.73 mg/dL, p=0.51). Conclusions: 
Prophylactic intravenous administration of the prostacyclin analogue iloprost appears to 
prevent CIN in high-risk patients undergoing a coronary procedure.
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2900-265 Risk Scoring System for Prediction of Contrast 
Induced Nephropathy In Patients With Preexisting 
Renal Impairment Undergoing Percutaneous Coronary 
Intervention
Eric Chong, Shen Liang, Kian Keong Poh, Huay Cheem Tan, The Heart Institute, 
National University Hospital, Singapore, Singapore, Biostatistic Unit, National University, 
Singapore, Singapore
Background: Renal impairment is the most recognized risk factor for developing contrast 
nephropathy (CIN) post percutaneous coronary intervention (PCI). We examine other risk 
factors in this group and develop a risk model for prediction of CIN.
Methods: A cohort of 770 patients with existing renal impairment (estimated glomerular 
filtration rate (GFR) < 60ml/min/1.73m2) who received prophylactic saline hydration and 
oral N-acetylcysteine while undergoing PCI between May 2001 to March 2007 in our 
centre were enrolled. The study endpoint CIN, is defined as >25% increase from baseline 
creatinine within 48 hours post PCI.
Results: Despite prophylaxis, CIN occurred in 11.4% of patients. Uni-variate tests showed 
that clinical predictors for CIN were age (OR 1.59 95% CI 1.0-2.52 p=0.049), anemia with 
hemoglobin < 11g/dl (OR 2.26 95% CI 1.41 - 3.61 p=0.001), post PCI creatinine kinase 
rise (OR 1.12 95% CI 1.07 - 1.16 for every 500 U/l rise p<0.001), systolic hypotension 
with blood pressure <100mmHg (OR 2.53 95% CI 1.16 - 5.52 p=0.016), contrast volume 
(p=0.032) for every 50ml use. The incidence of CIN was significantly higher in patients 
with existing severe renal failure (6.3%, 17.4%, 40.8% in mild, moderate, severely 
impaired renal groups respectively, p<0.001). A prediction model was developed based 
on the findings: 
Clinical Predictors Assigned score
Age > 70 1
GFR (ml/min/1.73m2) 
Mild (40 - 60) 
Moderate (20 - 40) 
Severe (< 20)
0 
2 
6
CK (every 500 u/l increase) 0.5
Contrast volume (every 50ml increase) 0.5
Score range Risk Incident rate of CIN
0 - 4 Low 2.0%
4.5 - 6.5 Moderate 12.4%
7 - 8 High 35.0%
8.5 and above Extremely high 57.4%
Conclusion: Patients with impaired renal function undergoing PCI are at high risk of 
developing CIN despite traditional prophylaxis. A model of risk prediction could be used 
to predict its occurrence.
2900-266 Alpha Lipoic Acid for Preventing Contrast-Induced 
Nephropathy in Patients Undergoing Coronary 
Angiography (ALIVE study) - A Prospective 
Randomized Trial
Sang-Ho Jo, Hyun-Sook Kim, Jun-Hee Lee, Woo-Jung Park, Goo-Yeong Cho, Young-Jin 
Choi, Gyu-Rok Han, Dong-Jin Oh, Chong-Yun Rhim, Hallym University Sacred Heart 
Hospital, Anyang-si, Gyeonggi-Do, South Korea
Background: N-acetylcysteine and ascorbic acid have been reported to be efficacious 
in preventing contrast induced nephropathy (CIN) after coronary angiography through 
their antioxidants property. However there have been many controversies regarding their 
role. We evaluated the efficacy of widely used antioxidant- alpha lipoic acid (ALA) for 
prevention of CIN.
Methods: We conducted a prospective randomized controlled trial to evaluate the efficacy 
of ALA in CIN prevention. A total of 108 patients with basal renal insufficiency (creatinine 
clearance [CrCl] <60ml/min) were randomized to have ALA for 2 days (600mg orally three 
times a day before and after coronary catheterization, totally 3600mg, n=53) or placebo 
(n=55). All the patients received hydration with iso-tonic saline at a rate of 1mL/kg/hour 
at least for 12hours before and 12hours after administration of contrast agent. Only iso-
osmolar contrast medium - iodixanol was used in the procedure. The primary end point was 
the peak increase of SCr and the secondary end point was the incidence of CIN within two 
days. CIN was defined as an increase in SCr of either ≥ 25% or ≥ 0.5 mg/dL.
Results: There were no differences in age, sex, prevalence of diabetes, prevalence of 
hypertension, baseline SCr, baseline left ventricular systolic function, and contrast media 
dose. The mean peak increase of SCr was significantly higher in ALA group than placebo: 
0.004±0.37mg/dL vs. -0.115±0.186mg/mL in ALA and placebo respectively (p=0.037). 
The SCr did not change from baseline of 1.24mg/dL to 1.24mg/dL within 2 days in the 
ALA group (p=0.941), but decreased significantly from 1.16mg/dL to 1.04mg/dL in the 
simple iso-tonic saline hydration group (p<0.001). The incidence of CIN was similar in 
both groups, 3.8% vs. 3.6% for ALA and placebo group (p=1.0).
Conclusions: We found for the first time that alpha lipoic acid - a well known antioxidant 
may be inferior to simple hydration with iso-tonic saline in CIN prevention. This study may 
imply that not all antioxidants are beneficial for preventing CIN in patients undergoing 
coronary angiography.
2900-267 Comparison of Risk Predictors for Contrast Induced 
Nephropathy Post Percutaneous Coronary Intervention 
in Patients with Normal versus Impaired Baseline Renal 
Function
Eric Chong, Shen Liang, Kian Keong Poh, Huay Cheem Tan, The Heart Institute, 
National University Hospital, Singapore, Singapore, Biostatistics Unit, National 
University, Singapore, Singapore
Background: We compare clinical predictors of contrast nephropathy (CIN) post 
percutaneous coronary intervention (PCI) in patients with impaired renal function (RF) 
who receive prophylaxis versus patients with normal RF who receive no prophylaxis.
Methods: A cohort of 3309 patients undergoing PCI between 2001 and 2007 was 
enrolled. Among them, 770 patients who had impaired RF (estimated glomerular 
filtration rate (GFR) < 60ml/min/1.73m2) received prophylactic saline hydration and oral 
N-acetylcysteine treatment. 2539 patients with normal RF did not receive any treatment. 
We examine the incidence of CIN (>25% increase from baseline creatinine within 48 hours 
post PCI) in the two groups and aim to identify the clinical predictors of its occurrence.
Results: In patients with normal RF, age, female gender, periprocedural myocardial 
infarction (MI), anemia and diabetes mellitus (DM) were significant predictors. In patients 
with baseline renal impairment who received prophylaxis, baseline GFR confers significant 
risk. CIN occurred in 6.3%, 17.4% and 40.8% in patients with GFR of 40-60, 20-40 and 
<20 ml/min/1.73m2 respectively, p<0.001. Other significant predictors of CIN in this group 
include age, periprocedural MI and hypotension. 
Clinical predictors
Normal Baseline 
Renal Function 
(Odd ratio) 
p value
Impaired Baseline 
Renal Function 
(Odd ratio)
p value
Age 1.67(1.07-2.58) 0.02 1.59(1.0-2.52) <0.001
Post-PCI Creatinine 
Kinase (CK) rise 1.43(1.04- 1.96) 0.03 2.74(1.75- 3.61) <0.001
Female Gender 2.07(1.48- 2.9) <0.001 Not Sig.
Diabetes Mellitus (DM) 1.41(1.03-1.93) 0.03 Not Sig.
Anemia (Hemoglobin 
<11g/dl) 1.82(1.04- 3.18) 0.04 2.26(1.41- 3.61) 0.001
Systolic BP 
< 100 mmHg
Not 
Sig. 2.53(1.16- 5.52) 0.02
Conclusion: Different predictors of CIN exist between patients with and without existing 
renal impairment. DM is a predictor in those with normal renal function, whereas baseline 
GFR and periprocedural hypotension are important in those with impaired renal function.
2900-268 Previous Chronic Renal Failure Affects Long-term 
Mortality in Patients With Cholesterol Crystal 
Embolization After Percutaneous Coronary Intervention
Yasushi Fuku, Kazuaki Mitsudou, Tsuyoshi Goto, Kazushige Kadota, Satoki Fujii, 
Hiroyuki Yamamoto, kurashiki central hospital, kurashiki, Japan
Introduction: Little is known about the correlation of baseline renal function with the clinical 
outcomes in patients with cholesterol crystal embolization (CCE) after percutaneous 
coronary intervention (PCI). We evaluated the impact of previous chronic renal failure on 
long-term mortality in patients with CCE after PCI.
Methods: Clinical records of patients with clinical or histopathologic diagnoses of CCE 
seen from January 1999 through December 2006 at our hospital were reviewed. The 
clinical diagnosis of CCE was made when patients had peripheral cutaneous involvement 
(livedo reticularis, blue toe syndrome, and digital gangrene) with eosinophilia or renal 
function deterioration with eosinophilia. Previous chronic renal failure was defined by the 
presence of serum creatinine levels; ≥1.5 mg/dl in men and ≥1.3 mg/dl in women. Chronic 
hemodialysis patients were excluded.
Results: 23 consecutive patients were eligible for this study (0.21% of the total) and 
divided into 13 patients with previous chronic renal failure and 10 patients without 
previous chronic renal failure. Baseline parameters, including age, gender, coronary risk 
factors, peripheral artery disease, aortic aneurysm, steroid use and statin use, were not 
different between two groups. During 3 years of follow-up (a mean follow-up of 1.9 years), 
cumulative survival was significantly lower in patients with previous chronic renal failure 
than those without previous chronic renal failure (log-rank p=0.021).
Conclusions: We conclude that previous chronic renal failure is associated with high 
mortality in patients with CCE after PCI.
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2900-269 Impact of renal insufficiency degrees, and mode of initial 
coronary revascularization on the long-term outcome for 
multi-vessel diseases without left main trunk diseases: 
from the Coronary Revascularization Demonstrating 
Outcome Study in Kyoto (CREDO-Kyoto)
Ryoji Taniguchi, Natsuhiko Ehara, Satoshi Shizuta, Yoshisumi Haruna, Mitsuru Abe, 
Takahiro Doi, Yutaka Furukawa, Yoshiki Takatsu, Shinichi Nomoto, Ryuji Nohara, Mitsuo 
Matsuda, Masahiko Onoe, Misato Yamauchi, Takeshi Morimoto, Satoshi Teramukai, 
Masanori Fukushima, Toru Kita, Takeshi Kimura, Hyogo Prefectural Amagasaki Hospital, 
Hyogo, Japan
Background: End-stage renal disease is an established predictor in patients (pts) 
undergoing coronary revascularization (CR). However, the differences in the long-term 
outcome of such pts depending on the severity of renal insufficiency (RI) and on the mode 
of CR have not been clearly shown.
Methods: CREDO-Kyoto is a multi-center registry in pts undergoing first CR (PCI or 
CABG). Among 9877 pts enrolled, 5564 (PCI 3586 (85% stent use), CABG 1978 (39% 
off-pump)) pts were identified to have multi-vessel diseases excluding pts with left main 
trunk diseases. The study subjects were divided into the 5 groups by their renal functions; 
normal function (90 mL/min<GFR, n=1024) mild RI (60<GFR<90, n=2111), moderate 
RI (30<GFR<60, n=1857), severe RI (GFR<30 without hemodialysis (HD), n=303), HD 
(n=269). Incidence of all cause death was compared.
Results: During follow-up (median period = 42.6 months), 670 pts died. There is no 
difference of all cause mortality rate between PCI and CABG in all 5 groups. Mortality 
rates were significantly higher with each increasing degree of RI irrespective of mode of 
CR (p<0.0001). Multivariate analysis indicated that groups with a lower estimated GFR 
had worse outcomes than the normal function (reference) group (table) and the mode of 
CR had no influence on all cause mortality in varying degrees of RI.
Conclusions: In this cohort, RI degrees are strong predictors of all cause death in pts 
undergoing CR and the mode of CR had no influence on all cause mortality in pts with 
varying degrees of RI. 
2900-270 Effects of Continuous Hemofiltration During Coronary 
Catheterization on Renal Function in Patients with 
Chronic Kidney Disease
Yoshimori An, Kouichi Tamita, Kite Kim, Takeshi Kitai, Takahumi Yamane, Minako 
Katayama, Tomoyuki Oda, Natsuhiko Ehara, Makoto Kinoshita, Shuuichirou Kaji, 
Atsushi Yamamuro, Tomoko Tani, Kazuaki Tanabe, Yasuki Kihara, Yasuyo Matsushima, 
Yasuyo Matsushima, Ichirou Sakaji, Kobe City Center General Hospital, Kobe, Japan
Background: Contrast medium-induced nephropathy (CIN) is one of the major 
complications of coronary catheter procedures in patients with chronic kidney disease 
(CKD). The effect of continuous hemodiafiltration (CHDF) and that of hemodialysis (HD) 
on the occurrence of CIN have not been fully elucidated. The aim of this study was to 
determine the efficiency of CHDF during the procedure on the occurrence of CIN as 
compared with prophylactic hemodialysis.
Methods: We investigated 28 consecutive patients with CKD (estimated GFR<60 mL/
min/1.73m2 ) undergoing CHDF during the procedure (CHDF group; 14 patients) or 
undergoing HD after the procedure (HD group; 14 patients). We intravenously administered 
isotonic-saline before and after procedures to all patients. CIN was defined as an increase 
in the serum creatinine level more than 0.5mg/dL or 25% above the baseline within 48 
hours. Nonionic and low-osmolality contrast media was used during the procedure . 
CHDF was performed through a double-lumen intravenous femoral catheter during the 
procedure, and HD was performed without fluid removal in the same way about three 
hours as soon as technically possible after the procedure.
Results: Mean estimated GFR was similar between the CHDF group and the HD 
group (26.8±10.7 mL/min/1.73m2 vs. 24.4±7.8mL/min/1.73m2; p=0.433). The amount of 
contrast media was also similar between the two groups (140.3±68.1mL per patient vs. 
175.5±64.1mL, respectively; p=0.238).Among the CHDF group, no patients were suffered 
from CIN nor required regular hemodialysis at one month later. However, among the HD 
group, 4 of 14patients (28.6%) were suffered from CIN and 1 patient required temporary 
hemodialysis during the hospitalization.
Conclusions: While CIN is common in patients with renal insufficiency, no patients 
among the CHDF group were suffered from CIN. CHDF during coronary catheter 
procedures is more effective than HD after the procedures on the prevention from CIN in 
patients with CKD. Advanced application of CHDF during coronary catheter procedures 
may prevent the deterioration of renal function due to CIN in patients with limited renal 
function.
2900-271 Safety and Performance of Targeted Renal Therapy: 
Final Results of The Be-RITe! Registry
Giora Weisz, David E. Allie, Barry S. Weinstock, Mauricio G. Cohen, Dimitris Kyriazis, 
Craig M. Walker, Jeffrey W. Moses, Paolo Danna, William F. Fearon, Naveen Sachdev, 
Bret N. Weichmann, Matthew J. Price, Roxana Mehran, Martin B. Leon, Paul S. 
Teirstein, Columbia University Medical Center, New York, NY, Cardiovascular Research 
Foundation, New York, NY
Background Targeted renal therapy (TRT), the delivery of therapeutic agents directly to 
the kidneys by renal arterial infusion (IR), has the advantage of providing a higher local 
dose, while limiting systemic adverse effects. We evaluated the safety and patterns of 
use of TRT with the Benephit system, especially focusing of patients that received TRT 
with fenoldopam (FEN) during cardiovascular interventions. IR but not IV fenoldopam 
has been shown to significantly increase glomerular filtration rate in patients undergoing 
cardiac catheterization.
Methods The Benephit System Renal Infusion Therapy (Be-RITe!) Multicenter Registry 
is a post-market registry of patients in which the Benephit catheter was used for TRT. 
The system consist of a designated sheath and a bifurcating catheter that engages 
simultaneously both renal arteries. We used the Mehran’s score to compare the actual to 
predicted incidence of CIN within 48 hours post-procedure.
Results: Total of 501 patients at high risk for CIN during coronary or peripheral 
angiography and/or intervention or cardiovascular surgery were enrolled. Bilateral 
renal artery cannulation with the Benephit system was successful in 95.8%, with mean 
cannulation time of 2.0±1.6min. Only one patient had renal artery dissection that was 
stented without complications. Either Fenoldopam-mesylate, sodium bicarbonate, 
alprostadil, or Nesritide were infused for 120±212min. In 285 patients who received 
TRT with FEN and were followed for at least 48 hours, the incidence of CIN was 71% 
lower than predicted (8.1% actual CIN vs. 28.0% predicted; p<0.001). Rate of CIN was 
significantly lower with FEN dose of 0.4mcg/kg/min as compared to 0.2 mcg/kg/min (3.7% 
vs. 30.3%, p<0.01), and when FEN was administrated ≥60 min as compared to <60 min 
(3.5% vs. 27.3%, p<0.01).
Conclusions The Benephit system and TRT during coronary and endovascular procedures 
in patients at high risk for renal failure is simple to use and safe. With the infusion of intra-
renal fenoldopam, the incidence of CIN was significantly less than predicted, especially at 
higher dose and longer duration.
2900-272 The Association of Race/Ethnicity with Contrast 
Induced Nephropathy in Patients Undergoing 
Percutaneous Coronary Intervention
Amala Chirumamilla, Somjot Brar, George Dangas, Vanessa Isiaka, Elene Papakostas, 
Andy Morales, Theresa Franklin-Bond, Gregg W. Stone, Martin B. Leon, Jeffrey W. 
Moses, Alexandra Lansky, Roxana Mehran, Columbia University, New York, NY, 
Cardiovascular Research Foundation, New York, NY
Background: Important racial/ethnic differences in chronic kidney disease have been 
described in patients with heart disease. However, little is known about the effect of race/
ethnicity on the development of contrast induced nephropathy (CIN).
Methods: We prospectively identified 857 patients undergoing PCI between 2004-2007. 
CIN was defined as a 25% increase in serum creatinine. Using logistic regression we 
developed unadjusted and adjusted models with development of CIN as the dependent 
variable and race/ethnicity as the independent variable. Caucasian race was used as the 
referent group for all analysis.
Results: Of the 857 patients, 59% were Caucasian, 11.4% Hispanic, 5.4% African 
American, and 24% were Other. The incidence of CIN for Caucasian, Hispanic, African 
American and Others were 4.6%, 14.4%, 13.0%, and 8.2%, respectively (p=0.001). 
Unadjusted and adjusted logistic regression models for contrast nephropathy appear in 
the Table: 
Odds Ratio 95% CI
Unadjusted
African American vs. White 3.14 1.21 - 8.17
Hispanic vs. White 3.54 1.75 - 7.15
Other vs. White 1.88 0.98 - 3.59
Adjusted*
African American vs. White 3.15 1.07 - 9.25
Hispanic vs. White 2.9 1.30 - 6.46
Other vs. White 1.81 0.98 - 3.63
*Adjusted for: age, gender, baseline GFR, body mass index, diabetes, congestive 
heart failure, myocardial infarction, days hospitalized, contrast type, contrast volume, 
N-acetylcysteine use, and systolic blood pressure.
Conclusion: There is marked racial variation in the incidence of CIN among patients 
undergoing percutaneous coronary interventions. Hispanics and African Americans are 
at particularly high-risk for this serious complication.
2900-273 Percent Change in Renal Function After Contrast 
Exposure is Associated with Long-term Adverse 
Events in Patients Undergoing Percutaneous Coronary 
Interventions
Amala Chirumamilla, Somjot S. Brar, George Dangas, Alexandra Lansky, Giora Weisz, 
Ajay Kirtane, Laura Higginbotham, Theresa Franklin-Bond, Martin B. Leon, Jeffrey 
W. Moses, Gregg W. Stone, Roxana Mehran, Columbia University, New York, NY, 
Cardiovascular Research Foundation, New York, NY
Background: Data are limited on long-term outcomes of patients undergoing 
percutaneous coronary intervention (PCI) by periprocedural change in renal function.
Methods: We identified 778 consecutive patients with an estimated GFR <60 mL/
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min/1.73m2 (modified MDRD formula) who underwent PCI between 2004-2007. We 
excluded patients with current or prior dialysis. Based on the percent change in pre 
versus post procedural estimated GFR, patients were categorized into three groups: 
25% decrease in estimated GFR post contrast exposure. Kaplan-Meier analysis was 
used to plot survival from MACE (death, MI, unplanned revascularization) with the log-
rank p-value reported. Cox proportional hazards models were constructed for the MACE 
endpoint taking the <15% change group as referent.
Results: The mean age of the cohort was 71.6 +/- 9.8 years, and 43% were female. 
There were 49 patients (6.3%) whose renal function changed 15-25%, and 59 (7.6%) 
with a >25% change. The unadjusted hazard ratios (95%CI, p-value) for the 15-25% 
and >25% change groups were 1.68 (1.00-2.81, p=0.05) and 1.79 (1.12-2.87, p=0.01), 
respectively. The adjusted values were 1.66 (0.97-2.86, p=0.07) and 1.62 (0.99-2.67, 
p=0.06), respectively. The Kaplan-Meier curve for MACE for the three groups is shown.
Conclusion: In this cohort, the MACE event rate did not differ between the 15-25% and 
>25% groups. The risk of MACE may be increased when renal function declines by as 
little as 15% or more following contrast exposure. 
2900-274 Impact of High Clopidogrel Maintenance Dosing in 
Patients Undergoing Elective Percutaneous Coronary 
Interventions: Results of a Randomized Study
Dominick J. Angiolillo, Esther Bernardo, Marco A. Costa, Jorge Palazuelos, Bhaloo 
Desai, Ian Weisberg, Fernando Alfonso, Luis A. Guzman, Liudmila Rozum, Piera 
Capranzano, Rosana Hernández-Antolin, Martin Z. Zenni, Carlos Macaya, Antonio 
Fernandez-Ortiz, Theodore A. Bass, University of Florida-Shands Jacksonville, 
Jacksonville, FL, San Carlos University Hospital, Madrid, Spain
Background: In clopidogrel treated patients, inadequate dosing contributes to 
suboptimal antiplatelet effects. Numerous reports have demonstrated that high loading 
dose regimens improve clopidogrel-induced antiplatelet effects. However, limited data is 
available on the functional impact of a high maintenance dose regimen.
Methods: This is a prospective, randomized, platelet function study. Patients (n=40) 
undergoing elective percutaneous coronary intervention (PCI) were randomized to receive 
a 75mg or 150mg daily maintenance dose of clopidogrel for 30 days; afterwards, patients 
resumed 75mg dosing. All patients were on low dose aspirin. Platelet aggregation (PA) 
was performed using light transmittance aggregometry following ADP (20Μmol/L and 
5Μmol/L) stimuli at 2 time points: 30 days after randomization (T1) and 30 days after 
resuming 75mg dosing (T2).
Results: No differences in baseline demographics were observed between patients 
randomized to clopidogrel 75mg (n=20) or 150mg (n=20). At T1, patients randomized to 
clopidogrel 150mg had lower PA following 20Μmol/L ADP stimuli compared to patients 
on clopidogrel 75mg (52±10% vs 63±11%; p=0.002; primary endpoint). At T2, once all 
patients resumed 75mg dosing, there were no differences in PA between the 2 groups: 
20Μmol/L ADP stimuli (61±10% vs 63±11%; p=ns). Inhibition of PA (IPA) calculated 
between the 2 time points in each group was significantly higher in the 150mg group 
following 20Μmol/L ADP stimuli (15±12% vs -4±17%; p<0.0001) . Patients with high 
platelet reactivity while on a 75mg dose (>68% using 20Μmol/L ADP), defined as the 
upper tertile of ADP-induced platelet aggregation in the steady state phase of clopidogrel 
75mg therapy, had greater responsiveness to 150mg compared to patients with moderate 
and low platelet reactivity (p=0.01). Parallel findings were observed for all platelet function 
analysis using 5Μmol/L ADP stimuli. No bleeding events occurred.
Conclusions: A 150mg maintenance dose regimen of clopidogrel is associated with 
reduced platelet reactivity and enhanced platelet inhibition compared to that achieved 
with the currently recommended 75 mg maintenance dose in patients undergoing elective 
PCI.
2900-275 Underutilization of Clopidogrel Pre-treatment in the 
NHLBI Dynamic PCI Registry: A Missed Opportunity?
Herbert D. Aronow, Ruchira Glaser, Faith Selzer, J. Dawn Abbott, David O. Williams, 
Timothy A. Shapiro, Kevin E. Kip, Sheryl F. Kelsey, Michigan Heart & Vascular Institute, 
Ann Arbor, MI, University of Pittsburgh, Pittsburgh, PA
Background: Clopidogrel pre-treatment reduces ischemic outcomes following 
percutaneous coronary intervention (PCI). Nevertheless, many patients do not receive 
clopidogrel until after their PCI.
Methods: We examined the rate and predictors of clopidogrel pre-treatment among 1,991 
consecutive patients enrolled in Waves 4 (2004) and 5 (2006) of the NHLBI Dynamic PCI 
registry. Clopidogrel pre-treatment was defined as a 300 or 600 mg loading dose given 
within 24 hours before the procedure.
Results: PCI was performed in the setting of an acute myocardial infarction (MI) in 
32% and unstable angina in 32%. Clopidogrel pre-treatment was administered in 389 
(19.5%) patients. In a multivariable logistic regression model adjusting for clinical center 
(Table), clopidogrel pre-treatment was more common in Asians (vs. Whites), those with 
a history of prior PCI, those presenting with MI, those who received unfractionated or 
low molecular weight heparin or bivalrudin before the procedure and later study year. In 
contrast, clopidogrel initiation was less common before PCI among African Americans 
(vs. Whites), those in cardiogenic shock, ad hoc procedures and among patients who 
received beta blockers beforehand.
Conclusions: In this contemporary national multicenter PCI registry, the decision to 
pre-treat with clopidogrel was influenced by ethnicity, clinical presentation, concomitant 
medical therapies and year of enrollment. Strategies to improve utilization of clopidogrel 
treatment before PCI are needed. 
Factor Odds Ratio 95% CI p-value
Race/ethnicity (vs. white) 
Black 
Asian 
Hispanic
0.53 
1.88 
1.20
0.33-0.84 
0.90-3.92 
0.57-2.56
0.007 
0.09 
0.63
Prior PCI 1.56 1.12-2.17 0.008
Acute MI 1.53 1.10-2.11 0.01
Cardiogenic shock 0.14 0.02-1.18 0.07
Ad hoc procedure 0.06 0.04-0.08 <0.001
Pre-PCI heparin 2.34 1.67-3.27 <0.001
Pre-PCI low molecular weight heparin 2.95 1.61-5.42 <0.001
Pre-PCI bivalrudin 22.88 1.15-415.95 0.04
Pre-PCI beta blocker 0.69 0.51-0.95 0.023
Recruitment wave 5 (vs. wave 4) 2.26 1.67-3.07 <0.001
Model c statistic = 0.86, Goodness-of-Fit p = 0.73
2900-276 Low dose aspirin increases aspirin resistance 
in patients undergoing percutaneous coronary 
intervention-Insights from the clopidogrel and aspirin 
resistance evaluation in patients undergoing coronary 
revascularization (CARE-PCR) registry
Ji Hye Yim, Jong Pil Park, Jae Hyoung Park, Jeong-Woo Lee, Won-Jang Kim, Duk-Woo 
Park, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Myeong-Ki Hong, Jae-Joong 
Kim, Seong-Wook Park, Seung-Jung Park, Asan Medical Center, Seoul, South Korea
Background: We sought to investigate the association of aspirin dose and aspirin 
resistance measured by a point-of-care assay in patients presented with stable coronary 
artery disease.
Methods: We prospectively enrolled 419 consecutive patients (291 men, age 63±31yrs) 
who underwent coronary intervention. All patients were divided into two groups according 
to the dose of aspirin: 100mg (228 patients, 54.4%) versus 200mg (191 patients, 45.6%) 
group. Blood samples were drawn at 48hr after intervention. Aspirin resistance was 
measured using the VerifyNow-ASA (ultegra rapid platelet function assay; Accumetrics, 
San Diego, CA). Aspirin resistance was defined as aspirin reaction unit (ARU) ≥ 550.
Results: Aspirin resistance was observed in 33 (7.9%) patients. There were no 
significant differences between the two groups in terms of age, gender, serum lipid profile, 
hemoglobin, and platelet count. In logistic regression analysis, independent predictor 
of aspirin resistance (ARU level ≥ 550) were aspirin dose (p=0.011, OR=3.606, 95% 
CI=1.337 to 9.726), hypercholesterolemia (p=0.025, OR=3.581, 95% CI=1.172 to 10.943), 
hemoglobin levels (p=0.031, OR=0.736, 95% CI=0.557 to 0.971), and platelet count 
(0.020, OR=0.991, 95% CI=0.984 to 0.999). The incidence of bleeding complications was 
not different between the two groups.
Conclusions: A low dose aspirin is associated with a higher incidence of aspirin 
resistance in patient undergoing percutaneous coronary intervention without reducing 
bleeding events. Therefore, the dose of aspirin at least 200 mg may be needed to ensure 
the optimal efficacy and safety.
2900-277 Frequency and Predictors of Clopidogrel Pre-treatment 
in Patients Undergoing Percutaneous Coronary 
Intervention: A Report From the Blue Cross Blue Shield 
of Michigan Cardiovascular Consortium PCI Registry
Herbert D. Aronow, Dean Smith, Michael J. Odonnell, Richard McNamara, Arthur Riba, 
Hameem Changezi, Eva Kline-Rogers, David Share, Mauro Moscucci, Michigan Heart & 
Vascular Institute, Ann Arbor, MI, University of Michigan, Ann Arbor, MI
Background: Clopidogrel pre-treatment reduces the incidence of periprocedural 
ischemic events following percutaneous coronary intervention (PCI). However, many 
patients undergoing PCI do not receive clopidogrel until after their procedure.
Methods: We examined the frequency and predictors of clopidogrel pre-treatment among 
80,062 consecutive patients from 17 hospitals enrolled in the Blue Cross Blue Shield of 
Michigan Cardiovascular Consortium PCI registry during the years 2003-2006 who were 
discharged on clopidogrel. Pre-treatment was defined as having received clopidogrel 
within the 24 hours prior to PCI.
Results: Clopidogrel pre-treatment was administered in 43.4%, 43.7%, 50.8% and 
51.3% in study years 2003 through 2006, respectively (p for trend < 0.0001). In a 
multivariable logistic regression model adjusting for clustering, age, gender, hypertension, 
atrial fibrillation, prior MI, previous coronary revascularization, non-coronary vascular 
disease, clinical presentation and year of PCI were significant predictors of clopidogrel 
pre-treatment (Table).
Conclusions: In this contemporary statewide multicenter PCI registry, only 1 out of 
every 2 patients undergoing PCI received clopidogrel pre-treatment. Demographic 
characteristics, atherosclerotic risk factors, prior revascularization status and presentation 
with MI influenced the decision to pre-treat. Strategies to improve the likelihood of 
clopidogrel treatment before PCI are needed. 
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Factor Odds Ratio 95% CI p-value
Age category (vs. < 60 years) 
60-69 
70-79 
80+
0.88 
0.82 
0.88
0.84-0.91 
0.78-0.85 
0.83-0.93
<0.001 
<0.001 
<0.001
Female gender 1.04 1.00-1.07 0.039
Hypertension 1.08 1.04-1.12 0.0002
Atrial fibrillation 0.80 0.76-0.85 <0.001
Prior MI 1.15 1.11-1.19 <0.001
Prior PCI 3.13 3.03-3.24 <0.001
Prior CABG 1.13 1.09-1.18 <0.001
Non-coronary vascular disease 1.27 1.22-1.32 <0.001
Year of enrollment (vs. 2003)
2004 1.07 1.02-1.12 0.002
2005 1.22 1.16-1.27 <0.001
2006 1.27 1.22-1.33 <0.001
Acute MI 0.69 0.64-0.73 <0.001
c statistic = 0.73
2900-278 Effects of clopidogrel and aspirin in combination 
versus aspirin alone on platelet activation and major 
receptor expression in diabetic patients: The PLavix 
Use for Treatment Of Diabetes (PLUTO-Diabetes) Trial.
Victor Serebruany, Alex Malinin, Alex Pokov, Gregory Barsness, Dan Hanley, Johns 
Hopkins University, Towson, MD
Background: Clopidogrel is widely used in diabetic patients after vascular events; 
however, the ability of this thienopyridine to yield additional antiplatelet protection on top 
of aspirin has never been explored in a controlled study with comprehensive assessment 
of platelet activity. The objective of this study was to compare the antiplatelet profiles of 
clopidogrel + aspirin in combination (C+ASA) versus aspirin alone (ASA) in patients with 
Type 2 diabetes mellitus.
Methods: Seventy patients with documented diabetes already treated with antecedent 
aspirin were randomly assigned to C+ASA or ASA in the PLUTO-Diabetes trial. Platelet 
studies included ADP-, collagen- and arachidonic acid-induced aggregometry, PFA-100 
and Ultegra analyzers, and expression of 6 major receptors by flow cytometry at baseline 
and at Day 30 after randomization.
Results: There were no differences in the baseline clinical and platelet characteristics 
between the C+ASA and ASA groups, or subsequent significant changes in platelet 
biomarkers in the ASA group, except for diminished collagen-induced aggregation 
(p=0.02). In contrast, when compared with ASA group, therapy with C+ASA resulted 
in significant inhibition of platelet activity assessed by ADP- aggregation (p=0.0001); 
closure time prolongation (p=0.0003), and reduction of platelet activation units with 
Ultegra (p=0.0001); expression of PECAM-1 (p=0.002), GPIIb/IIIa antigen (p=0.0002), 
and activity (p=0.0001).
Conclusion: Treatment with C+ASA for one month provides significantly greater inhibition 
of platelet activity than ASA alone in diabetics in this small-randomized trial. However, 
despite dual antiplatelet regimen, diabetic patients exhibit high residual activity of some 
platelet biomarkers, including unaffected PAR-1 receptor expression.
2900-279 Enoxaparin Clotting Times Monitoring During 
Percutaneous Coronary Intervention: The Sensitivity of 
Point of Care Tests to Different Dosages
Jose G. Diez, Jay Aliota, Soumaya El Rouby, Texas Heart Institute / Baylor College of 
Medicine, Houston, TX, ITC, Edison, NJ
Background: Experience has been obtained on use of enoxparin (EXP) during percutaneous 
coronary interventions (PCI). EXP acceptance during PCI has been limited by an increase in 
bleeding events and lack of monitoring. Monitoring may be required for high risk populations 
and/or transition from subcutaneous to intravenous administration before PCI.
Objective: To evaluate the sensitivity of 2 clot based point of care tests (POCT) 
Hemochron Signature+ HEMONOXTM (H-CT)and Rapidpoint Enox® (CCT) to different 
dosages of enoxaparin in patients (pts) undergoing PCI. Methods: Consecutive series 
of 28 pts received one IV bolus (see table). The 0.3 mg/kg IV dose was given to pts on 
prior subcutaneous (SC) EXP for ACS. Blood draws for POCT and chromogenic anti-Xa 
assay were obtained prior to PCI and post bolus. Results: Both CCT and H-CT achieved 
peak response 10 min post bolus. At any dose, peak H-CT and CCT corresponded to 
therapeutic anti-Xa level (>0.5U/ml) in 100 % of pts. The ranges for H-CT and anti-Xa 
levels increased with EXP in a dose dependent fashion. Only pts on prior SC dosing for 
ACS yielded detectable anti-Xa level at baseline (0.18-0.45U/ml) which corresponded to 
CCT and H-CT of 183-309 and 62-127 secs respectively. Anti-Xa correlation was r=0.81 
for H-CT and 0.63 for CCT. There were nor TIMI major or minor bleeding events. 
Dose (mg/kg) 0.30 0.50 0.75 1.0
Range Peak Anti-Xa (U/ml) 0.50-0.69 0.64-0.68 0.68-0.84 0.85-1.89
Range Peak HEMONOX CT (secs) 90-250 112-352 178-643 325-871
Range Peak ENOX-CT (secs) 427-647 340-609 538.1-538.3 398-654
# of patients 5 2 3 18
Conclusion: POCT methods yield appropriate CT increase with EXP. Adequate 
monitoring may help to optimize outcomes by decreasing bleeding events while assuring 
anticoagulation during PCI.
2900-280 First Evidence of The Stepwise Relation Between 
On-Treatment Platelet Reactivity to ADP And Post-
PCI Ischemic Events: First Evidence for a Potential 
Therapeutic Target for P2Y12 Inhibitors
Paul A. Gurbel, Kevin P. Bliden, Joseph DiChiara, Mark J. Antonino, Thomas Suarez, 
Udaya S. Tantry, Sinai Center For Thrombosis Research, Baltimore, MD
Background: The relation between platelet reactivity to ADP (ADP-R) and ischemic 
event occurrence is unclear. It is unknown whether events begin to occur after a cutpoint 
in a stepwise fashion.
Methods: We examined whether there was a threshold level of on-treatment ADP-R 
measured by light transmittance aggregometry that was associated with the onset of 
ischemic events after percutaneous coronary intervention (PCI). Data from 4 clinical 
studies (Clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR 
PLATELETS) I and II, Platelet reactivity in patients and recurrent events post-stenting 
(PREPARE POST-STENTING), and Clopidogrel effect on platelets in patients with stent 
thrombosis (CREST) conducted at our center were analyzed.
Results: The age was 65± 12years. ADP-R (20uM) was 46+/-14% in patients without 
ischemia and 60+/-13% with ischemic events. Based on cumulative distribution curve 
analysis, we observed a threshold for the occurrence of periprocedural myocardial 
infarction (~50% mean platelet aggregation over 24 hours), long-term ischemic events 
defined as the occurrence of death secondary to cardiovascular cause, myocardial 
infarction, unstable angina, and stroke that required rehospitalization (~48%-20uM ADP) 
and stent thrombosis (~40%-20uM ADP). ADP-R >40% identified 95% of all ischemic 
events.
Conclusions: A threshold of platelet reactivity to ADP exists that can identify 95% of 
patients at risk for post-PCI ischemic events, including stent thrombosis. These data have 
important implications for future prospective investigations to explore the concept of a 
therapeutic target for P2Y12 inhibitors.
2900-281 Determining the Optimal Duration of Dual Anti-platelet 
Therapy following Implantation of Drug-Eluting Stents 
by the Predictive Value of Clopidogrel Cessation for 
Stent Thrombosis.
Probal Roy, Rebecca Torguson, Teruo Okabe, Tina L. Pinto Slottow, Daniel H. Steinberg, 
Kimberly Smith, Zhenyi Xue, Lowell F. Satler, Kenneth M. Kent, William O. Suddath, 
Augusto D. Pichard, Ron Waksman, Washington Hospital Center, Washington, DC
Background: The optimal duration of dual anti-platelet therapy post drug-eluting stent 
(DES) implantation remains uncertain. Prolonged therapy remains limited by an increased 
bleeding risk. This study aimed to determine the predictive value of clopidogrel cessation 
for stent thrombosis (ST) over time.
Methods: Clinical and procedural characteristics of 61 patients who re-presented with 
definite stent thrombosis following successful DES implantation were compared with a 
cohort of 2828 unselected patients who remained free of ST. Predictors of cumulative ST 
were determined at 1,6 and 12 months using the proportional hazards model.
Results: Patients with ST were more likely to be on dialysis (8.3% vs. 2.1% p=0.009) 
and have worse left ventricular function (40±16% vs. 48± 14% p=0.002). Left anterior 
descending artery (50.0% vs. 37.1% p=0.02) and in-stent restenotic (12.2% vs.4.1% 
p=0.004) lesions were more common in patients with ST. ST group received more 
stents (2.0±1.1 vs. 1.6±0.8 p=0.01) and less intravascular ultrasound guidance (48.6% 
vs. 65.9% p=0.002). Independent predictors of cumulative ST are presented below. 
Clopidogrel cessation was no longer predictive of ST at 12 months. 73.8% of ST patients 
were clopidogrel compliant at the time of presentation.
Conclusion: Clopidogrel compliance is not prohibitive of ST. Furthermore, clopidogrel 
cessation is not predictive of cumulative ST at 12 months. These findings question 
prolonged dual anti-platelet therapy beyond 12 months. 
Hazards ratio Confidence interval P
1 month
Diabetes 2.0 1.1-3.9 0.03
Acute myocardial infarction 3.0 1.6-5.8 <0.01
Clopidogrel cessation 3.5 1.5-8.3 <0.01
6 months
Acute myocardial infarction 2.4 1.3-4.5 <0.01
Type C lesion 2.1 1.2-3.8 0.02
Number of stents implanted 1.4 1.0-1.8 0.04
Clopidogrel cessation 2.0 1.0-4.2 0.05
12 months
Acute myocardial infarction 2.2 1.2-3.9 <0.01
Lack of IVUS 1.8 1.0-3.1 <0.01
Number of stents implanted 1.5 1.2-2.0 <0.01
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2900-282 The Risk of Bleeding on Dual Antiplatelet Therapy After 
Drug-eluting Stent Implantation
Azeem Latib, Nuccia Morici, John Cosgrave, Asif Qasim, Flavio Airoldi, Nedy Brambilla, 
Erminio Bonizzoni, Cosmo Godino, Renata Rogacka, Davide Tavano, Enrico Romagnoli, 
Valeria Magni, Alaide Chieffo, Matteo Montorfano, Tiziana C. Aranzulla, Francesco 
Bedogni, Alfredo Castelli, Carlo Briguori, Antonio Colombo, San Raffaele Scientific 
Institute, Milan, Italy, EMO Centro Cuore Columbus, Milan, Italy
Background: Prolonged periods of dual antiplatelet therapy (DAT) are currently 
recommended to prevent late drug-eluting stent (DES) thrombosis. The aim of this study 
was to assess the risk of bleeding associated with such prolongation in a large real-world 
population.
Methods: Observational cohort study examining 2355 consecutive patients undergoing 
successful DES implantation at 4 hospitals in Italy between June 2002 and December 
2004. Bleeding events occurring on DAT and warfarin or in the first 30 days from stent 
implantation were excluded.
Results: The overall bleeding rate was 1.9% (45 patients) with major bleeding in 19 
patients (0.8%) and minor bleeding in 26 patients (1.1%). The median time from stent 
implantation to any bleeding complication was 216 days (interquartile range, 97-396 days). 
The median duration of DAT was 209 days (interquartile range, 178-444). Independent 
predictors of bleeding were: DAT (HR, 19.8; 95% CI 3.69-106.34, p<0.001) and age > 65 
years (HR, 2.15; CI 95% 1.16-4.00; P=0.02). In patients on DAT, the incidence rate of any 
bleeding event between 30 days and 18 months was 2.57 per 100 person-years (95% 
CI, 1.85-3.48), while the rate of major bleeding was 1.10 per 100 person-years (95% CI, 
0.65-1.74). The risk of bleeding on DAT remained constant over the 18 month follow-up 
period (See Figure)
Conclusion: The risk of major and minor bleeding on DAT occurs at a constant rate up 
to 18 months with a very low risk of major bleeding. DAT and older age are independent 
predictors of bleeding.
2900-283 A Comparison of Heparin Without Glycoprotein IIb/IIIa 
Inhibition Versus Bivalirudin in Elective Percutaneous 
Coronary Intervention
Christopher L. F. Gade, Dmitriy N. Feldman, Michael Ross, Nichole Polin, Geoffrey 
Bergman, S. Chiu Wong, Robert M. Minutello, NY Presbyterian Hospital, New York, NY
Background: Recent evaluation of anti-coagulation strategies for low-intermediate 
risk patients undergoing percutaneous coronary intervention (PCI) demonstrate no 
differences in outcomes when comparing strategies of heparin plus GP IIb/IIIa inhibitors 
to heparin alone. The efficacy of bivalirudin as an antithrombin agent in PCI was largely 
demonstrated in trials comparing it to heparin plus GP IIb/IIIa inhibitors. We compared 
short and long term outcomes in patients undergoing elective angioplasty and receiving 
intra-procedural bivalirudin vs. those receiving heparin alone.
Methods: We used the Cornell Angioplasty Registry to study 1222 patients undergoing 
elective PCI with intra-procedural use of only heparin or bivalirudin. Patients with acute 
coronary syndrome within the preceding 14 days, chronic total occlusion or apriori 
contraindication to either heparin or bivalirudin were excluded.
Results: A total of 804 patients (65.8%) received bivalirudin and 418 patients (34.2%) 
received heparin alone. There was no in-hospital mortality. The incidence of in-hospital 
myocardial infarction (MI) (5.5% vs. 5.6%, p=ns), and major adverse cardiac and 
cerebrovascular events (MACCE) defined as in-hospital death, MI, stroke, emergent 
CABG or PCI (6.2% vs. 6.5%, p=ns) were similar in the bivalirudin and heparin groups 
respectively. The incidence of major (0.37% vs. 0.24%, p=ns) and minor bleeding (3.6% 
vs. 5.9%, p=0.082) were also not significantly different. At a mean clinical follow-up of 
was 20.1 ± 8.7 months, there were 36 (4.5%) deaths in the bivalirudin group versus 16 
(3.8%) in the heparin group (p=ns). Multivariate Cox analysis, showed neither bivalirudin 
nor heparin use to be independent predictors of short or long term adverse clinical 
outcomes.
Conclusions: When comparing peri-procedural anticoagulation strategies of bivalirudin 
versus heparin alone, there were no significant differences in short term clinical or safety 
outcomes and in long term mortality in patients undergoing elective angioplasty.
2900-284 The Novel Factor VIIa/Tissue Factor Inhibitor, 
Recombinant Nematode Anticoagulant Protein C2, 
Alters PT/INR in Dose-Dependent Manner Proportionate 
with Plasma Concentration in Patients with nSTE-ACS: 
Data from the ANTHEM-TIMI 32 Trial
Vibhuti N. Singh, Stephen Wiviott, Daniel Simon, Marc Schweiger, Massoud Leesar, 
Peter Stone, Mike Goulder, Steven Deitcher, Robert Giugliano, University of South 
Florida, Tampa, FL, Brigham and Women’s Hospital, Boston, MA
Background: ACS involves tissue factor (TF) release and thrombosis yet unaddressed 
fully by current therapies, and is magnified by PCI. A novel fVIIa/TF inhibitor, rNAPc2, was 
evaluated in a phase-2 study, ANTHEM-TIMI 32, in patients with ACS.
Methods: 255 patients with moderate & high risk nSTE-ACS of <48 h onset and early 
invasive strategy received rNAPc2 (1.5--10 mcg/kg) or placebo. All patients had drug level 
and PT/INR measured at 2--6h, 48h, and 7 days, and wore 3-lead Holter.
Results: Ascending doses of rNAPc2 (1.5, 5, 7.5, and 10 mcg/kg) caused increasing 
plasma levels (ng/ml) of 25.0+11.4, 61.8+18.6, 80.8+34.6, and 153.0+87.5, and INRs of 
1.5+0.3, 2.0+0.7, 2.1+0.4, and 2.7+1.1 respectively at 2--6 h. These rNAPc2 levels and INR 
remained high until 48h, returning to baseline by 7d. The Log rNAPc2 level vs INR at 2--6h 
& 48h show adjusted r2 of 0.24 and 0.31 (p<0.0001), and correlation coefficient of 0.50 & 
0.57 (p<0.0001) respectively. Ischemia on Holter was reduced by >50% (trend) with higher 
quintiles of INR at 2--6h vs lowest INR quintiles, without higher major or minor bleeding.
Conclusions: Recombinant NAPc2 in nSTE-ACS patients shows dose dependent rise 
in plasma levels between 2--6 and 48h, proportionate to PT/INR, and reduces ischemia 
without increase in bleeding. Thus, in patients with nSTE-ACS undergoing early invasive 
strategy, an additional blockade of coagulation cascade at an earlier step through fVIIa/
TF inhibition with rNAPc2 appears to raise PT/INR and reduce ischemia on Holter (trend) 
without significant bleeding increase. These findings require confirmation in a larger trial 
to determine if rNAPc2 improves clinical outcomes. 
2900-285 Safety and effectiveness of bivalirudin compared to 
either abciximab or eptifibatide in patients with acute 
myocardial infarction undergoing primary angioplasty: 
The HORIZONS AMI trial
Giulio Guagliumi, Bernhard Witzenbichler, Jan Peruga, Bruce Brodie, Dariusz Dudek, 
Ran Kornowski, Janusz Kochman, Yaron Almagor, Dennis Nilsen, Ajay Kirtane, Helen 
Parise, Roxana Mehran, Gregg W. Stone, Ospedali Riuniti di Bergamo, Bergamo, Italy
Background. In the HORIZONS AMI trial, 3,602 patients with STEMI undergoing primary 
PCI at 123 centers in 11 countries were randomized to bivalirudin (Biv) vs. unfractionated 
heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI). Either abciximab or double bolus 
eptifibatide could be selected as the GPI per operator discretion, and randomization 
was stratified by this choice. As previously reported, Biv resulted in reduced 30 day 
rates of major bleeding, comparable rates of composite major adverse cardiovascular 
events (MACE) (though with decreased cardiac mortality), and enhanced freedom from 
net adverse clinical events (NACE). Whether the beneficial effects of bivalirudin are 
independent of GPI selection has not been reported.
Methods and Results. A total of 1,915 pts (53%) were randomized in the abciximab 
strata, and 1,687 pts (47%) were randomized in the eptifibatide strata. In the entire study 
population, Biv compared to UFH+GPI resulted in a 40% reduction in major bleeding 
(4.9% vs. 8.3%, P<0.0001), similar MACE (5.4% vs. 5.5%, P=1.0), and a 24% reduction 
in NACE (9.2% vs. 12.1%, P=0.006). As shown in the table, the impact of Biv was 
independent of GPI (interaction P value for these 3 endpoints = 0.79, 0.58, and 0.67 
respectively).
Conclusions. In patients with AMI undergoing primary PCI, Biv monotherapy significantly 
reduces major bleeding and net adverse clinical events compared to UFH with either 
abciximab or double-bolus eptifibatide. 
Abciximab strata (n=1,915) Eptifibatide strata (n=1,687)
Biv 
mono
UFH+GPI RR [95%CI] Biv 
mono
UFH+GPI RR [95%CI]
Major 
bleeding 5.3% 8.6%
0.62 [0.44, 
0.87] 4.5% 7.8%
0.57 [0.39, 
0.85]
MACE* 5.7% 5.3% 1.06 [0.73, 1.54] 5.2% 5.7%
0.91 [0.61, 
1.36]
NACE** 9.7% 12.3% 0.79 [0.61, 1.02] 8.6% 11.9%
0.73 [0.55, 
0.97]
* MACE = death, reinfarction, ischemic TVR or stroke; 
**NACE (Net Adverse Clinical Events) = MACE or major bleeding
2900-286 Impact of baseline renal function on the safety and 
effectiveness of bivalirudin in patients with acute 
myocardial infarction undergoing primary angioplasty: 
The HORIZONS AMI trial
Roxana Mehran, Bernhard Witzenbichler, Giulio Guagliumi, Victor Guetta, Harry 
Suryapranata, Kurt Huber, Jochen Woehrle, Chris Metzger, George Dangas, Helen 
Parise, Gregg W. Stone, Columbia University Medical Center/Cardiovascular Research 
Foundation, New York
Background. In HORIZONS, bivalirudin monotherapy (Biv) compared to unfractionated 
heparin (UFH) plus GP IIb/IIIa inhibitors (GPI) resulted in reduced rates of major 
bleeding and net adverse clinical events (NACE), with comparable composite major 
adverse cardiovascular events (MACE) (although with decreased cardiac mortality) in pts 
undergoing primary PCI. Whether the beneficial effects of Biv are independent of renal 
function, an important prognostic determinate after primary PCI, has not been reported.
Methods and Results. A total of 3602 pts at 123 centers in 11 countries with AMI 
undergoing primary PCI were randomized to Biv (n=1800) vs. UFH+GPI (n=1802). 30 
day outcomes were analyzed according to the presence of baseline renal insufficiency 
(RI; calculated creatinine clearance ≤60 ml/min). In the entire study cohort, Biv compared 
to UFH+GPI resulted in a 40% reduction in major bleeding (4.9% vs. 8.3%, P<0.0001), 
similar MACE (5.4% vs. 5.5%, P=1.0), and a 24% reduction in NACE (9.2% vs. 12.1%, 
P=0.006). Compared to pts with normal renal function, those with RI (16% of pts) had 
greater major bleeding (13.4% vs. 5.3%, P<0.0001), MACE (11.6% vs. 4.3%, P<0.0001) 
and NACE (21.1% vs. 8.7%, P<0.0001). The impact of Biv was independent of renal 
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function (interaction P value for these 3 endpoints = 0.20, 0.43, and 0.31 respectively).
Conclusions. In pts with AMI undergoing primary PCI, Biv monotherapy significantly 
reduces major bleeding and net adverse clinical events, independent of baseline renal 
function. 
Creatinine clearance >60 ml/min 
(n=2783)
Creatinine clearance ≤60 ml/min 
(n=554)
Biv 
mono
UFH+GPI RR [95%CI] Biv 
mono
UFH+GPI RR [95%CI]
Major 
bleeding 3.7% 6.9%
0.54 [0.39, 
0.75] 11.8% 14.7%
0.80 [0.52, 
1.24]
MACE 4.1% 4.4% 0.94 [0.66, 1.34] 12.6% 10.6%
1.19 [0.75, 
1.88]
NACE 7.1% 10.2% 0.70 [0.55, 0.90] 21.0% 21.2%
0.99 [0.72, 
1.36]
* MACE = death, reinfarction, ischemic TVR or stroke; 
**NACE (Net Adverse Clinical Events) = MACE or major bleeding
2900-287 Major Adverse Events in STEMI Patients Treated with 
Primary Angioplasty Occur More Frequently at U.S. 
Compared with Non U.S. Sites: Analysis from the 
HORIZONS AMI Trial
Bruce R. Brodie, Thomas Stuckey, Bernhard Witzenbichler, Giulio Guagliumi, Jan 
Z. Peruga, Dariusz Dudek, Ran Kornowski, Franz Hartmann, George Dangas, S. 
Chiu Wong, Helen Parise, Roxana Mehran, Gregg W. Stone, LeBauer CV Research 
Foundation/Moses Cone Hosp., Greensboro, NC, Columbia University Medical Center/
Cardiovascular Research Foundation, NY, NY
Background: Whether adverse event rates following primary PCI for AMI vary in different 
geographies is unknown.
Methods: HORIZONS AMI was an international randomized trial evaluating bivalirudin 
(Biv) vs unfractionated heparin + GP IIb/IIIa platelet inhibitors (UFH+GPI) in 3,602 pts 
with STEMI treated with primary PCI; 814 pts (22.6%) were enrolled in the US. Major 
endpoints adjudicated by central committee using original source documents included 
major bleeding, major adverse cardiovascular events (MACE), and net adverse clinical 
events (NACE = major bleeding or MACE).
Results: US compared to non US pts had more diabetes (20.8% vs 15.2%, p=0.0003), 
hypertension (59.1% vs 51.8%, p=0.0003), prior MI (13.8% vs 10.1%, p=0.004), prior PCI 
(14.9% vs 9.5%, p<0.0001), prior CABG (5.5% vs 2.2%, p<0.0001), renal insufficiency 
(4.7% vs 2.4%, p=0.002), and higher BMI (28.0 vs 26.8, p<0.0001). Age and sex were 
similar. MACE and major bleeding events were significantly higher at US vs OUS sites 
(Table). Biv compared to UFH+GPI reduced NACE to a similar extent at US sites (RR: 
0.80 [0.59-1.07]) and non US sites (RR: 0.74 [0.58-0.95]) (p for interaction = 0.83).
Conclusions: Compared to non US pts, US pts with AMI undergoing PCI had a higher 
risk baseline profile and reduced event-free survival. Multivariable analysis will be 
reported at presentation to determine whether the difference in baseline risk explains the 
varying prognosis. Regardless, Biv reduced NACE compared to UFH+GPI regardless of 
enrolment geography. 
US Non US p value
(n = 814) (n = 2788)
Death 3.8% 2.2% 0.017
Reinfarction 2.3% 1.6% 0.23
Ischemic TVR 2.8% 2.1% 0.23
Stroke 1.1% 0.5% 0.09
Major bleeding 12.2% 5.0% <0.0001
MACE* 8.0% 4.7% 0.0006
NACE** 17.8% 8.6% <0.0001
* MACE = death, reinfarction, ischemic TVR or stroke
**NACE (Net Adverse Clinical Events) = MACE or major bleeding
2900-288 Bare Metal Stents plus Oral Rapamycin are More 
Cost Effective than Drug Eluting Stents in Patients 
Undergoing PCI for De Novo Coronary Lesions: Insights 
From the Randomized,Controlled ORAR III Study
Carlos Fernandez-Pereira, Juan Mieres, Gustavo Risau, Omar Santaera, Alfredo M. 
Rodriguez-Granillo, Gaston A. Rodriguez-Granillo, Andrew O. Mauree, Igor F. Palacios, 
Alfredo E. Rodriguez, Sanatorio Otamendi, Buenos Aires, Argentina, Massachusetts 
General Hospital, Boston, MA
Background: In previous randomized study, ORAR II (Oral Rapamycin in Argentina), we 
demonstrated a significant reduction of restenosis with oral rapamycin (OR) in patients 
undergoing bare metal stent (BMS) implantation. Its role in comparison with drug eluting 
stent (DES) was unknown.
Methods: Since January 2006 to September 2007 at the Cardiac Laboratories of the 
Cardiovascular Research Center in Buenos Aires, Argentina, 200 patients with de novo 
coronary lesions(328) were randomized to treated with OR plus BMS (100 pts) or with 
DES (100 pts). OR was given as a bolus of 10 mg per day before PCI followed by daily 
doses of 3 mg plus diltiazem during 13 days after. Primary End points were to compare 
Hospital, Follow Up and Overall cost per patient at one, two, three and five years of follow 
up. Safety end point such death from any cause, Q and non Q myocardial infarction (MI) 
and stroke was analyzed as Major Adverse Cardiovascular Events . Target Vessel (TVR)
and Target Lesion Revascularization (TLR) were independently analyzed as Efficacy end 
point . Cost in U$ dollars included procedural resources, hospitalization, medications, and 
repeat revascularization procedures during follow up.Profesional fees are not included. 
Results: Baseline demographic, clinical and angiographic characteristics were similar in 
both groups. 10.7. + 6.1 months follow up results appears in Table .
Conclusions:This randomized study showed that a strategy of OR plus BMS is more 
cost effective than DES in patients with novo coronary lesions.
Table
OR(100) DES(100) p value
Death 1% 5% 0.23
Cardiac Death 1% 3% 0.62
MI 4% 8% 0.41
Stroke 0% 1% 0.99
TVR(vessels) 8.4% 7.7% 0.96
TLR(lesions) 5.7% 5.8% 0.86
Hospital costs 3070.7+/-779.7 5410.2+/-1510.4 0.0001
Follow up costs 632.7+/-1325.2 730+/-1467 0.62
Overall costs 3703.4+/-1052 6140.2+/-1488.7 0.0001
2900-289 Long Term Adherence to Dual Antiplatelet Therapy and 
Late Adverse Cardiovascular Events
Somjot S. Brar, Amala Chirumamilla, Roxana Mehran, George Syros, Varinder Singh, 
Binoy Singh, Gurkan Taviloglu, Laura Higginbotham, Gregg W. Stone, Jeffrey W. Moses, 
Martin B. Leon, George Dangas, Columbia University, New York, NY, Cardiovascular 
Research Foundation, New York, NY
Objective: Clopidogrel adherence is an important predictor of adverse events after PCI 
with drug-eluting stents. However, data are lacking on the incidence of clopidogrel non-
compliance and the impact of stopping therapy after prolong administration on late 
adverse cardiovascular events.
Methods: The MATRIX registry is a single arm study initiated in 2004 to evaluate the 
outcomes of 3,500 consecutive patients treated with sirolimus-eluting coronary stents in 
an unselected population. Post PCI, all study participants receive the same instructions 
on dual anti-platelet therapy: aspirin 325 mg daily for 1 month and 81 mg indefinitely 
thereafter, plus clopidogrel 75 mg daily for 1 year, physician discretion thereafter.
Results: The mean age was 64.8 ± 11.1 years, 74.6% were male, 33.3% had prior MI, 
44.4% had prior PCI, and 33.7% were diabetic. Adherence to aspirin therapy at 6 months, 
1 yr, and 2 yrs was: 93.5%, 92.2%, and 89.1%. Adherence to clopidogrel therapy at 6 
months, 1yr, and 2 yrs was: 78.7%, 74.0%, and 60.5%. The incidence of stent thrombosis 
(ARC definite and probable) at 6 months, 1yr, and 2 yrs was: 0.6%, 0.6%, and 1.0%. For 
patients with at least 1 year of clopidogrel use compared to <1 yr of use the event rates 
beyond 1yr post-PCI are shown in the Table. 
Clopidogrel Duration
>=1 year <1 year p-value
All-cause death 1.6% 2.5% 0.21
Cardiac death 0.0% 0.4% 0.18
MI 0.6% 1.2% 0.45
Death / MI 1.9% 3.7% 0.1
Death / MI / TVR 7.8% 4.7% 0.15
Stent thrombosis 0.7% 0.0% 0.2
Conclusion: In the first year after PCI, most clopidogrel non-adherence occurred in the 
first 6 months. After the first year post-PCI, there was no difference in death, MI, death/MI/
TVR, or stent thrombosis between continued clopidogrel users vs. non-users.
2900-290 Plaque Progression in Neighboring Segment of Stent: 
Comparison between Drug-Eluting Stent and Bare 
Metal Stent
Yong Hwan Park, Sang Yeub Lee, Bong Gun Song, Soo Jin Cho, Joo-Yong Hahn, Jin 
Ho Choi, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Sang Hoon Lee, Samsung Medical 
Center, SEOUL, South Korea
Background:Drug-eluting stent (DES) implantation was reported to be associated with 
paradoxical peristent vasoconstriction in response to exercise or acetylcholine suggesting 
endothelial dysfunction. Endothelial dysfunction can result in atherosclerosis progression. 
We investigated whether plaque progression is accelerated in the neighboring segments 
after DES implantation compared with bare metal stent (BMS).
Methods:We retrospectively evaluated 133 patients with stable angina who underwent 
successful stenting and completed follow-up coronary angiography (CAG). Patients were 
grouped into BMS (n=45) and DES (n=88). Late loss of minimal luminal diameter (MLD) 
of in-stent, proximal and distal stent edges (5 mm from stent) and proximal and distal 
neighboring segments (10 mm from stent edges) were measured in post-procedural and 
follow-up CAG.
Results:Baseline clinical and angiographic characteristics were similar between 2 groups. 
Mean follow-up duration was 263±176 days. Late loss of MLD in neighboring segments 
was significant in DES group, whereas not significant in BMS group. In-segment late 
losses were significant in both groups. But target vessel revascularization in neighboring 
segments was similar between 2 groups (4.4% vs 3.4%, p=NS).
Conclusions:In contrast to BMS, DES implantation seems to be associated with plaque 
progression in the proximal and distal neighboring segment. But the clinical implication 
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may be minimal.
Late losses of MLD in DES and BMS groups
Segment BMS(mm) p-value DES(mm) p-value
Proximal neighboring segment 0.08 ± 0.41 0.197 0.21 ± 0.47 <0.001
Proximal stent edge 0.22 ± 0.54 0.009 0.23 ± 0.51 <0.001
In-stent 0.87 ± 0.57 <0.001 0.21 ± 0.45 <0.001
Distal stent edge 0.27 ± 0.50 0.001 0.08 ± 0.42 0.096
Distal neighboring segment -0.02 ± 0.45 0.719 0.12 ± 0.53 0.042
2900-291 Sirolimus-Eluting Stent vs Balloon Angioplasty for the 
Treatment of Post-Sirolimus-Eluting Stent Restenosis: 
Insights From j-CYPHER Registry
Mitsuru Abe, Hiroshi Nonogi, Nobuhito Yagi, Takuya Taniguchi, Nobuaki Kokubu, Yoichiro 
Kasahara, Yu Kataoka, Yuji Yasuga, Yoritaka Otsuka, Atsushi Kawamura, Takeshi 
Morimoto, Kazuaki Mitsudo, Takeshi Kimura, on behalf of the j-CYPHER Registry 
investigators, National Cardiovascular Center, Osaka, Japan
Background: Sirolimus-eluting stents (SESs) are proven as an effective treatment 
for bare metal stent (BMS) restenosis, however, there are few studies comparing SES 
implantation with balloon angioplasty (BA) for the treatment of post-SES restenosis.
Methods: Design of j-CYPHER registry was multi-center prospective enrollment of 
consecutive patients receiving SES implantation from 41 centers in Japan. From August 
2004 to April 2006, 8752 patients with 12938 lesions were successfully implanted with 
SES. Among them, we identified 639 post-SES restenosis treated with SES (n=313) or 
BA (n=326) at their operators’ discretion.
Results: Baseline characteristics were as follows (SES vs BA): diabetes (50.2% vs 
58.3%, p=0.04), hemodialysis (13.7% vs 17.2%, p=0.2), treatment of in-stent restenosis 
(17.0% vs 29.5%, p=0.0002), long lesion length (>=30mm) (26.4% vs 27.3%, p=0.8), and 
small vessel size (<=2.5mm) (27.7% vs 31.2%, p=0.3). During median follow up of 174 
days, target lesion revascularization occurred in 9.6% (30/313) of SES-treated lesions 
and 25.8% (84/326) of BA-treated lesions (Log-rank p<.0001). Cox proportional hazard 
model showed that only an additional SES-implantation [hazard ratio (HR): 0.60, 95% 
confidence interval (CI): 0.48-0.74] and long lesion length [HR: 1.28, 95% CI: 1.04-1.57] 
were independently associated with recurrence of post-SES restenosis after adjustment 
(Table).
Conclusions: In our study population, SES is superior to BA for the treatment of post-
SES restenosis.
Variable Hazard Ratio 95%CI
SES-implantation 0.62 0.50-0.77
Diabetes 1.13 0.92-1.38
BMI>25 0.83 0.67-1.03
Hemodialysis 1.26 0.98-1.59
In-stent restenosis 1.22 0.99-1.50
Ostial location 1.13 0.89-1.42
Long lesion length (>=30mm) 1.30 1.05-1.60
Small vessel size (<=2.5mm) 1.00 0.81-1.24
Two stent technique 1.18 0.85-1.59
2900-292 Incidence and Clinical Impact of Longitudinal 
Geographical Miss following Sirlimus-Eluting Stent 
Implantation
Kengo Tanabe, Ken Kozuma, Toru Kataoka, Hitoshi Yasumoto, Shinsuke Nanto, Yuji 
Ikari, Mitsui Memorial Hospital, Tokyo, Japan
Background: Restenosis of sirolimus-eluting stent (SES) is sometimes attributable to a 
mismatch of lesion and injured segment with the stent site (geographical miss), however, 
there have been a few studies to survey the incidence and sequel of the technical failure. 
Methods: The study is a pre-specified analysis of Japanese multi-center post-marketing 
survey (PMS). From 2004 to 2005, the PMS enrolled 2051 patients (2459 lesions) who 
were treated with SES. Of the lesions, the study comprised 992 lesions of which serial 
angiograms (baseline and 8 months) were analyzed at an independent core laboratory. 
Longitudinal geographic miss included “balloon injury” or “uncovered plaque”. The “balloon 
injury” was defined as the presence of segment which was dilated by a balloon, but not 
covered with SES. The “uncovered plaque” was defined as the presence of proximal or 
distal edge segment of which diameter stenosis was greater than 30% post-procedure, or 
residual dissection. Results: The “balloon injury” and “uncovered plaque” were observed 
in 26.5% and 41.0%, respectively. The restenosis rate in lesions with uncovered plaque 
was higher compared to those without uncovered plaque (Table). However, there was no 
impact of balloon injury on restenosis at proximal edge. Conversely, there was a trend 
toward higher restenosis at distal edge in lesions with balloon injury. Conclusions: 
Geographic miss is associated with edge restenosis. There remains a room for technical 
improvement to achieve better outcomes of SES.
Restenosis rates at the edges
uncovered plaque (+) uncovered plaque (-) P
proximal edge 9.8% 2.5% <0.001
distal edge 4.6% 1.1% <0.001
balloon injury (+) balloon injury (-) P
proximal edge 0.8% 4.8% 0.07
distal edge 4.5% 1.8% 0.07
2900-293 Large differences in rate of clinical restenosis between 
different stents - Long term follow-up from the Swedish 
angiography and angioplasty registry (SCAAR)
Stefan K. James, Tage Nilsson, Jörg Carlsson, Iwar Sjögren, Per Tornvall, Fredrik 
Schersten, Bo Lagerqvist, Uppsala Clinical research center, Uppsala, Sweden
Background: The rate of restenosis and acute occlusion in a large number of different 
stent types in a real world situation is not well studied.
Methods: The Swedish angiography and angioplasty registry (SCAAR) is a continuous 
national registry covering all Swedish patients undergoing coronary angiography and 
percutaneous coronary interventions in Sweden. Since 2004 the database contains 
information about all cases of restenosis detected at a subsequent angiography 
and since 2005 also information about clinical presentation (acute occlusion) of the 
restenosis. All available stents on the Swedish market used at least 500 times, were 
included in Cox regression analyses adjusting for differences in patient, lesion and vessel 
characteristics. 
Results: From May 2004 to December 2006, 62822 stents were implanted at 39691 
procedures. Until August 2007 3402 restenosis have been reported. As expected, Drug 
eluting stents (DES) had a lower rate of restenosis as compared to bare metal stents 
(BMS). There was a great variation in the rate of restenosis between different DES and an 
even greater difference between different BMS.
Conclusions: In this large real world registry there were large differences between 
different types of stents among both BMS and DES which reinforces the need of larger 
randomized trials with head-to-head comparisons between the different stent types. 
2900-294 Large differences in rate of acute stentocclusions 
between different stents - Long term follow-up from 
the Swedish angiography and angioplasty registry 
(SCAAR)
Bo Lagerqvist, Tage Nilsson, Jörg Carlsson, Iwar Sjögren, Tomas Kellert, Jens Jensen, 
Stefan James, Uppsala Clinical Research Center, Uppsala, Sweden
Background:To investigate the rate of acute occlusions in a large number of different 
stent types in a real world situation.
Methods: The Swedish angiography and angioplasty registry (SCAAR) is a continuous 
national registry covering all Swedish patients undergoing coronary angiography and 
percutaneous coronary interventions in Sweden. Since 2004 the database contains 
information about all cases of restenosis detected at a subsequent angiography and since 
2005 also information about clinical presentation (acute occlusion) of the restenosis. 
All available stents on the Swedish market used at least 500 times since 2005, were 
included in Cox regression analyses adjusting for differences in patient, lesion and vessel 
characteristics. 
Results: From March 2004 to December 2006, 39178 stents were implanted at 24500 
procedures. Until August 2007 478 acute occlussions have been reported, 408 within 
1 year after implantation. Most of the occlusions occurred during the fist weeks after 
implantation. There was a great variation in the rate of acute occlusion between different 
DES and an even greater difference between different BMS.
Conclusions: In this large real world registry there were large differences between 
different stents which reinforces the need of larger randomized trials with head-to-head 
comparisons between the different stents. 
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2900-295 Early Development of Percutaneous Coronary 
Intervention lowered the Clinical need for Re-
intervention More than Recent Advances- A 15 year 
of follow-up from the Swedish Angiography and 
Angioplasty Registry.
Fredrik Calais, Stefan James, Tage Nilsson, Per Albertsson, Peter Eriksson, Hans 
Ohlsson, Ulf Stenestrand, Bo Lagerqvist, Department of Medical Sciences Akademiska 
sjukhuset, Uppsala, Sweden
Background: Clinical need for re-intervention after percutaneous coronary intervention 
(PCI) on very long term is not investigated.
Methods: The Swedish angiography and angioplasty registry (SCAAR) is a continuous 
national registry covering all Swedish patients undergoing coronary angiography and 
percutaneous coronary interventions in Sweden since 1989. All re-interventions after the 
initial PCI were recorded. Event curves for different years of the initial treatment were 
adjusted for differences in all available background characteristics.
Results: 77 259 procedures were included in the analysis. There was a dramatic lower 
need for a new revascularization in patients treated during 1999 to 2000 as compared to 
1996 to 1998 and 1989 to 1995 which timely corresponds to the introduction of, and wider 
use of, stents during these periods. In the time periods thereafter, the clinical need for a 
new revascularization was only marginally lower
Conclusion: The early development of PCI techniques and the introduction of stents 
apparently had a larger impact on the clinical need of new revascularizations than the 
introduction of more recent techniques and devices such as drug eluting stents. 
2900-296 Do Drug-Eluting Stents have Similar Efficacy for the 
Treatment of Drug-Eluting Stent Restenosis as they are 
for Bare Metal Stent Restenosis?
Daniel H. Steinberg, Michael A. Gaglia, Jr., Tina L. Pinto Slottow, Probal Roy, Teruo 
Okabe, Rebecca Torguson, Kimberly A. Smith, Saquib Samee, Zhenyi Xue, William O. 
Suddath, Kenneth M. Kent, Lowell F. Satler, Augusto D. Pichard, Joseph Lindsay, Ron 
Waksman, Washington Hospital Center, Washington, DC
Background: Drug-eluting stent (DES) implantation is the standard treatment for bare 
metal stent (BMS) instent restenosis (ISR) and is associated with low rates of target 
vessel revascularization (TVR). Outcomes in patients with DES ISR treated with repeat 
DES is less certain.
Methods: We evaluated 123 patients who presented with BMS ISR and 119 patients with 
DES ISR matched for baseline characteristics. Both groups of patients were treated with 
DES and they were compared with regard to major adverse cardiac events included death, 
myocardial infarction and target vessel revascularization (TVR) at one year (Figure1).
Results: Baseline characteristics were similar between the two groups. Compared to 
patients with BMS ISR, those with DES ISR had similar one year rates of death (3.4% 
DES ISR vs. 4.9% BMS ISR, p=0.75) and myocardial infarction (3.4% DES ISR vs. 3.3% 
BMS ISR, p=1.00) when treated with DES. However, at one year, patients with DES ISR 
experienced significantly higher rates of TVR (20.2% DES ISR vs. 10.6% BMS ISR, 
p=0.04).
Conclusion: Patients with DES ISR treated by DES experience a high rates (20.2%) and 
significantly more TVR at one year than patients who present with BMS ISR treated by 
DES. The optimal treatment of DES restenosis remains to be defined. 
2900-297 Treating drug-eluting stent restenosis in the real-world: 
Lessons learned from the DESIRE Registry
Jose de Ribamar Costa, Jr., Amanda Sousa, Adriana Moreira, Ricardo Costa, Galo 
Maldonado, Manuel Cano, Ibraim Pinto, Cantídio Campos, Rodolfo Staico, Maria Helena 
Dib, César Jardim, J Eduardo Sousa, Hospital do Coração - Associação do Sanatório 
Sírio, São Paulo, Brazil
Background: Despite the marked reduction in restenosis following drug-eluting stent 
(DES) use, this complication still happens in 5-15% of the cases. The natural history and 
the best treatment for DES in-stent restenosis (ISR) are yet to be defined. We sought to 
evaluate the long-term outcomes of a non-selected population with DES ISR treated with 
another DES.
Methods: Between May 2002 and March 2006, 2,081 consecutive patients were treated 
with DES in a single center. All consecutive cases of DES ISR treated with another DES 
were enrolled in this registry. The type of DES (Cypher vs. Taxus) to treat the ISR was 
at operator’s discretion. Follow-up (FU) was obtained at 1, 3 and 6 months and then 
annually up to 5 years. The primary goal of this study was to assess the incidence of 
target-lesion revascularization (TLR), stent thrombosis (ST) and cardiac death. ST was 
classified according to the ARC definition.
Results: A total of 61 pts (2.9%) evolved with ischemia-driven DES ISR. Sixteen of them 
were referred to CABG. Of the 45 pts (65 lesions) submitted to new PCI, 30 (66.6%) 
were men with mean age of 60 years-old. FU time was 2.7±1.1 years. Diabetes mellitus 
was observed in 29 (64%) pts and unstable angina in 26 (27%). Notably, 5 pts (11.1%) 
presented myocardial infarction as the restenosis clinical manifestation. Right coronary 
artery was the culprit vessel in most cases (32%). Most DES ISR cases were focal and 
occurred more frequently following the use of Taxus (1.6% vs. 1.3%, p=NS). No type IV 
ISR (total occlusion) was observed in this population. Reference vessel diameter and 
lesion length were 2.8mm±0.5mm and 9mm ± 3.1mm, respectively. Switch to a different 
type of DES was done in only 10% of the cases. More than one DES was required in 
10.7% of the cases. Direct stenting was performed in 67% of the procedures. At long-term 
follow-up no death/ST were evidenced. However, 6 patients (13.3%) presented ischemia-
driven TLR (recurrence of ISR).
Conclusions: Although infrequent, DES restenosis still has poor long-term clinical 
outcomes, mostly due to the recurrence of treated-lesion ischemia. Different strategies 
(e.g. switch to a different stent, PCI guided by IVUS) should be tested in this high-
complexity clinical scenario.
2900-298 Intravascular Radiation Therapy for Patients with 
Recurrences of In-stent Restenosis who Previously 
Treated with Either Radiation Therapy of Drug Eluting 
Stents
Ron Waksman, Rebecca Torguson, Kimberly Smith, Tina Pinto-Slottow, Daniel 
Steinberg, Probal Roy, Teruo Okabe, Saquib Samee, Augusto Pichard, Lowell Satler, 
William Suddath, Kenneth Kent, Washington Hopsital Center, Washington, DC
Background: Treatment of in-stent restenosis is challenging especially for patients who 
failed the initial treatment and present with recurrences of in-stent restenosis. Intravascular 
radiation (IRT) and Drug eluting stents (DES) are effective treatment for patients with in-
stent restenosis of bare metal stents (BMS). However, both modalities are associated with 
recurrences. This study evaluates and compares the safety and efficacy of repeat IRT for 
IRT failure versus IRT for drug-eluting stents (DES) failure.
Methods: Fifty-four consecutive patients treated with repeat IRT as adjunct therapy 
to percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) of a prior 
site treated with IRT were compared to 119 patients treated with IRT for ISR of a DES. 
Commercially available IRT systems were utilized. The antiplatelet regimen for both 
groups was life-long aspirin and at least 12 months of clopidogrel. Pts were followed up 
by telephone contact or clinical visit at 12 months.
Results: Baseline characteristics were comparable between the two groups except 
there were more current smokers in the IRT group (24.1% vs. 16.0%, p<0.001) and more 
patients who underwent prior coronary bypass surgery in the IRT for DES failure group 
(31.5% vs. 55.6%, p = 0.006). Beta radiation was used more frequently in the IRT for 
DES failure group (20.4% vs. 97.5%, p<0.001). There has been no report of subacute 
thrombosis in either group. (Table)
Conclusions: IRT for patients with multiple recurrences of in-stent restenosis who 
previously treated with either radiation therapy or drug eluting stents is safe and associated 
with acceptable results at 12 months. IRT should be considered as the treatment modality 
for this difficult subset of patients.
Table: 12 month clinical outcomes 
Variable (%) IRT for IRT failure 
n=50
IRT for DES failure 
n=84 P value
Death 1 (2.0) 3 (3.6) 1.00
Q wave MI 0 (0) 2 (2.4) 0.529
Target Vessel Revascularization 4 (8.0) 16 (19.0) 0.131
Major Adverse Cardiac Events 5 (10.0) 19 (22.6) 0.101
2900-299 Drug-Eluting Stent for the Treatment of Small Coronary 
Artery with Sirolimus, Paclitaxel, Zotarolimus, 
Tacrolimus-Eluting Stent and EPC Capture Stent: 
Multicenter Registry in Asia
Sunao Nakamura, Jang-Ho Bae, Yeo Hans Cahyadi, Wasan Udayachalerm, Damras 
Tresukosol, Sudaratana Tansuphaswadikul, New Tokyo Hospital, Chiba, Japan, Konyang 
University Hospital, Daejeon, South Korea
Aim: The aim of this study is to compare the safety and efficacy of Sirolimus (SES), 
Paclitaxel (PES), Zotarolimus (ZES), Tacrolimus-eluting stent (TES) and EPC capture 
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stent (ECS) on the outcome of patients with small coronary artery disease. Methods: A 
prospective analysis of 1947 patients with small coronary artery stenosis (808 SES, 602 
PES, 219 ZES, 165 TES, 153 ECS) in five high volume Asian centers after successful 
stenting for small coronary artery stenosis was performed. The study endpoints were 
major adverse events (MACE) at 30 days, 9 months restenosis rate and target lesion 
revascularization (TLR) at 9 months. Results: See table for clinical results. Conclusion: 
The use of drug-eluting stents in patients with small coronary artery stenosis was safe 
and feasible. Patients treated with SES showed lesser rate of restenosis compared with 
other drug-eluting stents. 
SES PES ZES TES ECS
Number of patients 808 602 219 165 153
Procedural success (%) 99.8 99.7 100 100 100
Reference diameter (mean: mm) 2.40 2.42 2.37 2.39 2.35
Lesion length (mean: mm) 12.6 11.3 13.7 12.6 12.9
Minimum lumen diameter post procedure (mean: mm) 2.32 2.30 2.28 2.29 2.30
Minimum lumen diameter at 9 months (mean: mm) 2.10 2.01 1.70 1.85 1.72
Restenosis rate at 9 months (%) 7.4* 13.0 20.1 17.6 21.6
TLR at 9 months (%) 7.4* 11.6 20.1 17.6 21.6
MACE at 9 months (%) 7.9* 13.0 20.1 17.6 21.6
*p<0.05 vs ZES, TES
2900-300 Long-Term Follow-Up After Deferral of Percutaneous 
Coronary Intervention (PCI) of In-stent Restenosis of 
Bare Metal Stenting on the Basis of Coronary Pressure 
Measurement
TAKAFUMI YAMANE, TAMITA KOUICHI, AN YOSHIMORI, KIM KITE, KITAI TAKESHI, 
EHARA NATUHIKO, ODA TOMOYUKI, KINOSHITA MAKOTO, KAJI SHUUICHIROU, 
YAMAMURO ATUSHI, TANI TOMOKO, TANABE KAZUAKI, KIHARA YASUKI, Kobe City 
Medical Center General Hospital, Kobe, Japan
Backgroung: Deferral of PCI on the basis of an myocardial fractional flow reserve 
(FFRmyo)>0.75 is implicated to be safe that maybe associated with a very low coronary 
event rate. FFRmyo has been demonstrated to be useful for determining the physiologic 
importance of a given coronary lesion. This study was conducted to determine the safety 
of deferral of PCI of angiographically intermediate but functionally nonsignificant stenosis, 
as assessed by FFRmyo in patients with in-stent restenosis of bare metal stenting.
Methods: The study included 70 anigiographically significant in-stent restenosis (>50% 
diameter stenosis; %DS by visual assessment) in 70 patients. In these patients, the PCI 
was deferred on the basis of an FFRmyo>0.75. All patients were performed bare metal 
stenting at least 6 months before. The FFRmyo was calculated as the ratio of mean distal 
pressure divided by the proximal pressure during hyperemia.
Results: During a follow-up period of 78 ± 28 months (mean±SD, range 4 to 116), three 
patients died of noncardiac causes. Target lesion revascularization (TLR) occurred only in 
one patient (1.4%). Non-target lesion revascularization (non-TLR) occurred in 16 patients 
(23%), and most of them occurred more than 2years later. 
Conclusion: In patients with intermediate in-stent restenoses after bare metal stenting, 
deferral of PCI on the basis of FFRmyo>0.75 is safe and is indeed associated with a very 
low coronary event rate.
2900-301 Stented length to diameter ratio (LDR) assessed via 
quantitative coronary angiography (QCA) is an effective 
bedside tool for prediction of bare metal binary in-
stent restenosis (ISR) as well as increased restenotic 
complexity
Sandeep Nathan, Martin K. Reriani, Ena Mahapatra, Victor Mwansa, Amit P. Amin, 
Sheetal N. Patel, Atul R. Chugh, Arun Kumar, Russell F. Kelly, Rush University Medical 
Center, Chicago, IL, Cook County Hospital, Chicago, IL
Background: Drug-eluting stent (DES) are ideally used in patients (pts) at increased 
risk for bare-metal stent (BMS) restenosis however no uniform criteria exists for accurate 
quantification of restenotic risk in BMS pts. Previously we demonstrated stented length to 
diameter ratio (LDR) to be an independent predictor of greater morphologic complexity 
in BMS ISR.1 We now evaluate the utility of LDR in prediction of binary restenotic risk in 
patient undergoing BMS implantation.
1. J Am Coll Cardiol 2006 Feb 21; 47(4) Supp. 132A
Methods: Clinical, angiographic and QCA data were collected from 425 consecutive 
pts with 470 BMS, undergoing cardiac catheterization for suspected BMS ISR. Pts were 
divided by the presence (n=300, 63.8%, ISR group) or absence (n=170, 36.2%, non-
ISR group) of binary (≥50%) ISR. Stented LDR was derived via multiple blinded offline 
QCA measurements using Centricity AI 1000 GEMnet GeQCA 2.0 software. Univariate, 
multivariate and ROC analyses were used to estimate the predictive value of stented 
LDR for binary ISR.
Results: In univariate analyses, stented length, diameter and LDR were all associated 
with increased likelihood of binary ISR (p<0.05). LDR was 6.03 ± 3.7 in ISR lesions vs. 
4.39 ± 1.8 in non-ISR lesions, p<0.006. Increasing LDR was also predictive of complex 
(vs. simple) ISR [OR 1.37, 95% CI 1.21-1.54, p<0.001] with an optimal cutoff value of 
6.0 by ROC analysis [AUC 0.74, 95% CI 0.68-0.79] and a prevalence of complex ISR of 
79.0% in stents with LDR of 6.00-6.99. In a multivariate model no clinical or angiographic 
variable (including diabetes), retained predictive value for binary ISR other than LDR.
CONCLUSION: LDR is a simple yet powerful independent predictor of binary ISR with 
value beyond conventional cardiac risk factors, stented length or diameter alone. LDR 
may be integrated into a clinical predictive model with a cut-off value of 5.0 for prediction 
of binary ISR and 6.0 for prediction of complex (vs. simple) ISR. LDR may serve as a 
future criterion for identification of patients with acceptably low binary BMS ISR risk that 
BMS (rather than DES) implantation may be justified.
2900-302 Outcomes Following Percutaneous Re-Treatment of in-
Drug-Eluting Stent Occlusive Restenosis
Tiziana Claudia Aranzulla, John Cosgrave, Enrico Romagnoli, Azeem Latib, Giorgio 
Gimmelli, Giuseppe Sangiorgi, Marcello Murino, Antonio Colombo, EMO Centro Cuore 
Columbus, Milan, Italy, San Raffaele Scientific Institute, Milan, Italy
Background: Albeit rare, occlusive restenosis following DES implantation (OIDR) 
represents a therapeutic dilemma.
Methods: We identified all cases of OIDR (Taxus or Cypher). Study endpoint was the 
re-occurrence of restenosis and target lesion revascularization.
Results: One-hundred-five patients developed OIDR in 108 lesions. Mean age was 
61±11 years: 88% male, 42% diabetic, previous CABG in 24%, 6.3% were on dialysis. 
The initial lesion (which then developed OIDR) was a chronic total occlusion in 42%; 
prior brachytherapy in 6.7%. Of the 108 lesions, 72 underwent repeat PCI of which 60 
were successful, 15 with POBA and 45 with repeat DES implantation. Angiographic follow 
up was available for 33 (55.9%). A second restenoses occurred in 27 lesions (82%), 
13 (39%) were once more occlusive. TLR was performed in 21 of these cases (35.6%). 
Among the 44 lesions re-treated with DES, 33 received a DES different from the one 
previously implanted and 11 the same. Angiographic follow up was available overall in 18 
(54.5%) and 7 (63.6%) lesions, respectively; a second restenosis was found in 19 cases: 
12 (66.7%) in the different DES group and 7 (100%) in the same DES group (Figure 1).
Conclusions: The treatment of occlusive restenosis is associated with a high restenosis 
re-occurrence rate. In this challenging cohort our data suggest that both POBA and repeat 
same DES implantation are associated with disappointing results. The only feasable 
percutaneous treatment strategy may be the implantation of the alternative DES.
2900-303 Constrictive Vascular Remodeling After Implantation 
of a Bioabsorbable Magnesium Alloy Stent in Porcine 
Coronary Arteries
Michael Maeng, Lisette O. Jensen, Leif Thuesen, Aarhus University Hospital, Skejby, 
Aarhus, Denmark
Background: Bioabsorbable magnesium alloy stents (AMS) represent an alternative 
revascularization modality. There is, however, very little information on the arterial 
response to the AMS stent as compared to other stent types.
Methods: Absorbable magnesium stents (n=11), sirolimus-eluting stents (Cypher®, 
n=11) and bare-metal stents (n=9) were randomly implanted in 31 porcine coronary 
arteries (n=11 pigs). Mechanisms of lumen loss were assessed by serial intravascular 
ultrasound and histomorphometry at 90 days.
Results: By histomorphometry, lumen [median (quartiles); AMS: 1.75 (1.07-3.26), 
Cypher 2.52 (2.22-5.01), BMS 4.55 (3.2-7.44); p=0.013] and external elastic lamina [AMS: 
5.56 (4.09-6.95), Cypher 7.95 (6.45-10.92), BMS 9.08 (7.85-11.63); p=0.014] areas were 
smallest in the absorbable magnesium stent group. By intravascular ultrasound, external 
elastic lamina area at follow-up [AMS: 7.5±2.8, Cypher 9.1±2.7, BMS 9.9±3.1; p=0.33] and 
change in external elastic lamina area from index intervention to follow-up [remodelling; 
AMS: -1.0±3.1, Cypher 1.02±0.83, BMS 0.9±1.2; p=0.30] were not statistically different 
between the groups. In a dichotomized intravascular ultrasound assessment of vascular 
remodelling, 6 AMS stents were remodelled (constrictive remodelling: n=5; positive 
remodelling: n=1) at 90 days follow-up (AMS versus SES+BMS: p=0.001). Neointima 
area was smallest in the AMS group [histomorphometry: AMS: 2.2±0.6, Cypher 3.5±1.4, 
BMS 2.6±0.9; p=0.013; intravascular ultrasound: AMS: 1.9±1.0, Cypher 3.5±1.9, BMS 
2.7±0.7; p=0.019].
Conclusion: Coronary implantation of absorbable magnesium stents, as compared to 
bare-metal and sirolimus-eluting stents, was associated with smaller lumen diameters 
and smaller external elastic lamina areas at follow-up despite lesser neointima formation. 
Constrictive vascular remodelling was the main cause of this result.
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2900-304 Differences in Angiographic Characterization of 
In-Stent Restenosis After Sirolimus Eluting Stent 
Implantation From Original De Novo Coronary Stenosis
Tomohiko Teramoto, Masashi Kimura, Yoshihisa Kinoshita, Kenya Nasu, Mariko Ehara, 
Etsuko Tsuchikane, Mitsuyasu Terashima, Tetsuo Matsubara, Osamu Kato, Takahiko 
Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Background: Bare metal stent (BMS) restenosis often mimics pre-stent lesion 
morphology and location. However, sirolimus-eluting stent (SES) restenosis is more often 
focal than BMS restenosis. However, it is unclear whether angiographic DES restenosis 
occurs at the same location or at a different location compared to the original de novo 
coronary stenosis.
Methods: We used quantitative coronary angiography (QCA) to compare baseline vs in-
stent restenosis (ISR) lesion locations in 35 pts (diameter stenosis [DS] >50 %) after SES 
implantation. The distances between the minimum lumen site and the coronary ostia were 
measured, and the distance between baseline stenosis site and ISR site were calculated. 
Pts were divided into 2 groups: (1) ISR <5mm from baseline stenosis and (2) ISR >5mm 
far from baseline stenosis.
Results: Baseline %DS measured 67.5±19.3%, and follow-up %DS measured 
63.0±15.8% (p=0.3). Baseline lesion length was longer than follow-up lesion length 
(12.0±7.1mm vs. 8.9±5.0mm, p=0.04). At follow up, the minimum lumen site was located 
11.2±8.6mm remote from baseline minimum lumen site; and 26 (74%) were >5mm 
remote from the baseline minimum lumen site. However, there were no QCA differences 
between the two groups (Table). Conclusion: Unlike BMS restenosis, SES restenosis is 
more focal; and 74% of SES restenosis lesions occur at sites remote (>5mm) from the 
original stenosis. 
<5mm from baseline 
N=9
>5mm from baseline 
N=26 P value
Reference, mm 2.9±0.6 2.8±0.4 0.4
Stent diameter, mm 3.0±0.3 2.9±0.4 0.5
Stent length, mm 21.2±6.7 18.7±6.5 0.3
Baseline DS, % 66.1±25.0 68.0±17.3 0.8
Baseline lesion length, mm 13.3±6.3 11.5±7.5 0.5
Follow up DS, % 67.3±11.1 61.3±17.2 0.3
Follow up lesion length, mm 8.8±4.5 9.5±6.3 0.7
2900-305 Scanning Electron Microscopy Analysis of Corrosion 
of Stainless Steel and Nitinol Stents from Autopsy 
Retrievals
Brigitta C. Brott, Dina Halwani, Peter G. Anderson, Andreas S. Anayiotos, Jack E. 
Lemons, The University of Alabama at Birmingham, Birmingham, AL
Background: Stent biomaterial properties are increasingly being reported as possible 
causes of in-stent restenosis, particularly in peripheral vessels and after drug-eluting 
stent placement. Mechanisms and prevalence of in vivo stent corrosion are being studied. 
We hypothesized that stent corrosion occurs clinically from stent-stent and stent-artery 
interactions.
Methods: We obtained 9 autopsy stent-artery specimens and evaluated them with 
scanning electron microscopy (SEM) with energy dispersive spectroscopy (EDS). 
Examples of overlapping Nitinol (NiTi) and stainless steel (SS) stents, and a SS stent 
are shown.
Results: Overlapping regions of NiTi and SS stents and SS stent alone revealed 
significant corrosion along the stent surfaces. Regions of overlap of the NiTi stent 
revealed fretting wear.
Conclusion: Stent corrosion exists in vivo, with particular prevalence in regions of stent 
overlap. Corrosion and release of metallic ions into surrounding tissue could impact in-
stent restenosis and the structural integrity of stents. 
2900-306 Optimal criteria for stent edge landing zones: An 
integrated intravascular ultrasound analysis from the 
TAXUS IV, V, and VI Studies
jian liu, Akiko Maehara, Gary S. Mintz, Neil J. Weissman, Stephen G. Ellis, Eberhard 
Grube, Keith D. Dawkins, Alan Yu, Hong Wang, Lazar Mandinov, Gregg W. Stone, 
Cardiovascular Research Foundation, New York, NY
Background:Stent edge restenosis can occur after implantation of either bare metal 
stents (BMS) or drug-eluting stents. Previous studies suggest that stent edge restenosis 
can be minimized by stenting from “normal to normal.” However, reference segments 
are rarely normal; and the optimal criteria for the stent edge landing zone have not been 
established.
Methods:In the combined TAXUS-IV, V, and VI trials, intravascular ultrasound (IVUS) 
was performed at implantation and analyzed in 809 BMS and 810 paclitaxel-eluting 
stents [PES] that had quantitative coronary angiography (QCA) at 9 months. Follow-up 
QCA diameter stenosis (DS) was compared to baseline IVUS measurements of proximal 
and distal stent edge lumen area and plaque burden (plaque/external elastic membrane 
areas).
Results:Receiver operating curve (ROC) analysis of BMS showed that only the stent edge 
reference lumen area predicted edge restenosis; a lumen area of 7.9mm2 best separated 
edge restenosis (QCA DS >50%) from no edge restenosis (c=0.751, right figure) while 
stent edge plaque burden did not predict edge restenosis (c=0.497). Conversely, ROC 
analysis of PES showed that only the stent edge reference plaque burden predicted 
edge restenosis; a plaque burden of 42% best separated edge restenosis from no edge 
restenosis (c=0.673, left figure) while stent edge reference lumen area did not predict 
edge restenosis (c=0.551).
Conclusions:The optimal criteria for stent edge landing zones are different for BMS 
and PES. After BMS only the lumen area influences edge restenosis; after PES only 
the plaque burden influences edge restenosis. This difference also indicates that the 
causative mechanisms of stent edge restenosis are fundamentally different between 
BMS vs PES. 
2900-307 ENDOTHELIAL CELL APOPTOSIS AFTER CORONARY 
STENT PLACEMENT: IMPLICATION FOR RESTENOSIS
Luigi Vignali, Giuseppe Talanas, Alberto Menozzi, Maria Alberta Cattabiani, Emilia 
Solinas, Enzo Emanuele, Diego Ardissino, U.O. di Cardiologia, Azienda Ospedaliero-
Universitaria di Parma, Parma, Italy
Background:Apoptotic endothelial microparticles have been described in several 
conditions of endothelial cell damage. Whether endothelial cells could represent an 
apoptotic target after coronary stent placement has not been investigated yet.
Methods:In this study, we have measured circulating endothelial cell apoptosis in 50 
patients undergoing coronary stenting (25 bare-metal stents -BMS- and 25 sirolimus-
eluting stents -SES). CD144+ cells (endothelial lineage) were analyzed by using a 
fluorescence-activated cell sorter scan flow cytometer. Cells that were positive for both 
CD144 and Annexin V (CD144AnnV+; i.e. apoptotic cells) and negative for 7-amino 
actinomycin D (i.e. dead cells) were assessed.
Results:After bare-metal stenting, CD144AnnV+ cells increased, reaching a maximum 
on day 8 after stenting. By 6 months of follow-up, angiographic restenosis was seen 
in 4 of 25 patients treated with BMS and in 2 of 25 patients with SMS. The maximum 
change compared with baseline before stenting in CD144AnnV+ cell count (13.4 ± 4.3 
cells/mL) was more striking in patients with restenosis (278±111%) compared to those 
without restenosis (137±37%; P<0.01). In contrast, CD144AnnV+ cells increased only 
slightly after sirolimus-eluting stenting (66±22% on day 8). In vitro experiments showed 
that exposure of rat aortic rings to CD144AnnV+ cells isolated from patients undergoing 
BMS placement, but not from SES patients, selectively impaired vasorelaxation after 
acetylcholine exposure (P<0.01).
Conclusions: Altogether, our study shows that circulating CD144AnnV+ cells 
are augmented in patients undergoing BMS placement. More importantly, we have 
demonstrated that the count of circulating CD144AnnV+ cells predicts the angiographic 
restenosis rate at 6-month follow-up. We also observed that circulating CD144AnnV+ 
cells of patients undergoing BMS placement specifically impaired endothelium-dependent 
relaxation to acetylcholine in the rat aorta in vitro. From our results, we have identified a 
novel pathophysiological mechanism of restenosis. We propose circulating CD144AnnV+ 
as a new potential risk marker in the occurrence of restenosis after coronary stent 
placement.
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2900-308 Low levels of the endogenous endocannabinoid 
arachidonoylethanolamide are predictive of 
symptomatic in-stent restenosis after coronary 
implantation of drug-eluting stents.
Luigi Vignali, Giuseppe Talanas, Alberto Menozzi, Maria Alberta Cattabiani, Emilia 
Solinas, Enzo Emanuele, Diego Ardissino, U.O. di Cardiologia, Azienda Ospedaliero-
Universitaria di Parma, Parma, Italy
Background. It has been recently indicated a role for cannabinoids in neointimal 
hyperplasia and smooth muscle cell proliferation. Additionally, the endocannabinoid 
system, consisting of two cannabinoid receptors (CB1 and CB2) and the endogenous 
ligands anandamide (arachidonoylethanolamide (AEA)) and 2-arachidonoylglycerol 
(2-AG), have been shown to control a number of immunomodulatory effects on lymphoid 
and myeloid cells at the vessel wall. Since impairment of the endocannabinoid system 
could influence restenosis risk, the goal of this study was to determine whether the 
plasma levels of AEA and 2-AG were impaired in patients with a history of symptomatic 
in-stent restenosis (ISR).
Methods. 707 patients who had a successful implantation of DES in native vessels for de 
novo lesions were eligible. After lipid extraction of venous blood, samples were analyzed 
for AEA and 2-AG levels by liquid chromatography-atmospheric pressure chemical 
ionization-mass spectrometry.
Results. Plasma concentrations of AEA resulted significantly lower in patients with ISR 
(odds ratio for the first quartile versus the top quartile, 2.11; 95% CI, 1.63 to 2.88, P < 
0.001) compared with the symptom-free stent group. The possible relationship between 
the AEA and the severity of ISR was also examined by comparing plasma levels with 
Mehran classification, percentage restenosis, and the number of stented segments with 
ISR in each patient. Patients with multiple sites of ISR had significantly lower levels of AEA 
compared with patients with only a single ISR lesion or no ISR (P < 0.01). No significant 
association was seen between the plasma levels of 2-AG and ISR in all the patients’ 
groups. The association between AEA levels and ISR retained its statistical significance 
even after controlling for index coronary disease extent and severity, number, diameter, 
and total length of stents, and plasma C-reactive protein.
Conclusions. These findings show that a derangement in the production of the endogenous 
cannabinoid AEA could be associated with ISR after DES implantation. Therefore the 
cannabinoid system may represent a potential therapeutic target for prevention of ISR 
after placement of DES.
2900-309 Insulin Resistance Alters Neointimal Extracellular 
Matrix Composition After Arterial Injury: Role of 
Versican
Michael C. John, Johanna Crimins, Scott Lajoie, Herman K. Gold, Thomas N. Wight, 
Aloke V. Finn, Cardiac Unit, Massachusetts General Hospital, Boston, MA, Department 
of Internal Medicine, Emory Crawford Long Hospital, Atlanta, GA
Background: Patients with type 2 diabetes are at increased risk for restenosis. 
Restenosis after angioplasty occurs secondary to smooth muscle cell accumulation 
and extracellular matrix deposition within the developing neointima, though the affect 
of diabetes and insulin resistance on extracullar matrix changes after arterial injury is 
unknown.
Methods: Using a rat carotid balloon injury model, we examined the extracellular matrix 
composition of insulin resistant Zucker Fatty (ZF) and non-insulin resistant Zucker Lean 
(ZL) rats by immunohistochemisty. Quantitative RT-PCR was also conducted on injured 
carotids from both types of animals to examine the effect of insulin resistance on versican 
mRNA upregulation.
Results: At 14 days after injury ZF animals had significantly greater percent stenosis 
(49%±4.9 vs. 21±3.0, p=0.002) and neointimal area (0.15±0.02 mm2 vs. 0.07±0.01, 
p=0.005) than ZL. Neointimal cell density was also significantly greater (4626 cells/mm2 
±735 vs. 3010±805, p=.05) Immunohistochemistry for versican revealed significantly 
greater percentage of the neointima staining for versican in ZF vs. ZL (16.3%±7.3 vs. 
2.4±0.8, p=0.03) whereas there were no differences in hyaluronan (25.6%±5.7 versus 
31.9±5.7, p=ns). Quantitative RT-PCR of balloon injured arteries revealed significant 
upregulation of versican transcripts at 3 and 7 days after injury (figure).
Conclusions: Insulin resistance alters neointimal extracellular matrix composition after 
injury. Inhibition of versican production may be a promising avenue to decrease restenosis 
in patients with type 2 diabetes. 
2900-310 Local Release of Metallic Ions from Stents into Vascular 
Tissue
Dina Halwani, Brigitta C. Brott, Peter G. Anderson, Andreas S. Anayiotos, Jack E. 
Lemons, The University of Alabama at Birmingham, Birmingham, AL
Background: Stent biomaterial properties are increasingly being reported as a 
possible cause of restenosis, particularly in peripheral vessels and after drug-eluting 
stent placement. We hypothesized that stent corrosion causes measurable release of 
metallic ions into surrounding tissues, which may result in an induced pathway leading 
to restenosis.
Methods: Nine stented arterial segments were obtained from autopsy. Examples 
of explanted Stainless Steel (SS) and Nitinol (NiTi) stents and surrounding tissue are 
presented. Tissue digestion and spectrochemical analysis (SA) were performed for ion 
levels in surrounding tissues, normalized to control [background (ppb) of system] and 
expressed as ppb/mg of dry tissue and stent weight.
Results: SA revealed that metallic ion levels in tissues dissolved from explanted stents 
were significant.
Conclusions: Metal ion release into surrounding tissue was significant in vessels 
removed at autopsy. Local stent corrosion is known to occur clinically. The presence of 
these ions could affect the process of in-stent restenosis, and studies are continuing. 
Units: ppb/mg tissue
Ti Cr Fe Ni
NiTi/SS Stents 
(Ni-Ti and Fe-Cr-Ni) 11 .44 7 9
SS Stent 
(Fe-Cr-Ni) 0 53 3
Units: ppb/mg stent
NiTi/SS Stents 
(Ni-Ti and Fe-Cr-Ni) 53 2 34 23
SS Stent 
(Fe-Cr-Ni) 0 320 18
2900-311 Evaluation of Endothelial Dependent Microvascular 
Function after Overlapping Bare Metal and Paclitaxel 
Stent in a Swine Heart
Jinsheng Li, Lakshmana Pendyala, Toshiro Shinke, Todd J. Brinton, William F. Fearon, 
Keith Robinson, Nicolas Chronos, Dongming Hou, Saint Joseph’s Research Institute, 
Atlanta, GA
Background: Recently, there is a growing body of evidence demonstrating that drug-
eluting stent (DES) may cause endothelial dysfunction in the epicardial conduit artery 
both proximal and distal to the stented segment but the potential effects of DES on 
coronary microcirculation, microvacular endothelium, and tissue perfusion is relatively 
unknown. We studied endothelial microvascular vasomotor function post overlapping 
paclitaxel-eluting stent (PES) in a porcine heart.
Methods: Each animal (n = 6) was randomly implanted with overlapping bare metal 
stent (BMS) and PES with S/A 1.1:1 and 3-5 mm overlapping. At 4 week f/up, index 
of endothelium-dependent microvascular resistance (ED-IMR) was measured in vivo 
by pressure wire via a thermodilution technique after intracoronary injection of freshly-
prepared substance-P (SP) 2ng/Kg. At termination, myocardium distal to the stented 
region was harvested and coronary microarteries (lumen diameter ~250 Μm) were 
dissected under microscopy and mounted on Myograph. Vasoconstriction and relaxation 
responses to SP, an endothelial-dependent (EDR) and sodium nitroprosside, (SNP) an 
-independent (EDiR) were studied in vitro.
Results: Angiographic late loss at f/up was significantly lower in PES compared to BMS 
(p = 0.002). The SP induced ED-IMR was increased about 41.9% in PES territory than 
BMS but not statistically significant (45.7±32.9 versus 64.8±35.5, P=NS). A similar results 
were observed from Myograph study, which showed the maximal EDR was diminished in 
PES compared to BMS (56.5±14.0% versus 84.5±7.3%, P=NS). Maximal EDiR to SNP 
was similar between both groups (98.5±12.1%, PES versus 97.9±12.1%, BMS; P=NS). 
Contraction to endothelin-1 was slightly increased in PES compared to BMS (4.41±0.42% 
vs. 3.23±0.82%, P=NS).
Conclusions: Associated with reduced neointimal formation of stented segment, 
there are trends towards increase ED-IMR in vivo and attenuation of EDR in vitro on 
the downstream myocardium. In contrast to the profound adverse effect on vasomotor 
function in coronary conduit artery, there are only subtle changes in the coronary 
microcirculation distal to PES.
2900-312 Vasorelaxation is Impaired Proximal and Distal to 
Paclitaxel-Eluting Stents
Lakshmana K. Pendyala, Toshiro Shinke, Jinsheng Li, Keith Robinson, Nicolas Chronos, 
Dongming Hou, Saint Joseph’s Research Institute, Atlanta, GA
Background: Clinical case studies have shown profound vasoconstriction associated 
with drug-eluting stents but the phenomenon remains poorly defined. We studied 
vasomotor function in conduit coronary artery segments adjacent to paclitaxel-eluting 
stents (PES) to elucidate potential mechanisms.
Methods: Pigs (N=6) received coronary implant of PES or bare metal stents (BMS). 
At 1 month endothelium-dependent and -independent relaxation (EDdR & EDiR) of 
arterial segments proximal and distal to the stents were assessed in an organ chamber. 
Superoxide anion (O.2−) production was also estimated with lucigenin.
Results: Angiographic late loss was lower in PES than BMS (P=0.002). In vivo, 
% diameter change to substance P was impaired (prox 0±6 versus10±7%; dist 1±11 
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versus 10±7%, P<0.05) but NTG response was preserved (prox 7±5 versus 12±7%; dist 
9±5 versus 13±6%, P=NS). In vitro EDdR of both proximal and distal stent segments 
to substance P and A23187 were significantly attenuated in PES compared to BMS, 
P<0.05, but EdiR to SNP was preserved, P=NS. O.2− production was higher distal to PES 
than BMS (71.6±3.1 versus 23.2±2.7 RLU/s/mg tissue, P<0.05).
Conclusions: A profound adverse effect of PES on endothelium-dependent vasomotor 
relaxation in conduit vessel segments both proximal and distal to overlapping implants, 
was observed both in vitro and in vivo and is related to increased oxidative stress. 
Endothelial dysfunction associated with PES likely contributes to pathophysiological 
clinical sequelae. 
2900-313 Blood Transfusion Associated with Death in Patients 
Undergoing Percutaneous Coronary Intervention in the 
NHLBI Dynamic Registry
Marc Z. Krichavsky, Zoran S. Nedeljkovic, Faith Selzer, James N. Slater, Alice K. Jacobs, 
Boston Medical Center, Boston, MA
Background: Blood transfusion (T) is associated with increased mortality in patients 
undergoing CABG. We sought to determine if a similar relationship exists with 
contemporary PCI.
Methods: We evaluated 4283 patients in the NHLBI Dynamic Registry waves 4 and 5 
(2/04-5/04, 2/06-8/06). Demographics, procedural characteristics, in-hospital, and one-
year outcomes were compared between patients who received T (n=80, 1.9%) and no 
transfusion (NT) during hospitalization for PCI.
Results: Patients treated with T were older (70.4 vs. 63.7 years, p<0.001), more often 
female (66.3 vs. 32.0%, p<0.001), and smaller (body surface area 1.8 vs. 2.0m2, p<0.001). 
T patients were more likely to present non-electively (60.0 vs. 42.3%, p<0.001), with ST 
elevation (26.3 vs. 14.2%, p=0.002), and shock (6.3 vs. 1.3%, p<0.001). IIbIIIa blocker use 
(45.0 vs. 33.1%, p=0.03) and major entry site complication (60.0 vs. 4.9%, p<0.001) were 
higher and mean length of stay longer (6.2 vs.1.9 days, p<0.001) for T patients. Vascular 
access site location did not differ. In-hospital outcomes are below.
Adverse Outcome (%) No transfusion (NT) (n=4203)
Transfusion (T) 
(n=80) p-value
Death 1.0 6.3 <0.001
CHF 1.2 7.5 <0.001
CVA 0.2 5.0 <0.001
MI 2.0 3.8 0.29
CABG 0.7 5.0 <0.001
Death/MI/CABG 3.4 12.5 <0.001
Multivariate analysis demonstrated a 4-fold increase in in-hospital death (OR 4.20, 95% 
CI 1.09-16.15, p=0.03) and Death/MI/CABG (OR 3.77, 95% CI 1.75-8.11, p<0.001) in 
patients treated with T. At I year, these differences were maintained.
Conclusions: These data suggest that blood transfusion is independently associated 
with mortality and adverse outcomes in PCI and emphasize the importance of strategies 
to decrease the need for T.
2900-314 Can Echocardiography Guide Transradial Coronary 
Angiography ?
Sunita Chugh, Sanjay K. Chugh, Ravi Ratan Kasliwal, Navin C. Nanda, Naresh Trehan, 
Indraprastha Apollo Hospitals, New Delhi, India
Background: Transradial Coronary Angiography (TRCA) offers greater patient comfort 
and is associated with lower risk of vascular complications compared to Femoral access. 
However procedural difficulties occur in some cases. .This prospective study was aimed 
at specifically identifying variations in origin of Brachiocephalic artery(BCA) and in size of 
aortic root by Color Doppler echocardiogram which could be associated with increased 
procedure time, incidence of radial artery spasm (RAS) & pain , rate of crossover to 
alternativevaccess and catheter exchanges >1 during TRCA from right radial access 
(RRA).
Methods: A proposed classification of origin of BCA (on Color Doppler Echocardiogram 
)used in this study is as follows: 1)Type- A: Origin of BCA from Proximal or middle third of 
aortic arch, pointing towards ascending aorta.; (2)Type-B:Origin of BCA from or beyond 
middle third of aortic arch, directed to descending aorta. TIG (Terumo, Japan) catheters 
were used via RRA in 970 consecutive patients prospectively. Procedure time, incidence 
of spasm, crossover to alternative access, need for alternative catheters and patient feed-
back was recorded in these patients.
Results: Overall, BCA origin Type B was found in 19% (n=184); Aortic root greater than 
3.9cm was noted in 7%(n=68). With BCA of Type -B origin and aortic root diameter> 3.9 
cm TRCA procedure time increased to mean 17±3.4 mins from average of 8.5 ± 3.8 mins 
(p<0.03) ; incidence of spasm & pain increased to 9.1% from average of 1% (p<0.05); 
crossover to alternative access increased from average of 0 to 0.3% and catheter 
exchanges >1increased to 13% from average of 3%(p<0.02).
Conclusions: BCA origin Type-B and aortic root diameter > 3.9 cm on Echocardiogram 
are associated with greater procedure time & need for > 1 catheter exchanges for TRCA,. 
more patient discomfort & RAS and greater need for crossover to alternative access. It 
helps identify difficult anatomy for TRCA.
2900-315 Left Radial Approach in Daily Practice. Results of a 
Randomized Study Comparing the Femoral, Right and 
Left Radial Approaches
Vicente Bodi, Juan Sanchis, Julio Nunez, Luis Mainar, Enrique Santas, Eva Rumiz, 
Francisco J. Chorro, Angel Llacer, Hospital Clinico Universitario, Valencia, Spain, 
University of Valencia, Valencia, Spain
Background. The right radial approach (R) has been incorporated into daily practice as 
an alternative to the femoral approach (F). The left radial approach (L) is used in selected 
institutions but randomized studies comparing it with F and R area lacking.
Methods. We randomized 1000 consecutive patients submitted to a tertiary university 
hospital for cardiac catheterization to L (n=333), F (n=333) or R (n=334). No exclusion 
criteria were applied. We compared L vs. F and R. As the primary end-point we evaluated 
the success rate. Success was considered when the whole procedure was finished through 
the pre-assigned approach. As secondary end-points we analyzed the total diagnostic 
time (including anaesthesia-aorta, diagnostic procedure and compression, min), the 
interventional time (min), the X-ray time (min), the vascular complications rate and the time 
to stand up (hours). All analyses were performed on an intention-to-treat basis.
Results. The success rate was higher in F (71% L, 92% F, 68% R, p <0.001). The pre-
assigned approaches were attempted in the vast majority of cases (L 90%, F 96%, R 
83%). Failed puncture in L, atherosclerosis in F and operator decision / vascular anatomy 
in R were the main reasons for failed approaches. The anaesthesia-aorta took longer in 
L (L 5±6, F 3±3, R 4±5 min, p <0.05), the diagnostic procedure in R (L 15±8, F 14±6, R 
16±8 min, p=0.002) and compression in F (L 8±6, F 12±4, R 8±6 min, p <0.001). Overall, 
the total diagnostic time was similar (L 28±12, F 29±9, R 28±11 min, p=0.5). The X-ray 
time was shorter in F (L 5±6, F 4±4, R 6±4 min, p=0.004). The interventional time (n=410: 
L 25±17, F 25±15, R 25±15 min, p=0.9) was comparable. The rate of major vascular 
complications was 0% L, 1.3% F, 0.9% R (all in the femoral area after shifting due to 
unsuccessful radial approach), p=0.6. The time to stand up was longer in F (L 9±13, R 
9±13, F 23±9 hours, p <0.001).
Conclusions. The left radial is an alternative as valid as the right radial to the femoral 
approach.
2900-316 Deep venous thromboses in association with 
catheterization
Raghu Kolluri, Daryl Pinedo, Jeffrey Goldstein, Nilesh Goswami, Gregory Mishkel, 
Prairie Vascular Institute, Springfield, IL, Prairie Heart Institute, Springfield, IL
Background: Vascular closure devices (VCDs) are widely used post arterial 
catheterization to achieve early hemostasis and ambulation. Groin hematoma, 
pseudoaneurysm, arteriovenous fistula, infection, arterial occlusion and embolization, 
are all known complications of VCDs. We report for the first time, six cases of acute deep 
venous thrombosis (DVT) associated with VCDs.
Methods: From August 2006 to September 2007, duplex ultrasound was used to 
prospectively evaluate all femoral access related complaints by patients who underwent 
arterial angiography in our catheterization laboratory.
Results: Of a total of 5,467 catheterization procedures, we utilized a VCD in 2772 cases. 
7 DVT’s were observed, 6 in association with a VCD and 2 without any form of arterial 
compression. Details are summarized in the following table. 
Pt 
no.
Age/sex Closure Device 
FemoStop 
duration
Manual 
compression Complication Treatment
1. 45 M AngioSeal None None Rt. CFV DVT. Anticoagulation
2. 35 M AngioSeal None None Rt. CIV DVT. Anticoagulation
3. 46 M AngioSeal
4h 40 min 
(at 40mm 
Hg).
None Rt. EIV DVT. .
Thrombolysis, 
EIV stent and 
anticoagulation
4. 72 F Boomerang None 6 min Rt. CFV-EIV DVT.
Thrombolysis, 
EIV stent and 
Anticoagulation
5. 80 M Boomerang None 6 min Lt. CFV DVT. IVC filter, Anticoagulation
6. 56 M AngioSeal
2h 50 min 
(at 40mm 
Hg).
None Rt. CFV-EIV DVT
Thrombolysis, 
EIV stent, 
Anticoagulation.
7. 44 F None None 6 min Rt EIV DVT Anticoagulation
Abbreviations: F, female; M, male; h hour(s); min, minute(s); Rt., right; Lt. left; CFV, common 
femoral vein; CIV, common iliac vein; DVT deep venous thrombosis; EIV, external iliac 
vein; IVC, intravenous filter.
Conclusion: Although uncommon, deep venous thrombosis should be considered in 
patients with groin complaints after catheterization. It may occur in association with a VCD 
with minimal or no manual compression. This complication is most likely due to the close 
proximity of the femoral vein to the femoral artery, compression and possible perivenous 
inflammation or fibrosis.
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2900-317 Superiority of Real-time Ultrasound Guidance for 
Femoral Arterial Access: A Prospective Pilot Study
Arnold H. Seto, William M. Suh, Alexander T. Harrison, Pranav Patel, Morton Kern, 
University of California, Irvine Medical Center, Orange, CA
Background: The common femoral artery (CFA) is the preferred point of access for 
cardiac catheterization to minimize vascular complications and allow for safe deployment 
of vascular closure devices. Real-time ultrasound (US) guidance, a standard of care for 
central venous access, has not been adequately assessed for femoral arterial cannulation, 
despite its unique ability to localize the CFA bifurcation.
Methods: 71 consecutive patients undergoing cardiac catheterization by a single 
operator were prospectively randomized to fluoroscopic (n=36) or US guidance (n=35) 
for sheath insertion. US guidance was performed with a real-time freehand technique by 
a single operator. Time of insertion, number of needle advancements, and incidence of 
venipuncture were recorded. Two blinded readers analyzed the femoral angiograms for 
the point of sheath insertion relative to the femoral head and CFA. A third reader resolved 
any disagreements.
Results: Compared with fluoroscopic guidance, US guidance resulted in a higher 
1st pass success rate (83% vs 47%, p=0.002), reduced venipunctures (0% vs 25%, 
p=0.002), and a higher rate of CFA insertion (89% vs 69%, p=0.048) (see Table). There 
was no difference in median access time (120 vs 132 sec for US, p=0.245), despite the 
inclusion of US probe setup time.
Conclusion: In this prospective pilot study, US guidance was superior to fluoroscopic 
guidance in femoral arterial access, without prolonging the time to sheath insertion. A 
larger multicenter study is warranted. 
2900-318 Use of Collagen Based Device for Femoral Artery 
Puncture Site Closure Following Percutaneous 
Coronary Intervention is Equally Safe in the Hands of 
Trained Technologists/Nurses and Cardiologists
Nicole Leone, Niksad C. Puthiya, Nowwar Mustafa, Angela Hoban, Maria Albert, Angela 
Di Sabatino, James Hopkins, William Weintraub, Ehsanur Rahman, Christiana Care 
Health System, Newark, DE
Background:Deployment of collagen based closure device by trained technologists/
nurses in the cardiac cath lab is an emerging practice. However, it is not known whether 
there is a difference in the complication rate in the deployment of this device between non-
physicians and cardiologists. In our institution, technologists, nurses, and cardiologists 
have been trained to deploy this closure device
Methods:Between April and September 2006, 978 patients underwent percutaneous 
coronary intervention (PCI) in our institution. Of these, 487 patients received the collagen 
based closure device ( Angioseal ™) and their records were reviewed. These patients 
were divided into two groups based on whether the technologists/nurses (Group 1) 
or cardiologists (Group 2) deployed the device. All patients received either heparin or 
bivalirudin. Additionally, some patients received IIb/IIIa inhibitors.
Results: Shown in Table 1.There was no difference in the baseline characteristics in the 
two groups and the complication rates also did not differ (Femoral artery dissections, loss 
of pulse, AV fistula or need for blood transfusions did not occur in either group).
Conclusions: For the deployment of this collagen based femoral artery closure device 
following PCI, we found no difference in vascular complication rate between trained 
technologists/nurses and cardiologists.
Table1 Baseline Characteristics/ Complications
Total patients Group1 
n =212
Group2 
n = 275 p value
Age 62.88± 12.12 63.90 ± 12.15 = 0.36
Male 147 (69.3 %) 183 (66.5 %) = 0.51
Body Surface Area 1.98 ± 0.24 1.95 ± 0.25 = 0.17
Elective 192 (90.6%) 245 (81.1%) = 0.59
IIb/IIIa Inhibitor 51 (24.1%) 75 (27.3%) = 0.72
Entry Site Bleed/Hematoma 1 (0.5%) 3 (1.1%) = 0.45
Pseudoaneurysm 0 1 (0.4%) = 0.38
Retroperitoneal Bleed 5 (2.4 %) 3 (1.1%) = 0.28
Total complications 6 (2.8%) 7 (2.5%) = 0.85
2900-319 Immediate and Long term Safety and Efficacy of 
Starclose for diagnostic and Interventional Cases
Ramin Ebrahimi, James Lee, Hormoz Babaei, M. Reza Movahed, Edward G. Toggart, 
University of California Los Angeles-GLAVA, Los Angeles, CA, University of Arizona 
Medical Center, Tucson, AZ
Background: Starclose is a new percutaneous arterial closure device that employs a 
circumferential nitinol clip. This device has been approved for use in diagnostic procedures 
such as coronary angiography. Long term safety and efficacy of Starclose has not been 
well documented. The purpose of this study is to evaluate immediate and longterm safety 
and efficacy of Starclose.
Methods: Data were collected on the first 600 consecutive cases using the Starclose 
device (including “start up” procedures) in a single academic center. The cases included 
diagnostic as well as interventional procedures. Deployment was performed by attending 
cardiologists or cardilogy fellows. Outcomes evaluated included: 1) Standalone success 
(immediate hemostasis without the need for manual or device compression). 2) 
Procedural success (Standalone success plus manual or device assisted hemostasis 
and no hematoma, transfusion, or vascular injury requiring any interventions). Patients 
were tracked over a six month period for late access site complications.
Results: Baseline Characteristics included average age of 63 years, Hypertension 
535 (89%), Diabetes 272 (45%), Peripheral arterial disease 85 (14%). Of the 600 
cases, 172 (29%) had coronary intervention (PCI), 264(44%) were obese (Ob) defined 
as a Body Mass Index of 30 or greater. Six french sheaths were used in all cases and 
bivalirudin nonotherapy was used as the antithrombotic agent in 97% of interventional 
cases. 277(46%) had received clopidogrel pre-procedurally. Outcomes are as follows: 
1) Standalone success-Overall 89%, PCI 90%, Ob 91%. 2) Procedural success- Overall 
97%, PCI 98%, Ob 98%. Hematoma: Overall 3%, PCI 4%, Ob 2%. No acute complications 
(leg ischemia, vascular injury requiring any interventions, or transfusion) occurred. There 
was one late vascular complication (psuedoaneurysm).
Conclusion: Starclose is a safe and effective arterial closure device with good immediate 
and long term outcomes. This device may be used safely in Ob and PCI cases.
2900-320 The StarClose Arterial Closure Device is Associated 
with Higher Rates of Bleeding Complications than 
the AngioSeal Arterial Closure Device in Patients 
Undergoing Coronary Angiography
Atman P. Shah, Victor Gabrielian, Grace Nam, David M. Shavelle, William J. French, 
Harbor- UCLA Medical Center, Torrance, CA
Background: Vascular closure devices (VCD) are used to enhance patient comfort in 
those undergoing coronary angiography (CA). This study investigated the safety and 
efficacy of two common VCDs, the AngioSeal (AS) and StarClose (SC) devices.
Methods: A retrospective analysis was performed at a high volume cardiac catheterization 
laboratory. Patients who underwent CA and percutaneous coronary intervention (PCI) and 
who received either AS or SC were assessed for minor (MIC) and major complications 
(MAC). MIC were defined as bleeding requiring prolonged manual compression (PMC), 
small (<2cm) hematoma (H) formation, and prolonged groin pain (>2 hours). MAC were 
defined as need for transfusion, large (>2cm) H, pseudoaneurysm, arterio-venous fistula, 
or device embolization requiring surgery.
Results: Of the 241 patients in the study (58.2 +/- 8.5 years, 71% male), AS was 
deployed in 138 (57.2%) and SC in 103 (42.8%). No baseline clinical differences were 
noted. Procedural success was similar [AS 135/138 (97.8%) vs. SC 97/103 (94.2%), 
p=.4]. No differences in MAC were observed [AS 1/138 (0.7%) vs. SC 2/103 (1.9%), 
p=0.51]. MIC was increased in the SC group [AS 5/138 (3.6%) vs. SC 14/103 (13.6%), 
p<0.01], predominantly due to bleeding requiring PMR [AS 2/138 (1.5%) vs. SC 10/103 
(9.7%), p=0.03]. An increase in MIC, but not MAC, was seen in patients who underwent 
PCI [AS 5/101 (5.0%) vs. 11/79 (13.9%), p<0.001].
Conclusions: AS use is associated with fewer complications than SC, especially in 
patients undergoing PCI. 
2900-321 Antibiotic Prophylaxis in Diabetic Patients Undergoing 
Cardiac Catheterization and Treated with Closure 
Devices Dramatically Decreases Infection Risk 
Emad F. Aziz, Catalin Florita, Sandeep Pulimi, Sripal Bangalore, Dan Musat, hyun 
kyung Rhee, Maged A. Hana, Deborah Tormey, Steven Lee, Eyal Herzog, David Coven, 
Tariqshah Syed, Jacqueline Tamis-Holland, Mun K. Hong, St. Luke’s-Roosevelt Hospital 
Center, New York City, NY
Background: Diabetes is a major risk factor for cardiovascular disease. More diabetics 
are undergoing percutaneous coronary procedures. Previously, we showed that infection 
was the most common post cardiac catheterization complication in diabetic patients 
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treated with closure devices (DMCD). We studied the effect of prophylactic peri-procedural 
antibiotic usage in DMCD on the infection risk. 
Methods: A cohort of 485 consecutive DMCD was retrospectively studied. Access 
related complications were analyzed. Patients were classified into two groups according 
to their prophylactic antibiotic therapy. Group A did not receive antibiotics whereas group 
B received either Cefazolin or Vancomycin antibiotics during the procedure. The primary 
endpoint was cumulative in-hospital incidence of major vascular complications, defined 
as hematoma, femoral artery thrombosis, vascular repair, and groin infection. Secondary 
endpoint was incidence of groin infection rate.
Results: Group (B) had higher admission glucose level (181±59 mg/dL vs 159±46; 
p=0.001), lower body mass index (26.5±7 vs 32±7 p=0.01), and more hypertension 
(91% vs 76%; p=0.0001). The primary endpoint of vascular complications was seen in 
33 (14%) patients in Group A, and 8 (3%) in Group B (p=0.0001). Multivariate analysis 
demonstrated that Antibiotic usage (OR 0.19; 95% CI= 0.08-0.42, P< 0.0001) was the 
strongest negative predictor for the primary endpoint. However higher glucose level (OR 
0.56; 95% CI= 0.38-0.81, P< 0.002) and a lower CrCl was a positive predictors (OR 
1.13; 95% CI= 1.001 to 1.029, P< 0.04) for groin complications. There was no significant 
difference in rate of complication between closure types. Higher rate of infection was 
the main contributor to the higher complication rate in group A (p=0.023). Interestingly; 
incidence of infection in group B was associated with subsequent in-hospital coronary 
bypass surgery.
Conclusions: Prophylactic antibiotic therapy in diabetic patients undergoing cardiac 
catheterization and treated with closure device can dramatically decrease access 
site infection rate . However, manual compression may be a better option for those 
subsequently undergoing coronary bypass surgery.
2900-322 The Quick-CloseTM Vascular Suturing System for 
Closing the Femoral Arteries II (STITCHES II)
Scott B. Hacking, Stephen Minor, Chris Cove, University of Rochester Strong Memorial 
Hospital, Rochester, NY
Background: The Quick-Close™ Vascular Suturing System (QC) is a suture-based 
percutaneous vascular closure device. The device remotely deploys a single mono-
filament suture into the femoral artery (FA) secured by a stainless steel clip. Previous 
generations of this device were shown to be safe and effective in the STITCHES I trial.
Methods: STITCHES II is a multi-center, prospective, randomized, safety and 
efficacy trial including 367 patients(pts) at 8 US sites. The pts were randomized in a 
2:1 fashion (QC:manual compression (MC)). All pts underwent a 5-8 Fr percutaneous 
diagnostic or interventional procedure via the FA. The primary efficacy end-points were 
time to ambulation and hemostasis. The secondary efficacy end-points were time to 
dischargability (DC), procedural success, and device success. The primary safety end-
point was the rate of major complications. The secondary safety end-point was the 
combined rate of minor complications.
Results: Times to hemostasis and ambulation were significantly improved by use of the 
QC device (p<0.001). The secondary efficacy end-points showed time to DC was not 
statistically significant. Device success was 98.4%. Procedural success was 97.9% with 
QC, 100% with MC (p=0.172).
There were 4 major complications in the QC and 3 with MC (p=1.0). There were 14-minor 
complications in the QC and 14 in the MC group (p=1.0).
Conclusion: The use of QC resulted in improved time to hemostasis and ambulation. QC 
was safe and was associated with high procedural and device success. 
Quick-Close™ Manual Compression p-value
Time to Hemostasis all pts 
Diagnostic pts 
Interventional pts
10.4 min (n=243) 
3.5 min (n=136) 
19.1 min (n=107)
23.4 min (n=124) 
16.6 min (n=70) 
32.3 min (n=54)
<0.001 
<0.001 
0.094
Time to Ambulation all pts 
Diagnostic pts 
Interventional pts
4.4 hrs 
2.8 hrs 
6.3 hrs
6.9 hrs 
4.8 hrs 
9.5 hrs
<0.001 
<0.001 
<0.001
Time to Discharge all pts 
Diagnostic pts 
Interventional pts
11.7 hrs 
5.4 hrs 
19.6 hrs
11.9 hrs 
6.7 hrs 
16.9 hrs
0.843 
0.316 
0.707
Device Success 98.4% n/a n/a
Procedural Success 97.9% 100% 0.172
2900-323 Vascular Complications and Time to Ambulation in 
Patients Undergoing PCI with Heparin & Glycoprotein 
IIB/IIIA versus Bivalirudin
Aloke V. Finn, Jae Oh, Maureen Daher, Rafael M. Byrne, Rafael M. Byrne, Igor Palacios, 
Michael C. John, Herman K. Gold, Massachusetts General Hospital, Boston, MA
Background: It is now routinely accepted that early sheath removal after PCI reduces 
femoral access site complications, leads to earlier ambulation, and most importantly, 
improved patient satisfaction. Although heparin in combination with glycoprotein IIb/IIA 
inhibitors (HGP) or bivalirudin (Angiomax) are routinely used during PCI, no study has 
examined which anti-thrombotic strategy is superior in terms of these measures. We 
conducted a trial in patients undergoing PCI randomized to either HGP or Angiomax 
examining vascular access site complications as well as time to ambulation.
Methods: 110 patients were randomized in all. Major hematoma was defined as presence 
of hematoma >1 cm. Time to ambulation was defined as period from end of procedure 
to first time the patient ambulated. Patients ambulating after midnight were excluded. 
Important exclusion criteria were current bleeding diathesis, ST-segment elevation 
myocardial infarction or current treatment with glycoprotein IIB/IIA inhibitors.
Results: The two groups did not differ in regards to age, sex, body mass index, creatinine 
clearance or sheath size (data not shown). As shown in the table, time to ambulation was 
less in the Angiomax group by 90 minutes. Incidence of any hematoma and average size 
of the hematoma (if present) was significantly less. There was no difference in need for 
groin US/abdominal CT.
Conclusions: In patients undergoing PCI, Angiomax reduced the incidence of hematoma 
and reduced time to ambulation in comparison to HGP.
Endpoints
Endpoint All Patients Angiomax Heparin/Glycoprotein IIB/IIA
P 
value
Not able to ambulate 
(%) 59 (54.1%) 26 (46.4%) 33 (62.3%) NS
Time to Ambulation 
(min) 448.5Â±161.9 412.1Â±114.4 503.2Â±205.9 0.08
Hematoma 
Occurence 35 (32.1%) 11 (19.6%) 24 (45.3%) 0.007
Hematoma Size (cm) 3.2Â±2.1 2.3Â±1.3 3.6Â±2.2 0.03
US or Abdominal CT 11 (10%) 4 (7%) 7 (13.2%) NS
2900-324 Vascular Complications Following Cardiac 
Catheterization and Interventions; Persistence of 
Gender Gap in the Contemporary Era.
Kalgi A. Modi, Faisal Bahadur, Kavit Desouza, Lee Gibbs, Sujata Agnani, James 
Atherton, Michael Goebel, Gloria Caldito, Pratap Reddy, Louisiana State University 
Heath Science Center, Shreveport, LA
Background: There are conflicting reports on gender difference in vascular complications 
following cardiac catheterization (CATH) and percutaneous coronary intervention (PCI). 
Earlier studies have shown that women experience more complications compare to 
men. While more recent reports have found no gender difference. Thus, we evaluated 
if vascular complications occur with greater frequency in women compare to men in the 
recent era.
Methods: A total of 1,287 (female n=618, male 669) consecutive CATH (938) and PCI 
(n=349) procedures performed via femoral access at our institution between 2005 to 
2007 were evaluated to determine if a gender gap exists in the vascular complication. We 
compared complication rates between categories of factors observed to be significantly 
associated with complication using the chi-square test. Multiple logistic regression 
analysis was used to determine independent risk factors for complication and to calculate 
adjusted odds ratios (OR). A 5% level of significance was used for all statistical tests.
Results: For the entire study population the incidence of any vascular complication was 
2.6%. For women it was 3.4% and for men 1.6%. Adjusted for the effect of each other in 
a multiple logistic regression analysis female gender was determined to be independent 
significant risk factors for vascular complication. The risk adjusted odds ratio for any 
vascular complications comparing women to men was 2.32 (95% CI 1.01 to 4.40, p0.04) 
for CATH and PCI.
Conclusions: Following CATH and PCI: 1) Women had more vascular complication 
than men 2) Female gender was an independent predictor of vascular complications 3) 
Gender gap for the vascular complications persist in the contemporary era.
2900-325 Safety of Cardiac Catheterization in patients with 
End-Stage Liver Disease Prior To Orthotopic Liver 
Transplantation
Madan Sharma, Celina Yong, Christian Zellner, Thomas Ports, Yerem Yeghiazarians, 
Andrew Boyle, University of California San Francisco, San Francisco, CA
Background: The morbidity and mortality of patients with coronary artery disease (CAD) 
who undergo orthotopic liver transplantation (OLT) is unacceptably high, necessitating 
pre-operative evaluation of coronary artery anatomy. Patients with liver failure are 
predisposed to bleeding complications due to thrombocytopenia, reduced synthesis of 
coagulation factors and increased fibrinolytic activity. Therefore, they are thought to be at 
high risk for vascular access site complications after cardiac catheterization. However, the 
exact incidence of vascular access site complications in this group remains unknown.
Methods: 89 consecutive patients with liver failure undergoing left heart catheterization 
(LHC) prior to OLT from August 2004 to February 2007. 82 patients without known liver 
disease, but matched for age, sex and BMI who had left heart catheterization during the 
same period were chosen as the control group. Vascular complications were defined as 
hematoma > 5 cm, pseudoaneurysm, arteriovenous fistula or retroperitoneal bleeding.
Results: Liver failure patients had lower baseline Hct (32.3±6.0 vs 39.2±6.2, p<0.001) 
and platelet count (90.1±66.3 vs 236.1±77.1, p<0.001) compared to controls. They also 
had higher serum creatinine (1.9±1.7 vs 1.2±0.8, p=0.002) and INR (1.6±0.7 vs 1.1 ±0.2, 
p<0.001). There was a trend towards more pseudoaneurysms 5.6 % (5/89 cases) in the 
patients with liver failure compared to 1.2 % in controls (1/82 cases) p=0.12. The incidence 
of significant hematoma was 0 % (0/89 cases) in the patients with liver disease compared 
to 1.2 % (1/82) in controls p=NS. There were no retroperitoneal bleeds in either group. More 
liver failure patients required blood transfusion (24.7 % vs 2.4 %, p<0.001), fresh frozen 
plasma (51.7 % vs 1.2 %, p<0.001) and platelet transfusions (48.3 % vs 1.2, p<0.001).
Conclusions: Despite severe coagulopathy, LHC may be performed relatively safely in 
this patient population with rigorous correction of coagulopathy and meticulous attention 
to procedural technique. Strategies to reduce transfusion requirements and the incidence 
of pseudoaneurysms should be studied in this patient population.
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2900-326 Percutaneous Femoral Closure Following Thoracic 
Aorta Stent Graft Placement: Preliminary Results and 6 
Month Follow up
Pablo Avanzas, María Martín, Iñigo Lozano, Jose Manuel Llaneza, Florentino Vega, 
Félix Fernández, José María De la Hera, José Miguel Vegas, Juan Rondán, Benjamin 
Camacho, José María Valle, César Morís, Hospital Universitario Central de Asturias, 
Oviedo, Spain
Background: Thoracic aortic disease has traditionally been treated by surgery. 
Endovascular stent grafting has emerged as an alternative treatment.The problem 
with these procedures is the large size of the implant systems, which require surgery 
for vascular access and closure.Surgical complications are not uncommon.The aim of 
this study is to describe our clinical experience and results using percutaneous femoral 
closure devices for femoral arterial closure after thoracic aorta stent graft placement 
(TASGP).
Methods: Thirty five consecutive patients were selected to use the Prostar XL® device 
for arterial closure after TASGP,according to preestablished criteria (femoral size, 
tortuosity, calcium).After arterial puncture two Prostar XL® devices in each patient were 
placed at the puncture site. The first is inserted using the conventional technique guided 
by a standard 0.038-inch guidewire and is left in the femoral artery after implantation of 
the 2 sutures.The artery is recanalized with a guidewire and the device is withdrawn.
The second device is then inserted, implanting the 2 sutures after rotating 45 degrees 
clockwise from the position of deployment of the first device.The access site is gradually 
dilated to 20-22 French.The aortic endoprostheses are subsequently implanted and upon 
completion of the procedure, hemostasis is performed by closing the sutures of the 2 
devices with a knot pusher.Patients were anticoagulated during the procedure with 10000 
U of IV heparin.Femoral sites were followed up (discharge-6 month). If a femoral murmur 
was detected, an echo-Doppler was performed.
Results: All femoral sites were correctly closed by the two devices.In one case surgery 
was needed because of oclussion of the iliac artery, due to intima disruption, not related 
with the closure device. In the other cases, predischarge physical examination revealed 
absence of mayor hematomas.At 6 months follow up, two echo-Doppler were performed 
and one of them revealed the presence of a femoral pseudoaneurysm.
Conclusions: Our data suggest that in TASGP,hemostasis of large puncture sites can 
be successfuly achieved with two Prostar XL® devices,when placed prior to arterial 
dilatation.
2900-327 Optimal Access to Prevent Complications: A Quantitative 
Assessment of Puncture Into the Femoral Target Zone
Zoltan G. Turi, Brian J. McEniry, Michael N. Turi, Cooper University Hospital, Camden, 
NJ, Robert Wood Johnson Medical School, Camden, NJ
Background: We have previously described a target zone (TZ) for vascular access, 
defined as that portion of the common femoral artery below the lowest sweep of the inferior 
epigastric artery (IEA) and above the femoral bifurcation (BIF) or bottom of the femoral 
head (BFH) [whichever is higher]. We have established that a cumulative target zone (CTZ), 
located between 5 and 14 mm below the femoral head centerline results in the lowest 
probability of access outside the TZ. We sought to assess the location of femoral punctures 
when the operator utilized fluoroscopy during vascular access to enter the TZ.
Methods: Using quantitative femoral angiography, we evaluated the location of femoral 
sheath placement in 187 consecutive patients. We compared puncture location from the 
centerline of the femoral head to the inferior sweep of the IEA, the BIF and the BFH. 
Since the location of the BIF and IEA is not known prior to sheath placement and femoral 
angiography, we also compared femoral puncture location to the CTZ.
Results: Puncture above the IEA occurred in 2.7% of patients, below the BIF in 3.7% 
and below the BFH in 2.1%. The CTZ was the location of puncture in 46.8% of patients. 
Puncture above the centerline, the location most likely to result in retroperitoneal 
hemorrhage, occurred in 7.4 % of patients.
Conclusions: Using fluoroscopy to guide femoral artery access results in a relatively low 
rate of puncture outside the TZ, and may contribute meaningfully to a decrease in overall 
femoral access site complication rates.
2900-328 Risk of bleeding in elderly patients undergoing 
percutaneous coronary intervention using radial 
access with and without concomitant glycoprotein IIb/
IIIa receptor blockade
Cindy Boulanger-Gobeil, Jean-Pierre Dery, Gérald Barbeau, Bernard Noël, Josep 
Rodés-Cabau, Olivier F. Bertrand, Eric Larose, Onil Gleeton, Can M. Nguyen, Guy 
Proulx, Louis Roy, Robert Delarochellière, Quebec Heart and Lung Institute, Quebec 
City, QC, Canada
Background: Octogenarians compose a rapidly growing segment of the population 
worldwide. Because coronary artery disease is highly prevalent in the elderly, many of 
these patients are referred for coronary angiography. However, few data exist on the 
benefits and safety of percutaneous coronary intervention (PCI) in octogenarians. In 
particular, bleeding risks associated with glycoprotein (GP) IIbIIIa inhibitors and the value 
of radial access (versus femoral) to limit these events need further investigation.
Methods: The study population consisted of all consecutive patients 80 years of age or 
older undergoing PCI at a single tertiary care center between January 2002 and March 
2007. Clinical and angiographic characteristics as well as outcomes measures were 
extracted by chart review. Bleeding rates were graded according to the TIMI and GUSTO 
classifications. We compared in-hospital bleeding rates and ischemic events of patients 
treated with a GP IIb/IIIa inhibitor to those of patients undergoing PCI without GP IIb/IIIa 
receptor blockade.
Results: During the study period, 1068 patients (mean age= 83) met the inclusion 
criteria. Of these, 313 (29%) patients were treated with a GP IIb/IIIa inhibitor (group 1) and 
755 (71%) patients without (group 2). PCI was performed using radial access in 91% of 
patients in group 1 and 85% of patients in group 2 (p=0.02). When compared to group 2, 
patients in group 1 had a significantly higher incidence of total bleeding (25.3% vs 13.3%, 
p<0.0001), access site bleeding (12.8% vs 7.7%, p<0.01) and TIMI major bleeding (6.4% 
vs 3.4%, p=0.03). Both study groups presented similar rates of GUSTO moderate/severe 
bleeds (7%), and blood transfusions (7%). There was no intracranial hemorrhage in either 
group.
Conclusions: In this non-randomized cohort of octogenarians undergoing PCI, 
administration of a glycoprotein IIb/IIIa inhibitor was associated with a significant increase 
in bleeding risk despite careful patient selection and use of radial artery as the preferred 
vascular access site. Bleeding remains a concern even without GP IIb/IIIa receptor 
blockade. This study highlights the need to develop strategies to limit bleeding risk at time 
of PCI in the elderly population.
2900-329 Safety Of Ulnar Approach For Cardiac Catheterizatio
Raúl M. Valdesuso, II, Francisco J. Lacunza, II, Juan R. Gimeno, II, José A. Hurtado, III, 
Juan García de Lara, II, Eduardo Pinar, Mariano Valdés, Raul Valdesuso, Murcia, Spain
Background: The Ulnar Artery (UA) could be a another acces for cardiac catheterization, 
but the the benefits and complications related to this approach have not been well 
established.
Methods: We included 621 consecutive patients (ps) in which the UA approach was 
attempted from Nov-2002 till May-2007. All studies were performed by a single operator 
with experience in transradial approach. Follow-up was achieved in 91% of ps at 24 hours 
and 3 months after procedure. Haematomas (H) and neurological complications related 
to the UA puncture were recorded
Results: Of a total of 5125 ps, 621 (12.1%) were done via UA. Mean aged 66+/-15 
years. 65% were males, 36% were diabetics, and more than 50% had hypertension, 
hyperlipidaemia or were smokers. Study was completed in 565 ps (91% of the attempted). 
The main cause of crossover was the puncture failure (45% of cases). In 63 ps (11%) 
UA was used after failure of radial puncture in the same wrist. Out to 848 procedures 
performed, 381 (45%) were PCI, 77% through the right UA. 34 H > 6 cm were documented; 
12 (12%) of them, within the first 100 cases done, and the rest, 22, in the following 465 
ps (4.7%)* (p <0.05); There was only 1 temporary neurological complication related to the 
nerve compression by H. In a Multi-Varible analysis of first 100 ps, H were related to a 
puncture proximal to the wrist skin folds, that led to a difficult compression of the artery.
Conclusions: Ulnar approach is as safe as the radial one, despite an slightly higher rate 
of complications at the puncture site. Puncture at the level of the wrist skin fold should be 
recommended to reduce complications. UA could be even better as approach than radial, 
when ulnar pulse is stronger than radial.
2900-330 Decreased Complication Rates Utilizing the 
Transradial Compared to the Transfemoral Approach 
in Percutaneous Coronary Intervention in the Era of 
Routine Stenting and Glycoprotein Platelet IIb/IIIa 
Inhibitor Use
Jonas Eichhöfer, Mark Osten, Joan Ivanov, Karen Mackie, Eric Horlick, Vladimir Dzavik, 
Toronto General Hospital, Toronto, ON, Canada
Background: Studies evaluating the efficacy and safety of the transradial approach for 
percutaneous coronary intervention (PCI) were mainly carried out before the widespread 
use of stents and glycoprotein (GP) IIb/IIIa inhibitors. We sought to determine the effect 
of the choice of the vascular access site on procedural complications after PCI performed 
with routine stenting and GP IIb/IIIa inhibition.
Methods: The data source was a prospective data registry of 12,951 consecutive patients 
undergoing PCI in the Toronto General Hospital from April 2000 to September 2006. 
Logistic regression was used to calculate the probability of selection to the radial access 
group. Using propensity score methodology, 3198 patients with femoral access were 
randomly matched to 3198 patients with radial access based on baseline characteristics 
(age, height, weight, gender, hypertension, diabetes, renal function, recent myocardial 
infarction (MI), peripheral vascular disease and prior revascularization), PCI indication, 
angiographic and procedural characteristics. Multivariable logistic regression analysis 
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was used to identify the independent predictors of access site related complications. 
MACE was defined as death, MI, abrupt vessel closure or coronary artery bypass graft.
Results: The transradial approach was associated with fewer vascular access 
complications than the transfemoral approach (1.5% vs 0.6% p<0.001) and a shorter 
length of hospital stay. Multivariable analysis revealed transradial access (OR 0.39 95% CI 
0.2, 0.7), to be an independent predictor of lower risk of access site related complications, 
while primary PCI (OR 4.36 95% CI 1.4, 13), recent MI (OR 2.0 95% CI 1.2, 3.4), age (per 
10 years increase: OR 1.37 95% CI 1.1, 1.7) and female gender (0R 2.78 95% CI 1.7, 
4.6) were independent predictors a higher risk of access site complications. A trend was 
also observed indicating transradial access to be independently associated with a lower 
risk (rate) of major adverse cardiac events (1.9% vs 1.5% p=0.18).
Conclusions: The use of transradial PCI is safe and is independently associated with a 
reduced rate of in-hospital access site complications and reduced length of hospital stay.
2900-331 Outcomes of Non-physician Vascular Access and 
Closure; A Single Center Clinical Evaluation
Daniel Lee, Matthew Lee, Patrick Rim, Thomas Tomczak, Karen DiDonato, Bay Regional 
Medical Center, Bay City, MI
Background: Standard of care at most hospitals is for the physician to perform the femoral 
artery puncture required for vascular access, with the arteriotomy then being closed via 
manual compression or a VCD (vessel closure device). Clinical trials demonstrating safety 
and efficacy of VCDs have been mandated by the FDA, with participation restricted to 
interventional cardiologists. Little to no data has been published regarding the utilization 
of non-physician cath lab staff for providing vascular access and closure.
Methods: This study was a single center, retrospective evaluation of 1000 consecutive 
femoral artery punctures and closures using the Abbott Vascular (Redwood City, CA) 
StarClose® device between March 2006 and September 2006. The objective was to 
evaluate the safety and efficacy of the device in achieving hemostasis following diagnostic 
and PCI (percutaneous coronary intervention) procedures, where femoral arterial access 
and closure was obtained by a trained cath lab nurse, radiology technician or RCIS 
(Registered Cardiovascular Invasive Specialist). Device success was the primary endpoint 
and was defined as achievement of hemostasis in the catheterization lab allowing transfer 
to the cardiovascular holding unit.
Results: Of the 1000 patients analyzed, 749 (75%) were diagnostic catheterization 
procedures while 251 (25%) were PCI. Overall device success rate for the combined 
population was 96.3% (963/1000). Diagnostic patients demonstrated a device success 
rate of 96.5% (723/749) while interventional patients were successfully closed with the 
StarClose device 95.6% (240/251) of the time. There were a total of 37 failed closures; 26 
of which occurred in the diagnostic population, and 11 in the interventional.
Conclusion: Successful femoral artery access and closure when performed by trained, 
non-physician cath lab staff is feasible and appears to be safe and effective based on this 
preliminary observational study in patients who underwent diagnostic and interventional 
catheterization procedures. Additional, prospective studies with the StarClose device 
utilizing a more formalized hypothesis testing should now be attempted.
2900-332 Single Center Results of PFO Closure with a Non-
Implantable Device Using Radiofrequency
Julia Wallenborn, Laura Schrumpf, Christiane Bußmann, Nicolas Majunke, Corinna 
Heinisch, Andreas Baranowski, Wibke Zimmermann, Stephan Staubach, Niko Wawra, 
Evelyn Fischer, Michaela Leetz, Marijke Skowasch, Nina Wunderlich, Horst Sievert, 
CardioVascular Center, Frankfurt, Germany
Background: Percutaneous closure of patent foramen ovale (PFO) to prevent recurrent 
paradoxical embolism is frequently performed, however, currently available closure 
devices are implantable, leaving a foreign structure in the atria. The PFxTM Closure 
System (Cierra, Inc., Redwood City, CA) is a novel method employing radiofrequency 
energy to effect closure of a PFO by welding the tissues of the septum primum and 
septum secundum together without leaving foreign material in the body.
Methods: From April 2005 through June 2007, 80 patients (age 18 - 65 years, mean 48 
+ 11 years) with history of paradoxical emboli were treated using the PFx catheter. The 
PFx catheter is positioned over the PFO on right atrial surface using fluoroscopy and 
TEE guidance. Vacuum is applied to hold the septum primum and septum secundum in 
place. The two layers of tissue are then fused with radiofrequency energy applied via an 
electrode. All patients received a minimum of 100 mg of aspirin and 75mg clopidogrel for 
at least 6 weeks. Transesophageal Echocardiography (TEE) and ECG was carried out at 
1, 3 and 6 months post-procedure.
Results: In 76 of 80 patients (95%), the catheter was successfully placed and energy 
applied. Average time of radiofrequency application was 8 minutes (range of 3 - 20 min). 
Mean stretched balloon diameter was 8.0 mm (range 3 - 15mm). Average follow up is 5 
months. Overall closure rate in patients where radiofrequency energy was successfully 
applied was 57% (43/76) after the first procedure.
The first 45 patients in the study were treated with a 15mm device. In these patients, the 
overall closure rate was 47% (21/45). The closure rate was impacted by the diameter of 
the PFO. A 19mm device was introduced during the study and evaluated along with the 
15mm in the last 35 patients. The overall closure rate in this subset of patients improved 
to 63% (22/35) with a closure rate of 76% (19/25) in PFO with a diameter of less than 
10mm. In 13 patients with a residual shunt a second procedure was performed which 
was successful in 10.
Conclusions: Initial experience demonstrates that PFO closure using radiofrequency 
energy is technically feasible and safe..
2900-333 Coronary Angiography is Safe in Patients with Peripheral 
Arterial Disease: A Sub-Study of the Coronary Artery 
Revascularization Prophylaxis (CARP) Trial
Santiago Garcia, Brack Hattler, Thomas Moritz, Steven Goldman, Kendrick Shunk, 
Fred Littooy, Domenic Reda, Herbert Ward, Edwards McFalls, University of Minnesota, 
Minneapolis, MN
Background: The safety of diagnostic coronary angiography has not been systematically 
studied in a large cohort of patients scheduled for an elective vascular operation.
Methods: Between March 1, 1999 and February 28, 2003, 5398 patients were screened 
at 18 VA Medical Centers and considered for enrollment into the Coronary Artery 
Revascularization Prophylaxis (CARP) trial. Coronary angiography was performed in 
1298 patients prior to vascular surgery and comprised the study cohort. Complications 
were assessed 24 hours post-procedure.
Results: Indications for vascular surgery included an expanding aortic aneurysm (AAA) 
(35%) or arterial occlusive disease with either claudication (35%), or rest pain with or 
without tissue loss (30%). A major complication occurred in a total of 16 patients (1.23%) 
and, as shown in the Table, tended to be more common in patients with arterial occlusive 
symptoms compared to those with expanding aneurysms (1.6% vs. 0.4%; p=0.07).
Conclusions: Coronary angiography is safe in patients with peripheral arterial disease 
undergoing preoperative screening prior to elective vascular surgery. Vascular access 
complications are more common in patients with arterial occlusive disease.
Table
Complication Arterial Occlusive Disease (n=852) AAA (n=446)
Death 0 0
MI 2 0
Stroke 1 0
Renal failure 2 0
VT/VF 2 0
Allergic reactions 0 1
Vascular access 7 1
All (%) 14 (1.6) 2 (0.4)
2900-334 Can Femoral Artery Angiography Reduce Vascular 
Complications of Cardiac Catheterization
Takeshi Onizuka, Akio Kawamura, Shinsuke Yuasa, Takashi Kohno, Kentarou 
Hayashida, Yuichirou Maekawa, Satoshi Ogawa, Keio University School of Medicine, 
Tokyo, Japan
Objective: We sought to reveal whether femoral artery angiography (FAA) could reduce 
vascular access complications associated with trans-femoral arterial catheterization.
Background: Trans-femoral approach is widely used in cardiac catheterization 
and percutaneous coronary intervention. Despite meticulous care to reduce access 
site complications, vascular complications such as, retroperitoneal hemorrhage, 
pseudoaneurysm, arterio-venous fistula, remain to be serious problems related to trans-
femoral approach.
Methods: Between September 2006 and August 2007, consecutive 580 patients 
underwent trans-femoral catheterization after FAA. The FAA was performed immediately 
after femoral arterial access. Unless any bleeding or arterio-venous fistula was found, 
heparin was administered and procedure was commenced. The incidence of vascular 
complications of this group was compared with that of consecutive 953 patients who 
underwent trans-femoral catheterization without FAA in preceding period between 
January 2005 and September 2007.
Results: Baseline demographics were similar between the 2 groups except that patients 
with FAA were less likely to have second arterial access on the same side of the femoral 
artery (5.1% vs. 1.2%, p < 0.05). The incidence of vascular complications was lower in 
patients with FAA than in patients without FAA (0.34% vs. 1.37%, p < 0.05). By performing 
FAA immediately after femoral access, 2 vascular complications (arterio-venous fistula 
and extravascular bleeding) were promptly recognized and treated before the procedure.
Conclusions: FAA immediately after femoral arterial access can reveal vascular 
complications in its early stage and facilitate swift treatment.
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